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Summary 
 
Background 
 
Elevated blood lipids (particularly cholesterol and sub-fractions) contribute to the risk of 
developing cerebral, peripheral and cardiovascular disease and associated complications 
which are leading causes of morbidity and death.  
 
Statins reduce the risk of suffering vascular events, with or without decreasing cholesterol 
levels. Statin prescribing continues to increase but there is scope to improve prescribing 
and dosing, particularly in primary care. However, there is insufficient empirical evidence 
to inform approaches to quality improvement.  
 
 
Methods 
 
Following pilot work, we designed a new model of primary care based pharmacist-led 
intervention for General Practitioners (GPs) and nurses. The aim of the intervention (called 
Statin Outreach Support, SOS) was to improve statin prescribing by GPs, in line with 
recent evidence, targeting patients at highest risk of suffering a vascular event.  
 
Eleven trained pharmacists worked in SOS allocated practices one day per week for a year. 
During this period, the pharmacist met three times with all GPs, all nurses and other 
practice staff. Between meetings, pharmacists used patient level clinical and prescribing 
data to identify eligible patients and help practices initiate, up-titrate the dose or switch to 
simvastatin 40mg where indicated.   
 
The effectiveness of SOS was tested in a prospective single blind cluster randomised 
controlled trial.  
 
Usual care (UC) practices received no pharmacist support during the study. 
 
With a mean of 1.7 years follow up, the study had over 90% power (at 5% significance) to 
detect a difference of 12% in the proportion of patients with controlled cholesterol after 
practices had received the SOS intervention. 
 
 
Results  
 
Thirty one practices were recruited from the UK’s largest Health Board area. At 
randomisation, 16 practices were allocated to the SOS intervention and 15 to UC with 
4,040 patients included at baseline. Recruited practices showed few differences compared 
with invited, non participating practices. Practices and patients randomised to each arm of 
the study had similar distributions with respect to age, complications, cholesterol levels 
and statin prescribing. The mean age was 68 years; 53% male, 45% ischaemic aetiology. 
Fifty nine percent had no statin prescribed at baseline; only 51% had cholesterol 
controlled.  
 
Follow up included 7586 patients in 29 practices (one practice had disbanded between 
recruitment and randomisation and another practice dropped out). Compared with UC, the 
SOS intervention achieved the primary endpoint of increasing the proportion of patients 
prescribed Simvastatin 40mg with controlled cholesterol (SOS 44.9% vs. UC 27.9%; odds 
ratio 1.79 (95% CI: 1.61, 1.98), p< 0.001). Secondary endpoints were also improved in the 
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SOS arm practices. The intervention effect was strong and consistent across most 
subgroups including a positive impact on patients from practices in areas of greater 
socioeconomic deprivation. 
 
 
Conclusion 
 
A pragmatic, new, complex intervention was developed, tested and shown to be effective 
in a cluster randomised controlled trial with good internal and external validity.  
 
If implemented on a wider scale, in practices with comparable characteristics and baseline 
prescribing, the SOS intervention has the potential to reduce the burden of vascular events 
for patients with vascular disease.   
 
This work provides a convincing evidence base for the role of pharmacists collaborating 
with primary care practices, to improve statin prescribing and drug based cholesterol 
management, for patients at highest risk of suffering vascular events. 
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Chapter 1 
 
Introduction 
 
1.1 Primary Care 
 
In the 1978 Alma Ata Declaration, primary care was described as constituting the first element 
of a continuing health care process (WHO 1978) and more recently, ‘Now More Than Ever’ 
(WHO 2008) reaffirmed the central importance of a strong primary health care system as a 
means of tackling the epidemic of chronic conditions. A key aspect of primary care described 
by the declaration was the delivery method being reliant on good teamwork, with the most 
recent report describing the primary care team as a “hub of coordination” (WHO 2008). This 
included the involvement of “outside partners” e.g. housing, employment. Primary care is 
regarded as an essential and cost effective component of a health system (Starfield 1994).  
 
The importance of preventive medicine, the contribution of essential drugs and the increase in 
noncommunicable disease were acknowledged. The increase in the number of people in 
developing and industrialised countries with Long Term Conditions (LTCs) such as heart 
disease and the challenge of individuals presenting with multiple illnesses was recognised.  
 
These references to teamwork and preventive medicines underscored the potential for the 
pharmacy profession to make a meaningful contribution to primary health care.  
 
1.1.1         Primary Care in the United Kingdom and the policy context for teamwork 
 
While there have been numerous health care reforms and changes in delivery between and 
within different countries over the past 50 years, the UK has retained the National Health 
Service (NHS) model. It was established in 1948 as the first publicly funded, comprehensive 
health system.   
 
When the NHS began, general practice was often perceived to be of low quality. Since then, 
however, general practice and primary health care delivery has shifted from single handed GPs 
working in isolation to a multidisciplinary team based model which brings advantages in terms 
of co-ordination and comprehensiveness. Effective teams improve the quality of primary care 
from the perspective of patient, organisation and team members. However, many teams fail to 
work together for complex reasons. In this context, together with a general trend of shifting 
responsibility, workload and resources from acute care to primary care, healthcare 
professionals’ roles have evolved. Expansion of professional roles, opportunities afforded by 
skill mixing and professional substitution have contributed to the evolution of primary care 
teams. Relentless changes in the way the NHS delivers primary care has led to more emphasis 
on joint working within teams, with the locus of control remaining within primary care general 
practices.  
 
One of the main policy drivers in this context included ‘Primary Health Care – an agenda for 
discussion’ (Department of Health and Social Security, 1986) which expressed the need for 
the development of working teams and asserted ‘Primary health care is best provided when 
family doctors, community nurses and practice nurses work together as members of a primary 
care team’. ‘Promoting better health’ (Department of Health and Social Security, 1987) 
changed the structure of the contract which GPs had with the NHS, requiring greater 
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concentration on health promotion and the prevention of disease. Practices began to involve 
nurses as salaried employees, in different roles within the practice, to support delivery of 
contractual obligations. ‘Working for patients’ (Department of Health 1989) facilitated GPs to 
expand and innovate further. GP fundholding was introduced and, with this, innovation and 
increased opportunities for inclusion of different professional groups in practices e.g. 
physiotherapists, pharmacists. Practice nurses’ roles began to diversify.  
 
 
1.1.2         Opportunities for pharmacists in general practices 
 
This diversification, albeit restricted to practices with fundholding status, led to opportunities 
for pharmacists to deliver bespoke services aimed at improving prescribing. Prescribing was 
acknowledged as an area of high cost with scope for improvement. In 1996, during 
fundholding, and for the first time in the UK, some pharmacists became salaried Practice 
employees, working within Practice teams. The author was one of the few clinical pharmacists 
to work in Glasgow general practices at that time, following pioneering work by Clare 
Mackie, which confirmed the contribution of medication review by pharmacists for patients 
receiving multiple medications (Mackie 1999).   
 
At that time, the remit of many general practice based pharmacists was to review patients’ 
medicines with full access to relevant clinical records and, if indicated, with patient and then 
GP agreement, modify them in line with evidence of cost effectiveness and quality 
improvement. Patients targeted for review were those receiving polypharmacy and were often 
prescribed expensive medicines. The objectives of the medication review included 
improvement in the quality of care through prescribing improvement and maximisation of cost 
effective prescribing and use of medicines. At that time, a lack of empirical evidence existed 
to justify medication review as a means of reducing hospitalisations or impacting on mortality. 
Since then, the evidence base around this form of pharmacist-led support has developed and 
some variants of medication review have become established practice. However, some reports 
have described a lack of convincing evidence of long term benefit on morbidity/mortality 
endpoints, suggesting the evidence base could be improved (Holland, 2007).  
 
Other models of pharmacist-led prescribing support which did not involve direct patient-
facing activity were described, with short term improvements in prescribing, but studies have 
not considered longer term outcomes (Oxman 1995; Davis 1995).  
 
In 1997, the Labour government initiated major changes in the organisation of the NHS with 
the White Paper ‘The New NHS: Modern, Dependable’ (Department of Health 1997) which 
signalled the end of the ‘internal market’ concept. Fundholding was replaced with an ethos of 
co-operation. This government policy paper, with a focus on the efficient use of resources, 
also encouraged teamwork in primary care to help meet the increasingly complex needs of 
service users. To enable this change, interdisciplinary learning involving different healthcare 
professionals was promoted as a way forward (Leathard 1994). A subsequent systematic 
review concluded that more research was required to demonstrate whether and how this 
approach impacted on professional practice (Cooper 2001).  
 
Now, over 10 years later, primary care groups and trusts have been replaced by health and 
social care partnerships. The General Medical Services contract is in place, incentivising 
evidence based prescribing for specified LTCs (Roland 2004). Pharmacists’ opportunity to 
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support prescribing in primary care by working collaboratively with GPs has continued to 
grow in response to increases in the number, diversity and availability of preventive medicines 
for LTCs (NHS Executive, 1999).  
 
 
1.1.3         Drivers for primary care prescribing support  
 
Since the inception of the NHS, organisational change has been constant. Efficiency savings 
are now the key driver for change, which is not surprising given the current level of 
expenditure on healthcare and the global economic situation (Ramesh, 2010). 
 
Quality improvement together with improved patient safety is also high on the NHS agenda, 
with delivery mechanisms such as clinical governance and audit supporting implementation. 
Improving prescribing is seen as an important means of delivering quality improvement and 
achieving cost effective use of resources. For example, statins reduce the risk of vascular 
events if prescribed appropriately for targeted patients but they account for a large item of 
expenditure: in 2000, statins cost NHS Glasgow £5.5million per year. Since then, the cost of 
statin prescribing has increased to approximately £20 million per year, and there are cost 
savings to be made by choosing to prescribe Simvastatin instead of other, equally efficacious 
alternatives. 
 
 
1.2 LTCs 
 
A LTC is a condition that “requires ongoing medical care, limits what one can do, and is likely 
to last longer than one year” (World Health Organisation (WHO) 2005). Managing LTCs has 
been described by the WHO as “the health care challenge of this century”. Approximately 
78% of healthcare resources are directed towards the care of people with LTCs.   
 
 
1.2.1  The prevalence of LTCs 
 
Major health gains experienced in recent years coupled with increasing advances in treatment 
and prevention, have resulted in the majority of people living longer lives. For example, the 
population in Scotland is both ageing and declining: the proportion of Scots aged over 65 is 
predicted to increase from 15.9% in 2001 to 26.6% in 2031. Estimates from the Scottish 
Health Survey report show that in 2003, 26.5% of adults in Scotland reported a long standing 
illness, disability or infirmity which limited their activities in some way. A further 14.7% 
reported LTCs that were not limiting. Both increased markedly with age, particularly the 
proportion of adults in the oldest age group (over 75 years) (Scottish Health Survey 2003). As 
there is an association between increasing age and risk of developing a chronic condition, the 
proportion of households containing someone with a LTC showed an increase from 30% in 
1999 – 2000 to 33.8% in 2005 - 2006 (Loretto 2007).  
 
 
1.2.2  Co-morbidities and polypharmacy  
 
Many patients with one LTC can remain relatively stable over the long term.  However, it is 
estimated that up to 45% of patients suffer from more than one condition (National Public 
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Health Service for Wales 2001). Patients with multiple LTCs have healthcare costs that are 
six times higher than patients with only one condition, with the cost of repeat medicines 
forming a part of this (Naessens 2011). Medicines are used extensively by patients who have 
LTCs because medicines can help delay or prevent the onset of conditions worsening e.g. 
Beta Blockers reduce the risk of recurrent myocardial infarction, preventing the onset of 
associated illness, loss of function and costs associated with treating symptoms and 
preventing complications. As the number of conditions suffered by an individual increases, 
so does the number of medicines and therefore, the need for prescribing decisions to be 
based on sound evidence of effectiveness and efficiency. 
 
 
1.2.3  Polypharmacy and determinants of care management 
 
Several ‘disease management models’ aim to reduce the impact of LTCs. Many of these 
acknowledge the importance of recognising that when a person is prescribed polypharmacy for 
multiple co-morbidities, it may be an indicator of the need for the provision of more intensive 
care. The Castlefields model is a disease management model which stratifies the population at 
risk by a number of factors, one of which is polypharmacy (Lyon 2006).  Polypharmacy often 
arises from co-morbidities and patients with co-morbidities are estimated to use a 
disproportionate amount of healthcare resources (Yu 2003). Polypharmacy is thought to be an 
independent risk factor for elderly people falling and in patients with heart failure, 
polypharmacy (or the number of co-morbidities) may predict worse outcomes. These 
examples, and the pressure to prescribe cost effectively, suggest that effective models of 
prescribing support in primary care would be useful. 
 
 
1.3 Prescribing in Primary Care 
 
An overview of the history and the processes involved in repeat prescribing gives an insight to 
potential ways to improve prescribing effectiveness and efficiency. As with many 
interventions in primary care, prescribing support models are likely to be complex. To be 
effective, support may need to target and influence different parts of the repeat prescribing 
process e.g. the GPs’ choice of drug and patient attendance at the practice for prescription 
collection. It is recommended that complex interventions require extensive piloting before 
testing in a randomised controlled trial (Medical Research Council 2011).  
 
 
1.3.1  Long term and repeat prescribing 
 
In Primary Care, drugs are the most common intervention for LTCs with up to 75% of patients 
receiving a prescription on consulting their GP (Soumerai 1990; Bligh 1992). Over the past 50 
years there has been a steady increase in the availability and range of medicines. In response, 
the proportion of NHS expenditure allocated to pharmaceutical products has continued to rise, 
with estimates suggesting primary care prescribing accounts for over 80% of the cost of all 
medicines and 10% of the total NHS budget (National Prescribing Centre Resource 
Document, 1999). Much of the volume increase stems from increasing numbers of people with 
LTCs receiving repeat prescriptions (prescriptions issued from a general practice computer 
using a repeat prescribing program, enabling supply of medicines within a given time period). 
In the United Kingdom over 30 years ago, the proportion of repeat prescriptions was estimated 
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to be around 25% of all prescribed items. Twenty years later, it had increased to about 75% of 
all prescribed items (Diikers 1977; National Prescribing Centre Resource Document, 1999).  In 
1996, one quarter of the population received some form of repeat medication, increasing to 
90% of people aged over 75 years (Harris 1996).  Repeat prescriptions represent about 80% of 
the cost and 70% of the volume of prescribing in general practice (Audit Commission 1994; 
National Audit Office 1992).  
 
In the elderly, the volume of repeat prescribing, appropriateness and time requirement to 
review appropriateness have long been regarded as a concern (Anderson 1980; Tulloch 1981; 
Nicol 1984; Freer 1985). The true extent to which inappropriate prescribing occurs is 
unknown because of limitations associated with lack of agreement on objective measures of 
appropriateness, publication bias, and uncertainty about the context of prescribing decisions. 
Available reports indicate that inappropriate prescribing is mostly detectable through the use 
of drug doses above recommended limits (Buetow 1996; Buetow 1997). However, experience 
suggests ‘inappropriate’ prescribing should (in most cases, while appreciating the 
heterogeneity of patients) encompass sub-optimal use of medicines of known benefit, or sub-
optimal doses in comparison with guideline recommendations. 
 
Sixty six percent of prescriptions in primary care are issued as repeats, with no face to face 
contact between patient and GP (The Audit Commission 1994; The National Audit Office 
1993; Sykes 1996). GPs are reported to have difficulty protecting the time for an annual 
review (McGavock 1999; Zermansky 1996). During a review, it is recommended that the 
efficacy, appropriateness, adverse effects, interactions, value for money, the patient’s 
understanding of the treatment and compliance are all evaluated within the confines of a 
consultation (The Audit Commission 1994). Repeat prescribing can lead to excessive amounts 
of waste medicines (Zermansky 1996).  
 
Over and above the growth of LTCs, other reasons for the increase in repeat prescribing 
include: drugs causing habituation and dependence e.g. some analgesics, hypnotics or 
anxiolytics; improved detection and management of patients through screening; availability of 
new medicines for primary, secondary and tertiary prevention and societal and attitudinal 
changes towards diseases and medicines taking. With the advent of the GMS contract Quality 
and Outcomes Framework in 2004 (which coincided with the start of the intervention tested in 
this study) there has been a shift of practice towards evidence based management of diseases 
including the provision of financial incentives to prescribe statins for patients with vascular 
disease (QoF achievement Data 2005). Annual review of repeat prescribing for patients 
receiving four or more medicines is included in this annual review (BMA and NHS employers 
2011). The review incentivises and encourages critical examination of the ongoing 
appropriateness of repeat prescribing.   
 
 
1.3.2  Support for long term prescribing 
 
A balance needs to be struck between introducing new, evidence based medicines and 
maintaining patients on existing, well tolerated medicines. The benefits of introducing a new 
medicine might not outweigh the benefits of maintaining the status quo at an individual patient 
level. Ideally, each patient would receive a review of their medicines and conditions, in order 
that options can be discussed and changes made if required. Pharmacist-led ‘Prescribing 
Support’ can offer additional capacity to offer review of prescribing (NHS Executive 1999). 
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Recognition of the need to improve evidence based prescribing and minimise variation in 
prescribing formed part of the rationale for introduction of the General Medical Services 
Quality and Outcomes Framework in 2004 (Roland 2004).  
Many other objectives are potentially achievable through prescribing support:  
 
• Minimisation of iatrogenic hospital admissions, particularly for those with 
polypharmacy and the elderly (Tully 1991; Lindley 1992; Gosney 1984; 
Medical Expenditure Panel Survey 2001); 
• Minimisation of prescribing costs by encouragement to prescribe the least 
costly medicine when therapeutic equivalents are available e.g. in 2007, it was 
estimated that if Simvastatin was used instead of alternative statins for 10% of 
patients, this would generate £84.7M savings in England alone (Department of 
Health 2007);  
• Ease GP workload, by providing an annual medication review (MacRae 2003); 
• Reduce variation in prescribing outcomes (Carthy 2000).   
 
 
1.3.3  The prescribing knowledge – practice gap  
 
In relation to health related interventions including prescribing, there is often a failure to 
implement research findings (Effectiveness Matters 1998). Many recognised barriers are 
entirely rational e.g. patients or GPs deciding not to implement on a case by case basis, 
because circumstances differ from the trials upon which the evidence is based. These 
departures from the evidence base are common and account for much of this gap between 
research and practice (David 2003; Mair 1996; Sudlow 1997; Mashru 1997). However there 
are many other barriers to implementation of evidence based medicine and an associated range 
of theories on how to improve dissemination and implementation of research findings (Grol 
1997, Fraser 2003) which could be applied at the individual or health care system level (Smith 
2003).  
 
Discussions on the implementation of evidence based medicine have acknowledged factors 
influencing prescribing. These include GPs’ knowledge, professional experience, role 
perception of GPs, time pressures (patient and GP), patient expectations, patient demand and 
the number of GPs in a practice. An understanding of these has illuminated the processes 
shaping GP prescribing decisions (Carthy 2000; Watkins 2003; Webb 1994; Britten 1997, 
Cockburn 1997). According to Haynes (2002), clinical decisions should consider evidence 
based medicine at the individual patient level. They describe a four part model: 
 
1. Ascertainment of what is wrong with the patient and what treatment options are 
available; 
2. Consideration of options informed by research evidence concerning the efficacy, 
effectiveness and efficiency of medicines when this is available; 
3. Consideration of the patient’s preferences;  
4. Application of clinical expertise to bring these considerations together and 
communicate the decision with the patient. 
 
Anticipating specific barriers to implementation of the research evidence on a particular topic 
can inform solutions. Barriers are likely to vary depending on the practice, GP and patient’s 
circumstances. Finding out what the barriers are, before devising well intentioned solutions 
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may be the best way forward (Haynes 1998). There are many reasons why the evidence based 
model of prescribing is not followed. Failure to take the patient’s beliefs and preferences into 
account during a consultation might reduce the likelihood of agreement on an evidence based 
choice. Known difficulties in the process of effective communication of the benefits and risks 
of any particular treatment cannot be underestimated (Veldhuis 1998; McColl 1998; Freeman 
2001; Sweeney 1998).  
 
 
1.4 Pharmacy in the NHS and Primary Care 
 
1.4.1         Pharmacy  
 
The Royal Pharmaceutical Society of Great Britain was incorporated by a Royal Charter 
granted on 18th February 1843. A Supplemental Charter was granted on 19th November 1953 
in which the Council of the Society was agreed to have the function, for the benefit of the 
public, to be more appropriately equipped to:  
 
• regulate the members; 
• lead the strategic development and policies of the profession of pharmacy; 
• support the science and practice of pharmacy; 
• engage with the wider public debate on health related matters and on the role of 
pharmacy in contributing to the health of the public. 
 
In a 2007 White Paper named ‘Trust, Assurance and Safety’, there was a commitment to 
separating regulation from professional leadership in all health professions. In response, the 
Royal Pharmaceutical Society separated into two new organisations during 2010: the General 
Pharmaceutical Council, which regulates the profession, and a new professional leadership 
body, which focuses on supporting the needs of members. Members are those who have 
registered as pharmacists in Great Britain, having completed and passed a 4 year degree or 
masters degree in Pharmacy at an approved University, then completed a further pre-
registration placement for 1 year in practice and passed a pre-registration examination. In 1992 
it was estimated that the cost of training a pharmacist was at least £25,000 (The Royal 
Pharmaceutical Society 1992). 
 
 
1.4.2            Pharmacy roles in Primary Care 
 
In response to the mass manufacture of pre-packed patented and generic medicines over the 
past 20 years, pharmacists have spent less time compounding and preparing medicines. In 
parallel, increases in the prevalence and incidence of LTCs, together with increases in the 
number of available medicines has led to an increase in prescribing choices, volume and cost. 
This created a need for additional support to prescribers. Pharmacists’ ability to influence 
prescribing grew, including being able to independently prescribe. A more developed clinical 
focus in undergraduate courses, and policy shifts encouraging teamwork enabled these 
developments. 
  
As the cost of prescribing spiralled, some pharmacists’ roles moved from dispensing to 
supporting the management of prescribing. This move involved forming better links with 
practices, focussing on repeat prescribing and minimising waste. Increased capacity to 
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undertake these new roles was facilitated by a move to enable suitably trained counter 
assistants and dispensers in community pharmacy, to dispense and supply prescriptions. It 
could be argued that another stimulus for pharmacists applying their skills and knowledge 
within general practices was, and continues to be, the lack of opportunity for clinical career 
development or systematic opportunity to apply undergraduate and postgraduate clinical 
training within the community pharmacy environment. 
 
From the pharmacy workforce census in 2008 (www.rpsgb.org.uk/pdfs/census08.pdf) there 
were 43,845 registered pharmacists living in the United Kingdom with 82.8% in active 
employment. Community Pharmacy was the largest sector of practice with 71% of those 
actively employed working in this sector (23.1% of whom were registered as locums). There 
were over 15,000 community pharmacies in the UK. These were private for profit 
organisations with some income coming from NHS remuneration through prescription 
dispensing. Many were owned by contractors who owned multiple chains of pharmacies.  
Approximately 21% of pharmacists worked in Hospital pharmacy. Most of the remaining 8% 
operated as NHS employees in Primary Care, providing strategic prescribing guidance or 
based in general practices, supporting prescribing directly through patient interaction. The 
general practice based role is most commonly described as ‘Prescribing Support Pharmacy’. 
Numbers working in this sector are not available; it is probably the most recently established 
branch of the profession in relation to employment in Primary Care.  
 
 
1.4.3       Policy context for clinical role expansion 
 
The first policy recommendation for the expansion of new clinical roles came from the 
Nuffield report (Nuffield foundation 1986). Since then, opportunities have arisen for 
pharmacists to work within general practices, initially as prescribing advisers alongside 
medical prescribing advisers. In England, there were 50 prescribing advisers in 1991 and as 
the need evolved, numbers rose to 250 in 1998 (Prescribing Advisers: an update 1999). No 
additional information on workforce figures in primary care prescribing advice could be found 
after this period. Because of their few numbers, roles were necessarily strategic, working at a 
distance from practices, at regional level, supporting the achievement of rational prescribing 
targets through the provision of prescribing summaries and prescribing advice to practices. 
 
Around this period, pharmacists began to work within general practices. The opportunity arose 
from a demand from some practices for clinical medication review / repeat prescribing 
support. Inter-professional learning was facilitated. Some pharmacists became salaried 
employees in General practices. Pharmacists were found to generate savings in practices’ 
drugs bill by reviewing patients receiving polypharmacy and cutting back on the number of 
medicines or changing expensive medicines to less expensive but equally efficacious 
alternatives. Pharmacists also helped implement clinical evidence, acting as expert therapeutic 
advisers. The White Paper “Primary Care: the future” reinforced this move, consolidating 
Government interest in the potential for pharmacists to become more integrated into primary 
health care teams and medical practices. The paper noted that “regular attendance by 
pharmacists in surgeries would lead to greater understanding of drug use by patients and more 
effective use of drug budgets by GPs” (National Health Service Executive 1996). Since then, 
several other white papers have endorsed the view that pharmacists have a valuable 
contribution to make in patient care although none have cited an evidence base to substantiate 
this (Secretaries of State for Health, Scotland and Wales 1996a). Innovation and removal of 
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barriers to further development were encouraged. More inter-professional cooperation to 
provide services relating to prescribing and greater mixing of skills was promoted.  
 
From within the Pharmacy profession, the move towards clinical application of pharmacists’ 
skills and knowledge was supported albeit slightly belatedly. In 1997, The Royal 
Pharmaceutical Society’s ‘Pharmacy in a New Age’ strategy developed the concept further 
(Royal Pharmaceutical Society of Great Britain 1997), reiterating the consensus that 
pharmacists, by virtue of their undergraduate training, were expected to know more about drug 
treatment than any other professional (McCreedy 1997). However, to become expert in the 
clinical use of drugs requires regular initiation and monitoring of the drugs together with the 
honing of relevant knowledge and skills. These pre-requisites were available to pharmacists 
working in general practices. For the majority of pharmacists working in community 
pharmacies, most of their working hours were spent in a dispensary, checking the accuracy of 
prescriptions before issue to patients, counselling patients on management of minor ailments 
without access to clinical records. The skills and knowledge maintained through this core role 
may lead to an unrivalled awareness of the names, strengths, manufacturers and indications of 
commonly available medicines. The status of the clinical conditions of patients presenting 
with prescriptions and their demographic variables, co-morbidities and relevant medical 
histories remain largely unknown to most community pharmacists, making it difficult for most 
community pharmacists to develop an expertise of drugs in use.  
 
In 1999, in an editorial, the Pharmaceutical Journal said ‘Supply is, of itself, no longer an 
adequate role for the 21st century pharmacist’ indicating that pharmacists were still requiring 
encouragement to establish and extend their clinical role, ten years after the idea was first 
mooted (Parkin 1999).  
 
The 2003 Health and Social Care act enabled primary care organisations to contract with the 
private sector for the provision of pharmaceutical care services (Pollok 2005) and the NHS 
Pharmaceutical Care services regulations (2005) allowed community pharmacists to provide a 
range of services e.g. anticoagulant monitoring. 
 
More recently, the need for greater involvement of pharmacists as part of the multidisciplinary 
team has surfaced again (A report on the future of the NHS in Scotland 2005), some 20 years 
since the concept of multidisciplinary team working was advocated in the WHO declaration of 
Alma Ata. These policy drivers recommended ‘Shifting the balance of care’ from medical to 
team based models, a better community based preventive focus, aiming to reduce secondary 
care and primary care health service utilisation in favour of better self management in the 
community, improving medicines management and involving pharmacy to a greater extent 
(particularly in relation to LTCs).  
 
 
1.4.4        Evidence base for pharmacists adding value to LTC management 
 
There are few examples of long term trials demonstrating improved morbidity or mortality 
outcomes from pharmacists collaborating with primary care providers. One reason for this 
may be the difficulties inherent in measuring and valuing benefit from the complex 
interventions delivered by pharmacists as they collaborate with other healthcare professionals. 
Another reason may be the choice of patients in most trials of medication review. Patients 
have tended to be recruited on the basis of their polypharmacy and therefore multiple co-
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morbidities, rather than their ill health. Patients who are more seriously ill or clinically 
unstable are often excluded, which may make it more difficult to demonstrate changes in 
clinical outcomes. However there are some disease areas such as hypertension, diabetes and 
heart failure where multidisciplinary input (including pharmacy support) is recommended, due 
to evidence of usefulness in terms of prevention of hospitalisations or intermediate outcomes 
(Carter 2009; McAlister 2004).  Heart failure is the only example of a LTC where a systematic 
review has confirmed the utility of pharmacists working collaboratively (with GPs and other 
healthcare providers (Koshman 2008) rather than independently e.g. based in community 
pharmacies, where lack of access to relevant clinical information may limit impact (Holland 
2007a).  
 
In reducing the risk of recurrent falls in the community dwelling elderly, medication review by 
pharmacists appears to be synergistic with other interventions (Gillespie 2004).  
 
These positive findings have largely been shown in the context of trials involving medication 
review delivery by few, specialist pharmacists, collaborating within specialist teams. When 
pharmacists involved in trials are non-specialist, or the interventions are characterised by a 
lack of formal collaboration within a team, outcomes are generally neutral ( Holland 2007a, 
Holland 2008, Lowrie 2011). Nevertheless, the prevailing view does not differentiate between 
pharmacists with different levels of knowledge and skills (NHS Executive and National 
Prescribing Centre1996). However, there is some evidence of a positive impact on prescribing 
changes by non specialist, community pharmacists. This includes a systematic review of 
community pharmacists’ interventions for patients with established coronary heart disease 
(Watson 1998; Blenkinsopp 2006),  improvement in anticoagulant control (Hall 1995), 
smoking cessation (Blenkinsop 2003;  Maguire 2001), emergency hormonal contraception 
(Anderson 2009), cholesterol lowering (over the short term, through patient-facing 
interventions)  (Gardner 1995; Tsuyuki 2002), and blood pressure control (Blenkinsopp 2000).  
 
When the focus is on improving CHD treatment appropriateness or reducing future risk of 
cardiovascular death through a multifaceted intervention for patients with CHD, Community 
pharmacists have not yet demonstrated a significant impact on long term clinical or surrogate 
clinical outcomes (Community Pharmacy Medicines Management Project Evaluation Team 
2007; Pharmacy Practice Research Trust 2009). 
 
 
1.4.5           Adoption of clinical roles by Community pharmacists  
 
One factor limiting the move of more pharmacists from supply / dispensing into clinical 
domains has remained constant throughout the years: the need for a pharmacist to be present 
in registered pharmacy premises to supervise the dispensing and supply of medicines. While 
this ruling is currently under review, a pharmacist is still professionally required to be present 
at all times when medicines are dispensed. This limits the movement of community 
pharmacists into practices, to deliver more clinical services, during regular working hours. 
Another limiting factor is the lack of progress in the transfer of clinical (diagnostic, test 
results) information between pharmacies and practices, which is an important factor in clinical 
and prescribing decision making. A large proportion of locums (The 2005 Pharmacy 
workforce census (Hassell 2006) found that locums represent over a third (37%) of all 
community pharmacists) may create additional difficulties for continuity of care and repeated 
contact with patients, both of which are important to monitor effectiveness and safety of 
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changes to medicines in primary care. A further (untested, fundamental) factor is whether 
patients and practices would be supportive of the concept and practicalities involved in 
community pharmacists delivering part of their chronic disease management on a shared basis 
between pharmacists and GPs.   
 
Meanwhile, community pharmacists are adapting to changing population demographics by 
expanding their roles to include advice on dispensed and over the counter medicines and self 
care. Community pharmacists have developed procedures for triaging: information gathering 
when responding to requests for advice that identify when the presenting problem can be 
managed within the pharmacy and when referral for medical advice is needed. A major policy 
shift supports this move – with the belief that costs are less and quality of care better if health 
professionals focus their efforts on prevention. There is growing emphasis on the pharmacist’s 
role as ‘first port of call’ in response to symptoms. This forms the core of a new contractual 
arrangement for pharmacists in Scotland (Scottish Government 2010).  
 
In parallel with these developments, the five year pharmacy undergraduate degree course 
includes a greater focus on improving students’ understanding and application of therapeutics.  
 
 
1.4.6          What has changed in pharmacy practice for patients with LTCs? 
 
In spite of all the policy drivers, organisational changes, shift in population demographics and 
disease burdens, the core functions for the majority of community pharmacists has remained: 
to safely provide medicines and advice to the public within registered premises. At present, 
pharmacists with clinical aspirations to prescribe and modify treatments for patients with 
LTCs working within Community Pharmacies remain few in number. There are likely to be 
proportionately more general practice based pharmacists applying their clinical skills e.g. 
prescribing, than community pharmacists.  
 
A new community pharmacy contract is operational in Scotland and the rest of the UK, with 
opportunities created for the delivery of clinical pharmacy skills and knowledge to improve 
the management of LTCs. However, at present, the majority of remuneration remains linked to 
prescription volume rather than introducing prescribing quality improvements or cost savings.  
 
Better long term evidence of effectiveness and efficiency would help underpin developing 
Pharmacy roles in community pharmacy and in general practice. As General practice based 
pharmacists’ roles are established and access to relevant clinical information is secured, it 
therefore makes sense to evaluate this model of care, to generate empirical evidence of impact 
and shape evidence based policy. Models of general practice based prescribing support will 
now be described.  
 
 
1.5 Overview and origins of pharmacist-led GP prescribing support in Primary Care 
 
1.5.1        ‘Rational’ prescribing and support 
 
Acknowledging variations in prescribing practice and that some prescribing decisions are 
more appropriate than others, the term ‘rational prescribing’ was introduced (Gilley 1994). It 
articulates the aim of ensuring “appropriate, safe, effective and economic” use of medicines 
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(Parish 1973) with some observers suggesting the aims should take into consideration the 
patient’s quality of life (Barber 1995).‘Prescribing support’ was therefore described as 
professional support to one or more of the components of the prescribing process, aiming to 
promote high quality, cost effective medicines use (Department of Health 1998). 
 
As expected from a process involving many inputs there are large variations in the extent and 
nature of prescribed medicines within and between practices. For example, variations in statin 
prescribing are well recognised, with studies explaining up to 20% of the variation (Packam 
1999; Majeed 2000; Gibson 2002; Bradshaw 1999; Ward 2007). Contributing factors include 
the prevalence of CHD, patient level deprivation and a combination of nitrate prescribing and 
age between 35 and 74 years. The assertion that up to 80% of patients consulting with their GP 
have common conditions that could be treated with similar medicines (Audit Commission 
1994) remains unproven. 
 
Prescribing support is indicated from a fiscal perspective. Factors contributing to a growth in 
drug expenditure include increases in spend on disease prophylaxis, high cost/new products 
for previously untreatable diseases, increased expectations from the public and media together 
with innovative marketing strategies from the pharmaceutical industry. All of these pressures 
lead to a greater need (or perceived need) for rational, cost effective prescribing. While GPs 
are independent contractors, NHS resources are used to pay for prescribing, which highlights 
the importance of the economic dimension (Avorn 1992; Panton 1993; Beard 1998).  
 
Programmes of prescribing support are intended to increase the rational use of medicines. 
Rational use should lead to decreased costs and improvements in the quality of care. The best 
case scenario is when both of these issues are addressed simultaneously, but it is difficult to 
choose a prescribing topic and prescribing support method which does both. There are 
examples of prescribing support initiatives that improve quality of care but increase costs, 
(Kreling 1989) and cost reduction programmes that lead to poorer quality of care (Bloom 
1985). One report found practice level pharmacist prescribing support to be cost effective, 
compared with no prescribing support, in the context of a controlled trial (Rodgers 1999). If 
prescribing support achieves stated aims it may provide a means of reducing the lag time 
between publication of clinical evidence and implementation of that evidence in practice 
(Burrel 1990; Getting evidence into practice 1998). 
 
 
1.5.2             Strategic prescribing advice  
 
In the late eighties and nineties, the responsibility for managing and financing prescribing 
budgets was devolved from some Health Boards and Health Authorities to practices, in a 
move to improve efficiency. Fiscal policies and incentives were introduced to bring about 
rapid change e.g. the Indicative Prescribing Scheme was introduced into the UK in the early 
1990s (Bligh 1992).  
 
Professional prescribing advisers were introduced, to raise awareness and communicate key 
messages on prescribing preferences. Those carrying out the role were medically or 
pharmaceutically trained. Their roles focussed on the promotion of rational, cost effective 
prescribing advice to GPs. Their approach to changing prescribing practice included meeting 
with GPs to discuss areas of prescribing, highlighting prescribing variation between practices 
and encouragement for practices to conduct prescribing audit. Practices’ prescribing trends 
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were summarised by the prescribing adviser (there was often a 3 – 6 month lag time in the 
availability of this information) and shared with the practice in advance of the meeting.  
 
Evaluation of the impact of this model of prescribing support is lacking, perhaps because a key 
part of the role aimed to raise awareness rather than effect direct change.  Prescribing advisers 
were based outwith practices and delivered strategic, general advice, without accessing patient 
level information. Therefore, only the GPs in the practice were aware of reasons for 
prescribing and their practice population’s demographics and health needs. This asymmetry of 
important background information possibly limited the relevance of the advice offered by the 
traditional prescribing advisers’ role.  
 
Methods adopted by prescribing advisers included many of the approaches known to be of 
variable effectiveness at bringing about prescribing change. These included facilitation of 
educational meetings, production of local bulletins, and passive dissemination of prescribing 
reports (Audit commission 1994). From available evaluation of the strategic prescribing 
advisory role, there is a lack of convincing evidence of effect (Harris 1984; Braybrook 1996; 
Newton –Syms 1992). However, the absence of evidence may not imply evidence of absence, 
because for many prescribers, a third party drawing attention to variations between their 
practice and that of others may have been a strong stimulus to change.  
        
 
1.5.3             Models of prescribing support  
 
Approaches to prescribing support have evolved in response to the changing needs of patients, 
GPs, the evidence base for management of targeted conditions and financial constraints. 
Service evaluations have shed some light on the apparent effectiveness of different models of 
prescribing support delivered by primary care pharmacists (Wilson 1997; Jesson 1997; 
National Prescribing Centre and NHS Executive 1998; Squires 1997; National Health Service 
Executive 1996).  However, due to a lack of adequate description of roles and methodological 
rigour in evaluation, much of the available published work has not clarified which models of 
support are effective and efficient. Inadequate design, lack of a control group, poorly defined 
interventions and an emphasis on process related outcomes limit the generalisability of 
findings and have led to a call for more rigorous comparative effectiveness research in this 
area (Beney 2004). 
 
 
1.5.4            Prescribing Support at practice level: prescribing support pharmacists 
 
Recognising the potential for improvements in patient care and prescribing efficiency through 
direct support to GPs, additional investment was made to deliver complementary prescribing 
support at GP, patient and practice level. This move aimed to bring about effective prescribing 
change together with cost savings, in addition to encouraging GPs to prescribe in line with the 
evidence. Better collaborative working between medical and pharmaceutical professionals was 
encouraged and Prescribing Support pharmacists were introduced into general practices. 
Methods included working in practices, with full access to patients’ medical and prescribing 
information at practice level, to ensure prescribing advice was tailored to practices’ and 
patients’ needs. This also helped translate prescribing decisions based on guideline or 
formulary advice into action at patient level. 
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There were some calls for more practice based pharmacists, because anecdotal evidence 
suggested they were able to reduce prescribing costs (Wells 1997; Wells 1998; Department of 
Health and NHS Institute for innovation and improvement 2007). Others have asserted that 
there are many ways to reduce prescribing costs without involving prescribing support 
pharmacists (Tant 1999).  
 
The methods adopted by General practice based pharmacists were diverse. So too are the 
terms used to describe the role. These have included “GP pharmacist” (Kempner 1996), 
“primary care pharmacist” (Marinker 1994) “clinical pharmacy service” (Who should provide 
a clinical pharmacy service to primary care?  1996) and “consultant or freelance pharmacist” 
(Powell 1997). By default, the role involves a pharmacist working with medical practitioners 
and others in the practice team. The core objective is to identify, with the practice, areas of 
prescribing in need of attention or support. The pharmacist gains agreement on how best to 
support the area of prescribing and bring about change. Methods include modification of 
prescribing mediated through presentations and patient or practice level reports, prescribing or 
clinical audits. All approaches aim to influence GPs, nurses or patients directly. Success is 
measured by cost saving, better adherence to clinical guidance or both. Being closer to the 
prescribing process also means that evaluation of impact was immediate: within 1-2 months of 
introducing or encouraging a prescribing change, a shift in prescribing could be detected 
through a search of the practice’s repeat prescribing on the practice computer system. This 
acted as a useful reinforcement to support subsequent prescribing change.  
 
 
6. Prescribing Support models 
 
The introduction of general practice based pharmacy prescribing support started during the GP 
fundholding era, when ‘early adopter’ practices contracted work on a sessional basis from 
freelance pharmacists or from NHS contractor pharmacists with a special interest in the 
clinical use of drugs in Primary Care. As Pharmacy led prescribing support models have 
evolved over the past 15 years, general descriptions of their characteristics, costs and benefits 
have appeared (National Prescribing Centre and NHS Executive 1998; Kempner 1996; Powell 
1997). The roles are not practised exclusively by pharmacists although the pharmacy 
profession has led the description (Jesson 1999).  Overall, the quality of evaluation varied and 
as is often the case with innovations in health care delivery, questions of reproducibility, 
effectiveness and value for money remained unanswered (Soumerai 1990; Soumerai 1989; 
Haaijer-Ruskamp 1995). 
 
There are few scientifically rigorous studies of the effectiveness of prescribing support models 
other than medication review, in Primary Care. They appear as a subset of the larger body of 
research involving educational and other interventions that aim to change health professionals’ 
behaviour (Thomson 2002; Oxman 1995; Davis 1995). One review of evidence on the impact 
of pharmacists providing a prescription review and monitoring service in primary care 
suggested improvement in patients’ clinical status and suggested reduced prescribing costs, 
while acknowledging the need for further research to confirm these findings (Tully 2000). The 
NHS Centre for Reviews and Dissemination subsequently disagreed with the authors’ 
suggestions of the likely effectiveness of pharmacists’ prescription review and monitoring 
activities, but agreed on the need for future research in this area. Further, the NHS centre 
recommended more independent and blinded outcome assessment, use of comparison groups 
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and appropriate statistical analysis in future research (NHS Centre for Reviews and 
Dissemination 2004).  
 
 
1.6.1        Requirements for the delivery of prescribing support 
 
There is no agreed guidance on the minimum skills and knowledge of pharmacists who are 
asked to deliver Prescribing Support roles. However, the training needs of pharmacists to 
deliver clinical support to patients within general practices and bespoke training programmes 
have been described (Webb 1998; Sykes 1997). These include developed clinical, analytical 
and communication skills, for pharmacists with no prior experience in the clinical use and 
review of drugs (Speak 1998).   
 
However, as might be expected for any developmental role, the nature of the working 
relationship and the conditions of employment varied, as did tenure and remuneration. In most 
cases, the pharmacist was recognised as a member of the practice staff, attending the practice 
on a full or part time basis, regularly e.g. one day per week (Lacey 1998). In Glasgow, the 
norm was (and remains), for pharmacists to work in the same practice, one day per week.  
 
An adequate description of prescribing support aims and key models is important, as this 
enables appraisal of effectiveness. Therefore, the remainder of this chapter draws on available 
literature and some personal experience of the following prescribing support models delivered 
in the UK over the past 15 years:  
 
• Pharmacist-led clinical medication review; 
• Passive dissemination of prescribing information; 
• Prescribing audit, analysis and feedback; 
• Prescribing formularies; 
• Academic detailing / educational outreach.  
 
The model described as ‘educational outreach’ or ‘academic detailing’ will be considered fully 
in Chapter 2 and subsequent chapters, because of all the above, it is the model most closely 
aligned to the new model developed and tested in the trial described in this thesis.   
 
 
1.6.2     Pharmacist-led clinical medication review 
 
1.6.2.1   Definition and delivery 
 
Clinical medication review is a process where ‘a person with knowledge of medicines reviews 
the patient, their medicines and their clinical diagnoses during a consultation’ ( Mackie 1999).  
Clinical medication review usually takes place during a face to face consultation. It involves 
evaluating the therapeutic efficacy of each prescribed or ‘over the counter’ drug, eliciting the 
patient’s unmet (medicine related) needs and minimising costs associated with prescribing. 
Other issues such as adherence, potential adverse effects, interactions and the patient’s 
understanding of their conditions and treatment are considered during the consultation.  
Another definition comes from the Task Force on Medicines partnership and the National 
Collaborative Medicines Management Services programme “a structured critical examination 
of a patient’s medicines with the objective of reaching an agreement with the patient about 
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treatment, optimising the impact of medicines, minimising the number of medicine related 
problems and reducing waste” (Medicines Partnership and The National Collaborative 
Medicines Management Services Programme 2002). From experience in Glasgow, it 
commonly takes place in the general practice or patients’ home, lasts up to an hour, depending 
on the complexity of the case and the pharmacist’s skill and knowledge set. Pharmacists are 
ideally placed to conduct medication reviews because it demands a combination of drug based 
clinical and technical knowledge of prescriptions and the prescribing process. It is valued by 
the NHS because it is thought to save money and improve the quality of prescribing (NHS 
Executive 1999). Although not necessary, access to full medical records and a face to face 
consultation with the patient is preferred, because there appears to be an evidence base in 
favour of accessing these data, and / or the collaboration that brings (Holland 2007b, Koshman 
2008).   
 
When a medication review aims only to detect and reduce waste from repeat prescribing, there 
may not be any need for a consultation with the patient, nor any need to access medical 
records, and no need for a pharmacist with additional skills and knowledge of the clinical use 
of medicines. When a consultation takes place, the review has been described as a ‘Brown Bag 
review’ because patients were posted an appointment with an empty brown bag enclosed, then 
asked to put all their medicines inside the bag and bring it along to discuss with the pharmacist 
at an appointment in the practice. The main part of such a review is a reconciliation of 
prescribed versus supplied medicines. Evaluation of this type of review led to estimates of 500 
tonnes of medicines wasted in England every year, worth approximately £100 million (Gilles-
Burness 1999). 
       
 
1.6.2.2    GP and patient views of medication review 
 
GP views on medication review are generally favourable, with the following benefits 
described by GPs who have had exposure to the service: improved prescribing practice, raised 
standards of patient care and patient satisfaction, increased GP knowledge and confidence, 
decreased workload, better multi-disciplinary working and communication (MacRae 2003a).  
It is popular with patients because it creates the protected time to ask questions about 
treatment (MacRae 2003b).   
 
 
1.6.2.3     Medicine reviews in context  
 
In view of the epidemic of LTCs (WHO 2005) and poor compliance with medicines (Haynes 
2008), medication review is seen as an important component of the broader issue of medicines 
management (the processes aiming to ensure medicines are used effectively). In the UK, as 
part of the National Prescribing Centre, the Medicines Management Services Collaborative 
has focussed on repeat prescribing systems and medication review as key areas for 
improvement (Medicines Management Services Collaborative 2001). The need for clinical 
medication review has entered into policy documents e.g. the National Service Framework for 
older people proposed that patients over the age of 75 should have their repeat medicines 
reviewed annually and those on 4 or more medicines twice yearly (Department of Health 
2001). Medication reviews are currently remunerated within the GP contract Quality and 
Outcomes Framework (QOF) (The NHS Confederation 2002). However, a relatively 
superficial review is incentivised through the QOF; it does not require the patient to be 
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engaged directly. Instead, the review can be paper or computer based, without patient 
involvement.  
 
 
1.6.2.4      Effectiveness of polypharmacy medication review  
 
There is good evidence from randomised controlled trials to support the effectiveness of 
pharmacist-led medication reviews for patients receiving polypharmacy. Effectiveness has 
been measured as the identification and resolution of drug related problems, improved 
compliance, better adherence with prescribing guidance, reduced need for GP consultations, 
improved patient knowledge of medicines or a reduction in polypharmacy and cost 
(Zermansky 2001; Mackie 1999; Krska 2001; Granas 1999; Forrest 1999; Petty 2001; 
Jameson 1995). When effectiveness criteria have included other endpoints e.g. prevention of 
hospitalisations, clinical events or delaying mortality, medication review is not yet proven 
(Holland 2007; Lowrie 2011).   
          
 
1.6.2.5       Collaborative disease management clinics  
 
When reviews are targeted at subgroups of patients with particular LTCs, outcomes appear 
more favourable (Suksomboon 2002; Soorapan 2002; Peterson 2004). However, as anticipated 
with any complex intervention evaluation, differences in the intervention characteristics and 
the organisational context in which the intervention is delivered have a bearing on efficacy. A 
recent systematic review underscored the importance of context in relation to pharmacists’ 
activities for patients with heart failure (Koshman 2008).  Pharmacist directed care 
(pharmacist initiated and managed medication review with little or no integration with the 
team based approach) was found to be less effective than pharmacist collaborative care 
(medication review as part of a multidisciplinary team approach). Collaboration appeared to 
enhance the effect of pharmacists’ reviews for patients with heart failure (Gattis 1999; Triller 
2007; Rainville 1999) and this finding is consistent with collaborative, team based review and 
intervention to prevent elderly, community dwelling people falling ( Zermansky 2006; Keys 
2004; Kannus 2005; National Osteoporosis Society 2002; Marsh 2003; American Geriatrics 
Society 2001; Hill-Westmorland 2002).   
 
Descriptions of the medication review process (duration, intensity, number of contacts per 
patient, training and experience of each pharmacist) and the healthcare environments in which 
the studies took place (primary/secondary care or at the interface, across different healthcare 
systems) are sufficient to enable generalisation of the results. Over time, outcomes have 
changed from numbers of drug related problems identified and resolved to hospitalisations 
prevented. This shift possibly reflects the medication review model gaining in maturity 
together with a growing need to demonstrate added value in terms of reduced hospitalisations 
for people with LTCs.  
 
Lessons from these observations include: 
 
• The importance of capturing drug, intermediate clinical e.g. cholesterol or blood 
pressure readings, and health service utilisation outcomes if possible;  
• Careful choice of the patient population;  
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• A clear description of the nature, intensity, duration and organisational context in 
which the intervention takes place; 
• An evaluation of the costs of delivering the intervention and impact on medication 
adherence;  
• Collaborative working and capturing, describing and valuing the contributions of the 
wider healthcare team;   
• Focus on a topic of importance, where there are recognised shortfalls in the quality of 
care; 
• Providing an intense intervention with long enough duration to achieve behavioural 
change. 
 
If more attention is given to these features, the chances of a longer term, positive impact is 
more likely. It is also important to pre-specify any anticipated unintended consequences in 
testing a new intervention; not many of the trials reported this. These features are likely to 
apply equally to the new intervention described and tested in this thesis. 
 
 
1.6.3      Passive dissemination of prescribing information 
 
Unsolicited, passive dissemination of printed educational material is characterised by a lack of 
targeting of the message or assessment of the educational needs of the recipient. The approach 
is thought to be relatively ineffective as a means of changing healthcare professionals’ 
behaviour according to a Cochrane Review on the subject (Freemantle 2005). While there 
were only 11 studies fitting the criteria for inclusion in the review, evaluation of their 
combined impact was impractical because of the poor reporting of results and inappropriate 
primary analyses.  
 
Much of the research in this area relates to the dissemination of prescribing guidelines, or 
clinical guidelines (‘systematically developed statements to assist practitioner decisions about 
appropriate healthcare for specific clinical circumstances’) (Institute of Medicine 1990).  
 
Passive dissemination of prescribing guidelines may act to raise awareness which may help 
pave the way for change at an individual level (Soumerai 1990; Denig 1990; Implementing 
clinical guidelines: can guidelines be used to improve clinical practice? 1994). However, 
some individual studies indicate that there is no significant change in GP’s attitudes and 
knowledge following direct mailing of consensus statements (Hunskaar 1996) or guiding 
prescribing decisions e.g. prescribing of antibiotics for acute conditions (Schaffner 1983).  
Davis reviewed the literature on different forms of prescribing support and concluded that 
commonly used methods of delivering education, such as conferences, have only limited 
impact on improving professional practice (Davis 1995).  
 
Of direct relevance to this thesis is the finding that publishing and distributing national 
guidelines on cholesterol management (focussing on the use of statins and dietary measures), 
does not appear to have contributed to changing doctors’ approaches to management (Sempos 
1993). However one report suggested that a simple, passive educational intervention can 
change prescribing behaviour, compared with feedback and education (Schectman 1995). In 
addition, it is thought that the publication of major trials heralding a significant shift in 
prescribing trends may lead to changes in prescribing (Muhammad 2001). Muhammad 
investigated whether the publication of three landmark statin trials were associated with an 
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increase in the market share of statins in Canada and found a study specific effect, post trial 
publication. However, the strength of this evidence was weak: their study lacked a control 
group and did not account for confounding. 
 
It stands to reason that strategies most likely to change practice are those which are actively 
communicated, underpinned and shaped by behavioural change and adult learning theory (Foy 
2001).  
 
It should be remembered that conferences, presentations and distribution of clinical guidelines 
may not aim to change professional practice. Instead, they may aim only to increase awareness 
of a particular topic, which in turn may create a better starting point for introduction of more 
active dissemination strategies to facilitate change, at some point in the future. In fact, there is 
some suggestion that the distribution of bulletins through post or email is a low cost approach 
and any small effects may be worthwhile in the long run (Soumerai 1986). One study in North 
America showed passive dissemination, in addition to educational outreach, improved 
marginal cost effectiveness (Soumerai 1986). The principle of combining different models to 
achieve a more powerful effect is analogous to the collaborative approach described in studies 
of medication review, and will be used in the intervention described in this thesis. 
 
Another prescribing support model combining passive dissemination with more tailored 
approaches is the use of postal prompts to GPs, for named patients. In a London based study, 
Feder et al trialled this approach, to improve cholesterol measurement together with the 
prescribing of Beta Blockers and statins, for patients who had recently been discharged from 
hospital after a coronary event. Their intervention increased the proportion of patients 
attending for cholesterol checks at their practice but failed to improve prescribing (Feder 
1999). 
 
 
1.6.4      Prescribing audit, analysis and feedback 
 
In general, published audit work in healthcare settings has focussed on standards of clinical 
practice or diagnostic performance rather than prescribing (Mugford 1991; Buntix 1993).     
Prescribing audit is the systematic, critical analysis of the quality of prescribing. It does not 
make inferences about the quality of life for the patient, but it can be used to estimate the 
population level impact of evidence based prescribing choices. For example, prescribing of 
angiotensin converting enzyme inhibitors (known to be effective and cost effective for heart 
failure due to left ventricular systolic dysfunction) may vary significantly across different 
practices. If the practices have similar demographics and access to effective services, then 
excluding any other justifiable reasons for the difference, prescribing audit enables recognition 
of what is feasible and a starting point for improvement.  
 
The Cochrane Collaboration assessed the effects of audit and feedback on healthcare 
professionals’ prescribing and patient outcomes. They found it to be effective, but only 
moderately so. One interacting factor consistently shown to predict the effectiveness of 
prescribing audit across studies was baseline non-compliance with recommended prescribing 
(absolute effects likely to be greater) (Jamtvelt 2005). This might be expected, because there 
may be more scope for change if the starting point is lower. 
 
  
20 
Practice level summary and analysis of prescribing data has been used to compare the 
prescribing of medicines between general practices, but the impact requires to be evaluated 
beyond the short term and include a comparator group (Harris 1993). Prescribing audit creates 
an opportunity for discussion and feedback on the reasons for prescribing variance and 
departures from ‘best’ practice. One study showed it to be effective and more efficient than 
educational outreach (Anderson 1996). 
 
Prescribing audit is a useful means of differentiating between established and best practice. In 
some cases, raising awareness of these differences during a face to face meeting may be 
sufficient to trigger a change in prescribing, but evidence is lacking for this effect. Perhaps the 
best approach is to combine it with several other models, again, to reinforce the 
communication of a message, in much the same way that multidisciplinary teams work 
together to achieve a more pronounced effect than uni-professional, solo efforts. One 
evaluation of prescribing audit delivered by community pharmacists (who worked on a 
sessional basis within General practices) showed cost savings and reported improved levels of 
communication and co-operation between GPs and community pharmacists. GPs also felt that 
the quality of the meetings was superior to other local postgraduate events (Pilling 1998). 
 
‘Prescribing indicators’ are now in common use across the UK. These are derived from 
prescribing audit and are set thresholds of prescribing of targeted medicines e.g. the least 
expensive bisphosphonate from the available options sharing the same indication. While 
opinions vary as to the suitability of some indicators (Asworth 2002), if a practice achieves 
their indicator threshold, a payment is triggered. This incentive to the practice is smaller than 
the savings generated as a result of the change in use the drug under question. While there is 
very little empirical evidence of the impact of such schemes on quality improvement, they are 
known to change prescribing, in the same way as evidence based prescribing for targeted 
LTCs has improved as a result of financial incentivisation through the new GMS contract 
(Roland 2004).   
 
Overall, there are few scientific assessments of the effectiveness of prescribing audit, and 
significant variation in the nature, intensity and delivery mechanisms, thus limiting 
transferability of the model as a tool for prescribing support. However, there may be merit in 
combining this with other approaches. As an example of this, Eccles showed that routine 
attachment of educational reminder messages by reporting software or coloured stickers (in 
addition to audit and feedback) was effective in changing radiology referrals (Eccles 2001). 
This study highlights one of the difficulties in evaluating studies of audit and feedback: 
describing the intervention and context sufficiently to enable appraisal.  
 
 
1.6.5      Prescribing formularies 
 
Formularies are a limited range of medicines for specified conditions. The medicines are 
chosen on the basis of clinical evidence of relative efficacy and relative cost. The main reasons 
for using formularies are to promote rational prescribing and limit costs (Jolles 1981; Reilly 
1989; Greenfield 1982; Department of Health 1990; Harding 1985; McGavock 1990) 
Formularies are designed to encourage the uptake of more effective prescribing (clinically and 
economically). They are also seen as a mechanism for quality improvement in general practice 
(Roland 1998).  
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A systematic review concluded that there is insufficient robust evidence to justify the use of 
formularies per se, or involvement in their development, as an effective model of modifying 
prescribing behaviour (Pearson 2003). Methodological weaknesses limited the usefulness of 
the authors’ conclusions. One report (only available as a supplement) described the use of 
“closed formularies” (a tighter list of options restricting choice to a bare minimum with non 
formulary prescribing disabled through computerised restrictions) combined with several other 
approaches e.g. academic detailing, and reported effectiveness (Sbarbaro 2001). 
 
 
1.6.6      Academic detailing (Educational Outreach) 
 
The original published account of “academic” detailing can be traced to a paper by Avorn and 
Soumerai in 1983 and then seven years later (Soumerai, Avorn 1990). The authors described 
in detail a technique for influencing prescribing behaviour and applied it across four states in 
North America in a randomised controlled trial. ‘Detailers’ (pharmacists with additional, 
clinical and communication skills), met with physicians in their workplace to communicate 
‘balanced, unbiased prescribing information’. The physicians were targeted because of their 
high use of apparently inappropriate medicines. The magnitude of the impact of the model was 
highly significant (14% reduction in prescribing of targeted drugs compared with controls; p = 
0.0001) compared with other studies of prescribing change. A comparable reduction was seen 
in drug costs (however a full cost effectiveness analysis was not conducted). The effect 
persisted for nine months after the start of the intervention. Since then, many investigators 
have tried variants of this model with different degrees of success.  
 
An ‘outreach visit’ is a term used to describe a personal visit by a trained professional to a 
health provider in his or her own practice, to improve the practice of health care professionals. 
(Braybrook 1996; Newton-Syms 1992). Several therapeutic areas have been targeted for 
change through outreach visits, and simple issues generally can be influenced through single 
visits to practices (Braybrook 1996; Newton-Syms 1992; Ekedahl 1994). It follows that more 
complex or multiple issues relating to prescribing may require more than one outreach visit or 
exploration of reasons for current prescribing practice, before any attempt is made to influence 
change through a single visit. However, the content, context, nature of the outreach visit, 
duration, training of the professional providing the support or the characteristics of the GP 
receiving the support are not well described. A Cochrane Review of the effects of outreach 
visits on health professional practice or patient outcomes commented on their promising 
effects, but stressed the need to ascertain the key characteristics of outreach visits that are 
important to success (Thomson 2002). 
 
The views of physicians receiving the intervention are not well chronicled: one report could be 
found in abstract form only, which related to work done in UK nursing homes by Boardman in 
1999. GPs and nursing home staff who received the programme reported that it was well 
received with nearly half of those GPs mentioning that it had directly influenced their 
prescribing. Overall the programme was viewed as important and useful (Boardman 1999).  
 
A new model of prescribing support could try to incorporate the theoretical principles 
described by Mullen and Cooper in their review of educational interventions (Mullen 1985; 
Cooper 2001). However Davis suggested that there are difficulties inherent in linking research 
findings to theories of behavioural change (Davis 1995). 
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Combining the learning from evaluation of educational outreach with learning from other 
prescribing support models, it would make sense for NHS pharmacists delivering outreach to 
diagnose practice and GP level barriers to prescribing change. These barriers (described in 
more detail in Chapter 2) can originate from the GP, practice organisation e.g. approach to 
call/recall, patients or prescribing guidance. As clinical practitioners with access to patient 
level information and experience reviewing patients’ medicines in primary care, practice based 
pharmacists can understand and empathise with GPs and practice nurses in the reasons why 
the evidence is not always implemented. Different barriers are likely to arise in different 
practices; therefore separate strategies could be used to address these barriers. Combinations 
of prescribing support models appear more effective than more simple models, and the lack of 
clear evidence of which models are effective, suggests the need to generate a new model by 
combining existing approaches, define it, pilot it then test it.  
 
An in depth review of the evidence for and against educational outreach/detailing is covered in 
Chapter 2, together with distillation of the implications for research and description of how the 
lessons learned have been incorporated into the SOS intervention model and trial.   
 
 
1.7     Therapeutic uses of statins in vascular disease 
 
Optimal drug based management of cardiovascular disease is important because it can reduce 
the risk of clinical events and delay early death. The management of dyslipidaemia has an 
important role in the reduction of these risks. Statins have revolutionised dyslipidaemia 
management and in the process, reduced the risk of morbidity and mortality in patients with 
coronary, cerebrovascular and peripheral vascular disease (Scandinavian Simvastatin Survival 
Study Group 1994; Sacks 1996; LIPID study group 1998; Shepherd 1995; Downs 1998; Heart 
Protection Study Collaborative Group 2002). The mean reduction in cholesterol was 25%, 
which resulted in clinically significant benefit. Contra-indications are limited to active liver 
disease, pregnancy and breast-feeding. 
 
Simvastatin is regarded as the treatment of choice in the secondary prevention of CHD within 
the UK population (Phillips 2000). Generic simvastatin is the least expensive and can achieve 
cholesterol control in the vast majority of patients, if prescribed at 40mg daily dose (HPS, 
Scandanavian Simvastatin Survival Study Group (4S) 1994). In terms of spend; statins 
represent the largest drug cost to the NHS (£738 million in 2004). It has been estimated that 
using simvastatin instead of more expensive alternatives e.g. Atorvastatin could save the NHS 
£1.1 billion over 5 years (Moon 2006) without any detrimental effects.  In Primary Care in 
Glasgow during 2005 there were more than 600,000 prescriptions for statins at a total cost of 
over £12 million; one fifth of which could be saved if simvastatin was used instead of the 
other prescribed statins. If a new approach to improving statin prescribing can be introduced, 
cholesterol levels at the individual level are likely to decrease. In the longer term (at 3 - 5 
years after daily use of a statin) clinical events are likely to become less frequent in those 
treated. If 19 patients with vascular disease (Appendix III) receive a statin (e.g. simvastatin 
40mg for 5 years) then it is likely that one major vascular event e.g. a myocardial infarction, 
will be prevented irrespective of the extent to which cholesterol levels are reduced.   
 
As a result, many clinical guidelines have summarised these findings with a view to changing 
prescribing practice accordingly.  
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1.7.1      The basis for clinical guidance on statins 
 
Prevention of atherosclerotic vascular disease requires control of all known risk factors e.g. 
smoking, hypertension, and glucose control. No single risk factor, including cholesterol level, 
should be viewed in isolation. While support for health related behavioural change (e.g. 
obesity, diet, physical activity, alcohol) should be offered at population and individual level, 
attention has focussed on statins, because they are more effective and efficient at reducing 
cholesterol and have the greatest measurable impact on clinical outcomes. The pathogenesis of 
atherosclerosis and the mechanism of action of statins are described in Appendix I.  
 
It is known that many more patients than those currently treated, could benefit from statins if 
they were offered them. However, resources are finite and in an example of the law of 
diminishing returns, benefits diminish as the estimated risk of suffering an event decreases. 
Trials which included patients at highest risk (i.e. with the highest end point rate in the placebo 
control arm) showed the greatest absolute risk reduction. For practical and economic reasons, 
the use of statins is therefore recommended only for patients who are at high risk and set to 
gain most.  
 
For patients who do not have any evidence of established vascular disease, the aim is to 
prevent the onset of a first coronary event e.g. heart attack. This approach is called primary 
prevention and emphasis is given to identifying patients at high-risk of developing 
atherosclerotic vascular disease, as they obtain greater benefit from treatment with a statin. A 
coronary event rate of 30% at 10 years (i.e. 3% per year) has been advised as the threshold for 
treatment. It is now recommended that risk stratification should be carried out using the Joint 
British Societies’ ‘Cardiovascular disease Risk Prediction Charts’ (British Cardiac Society, 
British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British 
Diabetic Association 1998) (Appendix II). This is the tool recommended by the Scottish 
Intercollegiate Guidelines Network (SIGN; Guideline 40). Cardiovascular disease risk takes 
account of the risk of stroke in addition to coronary heart disease risk for primary prevention. 
 
Secondary prevention includes patients with established vascular disease (coronary artery 
bypass graft (CABG), MI, Stroke, IHD, TIA, Angioplasty and peripheral vascular disease) and 
those with diabetes aged 40 years or above. All these groups should be offered a statin 
regardless of cholesterol concentrations, a recommendation based on the Heart Protection 
Study (HPS) (HPS Collaborative Group 2002).  Appendix III describes the respective risk 
categories for each subgroup, derived from the HPS and Chapter 2 describes a critical 
appraisal of the HPS. It was felt to have the greatest implications for immediate changes in 
clinical practice, and therefore, previous guidelines (UK, European and North American - 
Appendix IV) were updated in the year following publication of the study. 
 
This sudden change in recommended prescribing practice created the opportunity to test a 
novel intervention aiming to improve the use of statins in line with the new guidance, for those 
at greatest risk.   
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1.7.2       The need for better statin prescribing  
 
In response to growing acknowledgement of the benefits, their prescribing has increased more 
dramatically than most other medicines (Ramsay 2006; Bull 2003). However, this generates 
three linked questions: 
 
1. Of those with established vascular disease, are all eligible patients receiving a statin 
at the right dose? If not, what can be done to improve uptake of adequate prescribing 
and dosing? 
2. Can pharmacists based in practices turn their attention to improving uptake, through 
a model of prescribing support?  
3. Can this work be adequately described and tested, to ensure a robust answer to these 
questions? 
 
Based on the review of prescribing support models described above, there are no ‘off the 
shelf’ interventions to ensure maximal uptake of statin prescribing guidance. This argues for 
innovation in the design and application of a novel intervention, the testing of which forms the 
focus of this thesis.  
 
 
1.7.3      The need for better evidence of (Pharmacy led) improvements to prescribing 
 
Primary care needs more implementation research because of the variability in uptake of 
robust clinical evidence and the negative impact on effectiveness and efficiency of patient care 
resulting from this (Foy 2001). To date, qualitative research involving GPs has improved our 
understanding of possible reasons why clinical evidence may not translate into practice 
(Veldhuis 1998; McColl 1998; Freeman 2001; Sweeney 1998). Together, these reports and 
others (Hemminiki 1975; Avorn 1982; Bradley 1991; Virji 1991; McGavock 1993; Britten 
1995) suggest:  
 
1. A wide range of factors have been shown to influence the prescribing decision 
making process and many of these are independent of the acceptability or availability 
of clinical evidence; 
2. The evidence based model cannot be assumed to be robust;  
3. Practical issues e.g. time constraints to learn about new evidence and systematically 
apply it in practice, limit the application of some evidence-based prescribing 
guidelines.  
 
Therefore, in devising a prescribing support model, these points should be addressed.  
 
 
1.8      Could educational outreach help improve statin prescribing? 
   
There is a recognised need to evaluate the effectiveness of outcomes from outreach visits in 
terms of clinical outcomes whenever possible (Thomson 2002). If this is not possible, 
surrogate clinical outcomes could be used, particularly in cases where there is a robust link 
between clinical outcomes and the surrogate end point e.g. HbA1c, blood pressure, cholesterol 
levels. A strong link exists between cardiovascular, cerebrovascular and peripheral vascular 
morbidity/mortality and the use of statins (Scandinavian Simvastatin Survival Study Group 
1994; Sacks 1996; LIPID study group 1998; Shepherd 1995; Downs 1998; Heart Protection 
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Study Collaborative Group 2002). Educational outreach appears to be a promising way of 
delivering quality improvements in prescribing, but at present, there is insufficient evidence to 
enable routine application as a means of improving prescribing beyond 1 year, improving 
statin prescribing and clinical or surrogate clinical outcomes. Reasons for this include: 
 
• Inadequate description of the components of interventions; 
• Inadequate description of training and qualifications of those delivering the model; 
• Lack of pragmatic endpoints other than prescribing  
• Unknown efficiency;  
• Lack of generalisability of existing evidence;  
• Weaknesses in choice of methodology and analysis. 
 
 
1.9       The need for this research 
 
Pharmacists working in general practices provide education, counselling, drug use review and 
non dispensing services. The effectiveness of these services has been investigated for many 
years, but most studies in the field have been of poor quality e.g. only 23 of 104 studies 
reviewed in 1993 by Hatoum and Akhras included a control group (Hatoum 1993).  Morrison 
and Wertheimer updated the summary of the evidence in 2001 with a quantitative evaluation 
of randomised trials of counselling, education and other clinical services (Morrison 2001). 
Together, there was no robust evidence from the UK or North America of the benefits of 
pharmacists interacting with GPs, aiming to change prescribing with evaluation of clinical or 
surrogate clinical outcomes.  
 
This thesis aims to describe a pragmatic randomised controlled trial of a new type of 
educational outreach intervention delivered by pharmacists to GPs and practice nurses. The 
intervention aims to improve the appropriate prescribing of statins in primary care for patients 
at highest risk of a clinical event. Both the intervention and trial design are constructed to 
address shortfalls in the evidence base.  
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1.10      Potential importance of this work 
 
It remains the case, 20 years after prescribing support and new pharmacy roles were 
introduced, that there is very little evidence that the new roles adopted by pharmacists can 
impact significantly on population health in the long term or costs. This lack of empirical 
evidence may not pose a problem per se, but when decisions need to be made on how best to 
develop services when a new prescribing drive needs to be implemented, or scale back 
services in times of austerity, reference to an evidence base for prescribing support becomes 
important. 
 
In designing and testing an intervention to focus on statins and increase their appropriate use, 
this study has the potential to inform pharmacy developments in primary care, and improve 
population health.  
 
Chapter 2 describes the case for focussing on statins in more detail, and uses the lessons from 
previous research to: 
  
• develop a new prescribing support model;  
• design an appropriate trial to test the model. 
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Chapter 2 
 
Literature review 
 
This literature review includes relevant articles from the published and grey literature until 
February 2004, at which point the study design was in place and delivery of the SOS 
intervention had commenced. Learning from literature post 2004 is incorporated into Chapter 
6. 
 
The synopsis of the literature review is an appraisal of:  
 
1. Statins and the MRC/BHF Heart Protection Study (HPS) to clarify the strength of 
evidence for simvastatin 40mg prescribing, and the need for quality and efficiency 
improvements in statin prescribing in primary care. 
 
 
2. Educational outreach focussing on prescribing/related topics, designed to change practice, 
particularly those involving pharmacists. The literature was searched to identify key 
information and lessons from previous work that would prevent a repeat of any previous work 
and add to the body of research in the area of Statins, educational outreach, cluster randomised 
controlled trials and pharmacy.  
 
 
3. Design features of educational outreach trials because methodological shortfalls are 
common in previous outreach type trials, our trial methodology needs to be robust. 
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2.1 Literature review methods 
 
 
2.1.1    Systematic search of electronic databases 
 
Databases were searched from their inception until February 2004 although the actual date 
varied depending on the database e.g. for Medline, search period was 1966 to Jan 2004. The 
following were also searched: British Nursing Index, Pharmline, ERIC, IPA, CINAHL, EBM 
reviews from Cochrane Register of Controlled Trials, EBM Reviews, NPCRDC, SIGN, NICE, 
Cochrane Database of Systematic Reviews, EMBASE, National Research Register, 
PsychINFO and the Effective Healthcare Bulletin.  
 
Selected expert searches (filters) were constructed to increase selectivity and specificity. For 
the MEDLINE search these included SIGN Medline economics, SIGN Medline systematic 
reviews and SIGN Medline randomised controlled trial filters. The SIGN EMBASE and 
CINAHL economic, systematic review and randomised controlled trial filters were applied to 
the CINAHL and EMBASE database searches respectively. The search strategy used in the 
MEDLINE search was first run in 2003 then repeated automatically on the first day of each 
month until October 2011 using an ‘Autoalert’ function which updated the search on the 
specified databases on the first day of each subsequent month. Evidence gathered until 
February 2004 only was incorporated into this literature review.  
 
 
Search terms 
 
In general, electronic searches were constructed using search terms derived from the following 
keywords or synonyms: prescribing, drugs, medical education, academic detailing, facilitation, 
outreach visits, primary care, pharmacists, nurses, general practitioners. If a combination of 
terms generated a large number of citations, the keyword ‘statin’ was used. Mapping was used 
to help find relevant subject headings in databases where ‘Map term to subject heading’ was 
available. When this function was not available, the keywords were entered into the keyword 
fields for that database. All literature searching was limited to human and English language. 
As an example, the sequence of keywords used in the MEDLINE search is given in Appendix 
V. 
 
 
2.1.2     Ad hoc searches 
 
The National Electronic Library of Medicines (www.nelm.nhs.uk/home/default.aspx; part of 
the National Electronic Library for Health) generated an update twice weekly on current 
research and opinion relating to medicines, public health, prescribing practice focus and 
cardiovascular disease.  
 
The British Medical Journal runs an electronic messaging service relating to published 
research and comment. Through this, the following weekly citations were received and 
appraised:  
 
• general practice/Family practice/primary care: Health Services Research 
(http://bmj.com/cgi/collection/health_serv_reasearch?ecoll);  
• Non clinical: health economics; 
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• Statistics and research methods. This highlighted descriptions and examples of 
randomised controlled trials and systematic reviews.  
 
Bandolier’s back catalogue was searched using appropriate keywords (www.jr2.ox.ac.uk/cgi-
bin/htsearch ).  
 
 
Hand searches 
 
These included ‘The Pharmaceutical Journal’ on a weekly and ‘Pharmacy in Practice’ on a 
monthly basis. 
 
 
2.1.3      Selection of relevant articles 
 
Titles and abstracts from search strategies were screened for suitability. Some articles 
contained new information about statins or new learning on study methodology and were 
retained on that basis. If a title or abstract was not rejected, the full text was obtained for 
further evaluation. Bibliographies cited in screened articles were considered and relevant 
articles appraised as described below. 
 
 
2.1.4     Critical appraisal of relevant studies 
 
There are known to be difficulties in the funding, design and execution of trials of educational 
or complex interventions, which may increase the likelihood of there being methodological or 
analytical weaknesses (Foy 2001; O’Brien 2002). Therefore a systematic, rigorous approach 
was taken to interpret the scientific papers identified as most relevant to the study.  When 
necessary, one the following checklists were used:  
 
• for educational interventions, the checklist derived from the Educational Group 
on Guidelines on Evaluation (Educational Group on Guidelines on Evaluation 
1999) and the work by Morrison (Morrison 1999); 
• for randomised controlled trials, the checklist adapted from ‘Critical Appraisal 
Skills Programme (CASP)’ (Guyatt 1993a and b).  
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2.1.5  Examples of electronic search outputs  
 
Table 2.1 shows the number of articles generated by a sample of search strategies.  
Table 2.1 Summary of outputs from electronic searches 
 
Database Number of articles  
MEDLINE  
 
62 (search #1 see below) 
4 (search #2 see below) 
Psychinfo 8 (see below) 
CINAHL 52 
EMBASE 105 
Cochrane 1 
Pharmline and IPA 18 
NRR 7 
BNI 7 
EBM reviews – Cochrane Central Register of 
Controlled trials 
87 
EBM reviews – Cochrane Database of systematic 
reviews 
25 
ERIC 0 
 
Figure 1.1 gives the setup and outputs of selected search strategies. Search terms varied 
according to the database.  
 
Figure 1.1   MEDLINE search #1 
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 Figure 1.2       MEDLINE search # 2  
 
 
Figure 1.3       PsychINFO search 
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While many of the manuscripts identified through systematic electronic searches were 
relevant, other highly relevant papers or reports were identified directly or indirectly through 
the ad hoc searches described above. All relevant articles from the systematic and ad hoc 
literature review were then reviewed together. Findings from the most informative articles 
dated on or before February 2004 are described below.  
 
 
2.2  Statins 
 
2.2.1 Overview of evidence for effectiveness in secondary prevention 
 
There is an overwhelming body of evidence in favour of prescribing a statin for patients at 
sufficiently high risk of suffering a vascular event (typically, patients with established 
cardiovascular disease are considered to be at highest risk)  (Scandinavian Simvastatin 
Survival Study Group 1994; Sacks 1996; LIPID 1998; Shepherd 1995; Downs 1998; Veterans 
Affairs High Density Lipoprotein Cholesterol Intervention Trial Study Group (VAHIT) 1999; 
PROSPER study group 2002; Heart Protection Study Collaborative Group 2002). Prior to 
2002, the only remaining uncertainty surrounded whether some subgroups of patients, who 
were not adequately represented in previous trials, should be offered a statin. These included 
patients with: 
 
• cerebrovascular disease; 
• peripheral vascular disease;  
• diabetes;  
• over 70 years old; 
• patients with CHD over 75years old, within the normal cholesterol range 
(acknowledging the VAHIT study  which showed CHD event risk reduced by a non 
statin (Veterans Affairs High Density Lipoprotein Cholesterol Intervention Trial Study 
Group (VAHIT) 1999).  
 
Statins are of proven cost effectiveness when used for secondary prevention (established 
vascular disease), in diverse patient populations, up to at least 84 years (Ganz 2000; Prosser 
2000). From an economic standpoint, therefore, ensuring all patients with vascular disease are 
offered a statin at a therapeutic dose has the potential to limit the public health impact of 
vascular disease.  
 
However, inconsistent implementation of research evidence on prescribing (King 2000; 
Pearson 1997), and adherence to statins (Rasmussen 2007; Benner 2002) requires a change in 
response from the NHS and patients if the full benefits of statins are to be realised. There may 
be an additional need to support uptake of the evidence base in practices and patients from 
areas of socioeconomic disadvantage (a particular problem in Glasgow) who are at greater risk 
of low adherence (Dani 2007; Davis 2006) and ill health due to vascular disease. 
 
In 2002, the Heart Protection Study Collaborative Group (Heart Protection Study, HPS) 
identified the benefits of simvastatin 40mg daily for all patients with established vascular 
disease, regardless of cholesterol level. This study transformed the approach to cholesterol 
management and guidelines were reconfigured to fit e.g. GG&C Cholesterol guidelines 
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(Chapter 3, Appendix VIII). These guidelines formed the basis of the educational messages in 
the Statin Outreach Support (SOS) intervention. Therefore, a more detailed appraisal of the 
HPS is given below. 
 
 
2.2.2 Critical appraisal of the HPS  
 
HPS was an independently funded, randomised (allocation concealed), blinded (data 
collectors, patients, GPs, study nurses, outcome assessors) placebo controlled study with a 
minimum of 5 years follow up, analysed on an intention to treat basis. 
 
 
Participants and methods 
    
The number of participants in HPS was greater than all other statin trials combined, with 
20,536 patients. Eligible patients were aged 40 - 80 years with CHD, other occlusive vascular 
disease or diabetes. Research nurses identified eligible patients by screening hospital based 
records of discharges, relevant outpatient clinics and relevant wards. Therefore all participants 
had to have a recent history of secondary care admission or attendance at a specialist clinic. 
By design, this excluded primary care based patients fulfilling the clinical eligibility criteria 
without previous admission or secondary care attendance. On calculation, 9839 (28.3%) of 
participants were younger than 65 years, 4891 (23.8%) between 65 and 70 years, 5806 
(47.9%) at least 70 years. Twenty four point seven percent of patients (5080) were female. 
There was no information on numbers of patients aged over 75 years with CHD or over 70 
years without CHD; both were of interest because this age of patient had not previously been 
studied. 
 
A slightly unusual feature of the trial was the exclusion of a significant number of patients 
who were non adherent with their statin during the ‘run-in’ period. Over one third 
(11609/32145 (36.1%) of those entering the run-in period of the trial did not progress to 
randomisation. Twenty six percent of those not progressing were described as being non 
concordant or not keen to enter the trial. This makes generalisability of the study sample more 
difficult, because one year statin non adherence is estimated to be about 40% for patients with 
previous cardiovascular events outwith the trial setting, with a greater proportion not taking 
their statin for primary prevention (Colivicc 2007; Blackburn 2005; Jackevicius 2002; 
Perreault 2005).  
 
Recruitment criteria in randomised controlled trials often exclude patients with multiple and 
complex co-morbidities, making it difficult to anticipate efficacy in real world populations in 
primary care. Unfortunately, in HPS, it was not possible to identify how many patients were 
diagnosed with more than two disease categories and therefore the applicability of the results 
to this section of the population remains unanswered. Allocation concealment is assumed on 
the basis that the list was held at a telephone randomisation centre, as with most other large 
scale, multicentre studies. Assignment to study group and creation of the allocation sequence 
were performed separately, minimising this source of bias.  
 
Participating patients and their GPs were blinded to treatment allocation. They were advised of 
the results from other relevant statin studies, and encouraged to prescribe a non study statin if 
indicated; therefore 17% of the control group were prescribed a statin. All patients were 
required to have their cholesterol checked by their own GP during the trial. This design feature 
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has implications for blinding: participants made aware of their lower cholesterol may have 
inferred that they were in the active group. The implication is that performance bias was not 
prevented, and this might have affected other (health seeking) behaviours among the active 
group participants.   
 
 
Intervention  
  
Active group participants received simvastatin 40mg daily for 5 years while control group 
participants received placebo. Timing and duration of the intervention were clearly described. 
The control group were allowed to take any statin their GP decided to prescribe and analysis 
accounted for those in the control group who were prescribed a statin by their GP.  
 
The co-prescription of other vascular protective treatments included aspirin, beta blockers, 
ACE inhibitors, antihypertensives and smoking cessation products. The rates of prescribing of 
these medicines were shown to be comparable in both groups on entry to the trial. However, 
no information was available on the relative proportions initiated, stopped, or with dose 
changes throughout the course of the study, all of which could influence outcomes if not 
uniformly distributed across active and control groups. Patients were allocated simvastatin or 
placebo and, unusually, not asked to return for cholesterol or other blood tests. It could be 
inferred therefore, that patients need not re-attend their practice after starting simvastatin, thus 
decreasing the need for follow up. However, the heterogeneity of primary care based patients 
outwith the trial setting may result in a more unpredictable response, necessitating closer 
follow up. 
 
 
Outcomes  
      
The choice of primary (all cause vascular and non vascular mortality) and secondary (major 
coronary events including nonfatal MI or death from CHD, revascularisation, cancer, stroke) 
endpoints differed from other statin trials by the inclusion of revascularisations. However, 
baseline history of hospitalisations for revascularisations was not described across intervention 
and control groups, making it difficult to interpret the true impact of statins on this component 
of the composite endpoint. The concern here is that statins may have reduced vascularisations 
more than any other component, with secondary outcomes showing a positive effect for this 
reason. However, the improvement in the composite primary outcome in the simvastatin group 
was attributable in roughly equal proportions to the components of death due to coronary and 
vascular events. The primary outcome was also significantly improved across subgroups 
including patients with cholesterol less than 5mmol/l. This is an important finding because it 
legitimises offering simvastatin 40mg to all patients with comparable inclusion criteria, 
irrespective of starting cholesterol level.  
 
The timing of the appearance of differences in vascular events between groups was consistent 
with other statin trials. Total and LDL cholesterol decreased in the treatment group during the 
first year but there was no significant difference in the control group, while there was no 
divergence in the rates of first major vascular event between groups before one year. For 
patients taking a statin, two messages arising from these observations are the importance of 
persisting with the prescription over the long term, and a decrease in cholesterol over the first 
year is an indication of the statin beginning to reduce the risk of suffering an event thereafter.  
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The trial profile and accompanying figures show 20,536 patients were accounted for at the end 
of the study, with a clear description of the reasons why 67 were lost to follow up. All 
participants were analysed in the groups to which they were randomised.  
 
Table 2.2 All cause mortality in HPS 
 
 Outcome event: All cause mortality 
             Yes                                No 
Total 
Simvastatin Group 1328 (12.9%) 8941(87.1%) 10269 
Placebo Group 1507 (14.7%) 8760 (85.3%) 10267 
 
The absolute risk reduction in total mortality was 1.8% (from 14.7 to 12.9%). There was an 
18% relative reduction in coronary mortality, absolute rate reduction of 1.2% from 6.9 to 
5.7%. The rates of MI, stroke and of revascularisation reduced by approximately 25%. 
 
Communicating evidence from primary research in an understandable, concise way formed an 
important part of the new intervention planned in the trial. Evidence of benefit (or harm) can 
be more easily understood if converted into the ‘Number Needed to Treat’ (NNT). In this case, 
the NNT to prevent one death was 55, meaning an estimated 55 participants needed to be 
treated with 40mg simvastatin for 5 years before one patient can benefit. The corollary is that 
54 of the 55 patients treated with simvastatin 40mg daily for 5 years do not benefit in this way. 
From the placebo death rate in the trial, we know that about 15% of patients died over 5 
years). NNTs together with 95% Confidence intervals can be calculated from the data 
presented in the manuscript.  
 
 
All cause mortality 
 
The proportion of deaths observed in the active and control groups were:  
Simvastatin 1328/10269 = 0.129 and Placebo 1507/10267 = 0.147  
 
The Standard Error (SE) = 0.48%; the Absolute Risk Reduction (ARR) is: 14.7% - 12.9% = 
1.8%.  The NNT is given by 1/ARR = 55.  Other ways of describing the result are: Relative 
Risk = 0.88; Odds Ratio = 0.86 and Relative Risk Reduction = 0.12 (12%).   
 
The 95% CI for the ARR is given as 1.8% +/- 1.96 (0.48) = 0.86% to 2.74%.  
 
The 95% CI for the NNT is reciprocal of this: 100/2.74 to 100/0.86 therefore we can be 95% 
confident that the true population value of the NNT falls within the range 36 – 116, which is 
wide, reflecting the low absolute number of deaths prevented by simvastatin in this 
population. The intervention was more effective at preventing major vascular events. In this 
case, the NNT and associated CI can be calculated as follows: 
 
For any major vascular event (coronary, strokes, revascularisations) 
 
Experimental Event Ratio = 19.8%; Control Event Ratio = 25.2%; RR = 0.79; OR = 0.73; 
RRR = 0.21; ARR = 5.4%; NNT = 19, CI = 15 – 23. The NNT for revascularisation can be 
estimated as 39 (29 - 58), and the NNT for a major coronary event as 33 (26 - 46).   
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Therefore simvastatin 40mg for 5 years decreases all cause mortality (NNT = 55), vascular 
mortality (NNT = 66), and vascular events (NNT = 33) even in patients with CHD but low 
cholesterol, or in patients with CVD, PVD or diabetes (if aged over 45 years). 
 
The NNT decreased as the baseline cardiovascular risk increased e.g. 17 patients with a 
previous MI need to be treated for 5 years with 40mg simvastatin to prevent one patient 
suffering a vascular event. Key outcomes from HPS are summarised in Table 2.3, in NNT 
format. 
 
Table 2.3 Number needed to treat estimates from HPS 
 
Outcome NNT (95% CI) 
All cause mortality 55 (36-116) 
Any major vascular event 39 (29-58) 
Vascular event with diabetes but no CHD 21 (14-42) 
Revascularisation 39 (29-58) 
Major coronary event 33 (26-46) 
 
 
Applicability of the results to a primary care population 
 
As an example, for a 75 year old female patient with type 2 diabetes, no CHD, cholesterol 
controlled, taking an ACE inhibitor and aspirin, the NNT for preventing a vascular event with 
5 years of simvastatin 40mg daily is 21 (95% CI: 14 – 42). Therefore we would need to treat 
21 patients with comparable characteristics for 5 years, to prevent one patient suffering a 
vascular event.  
 
Patients enrolled into the trial were those who showed they could take at least 80% of their 
tablets. This suggests that a comparable primary care cohort would benefit to the same extent 
if patients were non compliant two days from every ten. This is a useful message to 
communicate to GPs and patients because good statin adherence is known to be illness driven 
rather than prevention driven, and some patients need to be reminded they are high risk, even 
if they are not acutely unwell. 
 
The findings strengthened and extended the results of previous statin trials. Simvastatin 40mg 
was safe (no need to check cholesterol, LFTs; muscle enzymes only if unexplained muscle 
symptoms) and the NNTs applied regardless of prior cholesterol, age, previous medical history 
and concurrent use of other treatments.  
 
 
Applicability to a pharmacist-led outreach intervention 
 
In primary care, systematic implementation of this evidence requires several complex steps. If 
agreement is reached on the need and generalisability of the findings to a primary care 
population then the biggest barrier may be the identification of eligible patients, invitation to 
attend the practice, re-invitation of those not attending initially, explanation of the reasons for 
starting a new prescription and provision of a prescription. Thereafter, a system is needed to 
ensure patients presenting with qualifying diagnoses are managed in the same way. Each step 
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requires staff commitment and weighing up the opportunity cost. Further, implementing 
evidence is likely to be more time consuming in areas of deprivation where high risk 
prevention strategies are notoriously more difficult to implement (ASPIRE Steering Group 
1996). 
  
Additional capacity may be required to systematically implement new evidence derived from 
HPS, because of the current demands on the management of presenting problems at the 
expense of preventative care (Hutchison 1996).  Therefore, it is likely that an educational 
outreach intervention would help if the pharmacists providing it were also able to identify and 
create a list of patients eligible for a statin then invite them to appointments in the practice. 
Providing follow-up for non responders and other ‘hard to reach’ groups e.g. the housebound, 
is likely to be welcomed by practices.  
 
 
2.2.3 The case for improving Statin prescribing  
 
Improving the quality of statin prescribing 
 
From the evidence described above, there is a robust case for prescribing statins for patients 
with established vascular disease. Prior to HPS, the evidence was less convincing for such a 
wide spectrum of patients. Publication of HPS led to reappraisal of statin guidelines and 
together, this is likely to account for the recent increase in statin prescribing, which has 
surpassed increases in any other risk reducing medicines (Bull 2003; Ramsay 2006). 
This finding has important implications for the design of a trial testing an intervention to help 
increase statin prescribing: usual care (due to passive dissemination of guidance) is likely to 
improve over time and this should be factored into the power calculation. That prescribing 
increases over time, coinciding with the publication of new evidence, is not a new finding. 
Calvo and Rubinstein evaluated prescribing pre- and post- publication of successful drug 
trials. They monitored the incidence of new prescriptions written by physicians in primary 
care in a 6 month period before and after publication of trials of the following drugs: 
alendronate, metformin, alpha1-blockers and finasteride. Among their findings was a clear, 
statistically significant temporal association between prescribing and the publication of the 
new evidence (Calvo 2002).  
 
However, the literature review gave a convincing account of there being shortfalls in the 
prescribing and use of lipid lowering agents (ASPIRE steering group 1996; Campbell 1998; 
Siegel 2000; Ramsay 2006; Sempos 1993; Clinical Quality Improvement Network 
Investigators 1995; Northridge 1994; McBride 1998; Sueta 1999; McCormick 1999; Aronson 
2006; De Wilde 2003; Primatesta 2000; Whincup 2002; De Wilde 2003; Minhas 2004; Smith 
2001; Missouris 2001; Sloan 2001; Frolkis 1998; Hoereger 1998; Reid 2002; Majeed 2000; 
Fernie 2006; Pearson 2000). Many of these papers reported suboptimal statin prescribing after 
the publication date of the HPS. The studies varied in design, methodology, sample 
characteristics, country of origin and severity of cardiovascular disease. There were biases and 
confounding inherent in most of these due to the absence of a comparator group but the 
consistent finding was there being considerable scope for improvement in the identification of 
patients eligible for treatment, statin prescribing in comparison with the evidence base, 
achievement of target statin doses and achievement of target cholesterol levels.  
 
In EUROASPIRE II, the investigators’ found half of those eligible were receiving statins and 
of those receiving them, half were reaching the target of 5mmol/l (EUROASPIRE II 2001). A 
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subsequent comparison of EUROASPIRE studies I and II led to the assertion that there was a 
collective failure across Europe, of practice to achieve the substantial potential among patients 
with CHD to reduce the risk of recurrent disease and death. Approximately 60% of those 
patients interviewed across the nine participating countries were prescribed statins between 
1999 and 2000 (EUROASPIRE I and II group. 2001). Since then, the introduction of the New 
General Medical Services (GMS) contract has proved that at least 60% of patients with CVD 
and diabetes can achieve total cholesterol levels below 5mmol/l (QOF Achievement Data 
2005). However, it is not known if there can be any further improvement in uptake beyond the 
60% audit target set by the GMS contract, or how many more patients would start and 
continue to take newly prescribed statins if the health care professionals adopted the best 
available implementation techniques, informed by implementation research. It is likely that 
there will remain a significant number of patients who will not take their statin out of choice, 
even if it were prescribed. 
  
 
Improving the cost effectiveness of statin prescribing 
 
As there are several statins available, it makes sense to prescribe the least expensive from the 
options, providing the evidence base for efficacy and adverse effects is similar. Generic 
simvastatin remains the least expensive statin. It can achieve cholesterol targets in a majority 
of patients, if prescribed at a 40mg daily dose (Scandinavian Simvastatin Survival Study 
Group 1994; HPS 2002) and if used instead of more expensive alternatives, could save over £1 
billion in 5 years (Aronson 2006).  
 
The Heart Protection Study Collaborative developed a model from the HPS and used it to 
estimate lifetime risks of vascular events, costs of treatment and hospital admissions in the UK 
(Heart Protection Study Collaborative 2006). Using the intervention of simvastatin 40mg daily 
versus placebo for an average of five years, the investigators found that generic simvastatin 
40mg for life was cost saving in most age and vascular disease groups studied. Their estimates 
included patients as young as 35 years and as old as 85 years.  
 
 
2.2.4  Pharmacist medication review / education for patients with hyperlipidaemia 
 
Several studies (although most were small scale, short follow up, without a control group) 
described successful pharmacist-led medication review, provided directly to patients with 
hyperlipidaemia, aiming to lower blood cholesterol levels (Simpson 2004; Peterson 2004; Ellis 
2000, Tsuyuki 2004; Bozovich 2000; Cording 2002; Traywick 2003).  
 
Alternatively, and possibly more efficiently, pharmacists could target GPs rather than patients 
in an attempt to provide a greater impact on a larger number of patients, and to maintain 
change for longer than can be achieved with the individual patient consultation route of face to 
face medication review. Educational outreach offers an untested way of achieving this aim, if 
coupled with organisational support at general practice level. Evidence of the existence, 
feasibility and effectiveness of such a multifaceted approach is lacking.  
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2.3 Educational Outreach: features of the intervention 
 
 
2.3.1  Overview 
  
Educational Outreach can change health professionals’ prescribing behaviour (New 2004; 
Boardman 1999; De Wilde 2003; Davis 2003). It involves a face to face meeting between a 
person knowledgeable in therapeutics and a healthcare professional, in the healthcare 
professional’s own setting. It commonly incorporates the provision of feedback on prescribing 
issues and the following key features and techniques are thought to maximise the chances of 
educational messages being understood and the learning being implemented:  
 
• Focussing on a targeted, small group of clinicians;  
• Defining clear educational and behavioural objectives;  
• Establishing credibility;  
• Stimulating active participation;  
• Using concise graphic educational material;  
• Highlighting and repeating essential messages;  
• Providing positive reinforcement in follow up visits.  
 
(Avorn 1983; van Eijk 2001; Soumerai 1990; Thomson 2002).  
 
The term ‘Detailing’ was originally coined to describe a form of educational outreach 
pioneered by the Pharmaceutical Industry through representatives promoting their products. 
Marketing and selling strategies are incorporated, tailored to the doctor’s personality, practice 
style and preferences. Acknowledging the usefulness of this approach in a commercial, for-
profit sense, the methods have been applied to benefit the ‘not for profit’ sectors e.g. the 
National Health Service. This led to the terms ‘Public interest’ or ‘academic’ detailing, and the 
process of non commercial, short, face to face, in-service interactive education by a trusted 
outsider trying to promote evidence based choices among physicians. The median 
improvement in prescribing from this approach is estimated to be approximately 6% with a 
range from -4% to 17%, up to 1 year (Grimshaw 2004) although Avorn achieved a difference 
of 18% (Avorn 1983: see Table 2.4). Core features of this complex model are not well 
understood. There is no consensus or guidance on how narrow or wide the topic should be, or 
the relative efficacy of components e.g. written compared with face to face feedback. 
Frequency of contacts between pharmacist and prescriber vary between studies. Some suggest 
that eight, one hour sessions per practice are sufficient to effect prescribing change at practice 
level (Squires 1997), while others recommend meetings every 4 – 8 weeks, of one hour 
duration (Pilling 1998), but there is no consensus, partly because of the differences in context, 
content and delivery, topics, training of staff involved. 
 
 
Limitations of current models 
 
Compared with conventional group based educational meetings, detailing is thought to be 
more effective (Bernal-Delgado 2002; Thomson 2002). Educational meetings generally focus 
on a wider subject, take place outwith the provider’s practice and involve groups of 
professionals together. To date, the published reports of educational outreach describe 
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interventions focussing on educational exchange, without any practical, ‘hands on’ assistance 
to introduce changes to practice, or without much thought about how changed practice can be 
sustained (O’Brien 2002). The messages conveyed during educational meetings are not 
usually individualised to each GP’s needs, unlike the approach taken by pharmaceutical 
industry representatives, who make every attempt to tailor their messages to meet GPs’ real or 
perceived needs. Marketing and behavioural or personality profiling are used to achieve this 
end.  
 
The level of interactivity in studies of detailing is difficult to ascertain from available 
evidence. Delivery of outreach appears to involve prioritisation of the message (usually 
abbreviated clinical guidance) over the process by which the message is communicated. This 
runs the risk of failing to acknowledge the GP’s circumstances, baseline prescribing habits, 
beliefs, opinions and not least, patient preferences. In 2000, the Medical Research Council 
acknowledged the importance of basing implementation on a scientific understanding of the 
behaviours that may need to change, the relevant decision making processes and the barriers 
and facilitators of change (Medical Research Council 2000). In view of this guidance, and the 
increasing reliance on prescribing as a means of tackling or preventing ill health, it is timely to 
introduce a new form of detailing, which supports implementation by tailoring the messages to 
each GP, and providing practical help in addition to educational outreach. 
 
 
2.3.2 Theoretical principles 
 
Theory building and testing are important considerations for developing new approaches to 
prescribing improvement. In 1990, Raisch produced a useful model of methods to influence 
prescribing (Raisch 1990a, 1990b). He drew on four bodies of literature to develop his 
theoretical model and suggested that the greatest chance of success comes from constructing 
an intervention which incorporates: 
 
• Theoretical prescribing models; 
• Theories of persuasion; 
• Research articles of programmes to improve prescribing; 
• Theories of human inference.  
 
The prescribing habits of individuals were acknowledged to be relatively stable over time. 
Changes usually occur slowly and as a result of various influences including scientific papers, 
specialist recommendations, postgraduate educational or practice meetings, feedback from 
patients and the pharmaceutical industry. Lack of knowledge is only one reason for suboptimal 
prescribing and may not be the factor limiting change in many cases. Raisch also suggested 
that of the numerous factors influencing prescribing decisions, it is likely that some are 
rational and others irrational. Accepting this to be true, and assuming the general aim is to 
change prescribing decisions in line with standards set out in clinical / prescribing guidelines, 
it follows that rational influences are more easily identified and resolved than irrational 
influences. Depending on the relative weight of rational and irrational influences, this is a 
limitation to any prescribing support model and should be borne in mind. Ignorance, 
incompetence, poor management, and sometimes a deliberate disregard of established 
knowledge may get in the way of best practice when it comes to implementation of guidelines 
in general (Clinical Resource and Audit Group 1993). This approach may also be seen as 
displaying healthy scepticism because guidelines are not always based on impartial, best 
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evidence (Delamothe 1999; Grol 1997).  Not all patients fit a guideline algorithm for each of 
their conditions. Doctors may be exercising a conservative approach to minimising the risk of 
exposing patients to treatments that (in some cases) have not yet gained sufficient exposure in 
a real world population. Practitioners may regard guidelines as documents that focus on 
scientific knowledge rather than the needs of their end users (Fairhurst 1998). There are many 
examples in general practice of so called “clinical evidence” being of questionable quality, 
relevance, objectivity or simply out of date by the time it arrives in practices. As one GP put it: 
“the fickleness of evidence is inconvenient but would be easier to live with if it was more 
widely acknowledged in discussions of implementation” (Temple 2002).  
 
From the available evidence, a novel intervention should include features which enable 
identification or anticipation of individual GPs’ reasons for not implementing the evidence.  
 
If a guideline has features that are conducive to increasing uptake, this is likely to improve 
implementation potential. Several features are known to be useful, including congruence with 
existing prescribing norms, precise descriptions of actions required and the need for the 
message to be compatible with GPs’ values (Grol 1997; Grol 1998; Burgers 2003). 
Involvement of GPs in the process of guideline development may be consistently effective as a 
means of improving prescribing (Pearson 2003). 
 
 
Information transfer 
 
Theories of information transfer are relevant to prescribing change interventions because few 
facts are learned unless they are presented in ways that enhance retention. It is therefore 
important to link new prescribing information to what the prescriber already knows. This 
creates the need to find out what the prescriber knows in advance – a marketing technique 
used extensively by the pharmaceutical industry. If prescribing information is presented in 
context e.g. at the time of an eligible patient’s appointment, timely retrieval is more likely. 
Active discussion e.g. using therapeutic dilemmas or clinical scenarios from practice may also 
help ensure detailing messages are absorbed, retained and used in practice.  
 
There is a recognised gulf between what is known about changing prescribing behaviour and 
what is practised by those aiming to change it. This has led to a range of theories describing 
how to improve dissemination and implementation. These can be applied at the individual or 
health care system level (Smith 2000; Prochaska 1984; Bero 1998).  
 
Some theories are intuitive e.g. Fraser argued that as evidence is translated into practice by the 
pushing out of ideas by the spreaders of best evidence, change was more likely to take place if 
the focus is on the prescriber (who they describe as the ‘adopter’) (Fraser 2003). It stands to 
reason that adult learning and persuasive communication theories could be put to good use in 
the move to improve prescribing. If the theories are applied by the person instigating the 
change in prescribing (in this case, the pharmacist), they suggest the importance of using 
repetition and reinforcement, recommending alternative prescribing strategies, supporting 
recommendations by credible third parties e.g. expert clinicians. Offering evidence based, 
unbiased advice and stimulating interactive discussion are ways of establishing and sustaining 
engagement compared to other strategies e.g. passive dissemination of sponsored promotional 
material. Other features likely to increase the ability to improve information transfer and the 
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uptake of better prescribing include features relating to the pharmacist delivering the 
information e.g. credibility, expertise in the relevant topic area (Lipton 1995).   
 
In reviewing the literature and combining this learning with observations from working in 
general practices in the past 15 years, it appears that prescribing problems cannot all be solved 
through ready access to evidence based medicine. Freeman demonstrated this point by 
showing that evidence based medicine can be viewed as a language to describe formalised 
explicit knowledge (Freeman 2001). In contrast, tacit knowledge includes intuition and 
problem solving ability that is gained through experience and interaction with people. It is 
important in decision making and is not often made explicit or externalised. In constructing a 
new educational outreach-type model, it is important to create an environment for the 
opportunities to arise when pharmacist-detailers find out GPs’ tacit knowledge about the 
detailing topic. One way to do this could be to arrange a face to face meeting to explore tacit 
knowledge. Another way to find this out is to carefully gather information from past 
prescribing decisions.  
 
 
Patient perspectives 
 
A frequently overlooked consideration in prescribing change models is the importance of 
patients’ beliefs and choices. Patient related barriers e.g. their beliefs and preferences ought to 
be acknowledged and addressed (Lipton 1995). In reviewing educational interventions 
targeted directly at patients, Mullen identified several principles which, if addressed, rendered 
the approach more effective (Mullen 1985). While Mullen’s principles do not apply directly to 
the model of pharmacists detailing with GPs, they are congruent with many of the techniques 
used as part of the academic detailing approach. These include provision of advice that is 
relevant to the receiver’s circumstances, involvement of the receiver in the design of the 
intervention, reinforcing desirable changed behaviours, anticipating and addressing practical 
barriers to changing behaviour and the importance of delivering educational messages through 
multiple media e.g. written and verbal. A scoring system based on these principles has since 
been used to evaluate the quality of inter-professional educational interventions, confirming 
the potential suitability of Mullen’s work in this context (Cooper 2001).  
 
 
 
2.3.3  Underpinning intervention design with theoretical approaches 
 
It is recommended that the design of interventions aiming to change health care professionals’ 
practice is underpinned by theoretical principles of behavioural change including adult 
learning theory (Foy 2001; Medical Research Council 2000, 2011). An understanding of 
theories of behavioural change and acknowledgement of factors known to influence 
prescribing practice is therefore a useful starting point to designing a novel intervention to 
change prescribing (Foy 2001). As with complex interventions in general, this is better 
understood in the context of other relevant intervening variables. Literature in this area is 
diverse and it is often difficult to extract practical lessons that could be transferred into a new 
prescribing change model. However a useful, pragmatic description of a range of factors 
recognised (by doctors) as important in changing clinical practice is given by Allery (1997).  
Fifty GPs and 50 consultants were interviewed and using a critical incident technique, they 
ascertained categories of reasons influencing their clinical practice. While the scientific 
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validity of their findings was not helped by the absence of a comparator group, (they did not 
ask a comparable group of GPs who did not make changes), it was clear that help with 
organisational factors combined with education, and contact with an independent professional 
e.g. a pharmacist, was regarded as a positive influence. They recommended that a wide range 
of factors need to be considered in the provision and evaluation of educational activities, 
because of the wide range of factors involved in changing practice.  
Schwartz explored 114 doctors’ motivations for apparently inappropriate prescribing decisions 
within a larger randomised controlled trial (Schwartz 1989).  Of the 110 responses elicited, the 
most common reason for prescribing medicines known to be of limited usefulness was patient 
demand. Most prescribing decisions seek to balance perceived efficacy with perceived risk of 
adverse effects. The authors recommended that greater attention should be paid to attitudes 
and motivations concerning suboptimal prescribing if ‘detailing’ programmes are to be 
successful. This observation has implications for the design of a study testing a novel outreach 
model: targeting prescribers known to prescribe sub-optimally (in comparison with clinical 
guidelines) is more likely to generate positive results compared with an untargeted approach. 
However, in the National Health Service, the level of equity is important, and in primary care 
general practices, all patients who are eligible for a statin or eligible for an optimal dose (i.e. 
those not prescribed a statin or those prescribed one, but at a dose less than guideline 
recommendations) ought to be offered one. These patients exist in every practice therefore 
targeting of all practices may be necessary. 
 
In 1996, Armstrong interviewed a purposeful sample of 18 GPs from London and 
hypothesised that there were three models of prescribing change (Armstrong 1996). Notes 
taken during semi-structured interviews were analysed and identified a challenge model, a 
continuity model and an accumulation model. An important practical conclusion from this 
work was the unanimous view of the participating GPs that the initial change in prescribing 
was precarious and needed reinforcement. This finding coincides with much of the literature 
describing effective educational outreach programmes, where repeated visits serve the purpose 
of reinforcing desired change (Oxman 1995). A similar observation was noted from effective 
programmes of changing patients’ health behaviours including adherence to medicines (Dolan 
Mullen 1985). Reinforcement and support for the initial steps towards prescribing change 
therefore appear worth integrating into a novel educational outreach model. Cognisance 
should also be given to doctors’ overriding concern when considering whether to prescribe: 
preservation of the doctor-patient relationship. Non clinical factors have an important 
influence on prescribing e.g. attitudes, perceptions and experiences of the GP (Bradley 1992). 
All of these factors should be acknowledged before introducing an educational programme. 
 
Prescribing support interventions should be designed in a way that enables the providers to 
recognise the barriers known to limit the translation of evidence into practice. Different 
adopters are likely to present different (often personal and wholly legitimate) reasons for not 
following the evidence based model of prescribing (Veldhuis 1998; McColl 1998; Freeman 
2001; Sweeney 1998). Organisational barriers are a recurrent theme. The EBOR study 
investigators were unsuccessful in their attempt to change clinical practice following outreach 
visits, citing organisational difficulties as one of the main barriers to implementation 
(Freemantle 1999). Different barriers are likely to arise in different practices, and between 
individuals in the same practice, so a commonsense approach would suggest separate 
strategies are needed to overcome these. In Glasgow, we have found that different approaches 
are needed to engage different patient subgroups. For example, inviting Urdu or Punjabi 
speaking South Asians in their native language through a phone call is more successful than 
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using English. We have found that a pro-active, empathic approach, tailoring appointments to 
the individual’s availability is more likely to lead to attendance in patient groups usually 
perceived as ‘hard to reach’ in areas of socioeconomic deprivation (Lowrie 2010b internal 
report). Communicating using methods used routinely by the individual e.g. appropriate 
language or texting on a mobile phone, is more likely to bring about success than a printed 
letter, particularly if levels of literacy are low (O’Donnell 2009 internal report; Fisk 2006). In 
their critical review of studies of educational programmes designed to improve prescribing in 
North America, Figueiras concluded that the more personalised the intervention to the 
prescribers’ needs, the more effective the strategy is likely to be (Figueiras 2001). The authors 
substantiated this by conducting their own pragmatic controlled trial evaluating the 
effectiveness of two multifaceted educational strategies aimed at improving prescribing 
standards in primary care. Comparing one to one education with group sessions, focussing on 
reduced prescribing of non-steroidal anti-inflammatory drugs, they showed that single 
outreach visits of one to one sessions were more effective than group sessions.  
 
In 2004, Schumock asked a sample of 150 doctors, pharmacists and formulary committee 
members to express their opinions as to the importance of factors influencing prescribing 
decisions. They found significant differences between professional groups. Doctors rated the 
recommendations of pharmacists, formulary committee members, prescribing guidelines and 
cost comparisons of lower influence than the pharmacists themselves (Schumock 2004).  If 
generalisable, this result highlights the importance of asking prescribers to identify their 
biggest prescribing influences, and seeking the views of whoever the prescriber identifies as 
being educationally influential.  
 
GPs’ perspectives of the utility of detailing information are sparse, but McColl produced a 
useful précis. He asked a sample of 302 GPs from Wessex, UK, what they rated most highly 
as helping clinical decision making.  Using a semi structured questionnaire, they reported that 
GPs wanted evidence presented in short, understandable packets, with recognisable quality 
standards, using understandable descriptions e.g. NNTs of useful outcomes (McColl 1998). 
None of their requirements are too challenging, even in the current resource restricted NHS 
environment.  
 
 
2.3.4 Tailoring interventions to overcome implementation barriers  
 
From Grol’s summary of factors limiting or restricting behavioural change, it is possible to 
identify barriers which may need to be overcome before implementing clinical guidelines:  
 
• Orientation: becoming informed about the existence of new guidelines; feeling 
interest and commitment;  
• Insight: understanding the guidelines, awareness of gaps in own performance and 
the need to change; 
• Acceptance: positive attitude to the new guidelines accompanied by intention to 
change; 
• Change: implementation in practice, experimentation, recognition of positive 
outcomes and maintenance of change (Grol 1992).  
 
Differences between guideline recommendations and prescribing in practice are inevitable 
when guidelines are drawn from discrete studies in populations and settings that may be far 
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removed from usual care. Many other factors contribute e.g. the organisational context of the 
practice or the nature of the clinical or prescribing topic compared with the priority assigned to 
it in the practices under scrutiny. It is therefore unreasonable to aspire to 100% guideline 
adherence in any given topic and it seems likely that tailoring interventions to address these 
issues in a GP by GP and Practice by Practice basis will have most chance of overcoming 
implementation barriers. Bero concurred with this view, suggesting that the methods of 
implementing evidence based prescribing should be guided by evidence on their effectiveness, 
the nature of the change being suggested and a prior assessment of the obstacles to change 
(Bero 1998). 
 
Fretheim constructed a tailored intervention incorporating an educational outreach visit with 
audit and feedback and computerised practice based reminders (Fretheim 2003). Pop up 
reminders appeared on physicians’ computer system in response to a consultation with a 
patient who had high blood pressure or high cholesterol. This enabled rapid calculation of 
cardiovascular risk and printed educational material for the patient; both factors had been 
previously identified as rate limiting. 
 
Psychological methods have been used to guide GPs in the implementation of guidelines for 
depression in primary care (Baker 2001). Baker used content analysis of interviews with GPs 
about their performance. This enabled assessment of the likely obstacles to guideline-led 
depression management and pinpointed a psychological theory that best explained the relevant 
obstacle. Implementation methods were constructed in response to these theories and 
obstacles, and GPs were encouraged to adopt the recommended implementation methods. 
Important learning from this trial included the importance of the individualised discussion 
with each GP as a means of identifying reasons why the guideline evidence was not 
implemented, followed by tailoring of interventions to support the GP to adopt evidence based 
practice. The researchers did not seek to identify organisational or other obstacles at the 
practice level because it was not possible to change them.  
 
In some cases, organisational inertia may be the rate limiting step and needs to be considered 
then tackled. For example, a new trial investigating statin prescribing for a cohort previously 
untreated would first require identification of those eligible to receive it within each practice. 
Following this, an invitation to attend an appointment, and offer of a statin would be required. 
Each step takes time and a systematic approach; adequate and persistent call and recall 
underpinned by accurate and complete practice based disease registers to maximise uptake and 
minimise dropout, particularly in areas where health literacy is poor and engagement with 
preventative or screening appointments is low.  
 
Fretheim attempted to implement an educational intervention aiming to improve prescribing of 
antihypertensive and cholesterol lowering medicines. In their analysis, they used structured 
reflection and focus groups to identify barriers to uptake of their educational messages 
(Fretheim 2004). Their findings were comparable to that of other teams: gaining commitment 
to change is predictive of actual change, which is a useful approach, easily replicated 
(Wakefield 2003), and worthwhile incorporating into a novel detailing approach. 
 
In the international Drug Education Project, a new educational programme facilitated by GPs 
or pharmacists for peer groups of doctors to improve the treatment of asthma patients in the 
Netherlands, Norway, Slovakia and Sweden, was developed and tested (Veninga 1999). The 
multicentre trial design was parallel, randomised and controlled to test the effect of an 
educational programme on competence and prescribing. The intervention comprised 
  
46 
individualised feedback on the underlying reasons for prescribing choices. Feedback was 
presented and discussed in small peer groups. Significant improvements were noted in all 
competence and prescribing outcomes in all countries except for Sweden, where 
improvements were made on all outcomes but the effect failed to reach statistical significance. 
Control group practices received prescribing guidelines only. The authors comment that the 
tailored approach was the key to effecting change. This result is striking because of the 
consistently positive effect despite the between, and within, country variation in continuing 
medical education programmes, organisational barriers to change, different baseline 
prescribing behaviours and attitudes of GPs. In reviewing this paper, it becomes apparent that 
a tailored intervention (if carried out effectively) may be more likely to work across different 
healthcare settings because it identifies and seeks to address the expressed educational and 
organisational needs of each individual, whatever the individual’s experience, background or 
practice organisation.  
 
Another group of researchers tailored their outreach visits to the needs of each practice and 
found that this feature predicted effectiveness (Hulscher 1998). However, the extent to which 
they enabled the doctor to shape the educational exchange led to wide variation in the intensity 
and duration of their input. In their discussion, they called for standardisation of visits and 
standardisation of the skill-set of those delivering them, from an economic perspective.  
 
Prescribing or other healthcare professional change interventions should be designed in a way 
that enables detection of the barriers known to limit the translation of evidence into practice. It 
is likely that these interventions need to be tailored to meet the needs of individual prescribers 
because of the considerable variation in the reasons given for not following the evidence based 
model of prescribing (Veldhuis 1998; McColl 1998; Freeman 2001; Sweeney 1998). Tailoring 
of prescribing support in line with each individual GP’s preferred learning method is an 
approach backed up by adult learning theory, and common sense. In their critical review of 
studies of educational programmes designed to improve prescribing in North America, 
Figueiras concluded that interventions personalised to the prescribers’ needs are more likely to 
be effective (Figueiras 2001). From a more pragmatic standpoint, the onus is on the person 
delivering the educational support, to tailor it in advance. This should happen, out of courtesy 
and acknowledging that GPs, like other front-line healthcare professionals in the NHS, are 
busy people with little time to waste on unnecessary or inefficient learning exercises. For 
educational interventions focussing on updating pre-existing knowledge, aiming to improve 
prescribing practice, it is likely that support should include constructing and updating lists of 
patients eligible for prescribing change, generating letters of invitation to eligible patients, 
ensuring call and recall systems are updated and applied, rather than reiterating guidelines.  
 
Most GPs do not work independently. Instead, they work as part of a practice team and 
therefore, educational interventions aiming to change prescribing need to be seen in the 
practice context. There will be organisational barriers and difficulties at practice level that 
need to be identified and overcome. For example, implementation of the evidence base around 
offering statins to all patients with established vascular disease will require careful verification 
of patients most likely to benefit. In addition, it cannot be assumed that acquisition of 
knowledge about the ‘best’ treatment strategy is sufficient to overcome change: the rate 
limiting steps may be the systematic call and recall, chasing of non attendees, not to mention 
the need to overcome prescribing inertia (Nazareth 2002).  
Anticipation of barriers to implementing change appears to be the exception rather than the 
rule, in previous research.  In keeping with the majority of educational outreach trials, Doyne 
constructed educational modules without involving the end users. They did not seek to 
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discover barriers to implementation in their randomised controlled trial involving an 
intervention to change antibiotic prescribing for acute conditions. Their control group received 
summary information by post only. Their intervention characteristics were poorly described; it 
is likely that they presented information in a didactic fashion, in small groups, without much 
discussion or interaction. Their ‘academic detailing’ model failed to achieve a statistically 
significant effect when the impact was measured by the under, or over, use of amoxicillin or 
cephalosporin antibiotics respectively (Doyne 2004).  
 
The EBOR trialists were unsuccessful in their attempt to change clinical practice following 
tailored outreach visits. In their discussion, they cite organisational difficulties as one of the 
main barriers to implementation, rather than a mismatch between the intervention and the 
GPs’ information needs (Nazareth 2002). In particular, they lamented that they did not 
anticipate the level of organisational difficulties they encountered e.g. setting up a disease 
register and the call/recall problems in practices.  
 
The Cochrane database of systematic reviews assessed studies of tailored interventions to 
overcome identified barriers to health professionals’ performance (Shaw 2005). Inclusion 
criteria were typically selective: randomised controlled trials that reported objectively 
measured professional practice in which at least one group received an intervention designed 
to address prospectively identified barriers to change. While one analysis of their findings 
found tailored interventions to be more effective (Odds Ratio 2.18 (95% CI 1.09 – 4.34; p = 
0.026), another analysis using a different criteria gave a comparable odds ratio, but failed to 
reach statistical significance. Overall, they concluded there was insufficient evidence to 
confirm interventions tailored prospectively to identify barriers actually improve care and 
patient outcomes. However, in defence of some of the available evidence, stringent criteria 
were applied before accepting studies into the review. While this approach confirms the rigour 
of the studies included, it leads to many useful studies being rejected, and raises the question 
of publication bias in choosing only published trials. In addition, sufficient funding and time 
are not always available to deliver and evaluate complex interventions in primary care.  
Further, complex interventions have, by definition, several interacting components, making it 
difficult to pinpoint the key feature.  
 
For general practice level interventions in the United Kingdom, it appears that involving 
participant GPs in the design of their own intervention could be important (Langham 2002).  
 
 
2.3.5 Features of academic detailing or educational outreach for prescribing 
 
In the original report of academic detailing, Soumerai described a comprehensive list of 
features of the intervention (Soumerai 1987). Brevity, repetition and reinforcement of desired 
prescribing practices were cited as key factors contributing to the success of their educational 
messages (Soumerai 1990). The same authors had previously concluded, from a randomised 
controlled trial involving 435 doctors, that face to face educational sessions are effective in 
improving prescribing practices. Their sample of doctors included different age groups, 
speciality, urban/rural setting or extent of prior prescribing of the target drug groups.  
 
In another report evaluating the effectiveness of academic detailing as a means of improving 
aspects of health professionals’ practices (focusing on mental health care), Soumerai stressed 
the importance of person to person contact with credible experts and the provision of 
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information for GPs to try structured alternatives to help facilitate change. Four trials which 
had tested detailing as a means of improving mental health care were reviewed. Detailing was 
found to be effective as a means of reducing the overuse of unnecessary medicines, however, 
improvements in markers of mental health or the detection of mental health problems 
remained unchanged (Soumerai 1998).  
 
Since then, many different permutations of the detailing model have been delivered and tested. 
The following appear to be important, and will be carried forward into the new model 
described and tested in the thesis. 
 
 
2.3.5.1  Multifaceted approaches 
 
Multifaceted interventions have tended to anticipate, facilitate and reinforce desired 
behaviours. They appear more likely to succeed compared with single strategies or single 
interventions (Getting evidence into practice 1998; Wensing 1998; Grol 1992).  It follows that 
approaches to changing prescribing that use a greater number of evidence based strands may 
be more effective than those using less. Madridejos-Mora used a combination of educational 
recommendations and feedback of individualised prescribing, to improve prescribing quality 
(Madridejos-Mora 2004). Quality in this context was defined as improvements in the uptake of 
evidence based recommendations for prescribing of non-steroidal anti-inflammatories, ulcer 
healing drugs and antibiotics. Improvements in the quality of prescribing, particularly 
reducing overprescribing, was noted in practices exposed to their combination approach 
compared with a single approach. However, their description of the intervention is short on 
detail, limiting further critical appraisal. 
 
Few trials other than that conducted by Madridejos-Mora have attempted to combine and 
compare more than two different components. None have accessed practice held patient level 
information and used that to identify patients who are eligible for change, then supported GPs 
to contact all eligible patients systematically.  
 
Attempting to influence patient behaviour is rare; only one account of academic detailing 
reported the use of posters in waiting areas together with patient level education. When the 
dual approach of GP education and patient information were combined, the intervention 
proved successful and the authors cited the combination as one of the key reasons for 
effectiveness (Harris 2003). 
 
While multifaceted approaches may be more likely to generate positive outcomes, simple 
approaches should not be overlooked because they may be easier, quicker and cheaper to 
deliver and evaluate. For example, Hux conducted a randomised controlled trial of antibiotic 
education and confidential feedback to GPs in Canada. They hypothesised that a decrease in 
the prescribing of inappropriate antibiotics and an increase in first line antibiotics would result. 
In achieving their primary outcome, they concluded that the simplicity of their programme, 
particularly the confidential aspect of their feedback, was vital in achieving desired outcomes 
(Hux 1999). 
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2.3.5.2  Multiple therapeutic topics 
 
Some researchers, like Madridejos-Mora, tried to effect change in several therapeutic areas 
within the same educational outreach programme. Assuming the detailing approach is 
effective, it might appear more efficient to deliver multiple messages. However, this approach 
needs to be balanced against the inevitable dilution of message when several are 
communicated at the same time. An associated reduction in effect size may be expected; a 
greater magnitude of effect might be achievable if only one focussed topic was chosen.  
 
In their detailing intervention to encourage GPs to avoid the many pitfalls from polypharmacy 
for the community dwelling elderly, Allard communicated multiple educational messages in 
the hope of changing physicians’ prescribing patterns accordingly (Allard 2001).  Using a 
primary outcome of ‘potentially inappropriate prescriptions’, it was perhaps not surprising that 
there were no statistically significant improvement in the intervention group because of the 
number of interventions recommended and the complexity of the steps involved in translating 
this information into practice. In a similar approach, the EBOR trialists tried to demonstrate a 
difference through their intervention, focussing their educational messages on multiple drug 
based topics. They failed to detect any difference in prescribing overall but had some measure 
of success in smaller practices compared with larger practices (Nazareth 2002).  
 
Crotty aimed to reduce falls and stroke risk in the elderly, through the delivery of two 
(pharmacist-led) educational outreach visits to nursing and medical staff in residential care 
homes (Crotty 2004). The study design was a randomised controlled trial, set in Australia. As 
risk factors for falls and stroke are multifactorial, the investigators covered multiple topics 
during their two detailing visits. Outcomes included a reduction in the percentage of falls, 
increase in the prescribing of aspirin, and reductions in the prescribing of various psychotropic 
medicines. In explaining the lack of achievement of any of these outcomes, the authors cite the 
difficulties they found in identifying and influencing the multiple contributors (and therefore 
barriers to change) of care for patients in the residential care setting. These included the need 
to explore barriers posed by physicians, nurses, care staff and family. If Crotty had carefully 
considered the suggested reasons for the success of earlier detailing interventions delivered in 
residential care settings e.g. Avorn 1983,  they might have noted the importance of anticipating 
barriers created by different care pathways and healthcare professionals’ or carers’ views 
within care homes. This may have prompted tailoring of their intervention accordingly. 
 
Avorn and Soumerai believed there to be a need to meet with all stakeholders in order to be in 
a position to identify and overcome barriers to implementation of their educational messages. 
Similarly, researchers in Sweden held bi-monthly outreach meetings with all caregivers in 
nursing homes recruited in a randomised controlled trial, over a 12 month period. The aim was 
to test the impact of their detailing package of multiple therapeutic topics, on the quality and 
quantity of psychotropic drug prescribing. (Schmidt 1998). They managed to achieve their 
desired effect. They suggested that improved teamwork in the nursing homes allocated to the 
experimental group was a key factor. It could be that repeated contacts with staff over 12 
months gave ample opportunity to reinforce the key messages, deliver feedback on improved 
performance and enabled stronger working relationships to develop, all of which are 
consistent with learning from theoretical approaches of behaviour change. Two important 
differences between the study designs of Crotty’s trial and that of the Swedish team were the 
degree of anticipation of the barriers to change and the length/intensity of the intervention. It 
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stands to reason that anticipating barriers to change and delivering a more intense intervention 
will increase the chances of a successful outcome.  
 
Goldberg conducted a randomised controlled trial comparing the effect of continuous quality 
improvement teams with academic detailing (Goldberg 1998). They focussed on several broad 
topics: hypertension prescribing, blood pressure control, depression recognition, prescribing of 
older tricyclic antidepressants and scoring of patients’ depression ratings using a novel 
depression scale. Process measures (prescribing, symptom scores) and blood pressure readings 
were collected. Academic detailing achieved a slightly greater effect size than the continuous 
quality improvement teams but neither improvement reached statistical significance. The 
authors concluded that academic detailing and continuous quality improvement were 
ineffective in improving hypertension and depression guideline compliance. Alternatively, 
their results may be highly conditional: the choice of multiple topics was overambitious a 
priori (certainly a posteriori), and a lack of anticipation of multiple barriers may have obscured 
the effect of the intervention.  
 
As there are many interacting features to the complex interventions delivered in the context of 
the trials described above, the features cannot be viewed in isolation. However, the trend 
appears to favour effectiveness when fewer topics are covered. Any reduced effectiveness of 
the intervention as a result of covering multiple topics could be attenuated or overcome by 
anticipation of barriers to change and addressing these, and adhering to the detailing principles 
and behavioural change techniques described in the original work (Avorn 1983). 
 
It is also worth noting that the choice of therapeutic topic is likely to have a bearing on 
outcomes in this type of comparative effectiveness research. From information generated by 
the literature search and associated reading, it appears that most published outreach trials have 
focussed on changing antibiotic prescribing for acute conditions, over the short term. These 
trials have been conducted in Australia, North America, Canada or the Netherlands (De Santis 
1994; Schaffner 1983; Ilett 2000; Welschen 2004; Gonzales 1999; Zwar 1999). This choice of 
therapeutic topic provides frequent consultations and ample opportunity to use new 
approaches to prescribing, but possibly limits the ability to evaluate the impact on longer term 
effects or on LTC management.  
 
 
2.3.5.3  Number of visits  
 
Most trials involve a single visit to general practices or primary care centres by the detailer. 
While single visits might be expected to achieve statistically significant changes in short term, 
frequently prescribed items, uncertainty surrounds whether the changes persist. All else being 
equal, it follows that multiple visits are more likely to achieve longer lasting changes.  
In a study by Peterson, a pharmacist visited GPs once only, after sending educational material 
in advance, but the duration of the effect was not evaluated beyond the end of the short 
intervention period (Peterson 1996).  
 
When sufficient information on the number of visits is available, fewer visits tend to predict 
less chance of success. Witt delivered a single visit to encourage the uptake of an asthma 
guideline in general practice (Witt 2004). Using changes in sales of asthma medicines as the 
outcome measure, their approach failed to make an impact. While the authors discuss a few 
reasons for the poor uptake, their expectation was that GPs would improve adherence to a 
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complex guideline and sustain improvements, after only one visit from an academic detailer. 
There was no reference to a pilot study and the sample size calculation was not described in 
sufficient detail to enable further appraisal of this work.  
 
The apparent increased likelihood of effectiveness following multiple visits may need to be 
balanced with acceptability and cost of repeated outreach visits. Gask found that two face to 
face visits per year by a detailer to general practices was feasible and acceptable to GPs in 
Belgium (Gask 2004). Crotty found that residential care home physicians accepted two 
outreach visits (Crotty 2004). In delivering their successful educational package to GPs in 
Anglia, Fender met with practices on 2 separate occasions (Fender 1999). Yeo and colleagues 
in Australian general practice describe a controlled trial involving three visits aiming to reduce 
prescribing of benzodiazepines and related medicines (Yeo 1994). While they do not report 
any change in prescribing behavior, the GPs who received the face to face support rated their 
benzodiazepine prescribing as much improved but objective assessment of their prescribing 
did not show any change. In their discussion, the authors reflected on the components of their 
intervention and stressed the importance of the initial meeting to “establish rapport”. Overall, 
they interpreted their findings as a reminder that “we do not always do what we mean to do, 
and we do not always do what we think we do”. Missing in their approach was anticipation of 
practical barriers to changing prescribing. For example, the detailers failed to identify those 
patients who were eligible for benzodiazepine reduction or discontinuation, or provide the GPs 
with this information to facilitate change. 
 
Soumerai appears to be the only researcher to have speculated on the dose-response of 
increasing the number of outreach visits. He conducted a randomised controlled trial of the 
effectiveness of face to face visits by clinical pharmacists, involving 435 doctors. They 
observed an approximate doubling of the magnitude of change in their targeted medicines 
when the number of visits was increased from one to two (Soumerai 1987).  
 
In a randomised controlled trial of practice based education (using principles of academic 
detailing) in east London by Feder, guidelines for asthma and diabetes were actively 
disseminated. Focusing on practice based small group multidisciplinary educational outreach 
sessions, the authors visited practices on three occasions. While the duration of meetings and 
the interval between meetings was not reported, the effects were positive and the three visits 
were viewed as an integral part of the successful model (Feder 1995). The investigators appear 
to have adhered to the principles of academic detailing during their meetings with practices. 
They also encouraged practices to make improvements in the accuracy of their disease 
registers.  
 
Only one report from the literature review described GP preferences regarding the frequency 
of academic detailing visits in practices. A feasibility study based in Belgium invited 184 
physicians to receive two visits from an academic detailer focusing on Non Steroidal Anti 
Inflammatory painkillers. One hundred and forty two received two visits and 105 physicians 
gave their opinion on the visits through a questionnaire. Most (90%) respondents expressed a 
wish to receive an academic detailer on other topics, agreeing that two visits per year was a 
suitable frequency (Habraken 2003). 
 
Another study used four, one to one visits between pharmacists and GPs in an attempt to 
increase the proportion of depressed patients taking antidepressants, and improve symptoms of 
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depression (Brown 2000). The intervention made a statistically significant difference on both 
outcomes. 
 
In 2002, the Cochrane collaboration considered the importance of the number of visits on the 
effect of academic detailing (Thomson 2002). They reported a wide range, from once weekly 
for seven months (Steele 1989), to single visits (Newton Syms 1992), with examples of 
successful and unsuccessful outcomes across the spectrum. The review concluded on the need 
for standardisation and formal evaluation of the incremental importance of additional outreach 
visits. 
 
The duration of effect after the last detailing visit is an important consideration, because the 
persistence of prescribing change will determine the extent of benefit incurred by patients. If it 
can be assumed that more frequent visits lead to a stronger and longer lasting effect, in 
designing a new intervention that builds on previous work, it makes sense to develop our 
understanding by increasing the number of visits and evaluating outcomes over a longer 
period. Therefore, the trial in this thesis tests the impact of three face to face meetings (as a 
balance between too few and too many) and evaluates outcomes over a longer period than any 
previous trials.  
 
 
2.3.5.4  Overcoming organisational barriers to implementation 
 
Organisational barriers are recognised as a key factor limiting the implementation of evidence 
based medicine (Haynes 1998). Some reports have highlighted practice or GP level 
organisational barriers as important factors limiting the introduction of prescribing change, but 
most investigators have not identified and addressed these prospectively. For example, none 
have set out to provide outreach visitors with the time and understanding to help practices with 
the additional effort needed to overcome organisational barriers. These might include patient 
identification, call and recall. A recurrent theme in the literature review thus far is that 
identification and addressing organisational barriers (at the level of the practice, the prescriber 
or the patient) is a key determinant of the success of detailing interventions.  
 
While some detailing interventions incorporate strategies to explore and resolve GP level 
barriers, few apply this logic to practice level organisational barriers and fewer still to patient 
level barriers and supports.  
 
Practice level barriers to implementation of (repeat) prescribing change can nullify or delay 
the detailer’s efforts. If we assume educational messages are accepted, even if these are 
implemented on a patient by patient basis by GPs, completion of this task may take a long 
time in primary care, if the prescribing change applies to large numbers of patients. The 
administrative burden involved in patient identification and engagement, arrangement of 
consultations to facilitate prescribing then follow up, cannot be underestimated. Additional 
work can be expected for patients who do not attend pre-arranged appointments. Overcoming 
these barriers might involve the detailer helping the practice to identify patients who would 
benefit from changed prescribing and set up a register or recall system which systematically 
invites and appoints patients.  
 
Moher tested this approach but not within a multifaceted, complex detailing intervention 
(Moher 2001).  He compared the effectiveness of three interventions (audit and feedback, 
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recall to general practitioner and recall to nurse clinic) aiming to improve the cardiovascular 
assessment of patients in Primary Care. Establishing a nurse led call/recall system in practices 
and comparing the impact (for secondary prevention of CHD) on patients with CHD, they 
found that it was no better than audit as a means of promoting secondary prevention measures. 
Outcomes included reductions in blood pressure, blood cholesterol and continine levels. Each 
approach was found to be better than doing nothing, because assessment and follow up of 
patients was improved within intervention groups. The authors account for the inability of 
their interventions to deliver clinical improvements on GPs’ unwillingness to initiate 
recommended preventative medicines including statins. If their practical support was 
accompanied by an educational exchange, this may have helped. They found that follow up by 
nurses appeared to be more effective than follow up by GPs.  
 
In other UK based studies, systematic registration and planned recall of patients for 
appointments was found to improve the quality of care (Feder 1995; Pierce 1989), although 
there are now financial incentives for practices to systematically identify and treat patients 
with several common chronic diseases, including CHD.  
 
An additional, often overlooked consideration in general practice which has a direct bearing 
on the chances of successful detailing outcomes is the accuracy and completeness of disease 
registers. These form the backbone of a successful call and recall system. Accounts of the 
accuracy and completeness of disease registers indicate variability (as expected) (Whitelaw 
1996; Jick 1991; Lowrie 2005; Jick 1992; VanStaa 1994; Hassey 2001; Moher 2000). 
However, this evidence is not recent, and recognition of the need to improve the accuracy and 
completeness of disease registers and therefore reduce variation in processes of care has led to 
improvements, evidenced from the achievement on practices’ GMS QOF points year by year. 
 
If the aim of educational outreach is to improve the drug management of all eligible patients 
with the targeted condition, the detailer needs to be aware of the potential variation in the 
accuracy and completeness of practice level disease registers. Support should be offered to the 
practice to improve this, prior to introducing changes.  
 
The UK based qualitative study by McColl further supports the idea that organisational 
barriers are important in the route to the implementation of evidence based medicine (McColl 
1998). In addition, the attitudes and extent of teamwork within practices was seen as a major 
tension which has the potential to lead to a collective failure to agree practice level policies on 
clinical management, scuppering practice level changes in prescribing  
 
Going a step further to involve patients and carers (in this case parents of children aged under 
6 years old), Finklelstein (2008) studied the impact of an intervention combining detailing 
with posted, printed educational material directed at families. On comparing this approach 
with usual care, they found that the use of antibiotics diminished significantly in their 
intervention group. The authors concluded by emphasising the importance of involving 
patients/carers or the public in attempts to change antibiotic prescribing practice.  
 
In healthcare systems where patients’ ability to pay limits the uptake of health and related 
services, financial incentives for patients may be effective in overcoming barriers to changed 
behaviour (Benedetto 2000). Within the NHS these principles are unlikely to apply therefore 
will not be considered further.  
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2.3.5.5  Educational outreach plus additional strategies 
 
As an example of how the detailing model has developed to include additional techniques, 
Brufsky conducted an interrupted time series study within a large health maintenance 
organisation covering four states in New England (Brufsky 1998). They compared a combined 
educational outreach and facilitation model to usual care, encouraging prescribing of 
Cimetidine instead of Ranitidine, for patients with gastrointestinal conditions. The prescribing 
of their preferred agent (Cimetidine), increased by 53.8% following the intervention. Other 
positive outcomes included an assessment of the rate of hospitalisations for gastrointestinal 
conditions. Their intervention proved effective and an accompanying economic analysis 
demonstrated cost effectiveness. Unfortunately, the intervention is not well described and for 
that reason, cannot be critiqued. The professional or other qualifications of those delivering it 
are also unclear, as are the content, duration, frequency of contacts, bespoke training received 
by people delivering it or the characteristics of patients and practices receiving it. Lack of 
information on these important features limits transferability. However, the authors assert that 
their combination of education and facilitation led to the successful outcomes. Facilitation 
included the use of bespoke forms to enable doctors to evaluate their own performance in 
relation to the prescribing of Cimetidine and the use of reinforcement strategies (e.g. 
feedback). In addition, the intervention team pre-screened lists of patients to clearly identify 
patients prescribed ranitidine who were appropriate candidates for Cimetidine. In this respect, 
the investigators employed marketing techniques and change methods not described 
previously or since then. Their methods resembled those used in everyday pharmacist 
prescribing support within general practices in the UK.  
 
Nilsson and colleagues incorporated detailing with additional techniques to effect change, but 
unlike Brufsky, they stopped short of providing GPs with lists of patients who may have 
benefitted from changes to their prescribing for hypertension, peptic ulcer or dyspepsia 
(Nilsson 2001).  Instead, they used patient level diagnoses and prescribing data from electronic 
patient records as part of their feedback. Feedback on prescribing rates, problem oriented 
educational outreach visits, educational material and the views of local opinion leaders were 
all used to encourage adoption of changed prescribing for the specified conditions. Within 
their randomised study which included three parallel intervention groups of GPs, they used 
before and after measures of prescribing change. Their intervention demonstrated a 
statistically significant improvement in prescribing.  
 
Although New et al described their UK general practice based nurse led intervention as 
educational outreach, additional strategies were incorporated (New 2004). These included 
seeking the names of diabetic patients who were poorly controlled and providing these, 
together with the names of patients requiring review of their lipid and blood pressure 
management, to participating GPs. In contrast with Brufsky’s study, New failed to achieve a 
statistically significant shift in their primary outcome of pre-defined targets for control of 
hypertension or hyperlipidaemia in patients with diabetes. In explaining this neutral result, 
organisational barriers were cited as an important limiting factor. These included apparent lack 
of additional activity within the practice, to review those patients with raised blood pressure 
and lipid levels. Already overburdened staff were resistant to accepting any additional work 
and some practices complained of a lack of resources to deal with the additional work. 
Practice nurses appeared more likely to support the outreach nurses than GPs but this 
dichotomy appeared to cause confusion among patients. Few practices have spare capacity, 
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ready to be deployed in this or any other way, without prior agreement or without 
reorganisation of existing staff or employment of additional staff.  
 
The setting for the Brufsky study was within a US Health Maintenance Organisation. New set 
their study in general practice in the UK. Both studies were primary care based and utilised 
similar interventions, albeit within different methodologies. However, one major difference 
that is likely to have led to the different outcomes is the incentives of the staff for changing 
their prescribing behaviour. In the Brufsky study, staff pay was directly linked to cost effective 
prescribing and the investigators provided a rich vein of income to the practice on 
achievement of prescribing change. In the UK at the time of the study, improvements in 
control of blood pressure and lipids competed with management of other clinical conditions, 
pre-dating the introduction of the QOF. Prescribing in the NHS operates independently of 
direct market forces; therefore, additional financial reward is not a viable option.  
 
The Cochrane Collaboration’s findings would tend to support the effectiveness of the use of 
financial incentives for GPs (Gosden 2005). They evaluated whether payment of primary care 
physicians (capitation, salary, fee for service and mixed systems of payment) impacted 
differently on clinical behaviour and found that there was some evidence to support the case. 
However, detailing models and studies are difficult to compare across different healthcare 
systems, because there is the possibility that an invisible hand, i.e. payment systems, can 
significantly influence outcomes. It is difficult to account for this confounding other than 
through a multicentre study.  
 
Recognising the need to help practices identify and target patients eligible for change, Feder et 
al used a combination of academic detailing together with disease register support. They 
demonstrated effectiveness in a cluster randomised controlled trial. They acknowledged the 
need to update disease registers as a pre-requisite to their detailing intervention and built their 
novel, multifaceted intervention on a sound knowledge and understanding of the context of the 
UK Primary Care and general practice system of organisation (Feder 1995).  
 
Overall, there seems to be a reasonably strong logistical argument backed up by some 
published evidence, for incorporating a combination of strategies, including addressing 
organisational barriers in addition to the original cognitive approach described by Avorn and 
Soumerai. However, there is no ‘off the shelf’ description or standardisation of the 
components of this hybrid model and it remains to be tested in the context of a trial for 
patients with CHD or other vascular disease, in the UK primary care system, with 
measurement of longer term surrogate clinical outcomes.  
 
Practice based prescribing support pharmacists are regarded as part of practice teams or, at 
least, the primary care team. Therefore, the pharmacists can support eligible patient 
identification, call and recall, and work in the practice for longer than other visitors. In so 
doing, the process of the original detailing model is developed to the point where the 
intervention offers a balance between educational exchange and facilitation of change through 
direct practical support to the practice. There are other examples of the application of 
prescribing support models combining educational outreach with additional strategies, but 
none involving the following: case identification, call and recall support, more intensive, 
repeated intervention with pharmacists working in practices on a weekly basis. Incorporating 
these features represents a necessary evolution in prescribing support, potentially providing a 
useful means of supporting prescribing decisions as the volume and complexity of prescribing 
for patients with LTCs continues to increase. 
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2.3.5.6  Cardiovascular disease focus 
 
Attempts at improving targeted aspects of the management of cardiovascular disease in 
primary care through educational outreach or academic detailing, have generated positive 
results (Cupples 1994; Feder 1999; Jolly 1999; McCartney 1997; Seigel 2003). However, no 
studies have involved pharmacists, followed patients for longer than 1 year, focussed on 
statins, measured impact on anything other than prescribing or described their interventions or 
study populations in sufficient detail. Three of the most relevant are described in Table 2.4.  
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Table 2.4   Key features of selected studies  
 
Authors/ 
Country/ 
Year 
Method Participants 
and setting 
Interventions 
 
Outcome 
measurement 
Control Effect on practice and 
patient 
Comments 
Avorn J, 
Soumerai SB. 
North 
America, 
1983.  
Cluster 
RCT 
435 physicians 
from a Medicaid 
programme in 2 
states of USA. 
Physicians 
selected on basis 
of high 
prescribing of ≥ 
3 target drug 
groups 
Educational 
group of 
physicians 
received 2 visits 
from an 
academic 
pharmacist or 
pharmacologist 
over 6 months. 
Aiming to reduce 
prescribing of 3 
drug groups. 
Up to 9 months after 
intervention, 
measurement of 
number of units of 
drug prescribed 
across randomised 
groups. 
Control 
and 
printed 
material 
only  
Detailing on a one to 
one basis is effective 
and saves drug costs 
compared with printed 
materials only and 
control groups. Effect 
size: 18% drop in 
prescribing (p< 0.0001)  
This trial was the first to implement a detailing 
programme and test it within a RCT. A market 
research consultant conducted interviews with 
non participating doctors, asking about their 
reasons for prescribing the 3 target drug groups. 
These insights were incorporated into the 
educational strategy. 
The pharmacist detailers made quantitative and 
subjective notes of their meetings.  
No information available on the characteristics of 
the pharmacist detailers, patients or physicians. 
No power calculation. 
 
Freemantle, 
UK,  2002  
Cluster 
RCT 
75 general 
practices in 12 
Health 
Authorities in 
England 
Between 4 and 6  
outreach visits 
by one of 12 
community 
pharmacists who 
had received 
three days of 
training covering 
4 clinical 
guidelines. 
Delivered the 
explicit 
techniques of 
academic 
detailing set out 
in Avorn and 
Soumerai’s 
original work.   
Change in 
prescribing of 
evidence based 
medicines advocated 
in the guidelines and 
in one case, 
alternatives. 
Secondary outcomes 
are changes in trends 
of medicines, 
collected by remote 
assessment of 
prescribing statistics 
without linkage to 
patients and 
diagnoses. 
Control 
practices 
without 
education
al 
outreach 
for 2 of 
the 4 
guidelines
.  
5.2% improvement 
(95% CI 1.7% - 8.7%) 
in number of patients 
treated according to 
guideline 
recommendation. 
Smaller practices 
responded more 
favourably than larger 
practices.  
Practices were given postgraduate educational 
allowances for participating, which limits 
generalisability and questions motivation for 
participation.  
The clinical guidelines were developed for the 
purpose of the trial. The results of this process 
are not likely to carry weight or support from 
participating practices because they were not 
involved in the production.  
No measure of prescription adherence or 
characteristics of patients at baseline.  
The authors concede that measurement of 
outcomes was complicated in each of the four 
clinical guidelines areas. Outcomes were positive 
for changes in 3 of the 4 guidelines; in the 
remaining guideline’s educational outreach 
programme, a decrease in guideline prescribing 
with an OR of 0.73 (95% CI 0.56 – 0.94), 
equivalent to a 3% reduction in patients managed 
in line with the guideline. 
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Authors/ 
Country/ 
Year 
Method Participants 
and setting 
Interventions 
 
Outcome 
measurement 
Control Effect on practice and 
patient 
Comments 
Diwan, 
Sweden,  
1995.  
 
Cluster 
RCT 
134 Health 
Centres in 
Sweden 
4 meetings 
lasting 30 
minutes each, 
over 5 months in 
the practice, 
group outreach 
by a pharmacist, 
covering 
guidelines on 
hyperlipidaemia 
management 
Number of 
prescriptions for lipid 
lowering drugs and 
prescription of first 
line lipid lowering 
drug.  
Data collected from 
pharmacies including 
lipid lowering dose, 
strength, quantity. 
Age and sex were 
only demographics. 
Usual 
Care 
20% increase in 
prescribing of first line 
lipid lowering drugs (p 
= 0.03) 
Power calculation; stratification by number of 
prescribers and list size which is important as 
both can influence uptake of evidence. No 
measurement of cholesterol levels or adherence 
or clinical outcomes. No testing of model on 
single handed practitioners.  
 
This trial includes a larger number of physicians 
than any other published. Follow up lasted 1 year 
after intervention finished. 
 
No patient demographics other than age and sex; 
no clinical co-morbidities available.  
 
Consideration given to existing and incident 
patients receiving lipid lowering treatment. 
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Studies involving pharmacists consulting with patients then making recommendations about 
changes to cardiovascular medicines were more common. One such study was conducted in 
1997 in Hawaii. It was randomised, controlled, lasted 6 months and involved 94 patients, all 
with cholesterol of 6.2mmol/l or more (Bogden 1997). It involved one pharmacist discussing 
lipid lowering therapy, diet and behavioural modifications with patients and doctors in 
primary care. In the control group, patients received usual care from their doctor, without 
pharmacist intervention. Doctors retained responsibility for implementing the pharmacist’s 
recommendations. The close interaction between doctor, pharmacist and patient resulted in a 
statistically significant increase in the number of patients with cholesterol levels below target 
and lower cholesterol levels among participants. The impact of the intervention was greater in 
the subgroup of patients with higher cardiovascular risk profiles (those with established 
disease and those with no established disease but with at least two coronary heart disease risk 
factors). The author attributed the success of the intervention to the initiation of lipid lowering 
medicines instigated by the pharmacist during the face to face encounter with the patient. Key 
discussion points were the likely importance of the aggressive nature of guideline 
implementation together with sustained positive rapport among physician, pharmacist and 
patient. The author also acknowledged the difficulty replicating their work in practice, because 
of the cost of the concerted effort to direct activities towards cholesterol lowering. 
 
In the study by Latour (2000), the pharmacist encouraged physicians to decrease the 
prescribing of lipid lowering medicines for patients at low risk of vascular disease. The 
primary outcome was not achieved. The study design did not incorporate a control group, was 
quasi randomised, did not adequately describe the intervention characteristics and had a short 
follow up period of five months, all of which limits the strength of the evidence. However, this 
work stands out as one of the few that attempted to decrease the prescribing of a medicine that 
is unlikely to cause any harm if continued indefinitely. In fact, over time, as subjects’ age, 
blood pressure and possibly other risk factors increase, it is possible that their cardiovascular 
risk profile reaches the point where a statin is indicated; this factor may have mitigated against 
the intervention working. The authors do not discuss this possibility. An important lesson from 
this work is the importance of carefully choosing the prescribing message to meet short term 
and long term patient and GP needs. 
 
 
2.3.5.7  Pharmacy led educational outreach  
 
This section considers lessons from the literature relating to pharmacist-led educational 
outreach, and considers direct implications for the new intervention to be tested in this thesis, 
which aims to improve statin prescribing.  
 
In the UK, the concept of a general practice based prescribing facilitator/manager (distinct 
from pharmacist-led patient facing activities e.g. medication review) appears to have been first 
described by Leach in 1999. He suggested that to secure effective implementation of an agreed 
prescribing change at practice or population level, someone needs to take the initiative to 
modify practice computer systems, organise and send letters to patients. Since then, many 
different models of prescribing change have developed. In parallel, practices have developed 
an infrastructure that is now more able to absorb these changes e.g. the availability of practice 
nurses and practice managers, better trained reception staff and expert information technology 
solutions. 
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A Cochrane Review sought to answer the question of whether educational services delivered 
by pharmacists to physicians result in better outcomes (improved patient outcomes or 
decreased use or costs of health services) compared to the delivery of the same services by 
other healthcare professionals (Beney 2000). Insufficient evidence was available to answer 
this question, with only one controlled pre-post study cited. In this study, pharmacist-led 
delivery of outreach was compared with physician – led delivery. The objective was to reduce 
the prescribing of three contraindicated antibiotics and oral cephalosporin antibiotics. 
Physicians’ educational support was found to be more successful, although more expensive 
(Schaffner 1983). 
 
Newton Syms (1992) trained pharmacists to operate as detailers, using selling techniques 
normally associated with the pharmaceutical industry e.g. training on communication and 
presentation skills, approach to GP appointments, promotional aids. Pharmacists delivered 
non-commercial advice on non steroidal painkillers, individually to GPs working in single 
handed and group practices. Their trial compared prescribing from patients registered with 
GPs who had received the intervention and those registered with GPs who did not. The authors 
found a positive shift in the prescribing of targeted medicines. However, little information was 
available on the baseline characteristics of the GPs or patients and the study results are not 
presented in enough detail to enable critical appraisal of the analysis.  It appears that the 
impact of clustering was not incorporated into the design or analysis which is likely to have 
led to overestimation of the significance of the observed effect. The follow up period was 5 
months post intervention. Implications of this work for the educational outreach intervention 
and study described in this thesis, include the need to describe the intervention and 
pharmacists’ training adequately, account for clustering and describe baseline characteristics 
of recruited practices and patients in sufficient detail. 
 
In their design paper, Freemantle (1999) describe key features of their educational outreach 
intervention delivered by pharmacists across 48 practices in England but the extent to which 
support was targeted to call and recall was unclear. Outcomes included prescribing, 
summarised at practice level only. However, a lack of characterisation of patient 
demographics and prescribing at patient level, make interpretation of the impact of the 
intervention difficult.  
 
One study involved community pharmacists in an attempt to improve the appropriateness of 
their recommendations for over the counter antifungal medicines. Community pharmacists 
received an educational outreach visit or attended a continuing professional education session 
(Watson 2002). This randomised controlled trial showed that there were no statistically 
significant differences in the appropriateness of antifungal sales from educational outreach.  
 
In another UK based randomised controlled trial, community pharmacists delivered outreach 
visits to general practices (Watson 2001). The study intervention comprised posted guidelines 
combined with two, face to face outreach visits from community pharmacists, encouraging the 
prescribing of a limited list of three Non Steroidal Anti-inflammatory Drugs. Comparison 
groups were practices with and without posted NSAID guidelines. A useful description of the 
intervention included the duration of each outreach visit: up to 10 minutes was allowed, and 
visits were three to four months apart. Watson found no statistically significant differences 
were demonstrable in the primary outcome. From a theoretical and pragmatic standpoint, it is 
difficult to envisage how this very short contact time between detailer and GP would have 
enabled the change process to take place. Grol mentioned the need to achieve orientation, 
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insight and acceptance to encourage implementation of change in practice, all of which may 
take longer than two 10 minute slots in the context of a busy day (Grol 1992).  
 
 
2.3.5.8  Pharmaceutical industry models  
 
As with every other commercial, for profit organisation, the pharmaceutical industry spends 
vast sums of money on marketing. This includes supporting their representatives to engage 
with Doctors in Acute and Primary Care settings, disseminating promotional materials, staging 
conferences, carefully choosing research questions that promise to illuminate the benefits of 
their products in comparison with competitors, and provision of equipment to support 
diagnosis and prescribing. In 1994, an enquiry into the influence of pharmaceutical industry 
representatives on the NHS in the UK, estimated that the industry spent approximately 
£10,000 per GP annually on marketing. The amount spent by the NHS on delivering 
prescribing advice (which included pharmaceutical advisers) was approximately £500 per GP 
(National Association of Health Authorities and Trusts 1994). The industry makes best 
possible use of known influences on behavioural change. Much can be learned from their 
marketing techniques. For example, printed material used by representatives is often 
persuasive and visually appealing. Together with repetition of key points during brief 
opportunities, industry representatives are able to effect behavioural change in prescribing. 
Affability and the provision of updates, self declared “cutting edge” innovation in drug 
selection and small gifts all help to convey the message. Leaving free gifts may lead to an 
increase in the prescribing of company sponsored products, up to two years after the event 
(Schumock 2004; Glare 2006).  In a review of the literature concerning interactions between 
doctors and pharmaceutical industry representatives from 1977 - 1993, Lexchin concluded that 
doctors’ prescribing behaviours are affected by their interactions (Lexchin 1993). This was 
found to be the case despite doctors’ lack of awareness of personal susceptibility to influence 
(Ruteledge 2003). To compound this finding, most GPs seem not to have a very high opinion 
of the information from pharmaceutical company detailers or company sponsored continuing 
medical education events (Lexchin 1993). This influence leads to increased prescribing costs 
(Brewer 1998), with one study showing that frequent general practitioner contact with drug 
industry representatives was strongly and independently associated with higher prescribing 
costs (Watkins 2003). However, there appears no reason why NHS pharmacists cannot adopt 
some of these techniques, although NHS pharmacists’ approaches are more limited in relation 
to provision of free gifts. 
 
Although not clearly reported, the pharmaceutical industry occasionally enlists the support of 
local opinion leaders to advocate their products in the hope that they can persuade other 
physicians to prescribe. In primary care, prescribing is influenced by many factors. One 
influence for some GPs is endorsement of a medicine by a trusted consultant in secondary 
care, and prescription of a new medicine by a consultant leads to familiarity by the GP who 
has responsibility for ongoing prescribing. While the broad literature about the usefulness of 
local opinion leaders as a means of impacting on professional practice appears inconclusive, 
there may be some merit in this approach (Thomson 2005). On this basis, it appears worthy of 
inclusion in a multifaceted, novel prescribing support model. 
 
Appropriate training appears instrumental to the industry’s success. It focuses less on 
pharmacology, more on communication skills:  developing rapport, anticipating GPs’ needs, 
profiling individual GPs and highlighting drawbacks of competitors’ products. One study 
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explored the complex attitudes and behaviours of groups of GPs attending reflective practice 
sessions focussing on their prescribing. In commenting on the skill profile of the group 
facilitators (detailers), the authors asserted that effective group facilitation skills to create a 
group process were more important than a professional background and sound knowledge of 
therapeutics (Watkins 2004). 
 
One study of the interaction between GPs and pharmaceutical company representatives, 
helped illuminate several marketing techniques used by the industry. These included 
“reciprocity” in which the GP is given a gift and in accepting, feels bound to make repayment, 
often through prescribing of the company’s product. As pharmaceutical companies and their 
representatives will show bias towards their own products, the authors recommended the 
introduction of a third party to provide unbiased educational information about the full range 
of medicines for specific conditions (Somerset 2001). Pharmacists, as NHS employees, 
particularly those working within the practice environment, seem ideally suited to this role.  
  
Therefore, in designing a novel pharmacist-led outreach intervention for delivery by NHS 
employees, an awareness and use of techniques derived from pharmaceutical industry 
representatives and their training programmes, are likely to support uptake of new prescribing 
practice. The content of pharmacists’ training will be described in Chapter 3: Methods.  
 
 
2.3.5.9  Targeted or untargeted outreach 
 
In choosing who should receive outreach or academic detailing in a trial context, researchers 
usually choose to target those who have the greatest scope for improvement in the 
intervention. In the context of routine service delivery, the decision is likely to be guided by 
economic principles, which leads to the same, targeted approach, by offering a service to those 
who need support most, thus minimising inefficient use of scarce resources. However, the 
decision can be more complex, e.g. the equity dimension of whether a service should be 
offered to all or some. In addition, in primary care, rapid access to sufficiently detailed 
information may not be available to inform targeting e.g. how much unmet need is there in 
each practice in relation to maximum guideline doses of statins for eligible patients. Therefore, 
targeting may not be an option.   
 
Soumerai and Avorn targeted high prescribers of inappropriate medicines with a view to 
decreasing prescribing (Soumerai 1990), and many other intervention studies since then have 
adopted the same strategy to maximise the chances of a positive result. For example, after 
exposing frequent prescribers of antibiotics to a 1:1 detailing session, there was a significant 
reduction in the number of days of inappropriate antibiotic usage in a large teaching hospital 
(Solomon 2001). Other evidence suggests delivery of academic detailing without targeting 
may lead to insignificant changes in the outcome of interest (Hall 2001). This observation is in 
accord with one of the barriers to implementation of change identified by the EBOR team 
(Nazareth 2002):  lack of perceived willingness to change among prescribers.  
 
However, untargeted detailing has the advantage of being more easily reproduced outwith the 
trial setting because it does not depend on the presence of prescribing outliers, who have a 
recognisable need to modify their prescribing towards the mean, and it does not rely on 
sufficient information to inform targeting.  
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2.4 Identifying and addressing weaknesses in research to date 
 
In a systematic review of the effectiveness of pharmacists’ activities on health service 
utilisation, costs and patient outcomes, it was concluded that more rigorous research was 
needed (Beney 2004). The following features were highlighted as important and in need of 
improvement in future work: 
 
• Intervention definition and description; 
• Health economic evaluation; 
• Generalisability of the intervention (e.g. more pharmacists delivering the 
intervention rather than one or two highly specialist practitioners); 
• Outcomes should include clinical events or surrogate clinical endpoints; 
• Design and analysis to account for clustering  
 
In designing the trial in this thesis, these features will be addressed as far as possible within 
the financial and time framework available. 
 
Aspects of design are commonly cited as weaknesses in trials of interventions aiming to 
improve the professional or clinical decision making behaviour of healthcare professionals or 
patients (Hatoum 1993; Morrison 2001). Inappropriate designs or analyses are common and 
create difficulties in interpretation (Campbell 1998). Examples of this include inadequate 
sample size and bias in selection of practices (Avery 1997), absence of a control group (Field 
1989; Green 1985; Wyatt 1992), lack of matching of controls and insufficient statistical 
analysis (Grant 1985), or lack of information on characteristics of the control group (Hill-
Smith 1996). Studies with design weaknesses are prone to misinterpretation.  
 
The literature review revealed the following recurring features needing particular attention.   
 
 
2.4.1  Clustering 
 
In primary care based randomised controlled trials in the UK, designed to study the effect of 
educational outreach, patient level randomisation is neither practical nor ethical. 
Randomisation by group (practice) is preferable because it avoids contamination of the usual 
care group and the effect of the intervention can be assessed in the natural practice 
environment. Using individual patient randomisation in an educational outreach intervention 
directed at general practitioners is not appropriate because the management of one patient is 
not independent of another (MacLennan 2003). 
 
Some studies involve randomisation of health professionals or groups of professionals (cluster 
randomisation) but analyse outcomes at the patient level, thus resulting in a possible 
overestimation of the significance of the observed effects (unit of analysis error) (Whiting -
O’Keefe 1984; Donner 1981; Donner 2000; Simpson 1995; Divine 1992; Donner 1990), 
without making corrections for the impact of clustering. Pill tested the impact of a patient 
centred intervention on GPs (Pill 1998). Twenty nine general practices were randomised and 
the results analysed at practice level; prescribing and other changes were measured at the level 
of the patient. However; analysis did not take account of clustering so the results are likely to 
be an overestimate of the significance of the effect. 
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Therefore it is important to build this learning into the methodology of a trial of a new 
intervention in primary care general practices, directed at GPs. 
 
 
2.4.2  Pre-Randomisation and randomisation  
 
Stratification (balancing influential variables other than the number of practices in each arm of 
the study) prior to randomisation is useful if there are characteristics of practices that make 
them more or less susceptible to changed prescribing.  
 
In a trial of prescribing rationalisation in primary care in the Netherlands, Van Eijk assessed 
some key characteristics of practices prior to randomisation (Van Eijk 2004). Three 
characteristics independently influenced their main outcome measure: practices’ use of 
prescribing feedback data, a formulary and a consensus on drug choice within the practice. 
Consequently, they stratified on this basis.  
 
As there may be differences in the organisation, response to educational interventions and 
uptake of evidence based medicine between single handed and group practices, stratification 
by practice size has been recommended (Soumerai 1989). In keeping with this, Nazareth 
found disproportionately increased uptake of their outreach intervention in smaller practices 
compared with larger practices, supporting the case for stratification of this potentially 
important confounding variable (Nazareth 2002).  
 
Van Eijk (2001) found more successful outcomes from group practice detailing, in their trial 
designed to compare the impact of both group and individual detailing on the use of highly 
anticholinergic antidepressants.  
 
These two reports draw conflicting conclusions on the effect of detailing in group versus 
smaller practices. They perhaps underscore the relative importance of heterogeneity of 
context, intervention duration, delivery, intensity and topic on the outcomes, and the 
difficulties inherent in comparing different trials using similar interventions in different 
healthcare settings. This emphasises the importance of adequately describing these variables in 
order that other researchers and policymakers can compare with their own healthcare settings 
and draw their own inferences. 
 
 
2.4.3  Recruitment and generalisability 
 
A description of the process of practice recruitment in detailing type trials is useful because it 
enables an understanding of the representativeness of participating practices and informs the 
success of different recruitment methods, for other researchers.  
 
Moher (2001) initially contacted eligible practices in writing. After two invitations, non 
respondents were telephoned to assess their willingness to participate.  From 79 eligible 
practices, 21 (27%) agreed to participate and were randomised. Fifty eight practices did not 
respond to the initial written invitation, were not interested or had other reasons not to 
participate. It is not clear over how long recruitment lasted, how much resource was required 
to follow up non responders or whether non respondents were contacted in person.  
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Nazareth managed to recruit 75 of 102 eligible practices in their Evidence Based Out Reach 
(EBOR) trial (Nazareth 2002) however, further details on how they approached practices is 
lacking.  
 
Van Eijk (2001), in common with most other trialists, do not describe their recruitment 
process. The lead investigator was known to the practices and it is likely that this helped.  
 
Hall (2001) offered either a single outreach visit or audit and feedback to 38 practices in the 
intervention arm of a randomised controlled trial aiming to improve the drug based eradication 
of Helicobacter pylori infection in Primary Care. At the time of recruitment (1996), all 
practices in their catchment area were invited and ethical committee approval was not 
required. No detail on their recruitment process was given.  
 
The transferability and generalisability of detailing studies is increased if the people delivering 
the intervention are less highly qualified, or representative of the majority of pharmacists 
practising in the community. Most randomised controlled trials involving pharmacists have 
recruited those with highly advanced training and postgraduate degrees (McMullin 1999; 
Lipton 1992). This drawback applies to the original pharmacist-led educational outreach work 
by Avorn and Soumerai in 1983, and, analogous to the targeting of outlying prescribers for 
intervention, specialists delivering outreach interventions will increase the chances of success, 
but reduces the generalisability of the results.  
 
From an NHS perspective, using a more representative sample of the pharmacy workforce to 
deliver an intervention would increase the implementation potential. Therefore, an important 
consideration in designing the intervention is that the pharmacists have some additional 
training but are not so different from other prescribing support pharmacists that the 
intervention cannot be reproduced.  
 
 
2.4.4  Choice and measurement of outcomes 
 
Evaluating prescribing change in relation to set prescribing criteria generates a process rather 
than an outcome measure of quality.  
 
In most studies involving guideline implementation, it is assumed that care is improved when 
a guideline is implemented. A direct, proportional relationship between prescribing change 
and guideline criteria might be assumed to result in improvements in quality of care. However 
without measuring health outcomes, it is difficult to confirm and quantify the effect size, yet a 
neutral or negative result from this type of intervention may represent an adequate response 
from the intervention but inappropriate guideline recommendations. Process outcomes may 
therefore be more appropriate for trials of health care delivery. They may be considered more 
sensitive indicators of quality than clinical outcomes because poor outcomes do not always 
result from poor processes (Brook 1996).  
 
When there is a proven impact on clinical outcomes from improvement in prescribing in a 
clinical trial setting, it is likely to be specific to a particular health care setting (Thomas 2000). 
To date, there is insufficient evidence to link educational outreach visits to reducing the 
number or prolonging the time to hospitalisation or impacting on mortality. Therefore, 
evaluating the effectiveness of outreach visits in terms of clinical outcomes is desirable 
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(Thomson 2002). If this is not possible, surrogate clinical outcomes could be used, particularly 
in cases where there is a robust link between clinical outcomes and the surrogate end point, 
e.g. cardiovascular, cerebro- and peripheral vascular morbidity/mortality and cholesterol 
lowering or simvastatin prescribing.  
 
On the other hand, it might be argued that given the unequivocal efficacy of some medicines 
e.g. Statins, it is an unnecessary duplication of effort to follow patients to the point where 
differences in clinical outcomes become apparent. ‘Care as usual’ as the control intervention is 
one acceptable way of dealing with this scenario. 
 
One of the lessons learned from the cluster randomised controlled trial of educational outreach 
conducted by Gask (2004), included the usefulness of measuring patient level outcomes. 
Participating GPs received an educational intervention aimed at improving the process of 
assessment and management of depression. Patients with depression presenting to GPs who 
had received this intervention were evaluated for their depression status and satisfaction with 
consultations. The only positive outcomes in the study were patient reports of the improved 
ability of intervention group GPs to listen and understand their symptoms better. Most studies 
do not assess this type of patient oriented outcome.  
 
The study by Solomon is also atypical in that it measured clinical outcomes. In their trial of 
antibiotic detailing in a hospital setting, they captured the impact on length of stay, intensive 
care unit transfers, readmission rates and in-hospital death rates. These were similar in groups 
of doctors receiving detailing and those with no support (Solomon 2001). However, their 
study was not powered to detect differences in any of these outcomes; the primary outcome 
was a reduction in prescribing of non-formulary intravenous antibiotics and this was achieved. 
 
An unusual feature of the study by Nazareth (Table 2.4) was the choice of outcomes. The 
researchers evaluated three steps considered pre-requisites for the achievement of the primary 
outcome. The steps were general practice agreement to participate in the study, attendance at 
outreach visits and the GP’s prescribing practice. While the trial did not show a statistically 
significant change in prescribing overall, their unusual choice of outcome measurement 
enabled a better insight to the reasons for the lack of impact, rarely seen in a randomised 
controlled trial design.  
 
An additional consideration in the choice of outcome relates to whether new (incident) or 
established (prevalent) prescribing is evaluated at follow up. Very few trials evaluate both; 
most focus only on incident prescribing, presumably because it is a more sensitive indicator of 
effect and easier to measure. While this is a legitimate approach, it perhaps lacks the 
comprehensiveness of measuring both. A greater effect size is likely if a larger number of 
patients receive the targeted changes, which means all those patients who are eligible and 
already receiving medicines for LTCs should be considered suitable for prescribing change. In 
addition, measuring impact on both incident and prevalent cases is likely to be of more interest 
because both groups require support. As a demonstration of this point, in their trial of 
educational outreach aiming to reduce benzodiazepine prescribing, Zwar considered both, but 
detected a reduction over time in only the maintenance (prevalent) prescriptions for 
benzodiazepines (Zwar 2000). In contrast, GPs described more barriers when attempting to 
change maintenance treatments for asthma rather than incident treatments in one randomised 
controlled trial based in the Netherlands (Veninga 2000). 
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One study aimed to evaluate the impact of two different methods of implementing guidelines 
on the management of hyperlipidaemia. The comparisons comprised guidelines displayed in 
general practice case records in an algorithmic format or in a standard (non algorithmic) 
format. Unusually, prescribing or cholesterol changes were not evaluated. Instead, the authors 
chose to ask participants’ opinions of their preferred guideline display and which method led 
to the most prescribing changes. A key finding was that there was a statistically significant 
mismatch between the perceived and actual proportion of patients managed appropriately 
between groups. However, as patient level and practice level prescribing data was not 
collected in sufficient detail, no more inferences can be made (Nguyen 2000).   
 
Little is known about the longer term outcomes from detailing research. In the original trial 
testing academic detailing against passive dissemination of printed materials, the effect waned 
after nine months (Avorn 1983).  Other evidence suggests effects weaken after 12 months 
(Pearson 2003) but no studies could be found where follow up lasted beyond 12 months. This 
argues for designing a study involving educational outreach with sufficient power to detect a 
difference in clinical outcomes over the longer term.  
 
Figueiras (2001), showed that one to one detailing using reminders and focussing on only one 
(narrow) topic was effective up to nine months post intervention. Only two studies from thirty 
four identified through a systematic review in 1997 found that changes to clinical behaviour 
including prescribing were sustained beyond nine months (Beilby 1997). Until an empirical 
evidence base is clear, it could be argued that outreach visits are not the method of choice if 
longer term change is required (Tamblyn 1997). 
 
The Anglia menorrhagia education study (Fender 1999), aimed to determine whether an 
educational package could influence the management of menorrhagia, increase the 
appropriateness of the choice of non - hormonal treatment and reduce referral rates from 
primary to secondary care. One hundred general practices were recruited within a randomised 
controlled trial. The intervention resembled academic detailing and the principles adopted by 
the independent academics were borrowed and acknowledged as being from Avorn and 
Soumerai’s original work. Results were positive for two of the three outcomes: significantly 
fewer referrals and higher use of tranexamic acid but no decrease in the use of norethisterone 
in the intervention group practices compared with controls. While the trial was the first to use 
academic detailing in the area of menorrhagia management, the process for measurement of 
outcomes is a weakness in the trial design. GPs in both groups were asked to place a self 
report pad in a prominent place on their desks, and complete it following consultations with 
suitable patients. This approach ran the risk of under reporting for GPs within practices 
allocated to the control group who have not received any educational outreach support. There 
was no assessment, or reporting, of the true, or baseline, prevalence of menorrhagia across the 
practices. A practice computer search for prescribing of the implicated medicines and a 
practice Read code search for menorrhagia diagnosis before, during and after the intervention 
in each participating practice could have addressed this potential source of bias. It is also not 
clear whether the one year follow up period commenced at the second of two outreach visits or 
at some point thereafter.  
 
Only one study could be found which was designed to explore long term outcomes from a 
detailing approach and a clinical endpoint. The trial design used historical and parallel 
comparator groups of practices; lack of matched controls and absence of randomised design 
limits the usefulness of the results (May 1999). However, doctors received intermittent visits 
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from detailers (pharmacists with teaching hospital experience) over a five year period, with the 
observation and data collection period spanning 11 years. With the outreach topic of ‘safer 
prescribing of Non Steroidal Anti-Inflammatory painkillers’, the research team from Australia 
measured the number of hospital admissions for gastrointestinal problems and found a 
profound (70%) reduction in the patients from practices continuing to receive outreach visits. 
What is surprising about this study is the magnitude of the effect: a 70% reduction over a long 
time period is an incredible achievement, but because of the way the researchers interacted 
with their GPs, is understandable. They gathered clinical and practice level evidence, weighed 
it up against other evidence, honed it by involving local experts and opinion leaders. Overall, a 
pragmatic study of this size is difficult to deliver, but due to the lack of randomised control 
group, the outcome remains uncertain.  
 
Overall, it is preferable to measure clinical outcomes whenever possible and the longer the 
follow up the better, if we are to generate definitive evidence of the longevity of the detailing 
effect. Most work has not addressed either, therefore both will be considered in the present 
research.  
 
 
2.4.5  Economic appraisal 
 
Insufficient and inadequate economic evaluation of educational interventions creates 
uncertainty in the decision to adopt trials of implementation research with positive results 
(Brown 2002; Thomson 2002; Beney 2004). Based on available evidence, there is insufficient 
information indicating cost effectiveness. However, Soumerai evaluated the cost effectiveness 
of academic detailing within a randomised controlled trial and found it to be highly cost 
effective. Two meetings lasting approximately 18 minutes each, between a trained detailer and 
GP, were focussed on three drug groups commonly used inappropriately. They found that 
target drug use was decreased beyond the point where the model became cost effective. They 
also observed that the reduction was not affected by pre-intervention prescribing levels 
(Soumerai 1986).  
 
Watson delivered educational outreach visits to GPs in England and found the costs of 
delivery were greater than the costs saved as a result of the (statistically insignificant) 
prescribing changes observed (Watson 2001). However, in this study based in 20 general 
practices in England, the team delivering the intervention did not explicitly make any 
recommendations of a cost saving nature which is unusual for pharmacist-led prescribing 
support in the UK. Without cost saving as one of the key outreach messages, and without an 
endpoint associated with significant costs (from an NHS perspective) e.g. hospitalisations, it is 
less of a surprise that cost effectiveness was unproven. May et al also found this to be the case 
in 1999.  
 
Possibly the most detailed study of the cost effectiveness of outreach visiting was described by 
Mason (2001). Their perspective was that of the policymaker faced with the decision to 
implement guidelines on ACE inhibitors for heart failure and tricyclic antidepressants rather 
than newer, more expensive SSRI antidepressants. While their analysis, like the original 
publication (Nazareth 2002), is at times difficult to follow, it appears that their model of 
outreach became cost effective if the focus was on improving quality (increasing ACE 
inhibitor use in heart failure) but not for cost saving (tricyclic instead of SSRI 
antidepressants). Key reasons behind this were discussed and included the large health benefit 
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achievable through the use of ACE inhibitors in heart failure while the relatively small cost 
savings accrued by switching antidepressants did not offset the cost of the outreach visits. 
Acknowledging that the process of implementation of best practice in prescribing incurs a 
cost, Mason summarised the importance of evaluating the policy cost effectiveness of 
prescribing change models, and argued for the measurement of costs to form part of 
implementation research design.  
 
2.4.6  The Hawthorne effect 
The Hawthorne Effect was first described following attempts to improve productivity in the 
Western Electrical Company’s Hawthorne works in North America in the 1920s (Mayo 1993). 
Subsequently, it was defined as ‘an increase in worker productivity produced by the 
psychological stimulus of being singled out and made to feel important’ (Franke 1978). More 
generally, the phenomenon of improved performance due to an awareness of being scrutinised 
or tested has been applied to participation in clinical research (Braunholtz  2001). In the 
context of clinical trials, it is not possible to control for the Hawthorne effect. In controlled 
trials involving educational outreach or other forms of support that cannot be masked by 
design, participants in the usual care arm are aware of their ‘usual care’ allocation and the fact 
that comparable participating practices are randomly allocated to receive an intervention. This 
may be enough to improve practice beyond that which might occur outwith the trial setting.  
 
Not being able to control for the Hawthorne effect suggests educational interventions tested in 
a trial context, will appear less effective than they are in clinical practice. The literature review 
did not generate any information directly, about the strength of the Hawthorne in the context 
of educational outreach or other pharmacist led educational or prescribing interventions.   
 
 
2.5 Template for a new intervention 
 
Based on this literature review, and an understanding of the workings of repeat prescribing 
and general practices’ approaches to disease management, the following are key features 
worth incorporating into the design and reporting of a multifaceted, new model of prescribing 
support:  
 
• Utilisation of multiple strategies to effect change (Brufsky 1998); 
• Face to face, brief educational exchanges with reinforcement;  
• Adequate training for pharmacists, paying attention to communication skills and 
approaches used by the Pharmaceutical Industry (Lexchin 1993 and Watkins 2003); 
• Clear definition of the components of the intervention and how they were delivered; 
• Multiple intervention components including: anticipation of barriers, interactive provider 
education, confidential feedback, make explicit links between everyday practice and 
published evidence of effectiveness (Watkins 2003); 
• Reminders, patient education; 
• Specific focus on statin prescribing/cholesterol lowering;  
• Involvement of local opinion leaders (Freemantle 2005); 
• Intervention underpinned by theoretical models of behavioural change (Davis 1998, 1995);  
• Delivery of the intervention to nurses and practice staff in addition to GPs (commonsense 
approach, recognising the dynamics of the general practice team); 
• Minimum of three outreach visits, with sufficient time within each visit to establish 
rapport, credibility and inspire change (Yeo 1994);  
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• Confidential feedback on a one to one basis (Hux 1999);  
• Twelve month duration of intervention with multiple meetings (Schmidt 1998); 
• Provision of organisational and administrative help (Renders 2005); 
• The use of pharmacists based in general practices (all previous work has involved 
community pharmacists or academics), with access to practice information and a peer 
support network between pharmacists delivering the intervention. 
 
 
2.6  Template for a study to test a new intervention 
 
Review of the literature spanning 20 years indicates that more and better evidence is needed to 
determine the effectiveness of pharmacists in their attempts to change prescribing behaviour. 
The available literature is difficult to interpret because of inconsistent or nonexistent 
nomenclature or explanations of the interventions delivered by pharmacists. Study designs are 
often inadequate, trial durations and length of follow up insufficient to enable evaluation of 
clinical outcomes and much of the outcomes are process related. Other trials have 
methodological weaknesses such as lack of control groups, poor methods of randomisation, 
inadequate statistical analysis and problems with internal or external validity (McLaughlin 
1991; Beaudry 1989).  
 
The following features of a trial are therefore likely to add to the body of literature in this area: 
 
• Sufficient power to detect differences in clinical or surrogate clinical outcomes; 
• Applied across different general practice settings (affluent, deprived, single handed, 
group practices, training and non training (while it is unlikely that statin prescribing 
patterns differ between training and non training practices (Ashworth 2006, Mackay 
2003), we considered it useful to have recruited both types of practices with examples 
in each arm of the study);  
• An assessment of prescription collection rates as an indication of the extent of 
adherence to newly prescribed medicines; 
• Recruitment of untargeted practices, where there is variability in the need for changed 
prescribing (this will help confer generalisability of the results);  
• Stratification of important measures of baseline prescribing;  
• Pilot work to ensure theoretical underpinning, feasibility of the model including 
acceptability to GPs; 
• Appropriate choice of methodology and analysis to take account of clustering; 
• Description of qualifications and training of pharmacists delivering the model; 
• Collection of patient and practice level prescribing data at baseline and follow up, 
including incident and prevalent cases; 
• Follow up of outcomes after 12 months (Pearson 2003);  
• Link any cost savings to health outcomes (Belby 1997).  
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2.7  Summary 
 
In view of the increase in LTC prevalence and the increased cost and complexity of 
prescribing, introduction and testing of a new prescribing support model is timely. The 
publication of HPS in 2002 signalled a change in the management of cholesterol and vascular 
risk using statins (HPS 2002). The message was that all patients with established occlusive 
arterial disease were at high risk and should be treated with a statin, regardless of total blood 
cholesterol level. In Glasgow, this recommendation was disseminated passively by post to 
each general practice in the form of an updated clinical guideline (Appendix VIII). In view of 
the potential importance of this updated guidance to the local population and the relative 
ineffectiveness of passive dissemination as a means of changing prescribing practice, it was 
appropriate to test a new intervention to improve statin prescribing for a high risk cohort of 
primary care based patients. Priorities included constructing, delivering and testing a novel 
educational outreach intervention with the objective of changing healthcare professionals’ 
prescribing behaviour relating to statins or the management of vascular diseases in a way that 
enabled measurement of outcomes of benefit to patients.  
 
Herbert (2004) summarised the need as follows: “Clear messages, proper trial design and 
sensitive outcomes are necessary to demonstrate changes in prescribing”. 
 
General practice based pharmacists will be trained to deliver this intervention, as they are 
ideally placed to implement guidelines in the long term, as part of their routine service 
delivery. 
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Chapter 3 
 
Methods 
 
3.1 Background 
 
This chapter justifies and describes the methodology of a cluster randomised controlled 
trial of a new, pharmacist-led intervention called Statin Outreach Support (SOS).  
  
 
3.1.1 Complex interventions and their evaluation 
 
The Medical Research Council’s guidance on developing and evaluating complex 
interventions describes dimensions of complexity and the implications for evaluation 
(Medical Research Council 2011). The SOS intervention constitutes a complex 
intervention on the basis of several dimensions of complexity:  
 
• Number of interactions between components in the experimental and control 
interventions; 
• Number, and level of difficulty, of behaviours required by those delivering or 
receiving the intervention; 
• Number of groups or organisational levels targeted by the intervention; 
• Number and variability of outcomes; 
• Degree of flexibility and tailoring of the intervention permitted. 
 
Consequently, the guidance recommends several features worth considering in an 
evaluation programme. Of relevance to the SOS trial are usefulness of a range of outcome 
measures and the suggestion to adapt the intervention to “a local setting” (in this case, 
practices).  
 
Using the learning from Chapters 1 and 2, describing the following features is important to 
enable comparison with previous work, and will be addressed in this chapter:  
 
• Number of visits and other contacts;  
• Duration of visits; 
• Timing;  
• Objectives of meetings;  
• Description of those present in the meetings;  
• Nature and duration of preparatory work and follow up support;  
• Level of access to patient information; 
• Clinical topic(s) considered and main messages delivered; 
• Extent to which the pharmacist identified organisational issues in addition to 
personal barriers relating to knowledge/beliefs;  
• Extent to which the pharmacist supported the practice or GP to implement change; 
• Rationale for choice of outcomes. 
 
 
3.1.2 Rationale for using a cluster randomised controlled trial design 
 
Poorly defined educational outreach interventions and methodological weaknesses in 
associated trials are common; a Cochrane review has recommended improvements in both 
(Thomson 2002).  
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Cluster trials are an important method of evaluating educational outreach and related 
interventions, but cluster randomised trials may be more difficult to design and perform 
than individually randomised trials, because of the threat of bias (Puffer 2003). There are 
opportunities for bias at cluster and individual patient level. In addition, the choice of 
cluster design brings a requirement for increasing the sample size. Therefore, the choice of 
cluster randomisation design was considered carefully.  
 
The questions to be answered by this trial were whether (and if so, the extent to which), the 
SOS intervention, delivered at practice level, increased the proportion of community 
dwelling patients receiving a statin at optimal dose, with cholesterol controlled (less than 
5mmol/l (less than 4.2mmol/l post Coronary Artery Bypass Graft; Appendix VIII). These 
questions were best answered through a prospective, randomised controlled trial design 
with sufficient follow up to enable the effect of any improvements in statin prescribing and 
cholesterol levels to develop.  
 
Practical reasons led to the decision to use cluster randomisation. During a pilot in five 
practices in 2002 (and extensive pre-pilot work in the years prior to that), the SOS 
intervention was found to be best suited for delivery at general practice level, because 
practice level organisational barriers were recognised as rate limiting when pharmacists 
attempted to change statin prescribing. For example, if one or two GPs or nurses within a 
practice were motivated to systematically identify and offer eligible patients simvastatin 
40mg, this might not translate into action because the other GPs and nurses needed to be 
supportive and share the workload. Agreement from all GPs and Nurses was necessary to 
enable identification of eligible patients and co-ordination of the process of patient 
invitation and follow up. Targeting and randomising individual GPs for an educational and 
organisational support intervention was therefore impractical, as was maintenance of 
blinding between GPs in the same practice. Contamination through exchange of learning 
between GPs from the same practice was unavoidable; and contamination of usual care 
leads to biased estimates of effect size (Ukomunne 1999). 
 
Randomisation at patient level was not appropriate either, because responsibility and 
prescribing decisions for individuals were subject to change and influence by multiple GPs 
and Nurses over the course of time. This meant that the prescribing and cholesterol 
management of patients in one practice were more similar to each other than patients from 
another practice. This violates the assumption of independence necessary for an 
individually randomised trial (and the assumption of independence of observations).  
 
Prospective, cluster randomisation offered the best way to eliminate these threats of 
systematic error (Campbell 2001).  
 
The need to account for clustering extended to most aspects of this trial: randomisation, 
sample size estimation and power, analysis and reporting. Campbell (2001) suggested 
describing these and other items separately, when reporting a cluster randomised controlled 
trial. Their checklist of items will be used in this chapter.  
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3.2 Methods 
 
3.2.1      Setting - NHS GG&C  
 
At the start of the SOS trial (2003), NHS GG&C existed as two geographically and 
organisationally separate Board areas: Greater Glasgow Health Board and Argyll and 
Clyde Health Board. In 2006, Argyll and Clyde Health Board split and the Argyll area 
merged with Highland Health Board. Greater Glasgow Health Board absorbed the Clyde 
component, and was renamed GG&C Health Board. The SOS trial involved practices and 
policies within Greater Glasgow only.  
 
NHS GG&C Health Board provides health care to almost 25% of the Scottish population. 
The GG&C population lives within a diverse geographical area, encompassing both urban 
and rural settings and suffers high levels of deprivation and unemployment with the worst 
health status and most extreme health inequalities in Scotland. Although overall life 
expectancy is increasing, the population faces a growing burden of morbidity and disability 
driven by LTCs. In addition, the Board area continues to attract an increasing migrant 
population, with their own health challenges. LTCs account for over 80% of total general 
practice consultations and 60% of hospital bed days (Department of Health 2004). 
Cardiovascular Disease (CVD), cancers and chronic respiratory disease account for the 
majority of premature deaths. In the Board’s Director of Public Health Report (2009), the 
following key health problems were identified: 
 
• CVD; 
• Health inequalities; 
• Substance Misuse (drugs, alcohol and smoking); 
• Obesity. 
 
A substantial proportion of CVD risk is attributable to high cholesterol and some of this is 
preventable through prescribing of statins in accordance with robust evidence from clinical 
trials. CVD encompasses several distinct conditions e.g. Coronary Heart Disease (CHD). 
Other conditions sharing the same vascular pathophysiology include stroke, Transient 
Ischaemic Attack (TIA), Peripheral Vascular Disease (PVD) and Diabetes. Underlying 
coronary vascular disease is the most common reason for Coronary Artery Bypass Graft 
(CABG) and Angiography, which classifies patients who have undergone these procedures 
as being at equivalent risk as patients with CHD. CHD is the largest subgroup of CVD and 
as such, is a strong predictor of CVD trends. A summary of the combined prevalence and 
impact of vascular disease within GG&C was not available. However, age standardised 
CHD death rates were available and are described in Fig 3.1. While the prevalence of CHD 
is decreasing, in GG&C Health Board it remains the leading cause of death, with rates 
consistently above the National average (Figure 3.1).  
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Figure 3.1   Coronary Heart Disease Death rates in NHS GG&C  
 
 
 
Several factors could have accounted for the steep decline in death rates in GG&C and the 
rest of Scotland over this period. These include improved primary and secondary 
prevention of CHD e.g. improved prevention and management of hypertension or 
myocardial infarction (Capewell 1999). Decreases in blood pressure over this period were 
confirmed by data from the Scottish Centre MONICA studies, with additional data 
showing reductions in smoking prevalence and cholesterol levels between 1976 and 1996 
(Evans 2001).  
 
The Heart Protection Study and derived GG&C guidance offered an opportunity to further 
tackle the burden of CHD and other vascular mortality for patients with vascular disease, 
because of the finding that simvastatin 40mg daily for 5 years reduced the rates of heart 
attack, stroke and revascularisation by approximately 25%. While cholesterol decreased in 
HPS, the use of simvastatin 40mg was sufficient to achieve benefit without cholesterol 
reduction. 
 
The challenge for GG&C and other health care providers is to maximise the uptake of 
robust evidence based treatments such as this.  
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3.2.2  Aim of study 
 
The aim of the study was to evaluate the effectiveness of pharmacist-led SOS intervention 
delivered at the level of general practices, to practice staff.  
The SOS study therefore tested the hypothesis that primary care, general practice based 
pharmacists delivering the SOS intervention at practice level, can increase the proportion 
of patients prescribed simvastatin 40mg with their cholesterol controlled, compared with 
care as usual. 
 
 
3.2.3 Endpoints 
 
The primary endpoint was the proportion of patients prescribed simvastatin 40mg daily 
with cholesterol controlled, evaluated at the level of the individual patient, in the SOS 
intervention arm practices compared with Usual Care (UC). Secondary endpoints were: 
 
• Prescribing of simvastatin; 
• Cholesterol control; 
• Prescribing of simvastatin 40mg;  
• Cholesterol tested since randomisation for patients prescribed simvastatin 
40mg; 
• Cholesterol levels of patients prescribed simvastatin 40mg;  
• Cholesterol levels tested since randomisation; 
• Cholesterol levels; 
• Prescribing of any statin. 
 
Outcomes were assessed between 1.4 and 2.2 years (mean 1.7 years) after randomisation.  
 
In a post hoc analysis we assessed the impact of the SOS intervention on safety outcomes 
using the time to first vascular event, for those patients who could be traced from baseline 
to follow up. The mean duration of follow up for safety outcomes was 2.5 years, ranging 
from 2 to 2.8 years.  
 
 
3.2.4 Sample size and power 
 
Cluster randomised trials require larger numbers of individuals because there tends to be 
correlation of outcomes within clusters which otherwise reduces the statistical power, 
compared to individually randomised trials. The method of calculation of sample size is a 
key difference between a practice randomised trial and an individually randomised trial: 
the sample size needs to increase to accommodate clustering, using a cluster inflation 
factor (also called the design effect, D). The design effect is related to the cluster size (m, 
the number of patients in each cluster) and the intra cluster correlation coefficient (ρ, 
which measures the size of the clustering effect i.e. the correlation of patient outcomes 
within a cluster) by the equation: 
 
D = 1 + ρ (m – 1) 
 
The design effect enables calculation of the amount by which the sample needs to be 
multiplied, to maintain sufficient power. 
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The original sample size calculation for the SOS trial was based on a pilot study in five 
general practices in 2002. Then, the intervention was planned to focus on statin prescribing 
for patients with CHD only. We found that approximately 50% of patients with CHD had 
controlled cholesterol before the intervention. For patients with no record of cholesterol 
level recorded in their case notes, we assumed cholesterol was uncontrolled. There was 
considerable variation between practices, with ρ = 0.4. We assumed that 40 patients would 
be recruited per practice in the subsequent cluster randomised controlled trial, demanding a 
sample size increased using a design effect of 16.6 (D = 1 + 0.4 {40 – 1}). On this basis, it 
was calculated that approximately 20 practices (10 per group) would be required for the 
study.  
 
Pilot work also showed that 80% of patients with CHD and uncontrolled cholesterol would 
achieve cholesterol control after the SOS intervention (resulting from increased 
prescription of simvastatin 40mg). Assuming the proportion of CHD patients controlled in 
intervention practices would be 90%, compared to 50% in control practices, and that 40 
patients were selected from each practice, then a study with 10 practices in both the 
intervention and control groups would have in excess of 90% power to detect this 
difference at a 5% significance level. If 30 practices were selected (15 in intervention arm 
and 15 in UC arm) this would allow for up to five pairs to drop out of each arm of the 
study. The high practice dropout was anticipated in view of the duration and intensity of 
the intervention, which was considered difficult to sustain, from practices’ perspectives. 
 
Recruitment secured the participation of 31 practices. At baseline, data were collected for a 
greater number of patients than anticipated (mean of 130 patients per practice). This was 
due to requests by practices, who were keen to use the data for audit purposes, irrespective 
of subsequent allocation. All practices therefore accessed their baseline information, as 
collected by the pharmacist. We found approximately 40% of patients had cholesterol 
controlled (Appendix VII). These findings led to a lower design effect of 7.45, and enabled 
re-calculation of ρ= 0.05 (Ridout 1999). The study was therefore powered to detect much 
smaller intervention effects than anticipated from the pilot. For example, assuming 88% of 
the intervention group would have cholesterol controlled at the end of the intervention 
period (Dec 2004) compared with 76% in the UC group, the study had 93% power to 
detect a difference in cholesterol controlled between groups at a 5% significance level.  
 
 
Ethical approval and study registration  
 
Ethical approval was granted in December 2002 (Appendix VI). At that time the 
intervention was called ‘clinical facilitation’ and a cost effectiveness analysis was planned 
to run in parallel to the study. As the unit of intervention, all practices provided written 
consent to participate. The study was registered: ISRCTN61233866. 
 
 
3.2.5  Practice recruitment 
 
All 232 single handed (SH) and Group (G) practices in Greater Glasgow (population 
962,106) were eligible to participate and invited as follows:  
 
1. The NHS Glasgow register of general practices was separated into SH (one GP listed 
against the practice cipher number, n = 63) and G practices (more than one GP listed 
against the practice cipher number, n = 169). Each practice’s CHI code was entered into 
MINITAB and random numbers generated. Forty eight practices (24 single handed and 24 
group) were randomly selected to obtain 30 consenting practices.  
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2. Each practice was contacted by phone to confirm the names of the GPs, practice 
manager and nurse(s). Although the register of practices was the most accurate available at 
that time, seven single handed practices were no longer in existence: six had dissolved and 
one had merged with a group practice. Therefore, eight additional SH practices (seven 
replacements and one additional in view of the rate of dissolution of single handed 
practices at that time) were randomly identified for invitation purposes.  
 
3. A draft invitation letter was passed to 4 practising GPs and the study supervisor (JM) for 
comment. Suggestions for change were incorporated and every GP, nurse and Practice 
Manager in each practice was posted an invitation to participate. A reminder was sent if no 
reply was received from the practice within two weeks.   
 
4. If no reply was received, after a further two weeks, another invitation was sent.  
 
5. Non responding practices were phoned and asked for a decision. Three SH practices did 
not reply in writing, but were keen to meet to find out more information before deciding. 
Two subsequently declined and one consented after meeting. One Group practice requested 
a meeting prior to deciding. At the meeting, the practice consented.  
 
6. On receiving written practice consent to participate, a meeting was arranged with each 
practice, to provide adequate information about the study to confirm all practice staff 
understood the study requirements and to minimise dropout.   
 
The invitation process was approached systematically, so as not to favour selection of one 
practice over another and minimise this potential source of bias. Thirty one practices (15 
SH and 16 G) representing a total population of 116,558 patients, (12% of the Glasgow 
population), agreed to participate. All practices routinely recorded patient demographic, 
clinical and prescribing information on their computerised administration support system.  
 
 
3.2.6  Participating practices and patients 
 
3.2.6.1  Practice staff 
 
All Practice staff (reception staff, practice managers, GPs, Nurses and any other staff) 
received a verbal reminder of the intervention and usual care arms of the study, from the 
pharmacist collecting baseline data.  
 
 
3.2.6.2  Eligible patients 
 
Practices were asked to identify patients who had confirmed vascular disease. These 
patients were at ≥ 30% risk of suffering a cardiovascular, cerebrovascular or peripheral 
vascular event in the next 10 years. In accordance with GG&C Cholesterol Guidelines 
(Appendix VIII), this level of risk was confirmed by the following confirmed diagnoses:  
 
• Myocardial infarction;  
• CABG / angioplasty; 
• Angina; 
• Angiographic coronary artery disease;  
• Stroke/transient ischaemic attack;  
• Peripheral ischaemic arterial disease/intermittent claudication; 
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• Diabetic patients aged over 45years.  
 
A validated computer search of each general practice’s computerised patient record 
generated a list of eligible patients. The validity of the computer search was evaluated 
during the pilot phase in two practices (Lowrie 2005). Sensitivity (completeness: how good 
the search was at identifying patients with a confirmed diagnosis of vascular disease 
recorded in the case notes) ranged from 88% to 100% and positive predictive value (the 
chance that patients identified by the search have a confirmed diagnosis of vascular 
disease) ranged from 63% to 66%. This lower than expected positive predictive value led 
to the decision to screen each patient’s handwritten case records to collect relevant data in 
addition to collecting data from computer records.  
  
 
3.2.7 Baseline data collection 
 
The following baseline data was collected by NHS employee pharmacists between May 
and November 2003, across all 31 practices: 
 
Practice characteristics 
 
Demographic field 
 
Qualifying 
diagnoses§ 
 
Drug field 
 
List size, Post code  
 
Number of whole time 
equivalent GPs  
 
Number of whole time 
equivalent practice 
nurses  
 
Number of patients at ≥ 
30% 10 year risk of 
suffering a 
cardiovascular, 
cerebrovascular or 
peripheral vascular 
event  
 
 
Practice CHI  
 
Date of data 
collection 
 
Patient 
identification 
number 
 
Date of birth 
 
Sex 
 
Patient status (left 
practice, case notes 
unavailable) 
 
MI  
 
Diabetes,  
 
CABG  
 
Stroke  
 
Angioplasty  
 
TIA,  
 
Angina/IHD 
  
PVD/Intermittent 
claudication  
Statin 
(description of 
which statin) 
Dose 
 
Start date 
 
 
Dose increase 
date 
 
Most recent 
cholesterol level 
 
Date of most 
recent 
cholesterol level 
 
§with accompanying date event(s) / diagnoses first recorded on practice computer 
 
The template used for baseline data collection is given in Appendix IX. Due to time and 
resource limitations, a systematic sample of every third eligible patient’s data was 
collected in 5 practices with the largest list sizes (12330, 7354, 7215, 7099 and 5616 
patients). Therefore, cross sections of data were collected at baseline. In addition, in all 
practices, some demographic data (in particular, the “Patient identification number”) was 
not collected. Both factors precluded longitudinal follow up of all patients. In all other 
practices, data was collected from each eligible patient’s record, anonymised in the 
practice and entered onto an ACCESS database.  
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3.2.8 Randomisation 
 
3.2.8.1  Sequence generation 
 
Due to the relatively small number of recruited practices and practice level randomisation, 
only two strata were used (Pocock 1983). To maximise the chances of practices in the 
intervention and UC arms of the study being comparable at baseline, we separated 
practices into the prognostic factors that were thought to impact on the primary endpoint: 
Single Handed (SH, n=15) or Group (G, more than one full time GP; n=16) and the 
proportion of eligible patients whose cholesterol was controlled at baseline. This 
distinction was made because we suspected that larger practices were more likely than 
single handed practices to implement the SOS intervention. Though we were not aware of 
an evidence base surrounding this (in fact, the results from the EBOR trial suggest the 
opposite (Nazareth 2002), however, we suspected that Group practices would have three 
features favouring better uptake of the SOS intervention: 
 
1. Multiple partner practices would have more advanced record keeping, systematic 
case finding, call /recall systems;  
2. Greater capacity and flexibility to absorb additional work incurred by the 
intervention;  
3. More spare rooms, enabling a pharmacist to work with the practice team on the 
same day each week. This would tend to increase the chances of the intervention 
working. 
 
To minimise imbalance between SOS and UC practices in proportions of patients with 
cholesterol controlled, our framework had this as a secondary division. We used the ratio: 
 
Number of eligible patients with cholesterol in target range 
Number of eligible patients 
 
 
Within their strata (SH or G), practices were arranged in ascending order according to this 
ratio, ordered then numbered sequentially, and paired (practice 1, practice 2), (practice 3, 
practice 4) etc.  
 
This approach to randomisation minimised the differences from these prognostic factors, 
between treatment groups, to validate the assumption that any differences seen in the 
outcomes were most likely due to differences between the SOS intervention and UC and 
not random imbalances in baseline characteristics between practices in the SOS and UC 
arms. 
 
 
3.2.8.2  Allocation concealment 
 
A table of random numbers (MINITAB statistical software) was used with one practice 
from each pair randomly allocated the number “1” and the other allocated “0”. The SOS 
intervention group was randomly allocated “1” and UC, “0” (Appendix X). This process 
sought to ensure a balanced allocation of practices between SOS and UC arms in respect of 
Practice status (SH or G). This type of matched cluster design (‘matched pair’ in which one 
of two matched clusters in a stratum are randomly assigned to each intervention) is 
frequently adopted in cluster randomised trials (Donner 2000). The allocation was 
therefore based on clusters rather than on individuals, and the identity of all the practices 
was concealed until after allocation to SOS intervention or UC. 
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3.2.8.3  Implementation 
 
The allocation sequence was generated by Alex McConnachie (AMcC). Richard Lowrie 
(RL) assigned practices to the SOS intervention or UC. Randomisation and random 
allocation took place on 4th November 2003, resulting in 8 group practices allocated to the 
intervention group and the corresponding 8 practices allocated to UC. In the single handed 
practice stratum, 6 pairs were formed and one from each was allocated to the intervention/ 
UC group. One SH triple was formed with two practices allocated to the SOS intervention 
and one to UC. However, on contacting the practices to notify them of their allocation to 
the SOS intervention or UC status, we found that one SH practice had already disbanded 
(this practice was one of the triple and had disbanded, unknown to us at the time, before 
the date of randomisation). This practice’s patients were dispersed across other Glasgow 
practices and could not be followed up. Therefore this practice’s patients were not included  
after baseline description of collected data.  
 
Sixteen practices (8 G and 8 SH) were allocated to the SOS intervention arm and 15 
practices (8 G and 7 SH) were allocated to the UC arm of the study. Progress of practices 
and patients through the initial stages of enrolment and allocation is described in Appendix 
XV. 
 
 
3.2.8.4  Blinding 
 
In common with trials of other educational interventions, double blinding was not possible. 
The study was assessor blind, because when data was collected at baseline, allocation had 
not occurred. At follow up, two independent researchers collected prescribing and 
cholesterol outcome data. Both were blinded to whether practices had received the SOS 
intervention or UC, therefore bias in the process of data collection was minimised. 
 
 
3.2.9  Statistical analysis 
 
Baseline analysis compared participating with non-participating practices, SOS with UC 
practices, and single handed with group practices. Patient level data was not collected for 
non-participating practices. Summaries used continuous and categorical variables, as 
appropriate. Practice-level data (e.g. number of GPs, list size) was compared using the 
Wilcoxon-Mann-Whitney test, or, for comparisons between SOS and UC practices, using 
the Wilcoxon Signed Rank test within pairs of practices. 
 
Patient level data were analysed at the individual level for greater power. Analysis of 
primary and secondary endpoints involved the use of regression models, to account for 
pairing. Each outcome was dependent upon whether or not an individual was in a SOS or 
UC practice, and on which practice pair they were in. The regression models therefore 
included an adjustment for the matching used in randomisation, in the form of a 15 level 
categorical variable with each outcome being dependent upon whether or not an individual 
was in an intervention or control practice, and on which practice pair they were in. 
 
Logistic regression was used for binary (categorical) outcomes e.g. male/female or 
qualifying diagnoses and normal (least squares linear) regression was used for continuous 
outcomes e.g. age. For comparisons of cholesterol levels, a (natural) log transformation 
was used due to the skewed distribution and back-transformed for reporting purposes. 
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For comparisons between single handed and group practices, data were aggregated up to 
practice level and compared using the same methods as for practice-level data.  
 
This approach was used instead of chi-square or t-tests, because of the need to adjust for 
the matching of practices.  
 
Subgroup analyses of the primary and secondary outcomes were: age, gender, practice 
level socioeconomic deprivation, practice type, patients eligible at baseline vs. eligible 
after baseline, cholesterol controlled at baseline vs. uncontrolled at baseline, statin 
prescribing at baseline, number of vascular diagnoses at baseline, presence / absence of 
CABG at baseline. A two-sided p-value of 0.05 was taken to represent statistical 
significance in all analyses. RL conducted all analyses (at baseline and follow up) using 
MINITAB version 13. Confirmatory analyses were conducted by The Robertson Centre for 
Biostatistics (Suzanne Lloyd, AMcC). 
 
 
Fixed and Random effects models 
 
There were multiple measurements from the same practice and pair. Regression analysis 
was used to investigate the relationship between the response variable and one or more 
predictors. Fixed effects regression models assumed the only source of variability was 
between subjects (and that this was constant across all practices); adjustment was made 
only for the pairing of practices. However, the data was not independent (patients within 
practices and pairs were more likely to be similar to one another than patients from 
different practices and pairs). Random effects regression models treated practice pairs as 
random effects, taking into account two forms of variability: within practice/pair and 
between practice/pair variability.   
 
Either fixed or random effects models could have been used; both were tried, and the 
results were very similar, with fixed effects being reported. In each case, models were 
adjusted for age, sex and deprivation in addition to the pair.  
 
 
3.3 The SOS intervention 
 
Appendix XI summarises the process of the SOS intervention. This summary was used as 
an aide memoire by practice staff. Pharmacists delivering the SOS intervention introduced, 
discussed and reinforced the main messages from this guideline during three face to face 
meetings. Between meetings, the pharmacist worked in the practice one day per week, to 
understand and whenever possible, improve the practice’s attempts at introducing a 
systematic approach to offering simvastatin 40mg to eligible patients.  
 
 
3.3.1 Overview  
 
Face to face meetings involved GPs, nurses and non clinical (administrative) staff in 15 of 
the 16 practices. One practice (Single handed), participated in the first meeting but then the 
GP declined further meetings due to time constraints. All intervention arm practices 
received meetings on different dates, but all three meetings were completed between 
December 2003 and December 2004. The gap between meetings was approximately 4 
months, depending on the availability of the GPs, size of the practice and pharmacists’ 
annual leave. The names and contact details of eligible patients (who were not prescribed 
simvastatin 40mg) were identified by the pharmacist and practice staff. The pharmacist 
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helped the practice to agree on whether, how and when to introduce a new prescription for 
simvastatin 40mg to eligible patients, on a case by case basis. GPs were asked to adopt and 
apply the same approach to statin use (i.e. guideline based) for incident patients as they 
encountered them during routine practice.  
 
 
Before the first meeting  
 
Pharmacists worked in their allocated practice one day each week for approximately one 
year. They accessed, collected and summarised patient level information to confirm that 
each patient who was eligible for a statin had been offered one, or was currently prescribed 
a statin. This involved confirmation of eligible diagnoses, statin prescribing (current and 
historical), prescription ordering, cholesterol tests and levels. Practice disease registers 
were validated and updated or amended where necessary. Objective or subjective 
confirmation of diagnoses was sought by looking through case notes, computer records or 
hospital (including Accident and Emergency) discharge letters.  
 
The pharmacists collected the names of eligible patients who had no history of having 
received a statin or who were prescribed a statin at a dose lower than 40mg simvastatin 
equivalent. If there were any obvious reasons for the patient not having a statin at sufficient 
dose, this was collected. Reasons for patients not receiving a statin included failure of the 
practice to offer one, the patient defaulting routine appointments, dropout from 
prescription ordering or a history of statin intolerance or contraindication. Some eligible 
patients had been overlooked by their practice; the pharmacist reinstated these cases onto 
the relevant disease register, in order that they would be subject to routine call and recall 
for review by the practice, or contacted with the offer of statin initiation. In some cases, the 
pharmacist noticed that the patient had moved house but the new address had not been 
entered onto the practice computer system, meaning the patient would not have received 
notification of the need for an appointment at the practice if a letter had been sent.  
 
The pharmacist used the time in the practice to collect and summarise eligible patient level 
information on diagnoses, statin prescribing history and cholesterol levels. Baseline 
information collected prior to randomisation was used as a starting point for this process. 
The time spent in the practice also enabled the pharmacist to identify prescribing traits and 
gaps in care e.g. lack of cholesterol levels which limited the practices’ ability to better 
manage eligible patients. The prescribing traits of individual GPs were recorded whenever 
possible. In turn, this provided a rich source of information help the pharmacist 
individualise attempts to improve prescribing. These traits were identified by running 
searches on the practice computer, or collection of information from handwritten case 
notes, where it was possible to identify which GP had contact with each patient. In Group 
practice when these could not be traced to individual GPs, the information was used in 
summary form during meetings, as a prompt for individual GPs and nurses to reflect on 
their practices’ approach to prescribing. Time spent in the practice and activities were 
recorded to inform a future economic analysis. 
 
Organisational barriers to increasing the uptake of simvastatin prescribing were noted. 
These included a lack of willingness in the practice to persevere with invitations for 
patients who had not attended one or two scheduled appointments. Letters of invitation 
were sometimes difficult to read, and only offered work-time slots for patients of working 
age. Updates of patients’ phone numbers were often not added to the practice computerised 
records, which made it difficult to contact patients to arrange appointments. For some 
housebound patients, who also appeared on the eligible list, practices possibly did not 
consider visiting at home to deliver an annual check and use the opportunity to start a 
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statin. In each case, the pharmacist attempted to support the practice in finding ways to 
engage and implement the key messages of the educational sessions. 
 
 
3.3.2  Meeting one 
 
Each pharmacist received clear instruction to address the following three objectives during 
meeting one:  
 
• To enable relationship building between pharmacist and practice staff;  
• To evaluate the GP or nurse’s awareness and understanding of the HPS trial and 
statin prescribing guidelines;  
• To identify perceived barriers to changing statin prescribing in line with guidance. 
 
Taking approximately 30 minutes, this face to face interactive discussion included a power 
point presentation, involving the pharmacist and each GP, nurse and other practice staff.  
 
The first meeting helped the GP or nurse to understand the the SOS intervention process 
and was conducted on a one to one basis in the practice. An open, honest exchange was 
encouraged. The pharmacist asked some open questions to explore the GP or nurse’s usual 
statin prescribing practice. For example, this may have included asking which statin was 
prescribed first line, at what point statins were initiated (what was the trigger for initiating 
a statin), whether patients were assessed for a statin (and other secondary preventive 
medicines) opportunistically or through planned appointments, was an up to date 
cholesterol and liver function test result need to be present before statin prescribing. The 
pharmacist asked about the GP or nurse’s awareness and views on the recent Heart 
Protection Study and recently disseminated statin guideline. The pharmacist took notes 
during the discussion; in one practice, the pharmacist tape recorded the discussion. All 
information was retained in the practice, stored alongside patient case notes if paper based 
or saved onto the practice computer if electronic e.g. power point presentation or summary 
statistics from baseline.  
 
Having already prepared a summary of the practice’s statin prescribing (numbers of 
patients, statin type, dose, trends over the past few years, cost), this was shared and 
discussed during the meeting. Other practices’ prescribing was used as a comparison. GPs 
and nurses were asked if they wished to hear the views of ‘educationally influential’ local 
opinion leaders and if so, who these opinion leaders were. Sometimes, the GP or nurse had 
a question about the guideline or HPS or statins, and the pharmacist could not answer it. 
This prompted a phone call, email or visit to the nominated expert, or to a local consultant. 
Answers were fed back to the GP/nurse during the second meeting, and if similar questions 
arose from GPs or nurses in other practices, answers and advice was shared across the 
network of pharmacists delivering the intervention. 
  
The pharmacist had observed the practice’s organisation before meeting one and was 
encouraged to use these observations and turn them into questions for each nurse and GP 
during meeting one. In this way, existing prescribing, call and recall procedures were made 
explicit and discussed openly. This helped to focus the meeting on target setting and 
consideration of new ways to improve the uptake of guideline based statin prescribing for 
patients with vascular disease.  
 
Each GP and nurse was asked what they considered to be their own and their practice’s key 
barriers to systematic offering of simvastatin 40mg to each (eligible) patient not prescribed 
it. If the discussion progressed well, targets were agreed for the desired proportion of 
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patients with statins and cholesterol controlled, in their practice, at the end of the 
intervention. Benefits to some GPs were conceptualised in terms of achievement of 
contract points and therefore remuneration for the practice. To others, the motivating factor 
was the prospect of offering evidence based prescribing for patients at highest risk. Some 
GPs and nurses declined to commit to discussions on targets. Instead, they opted to receive 
the relevant information on their practice’s statin prescribing and digest this in their own 
time before coming to a decision on whether change was necessary or desirable. If this was 
the case, the pharmacist ensured concise, relevant background information was tailored 
accordingly. On some occasions, scepticism around the funding of large randomised 
controlled trials (e.g. belief that the trials are funded by the Pharmaceutical Industry) or 
questions around the funding for the pharmacist’s role prevented the GP from accepting 
the main messages. Reassurance was developed over time, as the pharmacist was shown to 
provide added value to the practice, by working steadily, one day per week, carefully 
identifying patients who could benefit from the intervention, and providing support to the 
practice to implement change.  
 
Cost savings were projected, in view of the lower cost of simvastatin compared with other 
statins (one month’s supply of generic simvastatin 40mg once daily was £1.32; a 
commonly prescribed equivalent was Atorvastatin 20mg once daily, costing £26.64 per 
month).  
 
 
3.3.3 Between the first and second meetings  
 
Having met with all of the practice’s GPs and nurses, the pharmacist had sufficient 
material to enable preparation of a tailored learning/action plan for each individual 
GP/nurse and the practice. The pharmacist transcribed the learning and action plan 
gathered from the one to one meeting with each GP or nurse, into a concise power point 
presentation (Appendix XII gives an example of a power point presentation from Meeting 
2 in a Group Practice). An aggregated version (anonymised) combining all the points asked 
by all GPs and nurses and provided in response, was prepared for presentation to the 
practice as a whole. A printed report of the presentation was prepared and circulated after 
meeting two. 
   
While the content of this report varied between practices, common practical 
recommendations included the practice (with support from the pharmacist) categorising 
eligible patients into one of the following groups: 
 
1. Not prescribed a statin  
2. Receiving simvastatin but dose suboptimal; 
3. Receiving simvastatin 40mg;  
4. Prescribed a statin other than simvastatin, optimal dose; 
5. Prescribed a statin other than simvastatin, suboptimal dose. 
 
In each case, cholesterol was controlled, uncontrolled or unchecked. This process was time 
consuming and conducted systematically by the pharmacist, but agreed as necessary by the 
whole practice, if progress was to be made on the stated objectives.  
 
Appropriate actions were mapped to each category of patient e.g. for those prescribed a 
suboptimal dose of simvastatin, the pharmacist recommended each patient should receive a 
letter with a new prescription for simvastatin 40mg, barring contraindications. Based on 
the pharmacist’s impression of the practice’s repeat prescribing organisation and the 
willingness of GPs and nurses interviewed, the pharmacist suggested who should be 
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responsible for each agreed action. The pharmacist’s role in this process was to provide a 
concise summary of the evidence base and consensus opinion where required. Together 
with practice staff, the pharmacist screened case notes, noting and recording the category 
of each patient and updating the practice’s disease register. Practices were asked to 
continue the process of patient identification after the intervention period. In this way, 
eligible patients included existing and incident patients.  
 
The pharmacist therefore planned appropriate actions and responsibilities for practice staff 
and matched these to each category of patient. Table 3.1 describes a typical plan.  
 
Table 3.1  Typical actions following a SOS intervention meeting 
 
Category of patient with vascular disease Intervention by practice team 
(pharmacist, named nurse, named GP) 
Prescribed low potency  statin,§ cholesterol 
and LFTs known and at target 
Switch to simvastatin 40mg by contacting 
on phone then confirming by letter 
Prescribed low potency statin, cholesterol 
and LFTs not known/not at target 
Letter for blood test then switch to 
simvastatin 40mg 
Prescribed potent statin, cholesterol not at 
target 
Phone call to discuss concordance 
Prescribed potent statin, cholesterol and 
LFTs not known/not at target 
Letter for blood test then increase dose if 
necessary 
Prescribed potent statin, cholesterol at 
target 
No action 
Prescribed low potency statin, cholesterol at 
target 
No action * 
Check LFTs  
No statin; LFTs and Cholesterol known Letter for appointment for consideration of 
statin 
No statin, LFTs and Cholesterol not known Letter for appointment for bloods then 
discussion of need (GP/nurse), leading to 
Statin prescription 
Started on simvastatin 40mg (or other 
sufficiently potent statin), cholesterol not 
known 
Letter for appointment for bloods 
§   Potency relates to the cholesterol lowering ability of the statin. Low potency statins include Fluvastatin and Pravastatin. Potent statins 
are all others e.g. simvastatin, Atorvastatin, Rosuvastatin. * Some practices decided, on the weight of the HPS evidence base, to 
substitute low potency statins with simvastatin.  
 
For each scenario, the pharmacist quantified the number and confirmed the names and 
contact details (address, phone number) of patients fitting each category. The pharmacist 
encouraged the practice to agree a follow up date and to name the person responsible for 
ensuring action. Some patients were excluded from the intervention by the practice. 
Typical reasons for exclusion included: 
 
1. Patient known not to wish statin/dose increase; 
2. Pregnancy; 
3. Change to prescription inappropriate e.g. confused, terminally ill; 
4. Patient left practice/died since list produced; 
5. Documented intolerance to increased dose or statin. 
 
In practice, simvastatin was commonly prescribed at a suboptimal dose e.g. 10mg. Branded 
versions were sometimes used; these cost more than generically available alternatives, 
without conferring any additional benefit. Alternative statins with a less convincing 
evidence base e.g. fluvastatin, were prescribed. If the practice tended to overuse an 
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expensive statin e.g. Rosuvastatin instead of simvastatin, the pharmacist clearly articulated 
the estimated long term impact on prescribing budgets for the practice if the status quo 
remained. Prior to meeting two, pharmacists found out, from the GP, reasons why 
Rosuvastatin had been prescribed. All relevant information on Rosuvastatin was obtained 
and weighed carefully in comparison with the evidence of benefit and costs of simvastatin. 
The Pharmaceutical Industry representative for Rosuvastatin was contacted by the 
pharmacist, to ascertain their marketing approach and educational materials, because their 
detailing often underpinned the GP’s statin prescribing decisions.  
 
Workload implications for the practice were considered by the pharmacist in advance of 
meeting two. Key anticipated actions included time to generate letters to eligible patients, 
setup a call/recall system, consultation time and time to enter new information onto the 
practice computer system to ensure long term follow up and sustainability of the changes. 
The pharmacist anticipated these additional tasks and suggested ways to overcome them. 
Possible approaches included the practice dividing the list up and allocating part of it to 
each GP to action, or reception staff agreeing to call patients for an appointment, booked 
for the GP during any quieter slots. In view of the safety of simvastatin 40mg, some 
practices agreed to review and/or issue patients with a new prescription by post. The plan 
was prepared as an interactive, visually appealing presentation on power point, with 
concise graphic material. 
 
 
3.3.4 Meeting 2 
 
Practices were asked to protect approximately one hour for this meeting. The pharmacist 
and all GPs or nurses met together, because consensus building and agreement on next 
steps required input from all practice staff. If one GP or nurse could not make this meeting, 
the pharmacist met with them separately to cover the main educational points and practical 
decisions. 
 
The objective was to gain firm commitment (from all individuals and the entire practice as 
a unit) on whether, when and how to phase a plan for systematic implementation of the 
guideline. Having thoroughly considered each part of the implementation plan in terms of 
workload implications, the pharmacist delivered an interactive presentation including: 
 
• The evidence base; 
• A guideline summary; 
• Anonymised patient specific prescribing and clinical data;  
• Simulation of therapeutic challenges; 
• A comparison of the practice’s prescribing trends with neighbouring practices;  
• Possible targets.  
 
The pharmacist offered the views of respected peers/specialists, having sought and 
obtained these earlier. A plan for change was described, with timelines; targets (anticipated 
improvements in prescribing, including tentative quantification of improved clinical 
outcomes for patients) and lower prescribing costs were discussed. Named GPs and nurses 
and occasionally other practice staff e.g. Practice Managers were asked to undertake 
additional tasks to carry the plan to completion. Agreed action always involved the 
pharmacist committing to ongoing support for creating a register of patients with vascular 
disease, to complement the practice’s efforts. The pharmacist labelled suitable patients’ 
case records, identified barriers to GP or Practice nurse’s application of the evidence base 
in the use of simvastatin 40mg and coached them on ways to overcome these barriers. The 
pharmacist agreed to steer, monitor and feed back progress on behalf of the practice.  
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All pharmacists carried a checklist to standardise the content and steer their performance in 
meeting two, and these points were rehearsed during training: 
 
1. Agree clear educational objectives; 
2. Agree clear behavioural objectives; 
3. Present both sides of controversial issues; 
4. Stimulate active participation; 
5. Use concise graphics; 
6. Highlight and repeat essential messages; 
7. Obtain agreement and build on it;  
8. Be enthusiastic;   
9. Keep to allotted time. 
 
Meeting two therefore enabled the whole practice to agree on a course of action based on a 
plan created by the pharmacist, honed through discussion with each GP, nurse and 
sometimes reception staff or practice manager. Each plan was tailored to the practice’s 
organisation and capacity. It answered questions raised at the first meetings through an 
interactive presentation, keeping the name of the questioner anonymous if this was 
necessary (some GPs and nurses chose not to let their colleagues know of gaps in their 
knowledge although were happy to share this with the pharmacist on a one to one basis).  
 
On some occasions, GPs and nurses were made aware of the evidence base for the first 
time as a result of meeting two and subsequently agreed to change practice from that point 
onwards, without the need for further persuasion. However, while the GPs may have 
changed their first line prescribing to simvastatin 40mg daily, this only applied to incident 
cases with vascular disease. The bulk of prescribing applied to patients with pre-existing 
vascular disease; to change the practice’s prescribing required modification of prescribing 
for prevalent cases. If agreement to change prevalent cases was reached during meeting 
two, the challenge was to involve practice staff in this process.  
 
 
3.3.5 Between the second and third meetings  
 
Following the meeting, the pharmacist continued to work in the practice on the same day 
each week. This enabled a continued focus on the implementation of change, 
reinforcement and provision of feedback through progress reports, until the agreed actions 
were carried out. Through negotiation, the pharmacist encouraged the practice reception 
staff, management, GPs and nurses to systematically contact and follow up the agreed list 
of patients. Agreed actions commonly involved the identification of suitable patients 
followed by the issue of letters explaining the benefits of statins and requesting the 
patient’s attendance in the practice for a consultation with the practice nurse or GP. The 
objective of these consultations was to enable the GP/nurse to explain the benefits of 
simvastatin 40mg to the patient, with a view to the patient agreeing, a new prescription and 
regular adherence. In some practices, the decision was to identify eligible patients and send 
a new simvastatin prescription after a telephone call to the patient to explain the change i.e. 
without the need for a consultation. The pharmacist provided the practice with template 
letters, relevant to each subgroup of patients. The letters summarised the evidence and 
explained the benefits. In all cases, the pharmacists’ understanding of the practice’s 
capacity and skill mix guided the next steps. The pharmacist did not contact patients 
directly. Instead, practice staff were encouraged to ask patients to attend opportunistically 
by phone or letter.  
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The pharmacist collated feedback, monitored and recorded changes in prescribing. 
Together these data were summarised and used in the presentation for the third meeting.  
 
 
3.3.6 Meeting 3 
 
The objectives of meeting three were to: 
 
• Re-iterate key points agreed during meeting two;  
• Enable two way feedback, consolidate and reinforce changes to prescribing; 
• Address any ongoing implementation difficulties. 
  
It lasted approximately 20 minutes and was conducted face to face, one to one, at a time 
convenient to the GP or nurse. It enabled feedback on any prescribing changes made in line 
with the agreement reached during meeting two. This feedback involved comparison of the 
practice’s statin prescribing with targets and estimation of the benefits to patients and cost 
savings (if any) resulting from the changes. The statin prescribing of other (anonymised) 
practices over the same time period was used as a comparison. Reinforcement and 
repetition of key educational messages, reminders of agreed actions and open discussion of 
progress in relation to timescales were key components of meeting three.  
 
All pharmacists were asked to leave the practice with a firm commitment from the GPs and 
nurses to continue prescribing simvastatin 40mg for eligible patients.  
 
Key characteristics differentiating the SOS intervention from previous outreach – like 
interventions include: 
 
• Non academic, non commercialised pharmacists delivering the intervention; 
• Access to full patient level clinical and prescribing data; 
• Access to, and influence over disease registers and call/recall systems;  
• Repeated presence in the practice environment; 
• Ability to meet with and influence clinical and non clinical staff; 
• Three linked meetings, with sufficient time and opportunity for feedback and 
reinforcement between meetings; 
• The use of several techniques to induce changes in prescribing practice: educational 
outreach tailored to the needs of the individual practitioner and practice; audit and 
feedback; reinforcement; reminders; social marketing; educationally influential 
opinion leaders; and changes to practice administration/ procedures including 
support for systematic case finding and call / recall; 
• A single therapeutic topic combining quality improvement and cost minimisation. 
 
 
3.4 Usual Care 
 
The SOS intervention was introduced in addition to UC. Practices randomised into UC 
received no pharmacist-led prescribing support throughout the period of the intervention 
and did not receive any pharmacist-led prescribing support until at least the end of the 
follow up period. Usual Care practices were not denied any services and their patients were 
not denied any treatments. The clinical guideline (Appendix VIII) was posted to all 
practices in Greater Glasgow. It was based on the HPS. The key recommendation within 
this guideline was the prescription of simvastatin 40mg for all patients with vascular 
disease.  
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3.5 Characteristics of pharmacists and the SOS intervention training programme 
 
Describing the relevant experience of pharmacists and the training given in preparation for 
the SOS intervention is important for the following reasons: 
 
• Increases the likelihood of reproducibility; 
• Enables a better understanding of why the intervention was successful or 
unsuccessful; 
• Demonstrates an important quality control step within the SOS trial planning 
process. 
 
Eleven prescribing support, practice based pharmacists were selected from 23 employed by 
NHS GG&C in 2003. The author’s role was professional line manager and lead for the 
Prescribing Support team at that time. Selection of pharmacists to participate was based on 
availability to deliver the intervention over the year long intervention period. It was not 
determined by ability or prior knowledge/experience of cardiovascular therapeutics or 
communication skills. All worked in general practices as prescribing support pharmacists, 
on a full time or part time basis, all shared the same job description, and were remunerated 
at the same level under NHS terms and conditions. Key characteristics are given in Table 
3.2. 
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Table 3.2 Pharmacists’ characteristics 
 
* experience was mainly clinical medication review based in general practices, for patients receiving polypharmacy.  
 
To ensure a minimum level of knowledge and skills tailored to the SOS intervention, all 
pharmacists attended six and a half training days between September 2003 and January 
2004. Pre-requisites for delivering the SOS intervention were agreed amongst the 
pharmacists and included: 
 
• Attendance at all of the study days and achievement of a satisfactory standard (of 
motivation and performance; assessed by the principle investigator) during each 
training day; 
• Commitment to delivering the SOS intervention in the following 12 months. 
  
Pharmacist 
(Male (M) / 
Female (F) 
Years post 
qualification  
Number of 
years  
prescribing 
support 
experience* 
Role prior to 
general 
practice 
prescribing 
support 
Postgraduate 
clinical 
pharmacy 
qualification  
Part 
time  / 
Full time 
#1 (M) 5 4 Community 
Pharmacy 
Y FT 
#2 (F) 2 1 Community 
Pharmacy 
N FT 
#3 (F) 7 4 Community 
Pharmacy 
N PT 
(0.6wte) 
#4 (F) 7 4 Community 
Pharmacy 
N FT 
#5 (M) 4 1 Community 
Pharmacy 
N PT 
(0.2wte) 
#6 (F) 5 4 Community 
Pharmacy 
N PT 
(0.6wte) 
#7 (F) 15 3 Community 
Pharmacy and 
Hospital 
pharmacy 
(Psychiatry) 
Y PT 
(0.4wte) 
#8 (F) 13 3 Community 
Pharmacy 
N FT 
#9 (F) 6 3 Academia Y PT 
(0.8wte) 
#10 (F) 6 3 Community 
Pharmacy 
N PT 
(0.6wte) 
#11 (F) 12 4 Community 
Pharmacy 
N FT 
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Forty one contact hours of training were accrued by each pharmacist. The training was 
specific to the delivery of the three meeting approach to the SOS intervention. A mixture 
of academic GPs, GPs experienced in postgraduate education, a consultant cardiologist, a 
cardiac nurse and a senior lecturer delivered the training sessions. Training covered the 
following topics: 
 
• Evidence base for use of statins; 
• Educational outreach;  
• Study protocol; 
• Pharmacological actions of statins;  
• Aetiology of vascular disease;  
• Primary/secondary prevention thresholds;  
• Communication skills required to deliver the SOS intervention through three, 
linked meetings;  
• Practitioner and patient level barriers to systematic uptake of simvastatin 
prescribing;  
• Adult learning theory. 
   
An outline of the training provided is given in Appendix XIII. All pharmacists were 
competent in the operation and searching of practice computer systems. All 11 pharmacists 
attended the training events and performed satisfactorily.  
 
 
3.6 Delivery of the SOS intervention 
 
The intervention was delivered as described to 14 of the 16 practices randomised. One 
practice had disbanded prior to the date of randomisation (this was discovered when the 
practice was phoned to confirm their allocation) and another practice declined further 
support, after the first SOS intervention meeting, citing time constraints as the reason. 
Independent researchers were unable to access this practice for follow up data collection.  
 
With eleven pharmacists available to deliver the intervention, 4 were attached to two 
practices and the other 7 delivered the SOS intervention to one each. Pharmacists kept to 
their allocated practices throughout the duration of the study. The pharmacist from the 
practice that dropped out was retained in the study team and continued to support other 
participating pharmacists. 
 
 
3.7 Follow up data collection 
  
Follow up data was collected by hand, from the case notes and/or computer systems of 
eligible patients in the 29 remaining, participating general practices. Lists of eligible 
patients were identified using the same computerised search criteria used at baseline. Two 
trained, independent researchers (blinded to the allocation of practices) visited each 
practice at least once weekly (dependent on availability of space within each practice) to 
collect follow up data. The data fields collected by the researchers at follow up are 
summarised in Table 3.3.  
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Table 3.3 Data collection fields at follow up  
 
Patient status  
 
Clinical † 
 
Drug  
 
Demographic  
 
Deceased/left the 
practice 
Previous MI Statin (description 
of which statin) 
Practice 
identification 
number  
Diabetes Daily dose Date of data 
collection 
CABG Start date 
 
Patient identification 
number (CHI) 
Stroke, 
 
Dose increase date 
 
Date of birth 
Angioplasty Most recent 
cholesterol level 
Sex 
TIA Date of most 
recent cholesterol 
level 
 
Angina/IHD 
 
 
Eligible at baseline 
(confirmed by date of 
first eligible diagnosis) 
or  
not eligible at baseline 
(became eligible 
between baseline and 
follow up)  
PVD/Intermittent 
claudication 
 
 
† (eligibility criteria) definite or possible, with accompanying date event(s) first recorded in practice computer 
 
Follow up data collection started on the 4th April 2005 and was completed on 29th March 
2006. Across 29 practices, this gave a mean length of follow up of 1.7 years from 
randomisation (minimum 1.4 years, maximum 2.2 years) as described in Appendix XIV. 
 
  
Time to first onset of new clinical event/diagnosis  
 
To evaluate the contribution (if any) of the SOS intervention to the development of adverse 
events, we collected the number and dates of new vascular events in a sample of patients. 
These data were collected using a remote computer search by a central server (operated by 
NHS GG&C Information Technology Monitoring Team). In this way, collection of these 
adverse events was not subject to the same restrictions on access as follow up for 
endpoints. The mean duration of follow up for events data was 2.5 years (minimum 2.2 
years, maximum 2.8 years) (Appendix XIV).  
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Chapter 4 
 
Baseline data 
 
This chapter describes the characteristics of the SOS study participants at baseline, before 
randomisation. The characteristics of participating practices are compared with non 
participating practices and the characteristics of participating patients are compared 
between the SOS intervention and UC arms of the study. A comparison is made between 
characteristics of the SOS study participants’ and participants of other trials.  
 
 
4.1 Practice characteristics 
 
As described in the methods chapter, 49 practices were randomly identified from the list of 
practices in Greater Glasgow at that time and invited to participate. Thirty one practices 
agreed to participate in the study. The remaining 18 practices either declined to participate 
(n = 15), or did not reply (n = 3). Of those agreeing to participate, 15 were Single Handed 
(SH) and 16 were Group (G) practices.  Flow of practices through this stage of the trial is 
given in Appendix XV. 
 
By the time baseline data collection was complete (this process took 6 months from start to 
finish) across all 31 practices and practices were randomised, one (single handed) practice 
had disbanded. The data from this practice is shown in the baseline results for 
completeness, but is not included after this chapter or used in follow up analysis. 
 
For the 18 practices declining to participate, the number of GPs, practice nurses, list sizes 
and practice level modified Scottish Index of Multiple Deprivation (mSIMD) was available 
from routine data. These characteristics were used in comparisons with participating 
practices. The modified Scottish Index of Multiple Deprivation (mSIMD; McConnachie 
2003), is an aggregate score (excluding measures of population health and access to 
healthcare) indicating the level of socioeconomic deprivation of the practice population. 
Higher values indicate greater levels of deprivation. 
 
For eligible patients in participating practices, baseline data included the patient level 
variables described in Chapter 3.  
 
 
4.1.1 Comparisons between participating and non participating (invited) practices 
 
Characteristics of non participating (invited) practices were compared with the 
characteristics of participating practices to determine whether those recruited were 
representative of those invited and by inference, all practices in Greater Glasgow (Table 
4.1).  
 
Analyses suggested there were no statistically significant differences in the sizes of 
practice populations and number of GPs between participating and non participating 
(invited) practices. The average number of nurses showed a significant difference; 
participating practices had more (mean 1.2 in participating compared with 0.9 in non 
participating, p = 0.04). When participating and non participating practices’ mean values 
for mSIMD were compared, no statistically significant difference was detectable (38.0 for 
31 participating practices, 39.2 for 188 non participating practices; p = 0.696).
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Table 4.1 Comparisons between participating and non participating (invited) practices 
 
Variable Participating practices 
 
Non participating (invited) practices 
 
P value 
Mean (range) 
 
SH G All participating SH G All non 
participating 
 
 
Practices  
 
 
15 
 
16 
 
31 
 
9 
 
8 
 
17 
-  
 
GPs 
 
1  
(1 - 1) 
 
3.5  
(2 – 5) 
 
2.3  
(1 – 5) 
 
1  
(1 - 1) 
 
3.4  
(2 - 6) 
 
2.2  
(1 – 6) 
 
0.721 
 
Practice nurses 
(PNs) 
 
 
1  
(0.4 – 2) 
 
1.3  
(1 – 2) 
 
1.2  
(0.4 – 2) 
 
0.72  
(0.4 – 1) 
 
1  
(0.5 – 1.8) 
 
0.9 
(0.4 – 1.8) 
 
0.041 
 
List size  
 
 
2043  
(818 – 3536) 
 
5374  
(1787 – 12330) 
 
3657  
(818 – 12330) 
 
1711 
(1361 – 2126) 
 
5033 
(2584 – 7696) 
 
3323  
(1361 – 7696) 
 
0.481 
 
mSIMD (SD) 
 
 
36.2 (18.3) 
 
39.8 (10.8) 
 
38.0 (15.5) 
 
42.3 (22.8) 
 
38.0 (20.6) 
 
39.2 (18.9) 
 
0.702 
 
1Mann-Whitney test  2 Two sample t-test 
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4.1.2 Comparisons between the SOS intervention and UC practices  
 
Table 4.2 shows a comparison of the characteristics of participating practices, split by 
allocation to the SOS intervention and UC. The purpose of the analysis was to test for any 
differences in SOS intervention and UC practices, in relation to practice level variables at 
baseline. The number of Whole Time Equivalent GPs, practice nurses, practice list sizes 
and the eligible patients identified were all comparable between the SOS intervention and 
UC practices. The aggregated characteristics of SH and G practices within the SOS arm of 
the study were compared with aggregated characteristics of SH and G practices in the UC 
arm, using the Wilcoxon signed rank test or the two sample t test. 
 
In the SOS intervention practices, there were 39 GPs and 21 practice nurses. Practices 
allocated to UC had 32 GPs and 16 practice nurses.  
 
The variable ‘number of whole time equivalent GP or nurse’ was collected to give an 
indication of the number of meetings required during the SOS intervention, which was 
anticipated to be a key determinant of whether the SOS intervention would be feasible. 
Comparison of this variable between the SOS intervention and UC arms using the 
Wilcoxon Signed Rank test showed them to be well balanced at baseline. Another indicator 
of the extent of work needed to shift statin prescribing from existing to desirable was the 
practice list size. This was thought to be proportional to the number of patients eligible; 
practices with larger lists were thought to pose an increased workload for the practice and 
pharmacist. Again, SOS intervention and UC practices were found to be balanced in this 
respect. It might be argued that these variables should have been included in the 
stratification process, if they were key factors in determining the balance between SOS 
intervention and UC arms of the study. However, their effect was incorporated indirectly, 
because stratification involved making a distinction between Single Handed and Group 
practices, which are defined by the number of whole time equivalent staff (and patients). 
 
Table 4.2 describes a drop off in the number of patients between those labelled ‘eligible 
identified’ and ‘eligible included’ because of the systematic sampling of every third 
eligible patient at baseline in the five largest Group practices. Sampling was undertaken 
because of the limited availability of researchers to undertake the time consuming task of 
identifying patients from computer records, locating and obtaining paper case notes, 
finding and documenting relevant information. Three of these practices were subsequently 
allocated to UC and two were allocated to SOS. Therefore, fewer eligible patients were 
identified in UC practices than in SOS practices. The Table shows that the number of 
eligible patients included was modestly imbalanced between SOS intervention and UC, at 
baseline, as a result of this sampling process. However, the difference did not reach the a 
priori level of statistical significance (SOS: 296.6 vs. UC: 219.5 eligible patients; p = 
0.09).  
  
When the practice level mean values for mSIMD were compared between SOS 
intervention and UC practices, there was no statistically significant difference (p = 0.3; 
95% CI: -17.1, 5.5). We analysed this variable because those practices with the highest 
mSIMD are associated with an increased prevalence of CHD and other cardiovascular 
disorders. In addition, there is some evidence that uptake of general practice appointments 
for preventative care interventions are reduced among patients from practices with higher 
mSIMD (The Scottish Government 2008). The extent of social deprivation of recruited 
practices can also be described relative to the mSIMD of all Scottish practices, to give a 
broader perspective on practice characteristics. When Scottish practices are divided into 
deciles according to mSIMD, 10 / 15 SOS arm and 9 / 15 UC practices resided in the two 
most deprived deciles. 
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4.1.3 Comparison between Single handed and Group practices 
 
Table 4.2 subdivides practices within SOS and UC arms by their Single Handed and Group 
practice status. SOS and UC arms of the study were balanced in relation to the given 
variables.  
 
Overall, these analyses show that, with the exception of practice nurses, participating and 
invited, non participating practice characteristics were comparable. In the participating 
practices, practice characteristics were balanced between SOS intervention and UC arms of 
the study, at baseline, confirming in part, the appropriateness of the randomisation process.  
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Table 4.2  Baseline characteristics of participating practices  
    
 
SOS and UC (Single Handed practices) 
 
SOS and UC (Group practices) 
 
P value 
 
Variable  
Mean (range) 
 SOS 
(n=8) 
 UC 
(n=7) 
SOS 
 (n=8) 
UC 
(n=8) 
SOS  (n = 16) vs  
UC (n = 15)  
 
Whole Time Equivalent GPs 
 
1  
(1-1) 
 
1  
(1-1) 
 
3.8  
(3 - 5) 
 
3.1 
(2 - 5) 
 
0.451 
 
Whole Time Equivalent 
practice nurses  
 
1.1  
(0.4 – 2) 
 
0.9  
(0.5 - 1) 
 
1.5  
(1 – 2) 
 
1.1  
(1 – 2) 
 
0.441 
 
Practice List size  
 
 
1967 
(818 – 3474) 
 
2119 
(1087 – 3536) 
 
5519 
(4103 – 7215) 
 
5228 
(1787 – 12330) 
 
0.711 
 
Eligible patients identified 
 
 
137  
(91 - 252) 
 
186  
(107 – 275) 
 
545  
(426 – 676) 
 
446  
(125 – 982) 
 
0.511 
 
Eligible patients included  
 
 
66.5 
(33 – 133) 
 
89.4 
(50 – 135) 
 
230.1 
(90 – 296) 
 
130.1 
(80 – 237) 
 
0.091 
 
mSIMD (SD)  
 
 
34.5 
(21.3) 
 
37.8 
(15.2) 
 
47.1 
(11.8) 
 
32.6 
(9.8) 
 
0.302 
1 Wilcoxon signed rank test.  2 Two sample t-test. 
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Table 4.3 shows the numbers of patients in each pair and the triple (from which one 
practice subsequently disbanded) at randomisation.  
 
 
Table 4.3 Distribution of eligible, included patients at baseline, by pair 
 
Practice pair SOS UC 
   
1 253 155 
2 296 100 
3† 255 118 
4 234 133 
5 261 216 
6 215 132 
7 237 79 
8 90 108 
9 57 63 
10 33 135 
11 110 76 
12 97 89 
13 39 50 
14 63 114 
15 133 99 
   
Sub total 2373 1667 
Total  4040 
† Triple, containing 2 (Single Handed) SOS arm practices 
 
 
4.2  Patient characteristics 
 
4.2.1 SOS versus UC 
 
Baseline data collection included demographic, diagnostic and prescribing data from the 
computer and paper records of 4040 patients across 31 practices.  
 
Table 4.4 shows SOS and UC practices were well matched for mean age and sex of the 
patients recruited. Both variables were comparable to population estimates for patients 
with Coronary Heart Disease at that time (Allender 2007).  
 
The most prevalent qualifying diagnosis was Angina/Ischaemic Heart Disease (IHD) with 
a statistically significant higher prevalence in the SOS arm (49.3% versus 40.4%, p < 
0.001). The prevalence of all other diagnoses was balanced between SOS and UC practices 
at baseline.  
 
The co-morbidities collected during the study related only to those described in the HPS 
for patient inclusion criteria. The prevalence of vascular co-morbidities was significantly 
higher in SOS than in the UC arm, but the difference was nullified when adjusted for the 
contribution of Angina/IHD. There was no evidence of difference in the prevalence of any 
other diagnoses, indicating that practices randomised to the SOS intervention were broadly 
comparable to practices randomised to UC in relation to distribution of qualifying 
diagnoses.  
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Table 4.4  Patient characteristics at baseline (SOS vs. UC): demographics and co- 
morbidities 
 
 SOS 
(n = 2373 with 
vascular disease) 
UC  
(n = 1667 with 
vascular disease) 
p value 
 
Age (years) † 68.2 (12.1) 68.5  (12.0)   0.311  
Sex, male 1207/2373 (52.9%) 890/1667 (53.4%) 0.192 
Qualifying diagnosis  
Values shown are number (%) of patients with each type of vascular disease  
Angina / Ischaemic Heart Disease  1170/2373 (49.3%) 674/1667  (40.4%)  < 0.0012 
Diabetes Mellitus, age ≥ 45 years  825/2373 (34.8%) 647/1667 (38.8%)  0.342 
MI  495/2373 (20.8%) 355 /1667 (21.2%) 0.332 
Cerebrovascular event 334/2373 (14.1%) 236/1667 (14.1%)  0.112 
PVD 286/2373  (12.0%) 161/1667 (9.6%)  0.202 
TIA  223/2373  (9.4%) 121/1667 (7.2%) 0.162 
CABG 200/2373  (8.4%) 144/1667 (8.6%) 0.542 
Angioplasty  104/2373  (4.4%) 67/1667 (4.0%)  0.672 
Number of vascular co-morbidities †  1.53 (0.78) 1.44  (0.72)  < 0.0011 
Number of vascular co-morbidities 
excepting angina †  
0.81 (0.72) 0.84  (0.66) 0.761 
1 Linear regression 2 Binary logistic regression   † Mean (SD) 
 
Table 4.5 shows cholesterol levels of patients in the SOS intervention and UC arms of the 
study. Approximately one quarter of patients in the SOS arm had no record of their 
cholesterol ever being recorded in their primary care medical case records. The proportion 
of UC patients without cholesterol ever recorded was less (21.6% UC vs 25.4% SOS, p = 
0.01).  
 
Of those with cholesterol recorded, approximately half of all participants had cholesterol 
levels below target (threshold < 5mmol/l for all patients except those with a diagnosis of 
CABG, who had a target of < 4mmol/l). The values shown in Table 4.5 (49.7% SOS and 
52.0% UC) included all patients (with or without a statin) at baseline.  
 
Of those with cholesterol recorded, mean cholesterol levels for patients prescribed a statin 
(4.79mmol/l SOS, 4.71mmol/l UC) were (as expected) lower than in patients without a 
statin (5.11mmol/l SOS, 5.08mmol/l UC). Neither of these variables showed any evidence 
of difference when SOS practices were compared with UC. There were significant 
differences between the SOS intervention and UC in the prescribing of statins (38.6% 
SOS, 44.3% UC; p < 0.001) and in the prescribing of statins at optimal doses (21.9% SOS, 
24.5% UC; p < 0.001) when all patients (with or without a statin) were included.  
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Stratification comprised matching of practices according to the variable thought to be the 
most important predictor of effect:  
 
 
Number of eligible patients with cholesterol recorded and in target range 
Number of eligible patients 
 
 
This variable was balanced at baseline (49.7% SOS vs. 52.0% UC; p = 0.48) but other 
variables e.g. statin prescribed or prescribed at optimal dose, were not.  
 
 
Table 4.5 Patient characteristics at baseline (SOS vs. UC):  cholesterol levels and 
statin prescribing  
 
 SOS 
(n = 2373 with 
vascular disease) 
UC  
(n = 1667 with 
vascular disease) 
p value 
 
    Statin prescribing and cholesterol 
Cholesterol recorded 1768/2373 (74.5%) 1307/1667  (78.4 %)  0.012 
Cholesterol recorded and controlled 878/1768 (49.7%) 680/1307 (52.0%) 0.482 
Mean Cholesterol level , all patients with 
cholesterol level (SD) 
5.08mmol/l 
(1.1mmol/l) 
5.01mmol/l 
(1.1mmol/l) 
0.141 
Mean cholesterol level, all patients with 
cholesterol recorded and prescribed a 
statin  (SD) 
4.79mmol/l 
(1.2mmol/l) 
4.71mmol/l 
(1.1mmol/l) 
0.201 
Mean cholesterol level, all patients with 
cholesterol recorded and not prescribed a 
statin (SD)  
5.11mmol/l 
(1.1mmol/l) 
5.08mmol/l 
(1.0mmol/l) 
0.821 
Statin not prescribed 1456/2373 (61.4%) 929/1667 (55.7%)  < 0.0012 
Statin prescribed at optimal dose 520/2373 (21.9%) 408/1667 (24.5%)  < 0.0012 
1 Linear regression 2 Binary logistic regression 
 
Table 4.6 characterises all 1654 patients with vascular disease who were prescribed a statin 
at baseline. For patients with vascular disease prescribed a statin, there was no significant 
difference between SOS and UC arms in the proportion with cholesterol not recorded in 
medical case notes (assumed therefore that cholesterol has never been checked; 9.8% SOS 
vs. 8.8% UC; p = 0.61) and no difference in the proportion with cholesterol controlled 
(50.3% SOS vs. 51.2% UC; p = 0.93).  
 
For each statin and within each of the statin subcategories, there appeared not to be any 
significant imbalance between patients in the SOS intervention and UC arms of the study. 
For each of the statins (Simvastatin, Atorvastatin, Pravastatin and Fluvastatin) shown in 
Table 4.6, the SOS intervention and UC arms were balanced at baseline. Together, this 
indicates the randomization process achieved the desired effect and that any difference in 
this outcome at follow up could be attributed to the intervention effect. 
 
Simvastatin was the most prescribed statin at baseline, with almost double the proportion 
of patients than the nearest competitor, Atorvastatin. When patients prescribed a statin at 
baseline were considered, the only (weak) evidence of there being any difference in the 
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distribution of statin prescribing between SOS and UC practices was a slightly greater 
proportion of patients in the UC arm prescribed Atorvastatin (29.4% UC vs 27.7% SOS; p 
= 0.04). Only 63% of the simvastatin treated group were prescribed an evidence based dose 
compared with 100% in the Atorvastatin group. This is likely to be due to the starting dose 
of Atorvastatin (10mg) being accepted as a maintenance dose, due to it having greater 
potency. In contrast, simvastatin is commonly initiated at 10mg or 20mg with the 
requirement for the patient to re-attend their practice for up titration to 40mg (the optimal 
dose). This may take several weeks or months. The requirement for additional 
appointments can lead to dropout with those dropping out more likely to stabilise at a 
lower dose. 
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Table 4.6  Patient characteristics at baseline (SOS vs. UC): statin prescribing 
 
Variable  
 SOS  
(n = 916 prescribed a 
statin) 
 
UC  
(n = 738 prescribed 
a statin) 
p value 
Cholesterol not recorded  90/916 (9.8%)  65/738 (8.8%) 0.612 
Cholesterol recorded and 
controlled  461/916 (50.3%)  378/738 (51.2%) 
 
0.932 
All doses  529/916 (57.8%)  443/738 (60.0%) 0.152 
Suboptimal 
dose  318/916 (34.7%)  286/738 (38.8%) 
0.892 
Optimal dose, 
cholesterol 
controlled 
 91/916 (9.9%)  72/738 (9.8%) 
  
0.432 
All doses, 
cholesterol 
controlled 
 259/916 (28.3%)  226/738 (30.6%) 
 
0.312 
Simvastatin 
 
Mean 
Cholesterol 
level (SD) 
 4.77mmol/l (1.15mmol/l)  4.70mmol/l (1.13mmol/l) 
0.211 
All doses  254/916 (27.7%)  217/738 (29.4%)  0.042 
All doses, 
cholesterol 
controlled 
 143/916 (15.6%)  120/738 (16.3%) 
 
0.472 
Atorvastatin 
Mean 
cholesterol 
level (SD) 
 4.75mmol/l (1.20mmol/l)  4.66mmol/l (1.14mmol/l) 
0.691 
All doses  119/916 (7.7%)  70/738 (9.5%) 0.182 
Suboptimal 
dose  70/916 (7.6%)  37/738 (5.0%) 
0.892 
Optimal dose, 
cholesterol 
controlled 
 20/916 (2.2%)  17/738 (2.3%) 
 
0.562 
All doses, 
cholesterol 
controlled 
 55/916(6.0%)  28/738 (3.8%) 
 
0.322 
Pravastatin 
Mean 
Cholesterol 
level (SD) 
 4.98mmol/l (0.97mmol/l)  4.95mmol/l (1.15mmol/l) 
 0.931 
Other statins All doses  14/916 (1.5%)  8 (1.2%) -  
1 Linear regression 2 Binary logistic regression 
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4.2.2 Single Handed vs. Group 
 
Table 4.7 describes key patient variables by SH and G practice status. These data confirm 
there to be some important differences, therefore justifying the decision to stratify. Patients 
were on average, three years younger in SH practices, but the difference did not reach 
statistical significance. There were significant differences in the prevalence of PVD, Stroke 
and TIA. The prevalence of all of these diagnoses was lower in SH practices.  
 
 
Table 4.7 Patient characteristics (G vs. SH practices): demographics and vascular 
co-morbidities 
 
Variable Group (n = 16 
practices; 2,882 
patients) 
Single Handed (n = 
15 practices; 1,158 
patients) 
p value 
Mean age, years (SD) 68.6 (12.0) 65.8 (12.0) 0.041 
Sex, male (%) 51.7% 53.6% 0.102 
General Practice   mSIMD (SD) 39.8 (12.9) 36.0 (18.1) 0.511 
Qualifying diagnosis (median % prevalence, range) 1 
MI  21.0   (12.4 – 27.2) 19.3   (6.7 – 35.9) 0.36 
CABG 8.3   (4.6 – 16.5) 8.0   (0 – 15.1) 0.87 
Angioplasty  3.8   (1.2 – 8.2) 5.2   (0 – 11.1) 0.43 
Angina / Ischaemic Heart Disease  45.8   (23.7 – 64.7)  45.1   (10.4 – 59.6) 0.25 
PVD  12.5   (8.7 – 20.7) 7.1   (0 – 23.8) 0.003 
Diabetes Mellitus, age ≥ 45 years  32.5   (17.1 – 43.7) 35.3   (26.9 – 91.8) 0.05 
Cerebrovascular event 16.6   (9.0 – 23.7) 7.5   (1.5 – 23.7) 0.009 
TIA  10.1   (2.5 – 12.7) 5.3   (0 – 15.5) 0.05 
 Mean number of patients with more 
than 1 co-morbidity†  
0.52   (0.77) 0.44   (0.73)  0.16 
 
1 Two sample t-test.  2 Kruskal Wallis test   † Mean ± SD 
 
Table 4.8 shows that there was no evidence of a significant difference between G and SH 
practices in relation to statin prescribing or cholesterol variables. Amongst those prescribed 
simvastatin, fewer patients in SH practices were on the optimum dose and had their 
cholesterol controlled (one of the secondary outcome measures), justifying stratification of 
this variable (median proportion across Group practices 45.0%; range 16.7 to 72.2% vs 
25.0%; range 0.0 to 76.2% across SH practices; p = 0.001). 
 
The only other characteristic shown to be significantly different was the median proportion 
of patients receiving an optimal dose of statin with controlled cholesterol. However, the 
statistical power of the analyses comparing SH with G practices (Kruskal Wallis test of 
aggregated data; no need to take account of pairing in this analysis) was much reduced 
compared with the analysis of SOS versus UC (binary logistic regression of individual 
data). 
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Table 4.8 Patient characteristics (G vs. SH practices): statin prescribing 
 
Variable Group (n = 16 
practices; 2,882 
patients) 
Single Handed (n = 
15 practices; 1,158 
patients) 
p value1 
All participants: statin prescribing and cholesterol: median % (range) 
Cholesterol recorded   77.3%   (51.3 – 94.4%)  84.6%   (59.6 – 98.1) 0.09 
Cholesterol recorded and controlled  50.9%   (30.7 – 67.6%) 52.1%     (28.6 – 73.9) 0.50 
Statin not prescribed   58.7%   (32.3 – 78.0%)   58.6%    (38.0 – 
96.8%) 
0.86 
Statin prescribed at optimal dose  53.2%    (32.8 – 88.3%) 56.7%   (0.0 – 62.7%) 0.87 
Mean Cholesterol level (SD) 4.95mmol/l   (1.13) 4.92mmol/l   (1.07)  0.812 
Participants prescribed any statin 
Mean cholesterol level (SD)  4.78mmol/l   (1.14) 4.77mmol/l   (1.13) 0.90 
Participants prescribed simvastatin 
All doses  59.4%    (41.7 – 78.3%) 53.8%    (27.3 – 
100%)  
0.39 
Suboptimal dose  66.1%    (28.0 – 77.4%) 71.4%    (34.4 – 
100%) 
0.10 
Optimal dose, cholesterol controlled  45.0%    (16.7 – 72.2%) 25.0%   (0.0 – 76.2%) 0.001 
All doses, cholesterol controlled  51.2%    (28.3 – 72.1%) 45.8%    (16.7 – 
100%) 
0.45 
Mean Cholesterol level (SD) 4.72mmol/l    (1.14) 4.80mmol/l    (1.14) 0.49 
Participants prescribed Atorvastatin 
All doses  23.8%     (9.1 – 56.7%) 24.1%    (0.0 – 63.6%) 0.86 
All doses, cholesterol controlled  52.8%    (0.0 – 82.4%) 59.6%    (0.0 – 84.6%) 0.59 
Mean cholesterol level (SD) 4.81mmol/l   (1.19) 4.76mmol/l    (1.13) 0.6 
Participants prescribed Pravastatin 
All doses  8.8%    (0.0 – 29.5%) 10.6%    (0.0 – 40.0%) 0.77 
Suboptimal dose  50.0    (0.0 – 92.9%) 41.7%    (0.0 – 100%) 0.74 
Optimal dose, cholesterol controlled  37.5%    (0.0 – 100%) 83.3%    (0.0 – 100%) 0.24 
All doses, cholesterol controlled  25.0%    (0.0 – 100%) 64.6%   (0.0 – 100%) 0.09 
Mean Cholesterol level (SD) 5.04mmol/l    (1.06) 4.73mmol/l    (0.95) 0.23 
Other statins e.g. Fluvastatin 
All doses 0.0%     (0.0 – 3.3%) 0.0%     (0.0 – 19.0%) -  
1 Kruskal Wallis test  2  Two sample t test 
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4.3 Discussion of baseline data 
 
4.3.1 Practice characteristics 
 
Our 50:50 ratio of Group to Single Handed practices did not mirror the 70:30 ratio in 
Glasgow at the time of recruitment, therefore we compared key characteristics of our 
participating practices with invited, non participating practices as a way of demonstrating 
representativeness. Baseline data suggested the recruited sample of 15 Group and 16 
Single Handed practices was comparable to the 24 Group and 25 Single Handed practices 
invited to participate, although the number of practice nurses was slightly greater in 
participating practices. As the process for selection of these 49 practices from the Glasgow 
list of 169 Group and 63 Single Handed was random, recruited Group and Single Handed 
practices are otherwise likely to be representative of those in the largest Health Board in 
Scotland.  
 
While the greater number of practice nurses in participating practices reached statistical 
significance, it is not possible to speculate if the difference (0.3 whole time equivalent 
practice nurse between participating and invited, non participating practices) influenced the 
practice’s decision to participate in the study. If practices with fewer practice nurses can be 
assumed to be busier as a result, those with fewer may have declined to participate because 
of a perceived inability to accommodate the intensive schedule of meetings and pharmacist 
input. Alternatively, invited, non participating practices may not have viewed the topic of 
improving secondary prevention by statin prescribing as a priority. Both these potential 
reasons might suggest lower levels of achievement of the variables described, in non 
participating practices. 
 
Characteristics of practices allocated to SOS intervention showed no statistically 
significant differences compared to practices allocated to UC. Only one comparison 
generated a difference that approached statistical significance: the number of patients 
eligible for inclusion in the target group for pharmacist intervention. In UC, Group 
practices, the mean number of eligible patients identified by the researchers was almost 
half the number in the SOS arm (Group practices): 130.1 vs. 230.1. This difference was 
likely to have accounted for the difference between the SOS intervention and UC nearing 
statistical significance (p = 0.09; Table 4.2). The reasons for this imbalance did not appear 
to come from differences in the practice list sizes used to derive them, because these were 
comparable (p = 0.71; Table 4.2). It is likely that the sampling process (every third eligible 
patient in the five largest Group practices) led to the identification of fewer patients in the 
UC arm practices. As practices had not been allocated to UC or the SOS intervention at the 
time of baseline data collection, this imbalance occurred as a result of a greater number 
(three) of these practices being allocated to the UC arm and two to the SOS arm. 
Allocation to SOS or US was by a computer generated list of random numbers. It is 
unlikely to have confounded the results, because the lower number of patients identified 
did not account for any subsequent differences in any of the characteristics described in 
Tables 4.4 to 4.8 the numerator was expressed as a percentage of the number of patients 
sampled.  
 
Comparison of our recruited general practices’ characteristics with other studies is not 
possible because practice level characteristics are inadequately described in other studies 
of this nature. 
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4.3.2 Patient characteristics 
 
At baseline, only 41% of eligible patients were prescribed a statin, and just over half of 
these were prescribed a statin at an evidence based dose (Table 4.5). At best, 59% of those 
on a statin had controlled cholesterol, a finding consistent with the ‘rule of halves’ (Wilber 
1972). Although the findings were not aligned to the rule of halves, Primatesta found 
cholesterol targets were achieved in less than 50% of patients who receive lipid lowering 
treatment (Primatesta 2000). Other researchers have found a similar picture, in relation to 
LDL cholesterol levels (Bourgault 2005; Farahani 2009). These data indicate the potential 
importance of an intervention to improve statin prescribing and cholesterol levels, in 
primary care. 
 
There was a higher prevalence of angina/IHD in the SOS intervention arm (49.3% versus 
40.4%, p < 0.001. Table 4.4). Greater numbers of patients with angina/IHD may indicate 
the practice had improved approaches to detecting and recording angina/IHD, or higher 
baseline prevalence compared to practices with fewer numbers. Either way, a greater 
amount of effort is required to establish and maintain accurate disease registers if there are 
more patients. Associated with this is the need to manage call and recall systems for annual 
cholesterol, blood pressure and other checks, all of which increase workload in general 
practices (Moher 2001). It is therefore possible that the SOS intervention allocated 
practices were more accustomed to managing disease registers with larger numbers of 
patients with CHD compared with UC practices, and this prepared them better for 
additional work arising from the SOS intervention. The increased prevalence of 
angina/IHD caused the statistically significant difference in the number of vascular co-
morbidities, with a greater proportion in the SOS arm compared with the UC arm (SOS: 
1.53 (SD 0.78) vs. UC: 1.44 (SD 0.72). p-value < 0.001. Table 4.4). Baseline data collected 
in each practice was available to each practice prior to randomisation.  
 
Statin prescribing and optimum dosing was less in the SOS intervention arm, when all 
eligible patients (n = 2373, with or without a statin) in SOS intervention arm were 
compared with all eligible patients in the UC arm (n = 1667; Table 4.5). One reason for 
these imbalances could be the relatively small number of clusters, and large variation 
between clusters. Analysis of follow up data did not adjust for these baseline differences; 
only practice type (SH or G) and pairing were adjusted for in the regression analysis. 
However, these imbalances tended to work against the effect of the SOS intervention, 
rather than introduce bias to favour the SOS intervention.  
 
From Table 4.6, the proportion of patients receiving simvastatin with their cholesterol 
controlled was almost double the proportion controlled on Atorvastatin, a surprising 
finding in view of the greater potency of Atorvastatin and relative ease of attainment of the 
target dose. However, mean cholesterol levels were comparable in patients prescribed both 
statins. The explanation for this finding is uncertain, but local Guidelines (Appendix VIII), 
recommended Atorvastatin as second line, after attempts to bring cholesterol under control 
with simvastatin have failed. Therefore, patients commenced on Atorvastatin may be more 
likely to have higher cholesterol levels at the outset, or cholesterol levels less likely to 
show a decrease (for whatever reason e.g. poor adherence). 
 
Pravastatin is known to be less potent (mg for mg) than either simvastatin or Atorvastatin, 
which explains why patients receiving Pravastatin had higher cholesterol levels than 
patients prescribed simvastatin or Atorvastatin.  
 
As expected, mean cholesterol levels at baseline for patients prescribed a statin 
(4.71mmol/l UC, 4.8mmol/l SOS; Table 4.5) were lower than mean cholesterol levels for 
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patients without a statin (5.11mmol/l SOS, 5.08mmol/l UC), an approximate reduction of 
7%. This reduction is of a lower magnitude to that observed in landmark statin intervention 
trials where reductions in cholesterol were of the order of approximately 27% 
(Scandinavian Simvastatin Survival Study Group 1994; Sacks 1996; The LIPID study 
group 1998; Shepherd 1995; Downs 1998; The Heart Protection Study Collaborative 
Group 2002; Shepherd 2002; ALLHAT Collaborative research group 2002; ASCOT 
investigators 2003; Serruys 1999; Schwartz 2002; Athyros 2002) and differences in 
morbidity/mortality outcomes emerged over a minimum of 3 years. Possible reasons for 
the reduced effect of statins in our naturalistic study might include the use of lower than 
optimal doses, reduced statin adherence, recent initiation with insufficient time for 
maximal cholesterol lowering effect, and a more unpredictable impact in a heterogeneous 
group of primary care based patients not usually included in clinical trials. Patients 
consenting to participate in commercially driven, multicentre clinical trials may be more 
likely to be ‘health wary’: in providing signed consent to participate, they have agreed to a 
schedule of additional clinic visits and taking an additional tablet every day. In 
comparison, the SOS intervention trial participants were operating as they do in usual care, 
because Ethical approval did not stipulate the need for patient consent. Unlike participants 
in landmark statin trials, patients in the SOS intervention target group did not receive the 
additional attention from dedicated research staff for follow up blood tests, repeat medicine 
supplies and encouragement to adhere. Reinforcement through repeat visits to study 
centres in other trials may have the effect of improving adherence (Mullen 1985) and 
therefore reduced cholesterol to a greater extent.  
 
We hypothesised there would be significant differences between SH and G practices at 
baseline, and stratified for this reason. Although unsubstantiated by any empirical evidence 
collected during the study, pharmacists observed that group practices tended to have more 
advanced protocols for case finding, call and recall and more complete computerised data 
recording than single handed practices. All of these attributes might be expected to lead to 
increased detection and recording. Diabetes was the exception to this observation with an 
increased prevalence in single handed practices compared with group practices. This could 
be explained by the fact that four single handed practices were located in predominantly 
South Asian communities. South Asians are up to six times more likely to get diabetes, 
develop it on average 10 years earlier (Mather 1985; Greenhalgh 2001) and have a 50 per 
cent increased mortality risk from coronary heart disease compared with white Europeans 
(Wild 1997). The proportion of patients with vascular disease who had diabetes across 
these four single handed practices was 81.1% compared with 36.3% across the remaining 
11 recruited single handed practices. 
 
In 1995, for a primary prevention cohort of patients in the WOSCOPS (some of whom 
were from the practices recruited into the SOS intervention trial), mean cholesterol at 
baseline among screenees was 5.9 + 1.2mmol/l (Shepherd 1995). The mean cholesterol 
level among patients at baseline in the SOS trial, 10 years after WOSCOPS baseline, was 
lower. This was an expected finding because approximately 40% of our participants were 
already receiving a statin. In addition, at baseline (2003/4), there was greater societal and 
individual level awareness of the need to reduce cholesterol, compared with 1995, when 
cholesterol and statins were emerging as important factors in the management of CHD. 
However, our results demonstrate that important shortfalls in cholesterol control and statin 
use persisted in a higher risk, secondary prevention cohort: approximately half of patients 
had no statin prescription and had cholesterol above target. Other reports from around the 
same period indicated that only 1 in 10 eligible patients reached recommended targets 
(Primatesta 2000).  
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In 2002, a survey of British men with established CHD aged 60 – 75 years showed up to 
33% were prescribed a statin with only a third of those prescribed a trial validated dose 
(Whincup 2002). We report the results form a larger sample from the same period, with 
comparable results (approximately 40% prescribed a statin, half of those prescribed trial 
target dose) confirming the generalisability of our baseline findings. Simvastatin was the 
most prescribed, accounting for 59% of all statins and double the number of patients 
compared with the nearest competitor, Atorvastatin.  
 
We systematically collected few demographic variables other than age and gender, because 
of the limitations of time and the extent of missing data for other variables e.g. smoking 
status, blood pressure. Cholesterol levels were available in 81% of participants; we did not 
conduct any physical examination of the eligible patients in the study practices.  
 
Comparison of the characteristics of the SOS study participants with participants in 
published trials enables an evaluation of generalisability and an understanding of whether 
the study adds to current knowledge or understanding in this area. There are two types of 
study suitable for comparison with the SOS trial: landmark randomised controlled trials of 
statin therapy for secondary prevention and surveys of statin prescribing (Tables 4.9 and 
4.10). 
 
 
4.3.3 Characteristics of SOS trial participants compared with placebo controlled 
secondary prevention statin trials  
 
The SOS study population appears broadly comparable with those included in landmark 
secondary prevention studies. Demographics, physiological measures and co-morbidities 
are compared with other statin trials from that period in Table 4.9. Most parameters are 
similar, with two notable exceptions: the SOS trial had higher prevalence of Angina/IHD 
and Diabetes. This is likely to be a reflection of the underlying high prevalence known in 
the Greater Glasgow population (Figure 3.1).  
 
While acknowledging differences in funding, aims, multicentre location and methodology, 
the SOS trial participants are comparable with the PROSPER study (Prosper study group 
2002). PROSPER was a randomised controlled trial involving 5804 elderly people with or 
at high risk of developing cardiovascular disease or stroke. Patients were recruited from 
Glasgow, Cork and the Netherlands in 1998/9. The intervention comprised Pravastatin 
40mg daily for 3 years with a mean follow up of 3.2 years. While the follow up period was 
shorter in the SOS study and participants were younger, most other parameters were 
similar e.g. prevalence of stroke, peripheral vascular disease, CABG and angioplasty 
(Table 4.9). The proportion of males in SOS was 53% compared with 48% in PROSPER.  
PROSPER achieved a statistically significant reduction in the primary endpoint of a 
composite of coronary death, non fatal myocardial infarction or stroke. The difference 
between intervention and control group in the number of patients receiving Pravastatin 
40mg was 2900.  
 
In view of the similarities in the risk profiles of the participants in the SOS study and 
PROSPER, the SOS intervention participants receiving simvastatin 40mg may have 
achieved comparable endpoints, if there was sufficient difference between the SOS 
intervention arm and UC arm statin prescribing and the follow up period was longer. 
Chapter 6 discusses the scale of the changes in the SOS study and potential clinical 
significance of these.  
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HPS and LIPID (LIPID study group 1998; Table 4.9) recruited larger numbers of patients 
than those participating in the SOS trial. All three including CARE (Sacks 1996) recruited 
predominantly male, younger patients and followed outcomes for longer. Acknowledging 
the fundamental differences between the SOS intervention and these trials e.g. placebo 
controlled vs. comparative effectiveness, formal selection, recruitment and randomisation 
of patients vs. practices, a particularly novel aspect of the SOS trial is the involvement of a 
high proportion of diabetic participants.  
 
HPS had an age limit of 80 years at inclusion; therefore, the SOS participants were older 
on average (61% of participants over 65 years compared to 46% in HPS). The proportion 
of male versus female also differed: HPS (in common with all other landmark statin trials 
except PROSPER), recruited predominantly male participants. The SOS study included 
approximately equal numbers of males and females, suggesting better representativeness to 
usual care. Other baseline characteristics were comparable (e.g. prevalence of CHD, 
Stroke/TIA, PVD, Diabetes) between studies. The HPS investigators targeted patient 
groups who had been previously underrepresented or in whom the evidence of statin use 
needed to be reinforced (Chapter 3: methods). Patients entered into the trial were further 
selected on their ability to take their simvastatin. In the SOS study, pragmatic criteria were 
used to identify suitable patients on the basis of having at least one vascular co-morbidity. 
Disease prevalence also differed between the SOS intervention and HPS; the older age 
group in SOS had, as expected, a higher prevalence of CHD/ angina.  
 
Table 4.9 shows cholesterol levels (in statin – naïve individuals at baseline in all studies) 
were lower in the SOS trial. The reasons for this are not obvious, but in SOS trial we were 
only able to collect cholesterol levels if these were recorded in medical case records. 
Twenty four percent of eligible patients had no record of cholesterol levels: these patients 
are likely to have received an invitation for a cholesterol check at some point in the past, 
but did not attend. If this non attendance is taken as a signal of reduced health seeking 
behaviour or ‘health wary’ attitude, cholesterol levels may have been higher in patients 
without a record of cholesterol level. The mean cholesterol may have increased if the 
missing 24% had their cholesterol levels checked.  
 
 
4.3.4 Characteristics of SOS trial participants compared with secondary prevention 
surveys  
 
Statin prescribing and cholesterol levels in comparison with secondary prevention surveys 
from that period are compared in Table 4.10. It is acknowledged that different settings 
bring differences in lifestyle, healthcare systems and prescribing trends, all of which may 
impact on statin prescribing and cholesterol level.  
 
The SOS trial provides data from two time periods: baseline (2003/4) and follow up 
(2005/6). EUROASPIRE (2001) and PREVESE (De Velasco 2002) also collected statin 
prescribing and cholesterol levels from the same locations at two different time periods. 
However, only EUROASPIRE data is shown in Table 4.10. EUROASPIRE (2001) and 
ASPIRE (ASPIRE steering group 1996) recruited patients post discharge from hospital 
following a coronary event. ASPIRE was a cross sectional survey of a representative 
sample of coronary patients from a (retrospective) review of hospital medical records. 
 
The relatively high proportion of patients with cholesterol above the threshold in ASPIRE 
(86%) was comparable with the EUROASPIRE I (EUROASPIRE I and II group 2001) and 
L-TAP (Pearson 2000) surveys from the same period (1994 – 7). In 1996, when ASPIRE 
was published, the British Hyperlipidaemia Society’s guidelines were available and 
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passively disseminated, but these stressed the importance of first introducing dietary 
measures to reduce cholesterol and only if this approach failed, a statin prescription was 
recommended (Betteridge 1993). In practice, this guidance may have limited the 
prescribing of statins because some patients might have dropped out of follow up at the 
dietary modification stage, thus reducing numbers presenting for a statin.  
 
Nevertheless, CARE, LIPID and WOSCOPS had all been published at that point, and had 
clearly justified the prescribing of statins without the need for previous failed attempts at 
dietary modification. ASPIRE results from 3 years previously showed considerable scope 
for improvement in statin prescribing, when compared with reports from Europe and North 
American populations.   
 
A gradual reduction in cholesterol over time was noted by Evans in 2001 and this trend 
was confirmed in EUROASPIRE II (Table 4.10: 59% above target). The SOS study 
baseline results were collected three years after EUROASPIRE II and showed that only a 
marginally increased proportion of patients (61%) were above target. During this three 
year intervening period, five additional landmark trials had been published, consolidating 
and reinforcing the already strong evidence base for statin use: PROSPER, MIRACL 
(Schwartz 2002), GREACE (Athyros 2002), FLARE (Serruys 1999), and AFCAPS 
(Downs 1998). In addition, meta analyses had confirmed beyond reasonable doubt that 
reductions in cholesterol and LDL-cholesterol associated with statins caused a decrease in 
the risk of heart disease and all cause mortality (Law 2003; La Rosa 1999).  
 
Together, the widespread publication of additional evidence between EUROASPIRE I and 
II and the lack of progress with achievement of target cholesterol levels reinforces the 
weak effect of passive dissemination if the aim is to change prescribing practice.  
 
The North American L-TAP survey determined the percentage of patients with confirmed 
hyperlipidaemia who had reached cholesterol targets (Pearson 2000). One thousand, four 
hundred and sixty patients with established CHD were included, and only 18% were found 
to have achieved (LDL) cholesterol targets. Possible explanations included the low uptake 
of statin prescribing, use of sub-optimal doses (proportions were not described in the 
paper) and poor compliance among patients. Recommendations from this survey included 
more widespread prescribing of statins, and prescribing of higher doses.  
 
Other surveys have been conducted which reinforce the generalisability of SOS data shown 
in Table 4.10, but due to an insufficient description of the patient characteristics or 
prescribing, lack sufficient detail to enable comparison (Baxter 1998; Schrott 1997).  It is 
notable that Baxter highlighted the issue of variation between practices, finding that almost 
100 – fold variation existed during the period 1990 – 96, for prescribing of lipid lowering 
agents, within the South East Thames region. This was despite attempts to improve 
prescribing through dissemination of local cholesterol and statin prescribing guidance, 
again underscoring the need for some means of improving prescribing and reducing 
variation. 
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Table 4.9    Baseline characteristics of patients in the SOS study and landmark secondary prevention statin trials 
 SOS PROSPER CARE LIPID HPS 
 
Vascular disease Vascular disease / multiple risk factors MI CHD Vascular disease 
n = 4,040 5,804 4,159 9,014 20,536 
Mean follow up (years) 1.7 3.2  5 6.1 5 
Patient characteristics      
Age (yr) 68 75 59 62 40 – 80× 
Sex (male) % 53 48 86 83 75 
Physiological measures 
Mean Cholesterol (mmol/l)* 
 
5.1 
 
5.7 
 
4.5§ 
 
5.8 
 
5.9 
Co-morbidities (%) 
Angina/IHD 
MI 
Stroke 
TIA 
PVD  
Diabetes   
CABG 
Angioplasty 
 
46 
21 
14 
9 
11 
36 
9 
4 
 
27 
13 
9 
17 
9 
11 
6 
4 
 
21 
100 
- 
- 
- 
14 
27 
34 
 
36 
64 
4 
4 
10 
9 
27 
11 
 
24 
41 
16† 
- 
33 
29 
- 
- 
† combined with TIA   ‡ combined with angioplasty § entry criteria < 4.5mmol/l    * statin free   ×46% > 65
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Table 4.10       Statin prescribing at baseline in the SOS study and other statin surveys  
 
 SOS 
(2003/4) 
EUROASPIRE  
I (1995/6) 
EUROASPIRE II 
(1999/00) 
ASPIRE 
(1994/5) 
L –TAP 
(1996/7) 
n 4040 3569 3379 2583 4888 
Location Scotland Europe (excluding 
UK) 
Europe (excluding UK) UK  North America 
Patient characteristics MI, CHD, 
Angioplasty, 
CABG, Diabetes, 
PVD, Stroke, TIA 
MI, CHD, 
Angioplasty or 
CABG 
MI, CHD, Angioplasty 
or CABG 
MI, CHD, 
Angioplasty or 
CABG 
Hyperlipidaemic§ 
Cholesterol with statin 4.75 - - - - 
Cholesterol without statin 5.10 - - - - 
Cholesterol above target range 
(%) § 
61 86 59 78 82 
Any lipid lowering (%) 41 32 63 10 27 
Any statin (%) 41 19 58 - 21 
Any statin, any dose, controlled 
cholesterol (%) 
21 21 49 < 5 39 
§ Data shown for CHD participants only
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Chapter 5 
 
Follow up results 
 
This chapter presents the results of the SOS trial. These include the primary and secondary 
outcomes with subgroup analyses and exploratory analyses of adverse effects (restricted to a 
sample of patients with vascular events).  
 
In most studies, data is collected at follow up for as many of the patients identified at baseline, 
as possible. The SOS study was naturalistic, and, unusually, at follow up, in addition to 
collecting data for patients identified at baseline, the opportunity arose to collect relevant data 
for patients who became eligible (through first recording of a vascular diagnoses) between 
baseline and follow up. This created the opportunity to assess the treatment effect on incident 
(first recording of vascular diagnosis between baseline and follow up) and prevalent patients 
(who were known to the practice at baseline).  
  
 
5.1 Non participants and endpoint data 
 
At follow up, collected data was more accurate and complete for two reasons:  
 
1. Two dedicated, independent, experienced researchers collected data. All eligible patients 
were identified and had their data collected. 
 
2. The quantity and quality of computer recorded information was improved in 2005, as a 
result of the introduction of the GMS contract, which provided financial incentives for the 
creation and maintenance of computerised disease registers. This reduced the labour intensive 
task of finding and hand searching paper records for every patient, as had occurred at baseline.  
 
Therefore, at follow up, a total of 7586 eligible patients (SOS: 4234; UC: 3352) were 
identified in 29 practices. These 7586 patients comprised 5660 patients (UC: 2425; SOS: 
3235) with a first diagnoses of vascular disease before baseline and 1926 (UC: 927, SOS: 999) 
who were first diagnosed between baseline and follow up. From the 5660 patients identified at 
follow up who were found to have their first eligible diagnosis dated before baseline, 2619 
were matched from baseline to follow up.  
 
Table 5.1 describes the distribution of patients within the practice pairs matched at 
randomisation. Data in Table 5.1 and all subsequent Tables does not include values from the 
practice which had disbanded prior to the date of randomisation, or data from the practice 
which dropped out of the study (access to practice level data was not possible after this 
practice had dropped out).   
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Table 5.1  Distribution of eligible patients (by randomised pairs, according to date of  
   first diagnosis) 
 
Pair Eligible at follow up  
(n = 7586) 
 Subgroup eligible before 
baseline  
(n = 5660 / 7586) 
Subgroup eligible between 
baseline and follow up (n = 
1926 / 7586) 
 SOS UC SOS UC SOS UC 
       
1 251 237 245 174 6 63 
2 494 142 327 114 167 28 
3 369 366 276 176 93 190 
4 370 268 288 218 82 50 
5 336 603 247 506 89 97 
6 585 359 486 253 99 106 
7 484 160 416 95 68 65 
8 478 161 375 135 103 26 
9  § 82  § 66 §  16 
10 75 295 45 160 30 135 
11 193 141 110 115 83 26 
12 142 124 114 102 28 22 
13 84 76 55 54 29 22 
14 165 193 80 147 85 46 
15 208 145 171 110 37 35 
       
Subto
tal 
4234 3352 3235 2425 999 927 
Total 7586 
 
5660 1926 
§ Practice dropped out of study after first SOS visit (n = 57 patients); data not available at follow up 
 
This subdivision of 7586 patients separates those known by the practice as eligible (through 
their diagnosis date) before baseline data collection or eligible after baseline data collection. 
Differentiating patients in this way enabled testing of the effectiveness of the intervention on 
these important subgroups, helping to address the question of whether the intervention was 
effective in improving the statin prescribing and cholesterol control of either, neither or both 
groups.  
 
In 2006, due to advances in electronic recording and record linkage, the records of a sample of 
patients to be extracted from practices by a remote server based in the GG&C Information 
Technology centre, Gartnavel Royal Hospital. This facility enabled time to first new vascular 
diagnoses could be collected and evaluated for any differences between the SOS intervention 
and UC arms in the time to first event. This evaluation was applicable to 1911 (1078 from the 
SOS arm and 833 from UC arm) of the 5660 patients who had CHI recorded accurately, 
because this was the primary key for data linkage between baseline and follow up.  
 
Compared to the number with CHI recorded at baseline, a greater number of patients had date 
of birth and gender recorded at baseline and this enabled a greater number to be traced from 
baseline to follow up. Therefore, 2619 patients were traced from baseline to follow up, as 
described in Table 5.2.  
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Table 5.2   Distribution of eligible patients known to practices at baseline and follow up 
 
Randomised 
Pair 
Linked from baseline to follow up (n =2619) 
 
 
 SOS UC 
   
1 162 88 
2 197 67 
3 164 84 
4 154 96 
5 135 142 
6 140 80 
7 173 51 
8 49 77 
9 § 40 
10 24 101 
11 70 49 
12 59 58 
13 29 30 
14 39 98 
15 96 67 
   
Subtotal 1491 1128 
Total 2619 
 
§ practice dropped out of study after first SOS visit (n = 57 patients) 
 
Figure 5.1 summarises the relationships between subsets of patients identified at follow up. 
Categorising patients in this way enabled exploration of any differential effect from the SOS 
intervention e.g. on patients eligible at baseline (‘Prevalent’ in Fig 5.1: known to the practice 
for the whole period of the SOS study) compared with patients who became eligible after 
baseline data collection (‘Incident’). From the 5660 patients identified at follow up who were 
found to have first diagnosis before baseline, 2619 patients were confirmed as being part of 
the cross section of 4040 collected at baseline. The remaining 1421 / 4040 patients from 
baseline (880 SOS and 541 UC), could not be matched to the records of patients identified at 
follow up. These patients are not accounted for in the main analyses. As it cannot be assumed 
that the characteristics of these 1421 patients are balanced between SOS and UC and balanced 
in comparison with the 2619 patients who were followed up, relevant summaries and analyses 
are described below.  
 
The characteristics of the 1421 non participants are shown by their allocation to SOS or UC in 
Tables 5.2.1 to 5.2.3. Demographics and qualifying diagnoses were balanced between SOS 
and UC arms (Table 5.2.1).  
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Table 5.2.1  Baseline characteristics of non participants (SOS vs. UC): demographics 
and co-morbidities  
 
 SOS 
(n = 880) 
UC  
(n = 541) 
p value 
 
Mean age (SD), years† 70.5 (13.5) 70.2 (13.2)   0.411  
Sex, male 412/880 (46.8%) 266/541 (49.2%) 0.392 
Qualifying diagnosis  
Values shown are number (%) of patients with each type of vascular disease  
Angina / Ischaemic Heart Disease  413/880 (47.1%) 246/541 (45.6%)  0.712 
Diabetes Mellitus, age ≥ 45 years  253/880 (28.7%) 152/541 (28.1%)  0.512 
MI  171/880 (19.4%) 107/541 (19.8%) 0.632 
Cerebrovascular event 152/880 (17.3%) 114/541 (21.1%)  0.092 
PVD 103/880 (11.7%) 63/540 (11.7%)  0.682 
TIA  81/880 (9.2%) 61/540 (11.3%) 0.212 
CABG 48/880 (5.5%) 37/541 (6.8%) 0.302 
Angioplasty  28/880 (3.2%) 10/541 (1.9%)  0.082 
Number of vascular co-morbidities †  1.42 (0.78) 1.46 (0.72)  0.201 
Number of vascular co-morbidities 
excepting angina †  
0.95 (0.72) 1.00 (0.66) 0.181 
1 Linear regression 2 Binary logistic regression  † Mean (SD) 
 
Table 5.2.2 provides further supporting evidence that there was no statistically significant 
difference between the characteristics of non participants in SOS compared with UC arms.  
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Table 5.2.2 Baseline characteristics of non-participants (SOS vs. UC):  cholesterol  
 
 SOS 
(n = 880) 
UC  
(n = 541) 
p value 
 
    Statin prescribing and cholesterol 
Cholesterol recorded 578/880 (65.4%) 339/541 (62.7 %)  0.202 
Cholesterol recorded and controlled 279/880 (31.7%) 156/541 (28.8%) 0.452 
Cholesterol level (mmol/l), all 
patients with cholesterol level †  
4.99 (1.3) 5.06 (1.2) 0.361 
Cholesterol level (mmol/l), all 
patients with cholesterol recorded and 
prescribed a statin†   
4.88 (1.3) 4.96 (1.3) 0.401 
Cholesterol level (mmol/l), all 
patients with cholesterol recorded and 
not prescribed a statin†  
5.08 (1.2) 5.13 (1.2) 0.711 
Statin not prescribed 607/880 (68.9%) 377/541 (69.7%)  0.682 
Statin prescribed at optimal dose 156/880 (17.7%) 82/541 (15.1%)  0.452 
1 Linear regression 2 Binary logistic regression † Mean (SD) 
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Table 5.2.3 summarises Simvastatin prescribing, cholesterol control and cholesterol levels for 
all non participants, by treatment group.  
 
Table 5.2.3  Characteristics at baseline of non participants prescribed a statin  
(SOS vs. UC) 
 
  
 SOS  
(n = 273)  
UC  
(n = 164) 
p value 
Cholesterol not recorded  34/273 (12.5%)  29/164 (17.7%) 0.132 
Cholesterol recorded and 
controlled  126/239 (52.7%)  62/135 (45.9%) 
 
0.262 
All doses  158/273 (57.9%)  102/164 (62.2%) 0.582 
Suboptimal 
dose  100/273 (36.6%)  65/164 (39.6%) 
0.762 
Optimal dose, 
cholesterol 
controlled 
 21/723 (7.7%)  14/164 (8.5%) 
  
0.932 
All doses, 
cholesterol 
controlled 
 71/273 (26.0%)  43/164 (26.2%) 
 
0.472 
Simvastatin 
 
Mean 
Cholesterol 
level (mmol/l) †  
 4.82 (1.27)  4.79 (1.25) 
0.931 
1 Linear regression  2 Binary logistic regression  † Mean (SD) 
 
Overall, the characteristics of non participants appear balanced between SOS and UC arms.  
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Characteristics of non participants (n = 1421) are compared with participants who were 
tracked from baseline to follow up (n = 2169), in Tables 5.2.4 and 5.2.5.    
 
Table 5.2.4 Baseline comparison of 1421 patients lost to follow up and 2169 patients 
included at follow up: demographics and qualifying diagnoses 
 
 Participants 
(n = 2619 tracked from 
baseline to follow up) 
Non participants (n = 
1421 not tracked from 
baseline to follow up)  
 
p value 
 
Age (years)† 67.2 (11.1) 70.4 (13.7) < 0.0011 
Sex, male 1418/2619 (54.1%) 678/1421 (47.7%) < 0.0012 
Qualifying diagnosis  
Values shown are number (%) of patients with each type of vascular disease  
Angina / Ischaemic Heart Disease  1184/2619 (45.2%) 659/1421 (40.4%)  0.4801 
Diabetes Mellitus, age ≥ 45 years  1067/2619 (40.7%) 405/1421(28.5%)  < 0.0011 
MI  573/2619 (21.9%) 278/1421 (19.6%) 0.0801 
Cerebrovascular event 304/2619 (11.6%) 266/1421 (18.7%)  < 0.0011 
PVD 281/2619 (10.7%) 166/1421 (11.7%) 0.3601 
TIA  202/2619 (7.7%) 142/1421 (10.0%) 0.0131 
CABG 258/2619 (9.8%) 85/1421 (6.0%) < 0.0011 
Angioplasty  133/2619 (5.1%) 38/1421 (2.7%) < 0.0011 
Number of vascular co-morbidities †  1.52 (0.78) 1.44  (0.74)  < 0.0012 
Number of vascular co-morbidities 
excepting angina †  
1.08 (0.69) 0.98  (0.68) < 0.0012 
† Mean (SD)   1 Chi squared test   2 Two sample t-test 
 
These results suggest patients who were included at baseline but not traced to follow up were 
likely to be older and female. There were statistically significant differences in all eligible 
diagnoses except angina/ischaemic heart disease, myocardial infarction and peripheral 
vascular disease. However, prevalence was greater in some cases (stroke, transient ischaemic 
attack) and lower in others (diabetes, coronary bypass graft and angioplasty).  Non participants 
had fewer multiple co-morbidities. 
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Table 5.2.5 Baseline comparison of 1421 non participants and 2169 patients included 
at follow up: statin prescribing and cholesterol 
 
 Participants 
(n = 2619 tracked from 
baseline to follow up) 
Non participants (n = 
1421 not tracked from 
baseline to follow up)  
 
p value 
 
Cholesterol recorded 2153/2619 (82.2%) 913/1421 (64.2%) < 0.0011  
Cholesterol recorded and controlled 1115/2619 (42.5%) 435/1421 (30.6%) < 0.0011 
Cholesterol level (mmol/l), all patients 
with cholesterol tested† 
4.89 (1.24) 5.02 (1.25) 0.0052 
Mean cholesterol level (mmol/l), all 
patients with cholesterol recorded and 
not prescribed a statin† 
5.10 (1.22) 5.10 (1.24) 0.9792 
Statin not prescribed 1402/2619 (53.5%) 984/1421 (69.3%) < 0.0011 
 
Patients prescribed a statin 
Statin prescribed at optimal dose 694/2619 (26.5%) 238/1421 (16.7%) < 0.0011 
Cholesterol not recorded 101/2619 (3.9%) 63/1421 (4.4%)  0.3751 
Cholesterol recorded and controlled 647/2619 (24.7%) 188/1421 (13.2%)  < 0.001 
Cholesterol level (mmol/l), all patients 
with cholesterol recorded and 
prescribed a statin† 
4.71 (1.25) 4.91 (1.27) 0.0042 
 
Patients prescribed Simvastatin 
All doses 709/2619 (27.1%) 260/1421 (18.3%)  < 0.0011 
Suboptimal dose 439/2619 (16.8%) 165/1421 (11.6%) < 0.0011 
Optimal dose, cholesterol controlled 128/2619 (4.9%) 35/1421 (2.5%) < 0.0011 
All doses, cholesterol controlled 370/2619 (14.1%) 114/1421 (8.0%) < 0.0011 
Cholesterol level† 4.72 (1.26) 4.81mmol/l (1.26) 0.2752 
† Mean (SD)   1Chi squared test  2 Two sample t-test 
 
Table 5.2.5 describes statistically significant differences between patients who were not 
followed up compared with those who were traced to follow up. These differences extended 
across statin prescribing, cholesterol recording and control. Non participants had less 
recording of their cholesterol, less control but statistically significantly higher cholesterol 
(although the magnitude of this difference (0.1mmol/l) is not likely to represent a clinically 
significant difference in practice. A higher proportion of non participants were not prescribed 
a statin at baseline. Of those prescribed a statin, a lower proportion were prescribed optimal 
dose and a lower proportion had controlled cholesterol. The greater mean cholesterol level of 
non participants prescribed a statin reached statistical significance however, the magnitude of 
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the difference (0.2mmol/l) may not be of clinical importance. A similar trend was shown for 
patients prescribed simvastatin.  
 
Together, these results suggest there were differences between participants and non 
participants. 
 
 
The extent to which non participants were missing from follow up because of premature death 
was investigated using original baseline records. Of the 1421 non participants, 1168 (773 / 880 
(87.8%) SOS and 395 / 541 (73.0%) UC; p < 0.001) had sufficient demographic data to enable 
determination of whether they were alive or dead at the end of the study.  These data showed 
that 507/773 (65.6%) from SOS and 263/395 (66.6%) from UC were alive at least until the 
date of follow up within their practice pair. Binary logistic regression gave an odds ratio of 
1.04 (95% CI 0.79 – 1.38; p = 0.76) suggesting no statistically significant difference between 
SOS and UC, in the proportion of patients dying prematurely during the study. The mean 
duration of follow up was 1.7 years (range 1.4 to 2.2 years) and during that period, a high 
proportion (34%) of patients died prematurely. While this represents a rate of premature 
mortality in excess of that noted in the population enrolled in the Heart Protection Study 
(Table 2.2), these results represent mortality among an unselected primary care based 
population. In addition, limitations of the post-hoc analysis include uncertain accuracy and 
completeness of baseline demographic data for non participants. 
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Figure 5.1  Inter-relationships of subgroups of 7586 patients at follow up
 
 
 
†MI, stroke, TIA, diabetes, angina, CABG, Angioplasty, PVD/Claudication.   
 
 
Figure 5.2 gives the CONSORT flow diagram (Campbell 2004) for the passage of practices 
and patients through the study.  
7586 patients eligible at follow up 
Assessed for primary and secondary outcomes  
5660 / 7586 confirmed eligible before baseline  
(Prevalent) 
Assessed for Primary outcome 
1926 / 7586 confirmed eligible between 
baseline and follow up (Incident) 
Assessed for Primary outcome 
3041 / 5660 not 
linked from 
baseline to follow 
up 
2619 / 5660 (2619 from the cross sectional sample of 4040 patients 
identified at baseline) linked from baseline to follow up. Assessed for 
primary and some secondary outcomes; 1421 / 4040 not linked from 
baseline to follow up (non-participants) 
1911 / 2619 linked from baseline to follow up by CHI 
number 
Assessed for time to first onset of new clinical 
event/vascular diagnosis† 
708 / 2619 not linked from 
baseline to follow up using 
CHI number 
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Fig 5.2  CONSORT flow diagram 
§
 31 practices were randomised; one had already disbanded prior to the randomisation date. * excluded from 
follow up analysis due to insufficient baseline data or premature mortality, which precluded linkage to follow up.
Assessed for eligibility (49 practices, 173,046 population) 
18 practices: refused to participate 
(15); no reply (3) 
Baseline data collection (31 practices; 116,558 population, 
10,307 patients screened, 4040 included) 
Randomised: 31 practices§ 
Randomised to SOS intervention: 16 practices (G: 8; SH: 
8). 37 GPs, 19.5wte Practice nurses. Average 2.4 GPs and 
1.2 nurses/ practice. 2373 patients.  
9.9% Simvastatin optimal dose and cholesterol 
controlled 
Randomised to UC: 15 practices (G: 8; SH: 7). 
35 GPs, 18 Practice nurses. Average 2.3 GPs and 
1.2 nurses/practice. 1667 patients. 
9.8% Simvastatin optimal dose and cholesterol 
controlled 
 
- 1 SH practice withdrew (1 
GP, 1 nurse, 57 patients) 
- 1 SH practice had already 
disbanded 
Received SOS intervention:14 practices. 35 GPs, 
17.5wte Practice nurses. 
Received UC: 15 practices. 35 GPs, 18 Practice 
nurses 
Patients identified at follow up: 3352, average 
223/ practice 
 
Incident: 927 
 
Prevalent: 2425 (1126 patients linked   from 
baseline to follow up and 1299 patients identified 
for the first time at follow up data collection. 
These 1299 patients were eligible at baseline but 
not included in the cross sectional baseline 
sample). 
 
Patients identified at follow up: 4234, average 302/ 
practice  
 
Incident: 999 
 
Prevalent: 3235 (1493 patients linked from baseline to 
follow up and 1742 patients identified for the first time 
at follow up data collection. These 1742 patients were 
eligible at baseline but not included in the cross 
sectional baseline sample). 
 
Analysed: 14 practices, 4234 patients 
44.9%  
Simvastatin optimal dose and cholesterol 
controlled 
Range: 27.4 – 56.5% 
Analysed: 15 practices, 3352 patients 
27.9%  
Simvastatin optimal dose and cholesterol 
controlled.  
Range: 6.4 – 55.6% 
 
880 Non participants*  
 
541 Non participants*  
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5.2 Primary outcome: Prescribed simvastatin 40mg and cholesterol controlled 
 
Table 5.3  Primary outcome for all patients (n = 7586) 
 
Pair (n) UC† SOS† 
Odds 
Ratio 
95% Confidence 
Interval 
p-
value‡ 
1 (488) 82/237 (34.6%) 89/251 (35.5%) 1.04 0.72, 1.51 0.842 
2 (636) 65/142 (45.8%) 229/494 (46.4%) 1.02 0.70, 1.49 0.903 
3 (735) 43/366 (11.7%) 132/369 (35.8%) 4.18 2.85, 6.13 <0.001 
4 (638) 149/268 (55.6%) 159/370 (43.0%) 0.60 0.44, 0.83 0.002 
5 (939) 202/603 (33.5%) 139/336 (41.4%) 1.40 1.06, 1.84 0.016 
6 (944) 85/359 (23.7%) 310/585 (53.0%) 3.63 2.71, 4.87 <0.001 
7 (644) 46/160 (28.8%) 248/484 (51.2%) 2.60 1.77, 3.83 <0.001 
8 (639) 62/161 (38.5%) 270/478 (56.5%) 2.07 1.44, 2.99 <0.001 
9 (82) 7/82 (8.5%) Practice dropped out 
10 (370) 19/295 (6.4%) 21/75 (28.0%) 5.65 2.85, 11.21 <0.001 
11 (334) 41/141 (29.1%) 56/193 (29.0%) 1.00 0.62, 1.61 0.990 
12 (266) 34/124 (27.4%) 76/142 (53.5%) 3.05 1.82, 5.10 <0.001 
13 (160) 21/76 (27.6%) 31/84 (36.9%) 1.53 0.78, 2.99 0.212 
14 (358) 30/193 (15.5%) 82/165 (49.7%) 5.37 3.27, 8.80 <0.001 
15 (353) 49/145 (33.8%) 57/208 (27.4%) 0.74 0.47, 1.17 0.198 
All (7586) 935/3352 (27.9%) 1899/4234 (44.9%) 1.79 1.61, 1.98 <0.001 
Range 6.4 – 55.6%  27.4 – 56.5%    
†
 n achieving primary outcome / n eligible (%)   ‡ Fixed effects, adjusted   The ICC for the primary outcome was 
0.05. 
 
Primary analysis 
Table 5.3 shows the SOS intervention achieved a statistically significant increase in the 
primary outcome (simvastatin 40mg prescribed and cholesterol controlled at follow up). This 
finding was consistent across fixed and random effects models, using adjusted and unadjusted 
analyses. The change favoured UC in one pair and favoured SOS intervention in 8 pairs. There 
was no significant difference in 5 pairs. The range of values of the primary outcome was 
greater across UC practices than in the SOS arm practices, suggesting the SOS intervention 
may have had the unexpected and useful effect of reducing variation across practices. 
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5.2.1 Subgroup analyses of the primary outcome for all patients at follow up (n = 7586) 
 
Table 5.4    Subgroup analyses of the primary outcome  
 
Subgroup UC SOS 
Odds 
Ratio 95% CI 
p-value 
for 
SOS effect 
within 
subgroup 
p-value for 
differences 
between 
subgroups 
Practice level       
Deprivation <= median§ 657/2394 
(27.4%) 
524/1356 
(38.6%) 
1.24 1.04, 1.47 0.014 < 0.001 
Deprivation > median§ 278/958  
(29.0%) 
1375/2878 
(47.8%) 
2.17 1.79, 2.63 < 0.001  
       
Single Handed practices 201/1056 
(19.0%) 
323/867  
(37.3%) 
2.02 1.63, 2.51 < 0.001 0.206 
Group practices 734/2296 
(32.0%) 
1576/3367 
(46.8%) 
1.72 1.53, 1.94 < 0.001  
       
Patient level       
Male 518/1835 
(28.2%) 
1094/2256 
(48.5%) 
2.04 1.78, 2.34 < 0.001 0.005 
Female 417/1517 
(27.5%) 
805/1978 
(40.7%) 
1.53 1.32, 1.78 < 0.001  
       
≤ 60 years 306/1166 
(26.2%) 
628/1374 
(45.7%) 
1.87 1.56, 2.23 < 0.001 0.631 
> 60 years 629/2186 
(28.8%) 
1249/2777 
(45.0%) 
1.77 1.56, 2.01 < 0.001  
       
Eligible before baseline  
(n = 5660) 
688/2425 
(28.4%) 
1485/3235 
(45.9%) 
1.89 1.68, 2.13 < 0.001 0.056 
Eligible after baseline 
(n = 1926) 
247/927  
(26.6%) 
414/999  
(41.4%) 
1.51 1.23, 1.84 < 0.001  
§   practice level modified Scottish Index of Multiple Deprivation. Increased mSIMD scores reflect greater levels of 
deprivation. 
 
Table results in Table 5.4 indicate the SOS intervention was effective (p < 0.001) in nine 
subgroups, with a p- value of 0.014 in one subgroup (deprivation equal to, or lower than the 
median value). Odds ratios were consistently greater than 1, indicating a favourable effect 
from SOS intervention on the primary outcome; the same effect was observed in all other 
subgroups, as shown in the forest plot (Figure 5.3). Results of the following subgroups will be 
described in more detail: deprivation, practice type, gender/age and eligible before/after 
randomisation.  
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  Figure 5.3  Subgroup analyses of primary outcome  
 
 
‘Existing’: eligible at baseline. ‘Incident’: eligible after baseline.    
Point estimates of Odds Ratios to the right of 1 represent favourable effect of the SOS intervention  
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5.2.1.1  Socioeconomic deprivation  
 
The modified Scottish Index of Multiple Deprivation (mSIMD) score gives a measure of the 
level of socioeconomic deprivation in a practice, relative to other practices in Scotland. As 
described in Chapter 3, study practices were categorised as less than or equal to the median 
mSIMD or above the median mSIMD. Table 5.4 gives the effect of the SOS intervention 
compared with UC, evaluated within each category (‘p-value for SOS effect within 
subgroup’). The intervention effect estimate within each category was then compared between 
categories (‘p-value for differences between subgroups’). The results show an improvement 
due to the SOS intervention within each category, and a statistically significant interaction (in 
favour of practices falling into the more deprived category) between deprivation categories, in 
the proportions of patients receiving simvastatin 40mg with their cholesterol controlled. This 
finding suggests the SOS intervention tackles a small, but important manifestation of the 
inverse care law (Hart 1971).  
 
 
5.2.1.2  Practice type  
 
We hypothesised there would be a difference in the uptake of the SOS intervention’s 
educational messages depending on whether practices were Single Handed or Group. This was 
one of the stratification variables (the other stratification variable was the proportion of 
patients with cholesterol controlled in each practice). The primary outcome was achieved to a 
greater extent in Group (SOS 46.8%) compared with Single Handed practices (37.3%) as 
described in Table 5.4. However there was also a difference in UC (G: 32.0% vs. SH: 19.0%) 
hence there was no statistically significant difference in the intervention effect estimate 
between Group and Single Handed practices ( p = 0.206).  
 
At baseline, we noted a higher prevalence of diabetes in four Single Handed practices caring 
for patients within communities with predominantly residents of South Asian origin. 
Randomisation led to allocation of two practices to the SOS arm and two practices to UC. 
However, the SOS allocated practices had fewer eligible patients and had a lower proportion 
of patients with diabetes compared with the UC allocated practices within South Asian 
communities (SOS proportions with diabetes:154/203 (75.9%); UC: 419/488 (85.9%). X2 = 
10.1; p = 0.001). This test of association indicates an imbalance in the proportions of patients 
with diabetes in these practices however it is often the case in trials with a small number of 
clusters and stratified randomisation, that there are imbalances in baseline variables other than 
those factored into the stratification process.  
 
For patients with diabetes, subgroup analysis of the primary outcome (Figure 5.3) showed no 
interaction compared with non-diabetic patients (p value for interaction 0.136). The 
intervention improved simvastatin 40mg prescribing and cholesterol control for both. In the 
four practices serving South Asian communities, the two practices allocated to SOS also fared 
better in relation to the primary outcome (mean 33.6%) compared with the two South Asian 
practices allocated to UC (mean primary outcome 11%).  
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5.2.1.3  Gender and age 
 
Both males and females received improved prescribing of simvastatin 40mg with controlled 
cholesterol, but there was a larger benefit for males ( p = 0.005 for interaction).  
 
The SOS intervention achieved a statistically significant, positive impact in both age 
categories (≤ 60 years and > 60 years), with no evidence of interaction between subgroups 
defined by this age division (Table 5.4 or Figure 5.3).  
 
 
5.2.1.4  Eligible before vs. after randomisation  
 
The primary outcome was achieved to a greater extent in the SOS arm practices compared 
with UC practices, for the group of patients eligible before and for the group of patients 
eligible after baseline. There was some evidence of the SOS intervention having a even greater 
impact on those eligible before baseline as compared with patients who became eligible after 
baseline (p = 0.056). A preferential effect on those eligible before baseline might be expected: 
practices had a longer time to improve prescribing and cholesterol management for these 
patients, compared with those identified as eligible at some point after baseline. In addition, 
the 2619 patients known at baseline who were tracked to follow up represent patients who (in 
theory) had the best chance of improvement through the SOS intervention, because they were 
known to the practice at baseline and confirmed as being alive and registered with the practice 
at follow up. The impact of the intervention on 2619 patients known to the practice from 
baseline to follow up is described below. 
 
 
5.2.2 Subgroup analyses of primary outcome for subgroup linked from baseline to 
follow up (n = 2619) 
 
Table 5.5 shows the results of subgroup analyses on those patients who were linked from 
baseline to follow up (n = 2619). These indicate a favourable effect on the primary outcome, 
for 6 of the 8 subgroups shown. These analyses identified 2 subgroups where the SOS 
intervention did not have a statistically significant effect: patients with more 3 or more 
vascular diagnoses and those with a previous coronary artery bypass graft. The following four 
subgroups are described in more detail below: cholesterol controlled/uncontrolled at baseline, 
prescription/no prescription of a statin at baseline, number of vascular diagnoses at baseline 
and presence/absence of CABG. 
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Table 5.5    Subgroup analyses of primary outcome, for patients linked from baseline  
  to follow up (n = 2619) 
 
Subgroup UC SOS 
Odds 
Ratio 
95% 
CI 
p-value 
for 
SOS effect 
within 
subgroup 
p-value for 
differences 
between 
subgroups 
Uncontrolled cholesterol at 
baseline 
158/628 
(25.2%) 
346/867 
(39.9%) 
1.67 1.32, 
2.12 
< 0.001 0.260 
Controlled cholesterol at baseline 166/500 
(33.2%) 
333/624 
(53.4%) 
2.04 1.58, 
2.62 
< 0.001  
       
No statin prescribed at baseline 148/579 
(25.6%) 
389/823 
(47.3%) 
2.21 1.73, 
2.82 
< 0.001 0.015 
Statin prescribed at baseline 176/549 
(32.1%) 
290/668 
(43.4%) 
1.45 1.13, 
1.85 
0.003  
       
≤ 2 vascular diagnoses 227/866 
(26.2%) 
508/1104 
(46.0%) 
2.09 1.70, 
2.55 
< 0.001 0.004 
> 2 vascular diagnoses 97/262 
(37.0%) 
171/387 
(44.2%) 
1.19 0.85, 
1.66 
0.309  
       
Patients with no CABG  293/1008 
(29.1%) 
639/1357 
(47.1%) 
1.89 1.57, 
2.27 
< 0.001 0.049 
Patients with a CABG 31/120 
(25.8%) 
40/134 
(29.9%) 
1.04 0.59, 
1.84 
0.890  
 
 
5.2.2.1  Cholesterol controlled vs. uncontrolled at baseline 
  
From Table 5.5, in the subgroup of patients who had uncontrolled cholesterol at baseline, the 
SOS intervention achieved the primary outcome for 39.9% of patients at follow up, compared 
with 25.2% in the UC group (OR 1.67, CI: 1.32 – 2.12; p < 0.001). Patients with uncontrolled 
cholesterol had more to gain from the SOS intervention, and the favourable effect is likely to 
have reduced their vascular event risk.  
 
 
5.2.2.2  Patients with or without a statin at baseline 
 
In Table 5.5, we determined if there was any interaction, because during pilot work, some 
practices had suggested they would not benefit from the SOS intervention due to their 
perception of their practice having high baseline prescribing of statins. We therefore tested for 
any difference in the extent of uptake of the SOS intervention in the subgroup of patients with 
statins prescribed at entry to the study, compared with those without. Our expectation was for 
a relatively greater effect from the SOS intervention on the primary outcome in patients 
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without statins at baseline, because these patients had more to gain and the expectation was for 
practices to prioritise their management.  
 
The results shown in Table 5.5 confirmed a greater effect from the SOS intervention (p = 
0.015) on patients without a statin at baseline. These patients were more than twice as likely to 
achieve the primary endpoint compared with patients in the UC group.  
 
However, contrary to the expectations of several GPs in practices with high baseline statin 
prescribing, patients prescribed a statin at baseline also benefited (in terms of the primary 
endpoint) with an odds ratio of 1.45 (95% CI: 1.13 to 1.95). The intervention effect estimate 
between categories reached significance (p = 0.015). A Chi – squared test of the primary 
outcome between ‘statin’ and ‘no statin’ groups in the SOS intervention arm did not show 
statistical significance (X2 = 2.05; p = 0.15). This suggests that the primary outcome rate in 
SOS practices was similar for patients who were not on a statin at baseline compared to those 
who were. 
 
 
5.2.2.3  Number of vascular diagnoses at baseline 
 
We also determined if there was any difference in the uptake of the SOS intervention as 
measured by the primary outcome, between patients with two or less vascular diagnoses at 
baseline compared with more than two vascular diagnoses at baseline. There was some 
evidence of the SOS intervention having a significantly stronger influence on the primary 
outcome for patients with less vascular co-morbidities compared to those with more (OR 2.09 
vs. 1.19; p value for difference 0.004; Table 5.5). Of some concern was the finding that the 
intervention failed to demonstrate effect in those patients with three or more vascular co-
morbidities. 
 
Table 5.5 shows there was no evidence of effect from the SOS intervention on the subgroup of 
linked patients with more than 2 vascular diagnoses. While there is insufficient information to 
say why this was the case, it is possible that the relatively high proportion of patients already 
achieving the primary outcome in the UC group (37.0%) represented a value close to the 
ceiling level achieved through SOS intervention (44.2%). This suggests there was less room 
for the SOS intervention to increase the primary outcome. It is possible that patients with more 
vascular diagnoses are subject to more frequent call/recall in primary care and contact with 
secondary care clinics, thus increasing their chances of attaining cholesterol control and 
receiving a prescription for simvastatin 40mg, compared with patients who had 2 or less. 
In absolute terms, if the upper limit of the SOS intervention effect on simvastatin 40mg and 
cholesterol control is between 37% and 44% for patients with more than 2 vascular co-
morbidities. This perhaps represents a limitation of the model. Further analysis is required to 
explore whether this result signals a trend of a drop in effectiveness in proportion to the 
number of vascular co-morbidities. 
 
 
5.2.2.4  Coronary Artery Bypass Graft 
 
There is some evidence from the published literature that prescribing of statins is up to four 
times higher in revascularised patients compared with patients with Angina (De Wilde 2003). 
This might be an expected consequence of the need for tighter cholesterol targets for this 
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group as compared with others (the target cholesterol level for patients with a CABG is less 
than 4.2mmol/l). Therefore we determined if there were any significant differences in the 
uptake of the SOS intervention in this subgroup compared with the rest of the sample, as 
judged by the primary outcome measure.  
 
The impact of the SOS intervention was found to be negligible in those patients with previous 
CABG (Table 5.5): SOS 40/134 (29.9%) vs. UC 31/120 (25.8%) Odds Ratio 1.04 (CI: 0.59 – 
1.84). This follows from the unusually tight control of cholesterol and higher level of statin 
prescribing at baseline in this subgroup, perhaps indicating the SOS intervention is less 
successful when the baseline levels of cholesterol control and statin prescribing are already 
relatively high. However, the data show that the primary outcome was between 25 and 30% in 
UC and SOS arms, which was lower than the value of the primary outcome in most other 
subgroups. Therefore the explanation for this result is not clear from our data. 
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5.3  Secondary outcomes 
 
The SOS intervention had a statistically significant, positive effect in each of the secondary 
outcomes (Table 5.6), except cholesterol levels of patients prescribed simvastatin 40mg at 
follow up.  
 
Table 5.6 Secondary outcomes at follow up (all patients, n = 7586) 
 
Secondary outcome 
 
 
SOS* 
n = 4234 
(number (%; range) 
UC*  
n = 3352  
(number (%; range) 
OR 
 
 
95% CI 
 
 
   p-
value§ 
 
Prescribed simvastatin 
40mg 
2497 (58.9%;  
30.7 – 71.1%) 
1267 (37.8%; 
 15.2 - 65.7%) 
2.06 1.87, 2.28 <0.001 
      
Prescribed simvastatin 
(any dose) 
2673 (63.1%;  
42.3 – 73.4%) 
1730 (51.6%;  
31.2 – 73.7%) 
1.60 1.46, 1.75 <0.001 
      
Prescribed any statin, any 
dose 
3682 (86.9%;  
68.0 – 93.6%) 
2509 (74.9%;  
47.1 – 93.8%) 
1.82 1.60, 2.06 <0.001 
      
Prescribed simvastatin 
40mg and cholesterol 
tested since baseline 
2344 (55.4%;  
25.3 – 66.1%) 
1203 (35.9%;  
13.2 – 64.5%) 
1.80 1.61, 2.00 <0.001 
      
Cholesterol level, patients 
prescribed simvastatin 
40mg 
4.06mmol/l† 
(3.60 – 4.40mmol/l) 
 
4.15mmol/l† 
(3.54 – 4.52mmol/l) 
 
0.99 0.97, 1.01 0.221 
      
Cholesterol tested since 
baseline 
3869 (91.4%;  
72.5 – 98.8%) 
2932 (87.5%;  
65.8 – 97.4) 
1.26 1.07, 1.48 0.005 
      
Cholesterol controlled 
 
2943/4234 (69.5%;  
49.4 – 77.5%) 
2132 (63.6%;  
35.6 – 83.4%) 
1.11 1.00, 1.23 0.046 
      
Mean cholesterol level 
(all patients)† 
4.22mmol/l  
(4.03 – 4.48mmol/l)  
4.36mmol/l  
(3.82 – 4.95mmol/l) 
0.98 0.97, 0.99 0.005 
      
* all  pairs (28 practices, 14 pairs; 3352 SOS arm, 4234 UC)   § fixed effects, adjusted   † mean (range) 
 
A more convincing effect from the SOS intervention was apparent in those outcomes 
incorporating a measure of statin prescribing e.g. simvastatin or any statin, any dose.  
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Combining all the secondary outcomes gave an adjusted odds ratio of 1.92 (95% confidence 
interval 1.72 to 2.13; p< 0.001), indicating the strength of the SOS intervention on a range of 
prescribing and cholesterol related endpoints, 1.7 years post randomisation.  
 
The SOS intervention did achieve a statistically significant reduction in cholesterol levels. 
This may indicate the efficacy of simvastatin 40mg on patients who were prescribed it and 
adhered to their prescription, in both arms of the study.  
 
The ranges for each of the secondary outcomes are given in Table 5.6. Ranges in the SOS arm 
practices were consistently tighter than in UC practices. A similar picture was found in 
response to the SOS intervention effect on the primary outcome (Table 5.3).  
 
 
5.3.1  Subgroup analyses of secondary outcomes 
 
For each of the secondary outcomes, the effect of the SOS intervention on a pre-specified list 
of subgroups was analysed to determine if there were any particular strengths or weaknesses in 
the effect of the SOS intervention, which might inform service roll out of the intervention, 
depending on the needs of different practices and their patient subgroups. Summaries of these 
analyses are shown in the forest plots represented in figures 5.4 to 5.11. Selected findings with 
consistent results across the secondary outcomes are described below. 
 
 
5.3.1.1  Socioeconomic deprivation  
 
A disproportionately greater SOS intervention effect in patients from practices in areas of 
greater socioeconomic deprivation was apparent in relation to the following secondary 
outcomes: prescribing of simvastatin 40mg (Figure 5.4), prescribing of simvastatin (Figure  
5.5), prescribing of simvastatin 40mg and cholesterol tested (Figure 5.7), cholesterol levels of 
patients prescribed simvastatin 40mg (Figure 5.8) and the mean cholesterol level (Figure 
5.11). These findings reinforced the primary outcome result. The intervention was therefore 
strong enough to show improvement in the (theoretically) more challenging secondary 
outcomes including cholesterol levels checked and achieved, both of which are several steps 
removed from the targeted behavioural change at practice level. This was a surprise finding. 
Taken together, these results may originate from the increased awareness among study 
pharmacists of the limitations of previous interventions for patients from practices in more 
socioeconomically deprived areas, and the pharmacists’ additional efforts to overcome these 
during the delivery of the intervention to practices in more deprived areas. This (inverse) 
socioeconomic gradient was reversed in only two secondary outcomes: the SOS intervention 
favoured practices with patients from less deprived areas in relation to cholesterol levels tested 
for all patients (p-value < 0.001; Figure 5.9) and cholesterol levels on simvastatin 40mg (Fig 
5.8).  
 
 
5.3.1.2   Practice type  
 
There were statistically significant differences in four secondary outcomes when Single 
Handed practices were compared with Group practices and three of these outcomes were 
favourable for Single Handed practices: cholesterol levels of patients prescribed simvastatin 
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40mg (Figure 5.8); proportions receiving cholesterol checks (Figure 5.9) and those with 
cholesterol controlled (Figure 5.10). Prescribing of simvastatin (Figure 5.5) favoured patients 
in Group practices. The favourable findings may be of use for Single Handed practices with 
particularly low levels of achievement in relation to these variables, if the SOS intervention is 
subsequently rolled out. One report suggested that small or Single Handed practices may have 
more difficulty achieving QoF organisational domain points, compared with larger practices 
(Wang 2006). With our results showing greater improvement in some secondary outcomes and 
general improvement in all outcomes, the SOS intervention demonstrates how statin 
prescribing inertia (whatever the root cause) can be overcome. 
 
 
5.3.1.3   Gender and age 
 
In relation to gender, all secondary outcomes appeared to be reached to a greater extent by 
males, except ‘cholesterol levels tested’ (Figure 5.9) and cholesterol levels controlled (Figure 
5.10). The predominantly greater benefit in males was also a surprise finding.  
 
Age (60 years and younger compared with over 60 years) was considered in our subgroup 
analyses because there is some published evidence suggesting ageism in the prescribing of 
statins (De Wilde 2001). Using our arbitrary threshold of 60 years, we found no evidence 
supporting this finding.  
 
 
5.3.1.4  Other subgroups 
 
Patients eligible before or after baseline were considered in the subgroup analysis. On 
evaluating any differential SOS intervention effect for the secondary outcomes, the following 
were significant (p< 0.05), all in favour of patients identified at baseline: 
 
• Prescribing of any statin; 
• Cholesterol levels tested; 
• Cholesterol levels controlled. 
 
For the subgroup with a history of revascularisation, analyses of the secondary outcomes 
suggested no clear pattern of a differential impact of the SOS intervention. The wide 
confidence intervals displayed for both subgroups (CABG and angioplasty) across all 
outcomes may be due to the relatively small numbers of patients with these diagnoses.  
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Figure 5.4  Subgroup analyses of secondary outcome: Prescribing of Simvastatin 40mg 
  
 
 
 
Figure 5.5  Subgroup analyses of secondary outcome: prescribing of simvastatin 
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Figure 5.6 Subgroup analyses of secondary outcome: prescribing of any statin 
  
139 Figure 5.7 Subgroup analyses of secondary outcome: prescribing of Simvastatin 
40mg and cholesterol tested 
  
140 Figure 5.8 Subgroup analyses of secondary outcome: cholesterol levels of 
patients prescribed Simvastatin 40mg § 
§ Point estimates to left of 1 represent 
favourable effect of SOS intervention 
  
141 Figure 5.9 Subgroup analyses of secondary outcome: cholesterol levels 
tested (all patients) 
  
142 Figure 5.10  Subgroup analyses of secondary outcome: cholesterol levels 
controlled 
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Figure 5.11 Subgroup analyses of Secondary outcome: Geometric mean 
cholesterol § 
§ Point estimates to left of 1 represent 
favourable effect of SOS intervention 
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5.4 Safety outcomes 
 
A post-hoc analysis was conducted in order to determine if there was any significant 
imbalance in the time to occurrence of new vascular events (adverse events) in the SOS group 
compared with the UC group at a mean of 2.5 years follow up. Time to event analysis was 
used to test for differences between the intervention group and UC. Follow up duration varied 
between pairs, ranging from 2.2 – 2.8 years, but events were assessed during the same period 
within each pair of practices. Within pairs of practices, it was defined as the start date of the 
earliest baseline data collection until the end date of the last data collection at follow up or 
date of event if sooner (patients experiencing an event within this period were censored). If no 
events had occurred, the same date was used for follow up of the SOS and UC allocated 
practice within each pair. Cox proportional hazards models were fitted to the data; the model 
compared the rate at which patients first experienced any of the pre-specified vascular events, 
adjusting for pairing and treatment group. Hazard ratios were used to describe the difference 
between intervention and UC groups.  
 
As described in Figure 5.1, we were able to ascertain the impact of the SOS intervention on 
the development of new vascular events in those patients who were tracked from baseline to 
follow up using their CHI number (n = 1911). Table 5.7 shows the percentage of each group 
who have had a vascular event. Researchers did not scrutinise eligible patient records in the 
assessment of safety outcomes. Instead, data was collected using a remote computer search 
linking patients by CHI number. While more efficient, this process was not validated and 
endpoint detection not confirmed in the usual way, through an adjudicating panel of experts. 
Only one significant difference was shown: time to occurrence of first presentation of diabetes 
SOS: 4 (0.4%) as compared with UC: 19 (2.3%). hazard ratio: 0.14; 95% Confidence interval 
0.05 – 0.43; p < 0.001). Each hazard ratio was characterised by a wide confidence interval, 
reflecting considerable uncertainty about the point estimate, due to the low number of events 
within each diagnostic category. 
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Table 5.7 Comparison of adverse (vascular) events at follow up 
 
Event 
UC 
N=833 
SOS 
N=1078 
Hazard 
Ratio 
SOS vs. UC 
95% 
Confidence 
Interval p-value 
Diabetes 19 (2.3%) 4 (0.4%) 0.14 (0.05, 0.43) < 0.001 
CHD 6 (0.7%) 3 (0.3%) 0.29 (0.07, 1.17) 0.081 
Stroke 1 (0.1%) 6 (0.6%) 3.40 (0.40, 28.56) 0.260 
CABG / Angiography 3 (0.4%) 3 (0.3%) 0.58 (0.12, 2.96) 0.517 
Angina 1 (0.1%) 4 (0.4%) 4.10 (0.38, 44.70) 0.247 
TIA 1 (0.1%) 1 (0.1%) 0.84 (0.05, 13.64) 0.904 
MI 1 (0.1%) 2 (0.2%) 0.76 (0.07, 8.52) 0.826 
PVD 0 (0.0%) 2 (0.2%) NA   
Stroke/TIA/PVD 2 (0.2%) 9 (0.8%) 2.92 (0.62, 13.67) 0.174 
CHD/CABG/Angiography/An
gina/MI 
10 (1.2%) 11 (1.0%) 0.67 (0.28, 1.62) 0.373 
Any vascular event 29 (3.5%) 24 (2.2%) 0.55 (0.31, 0.97) 0.039 
 
A total of 324 events of any type (vascular or non vascular) occurred in 215 of the 1911 
patients who were tracked from baseline to follow up by virtue of their being identifiable by 
the remote, centralised data linking system. Only 53 / 324 of these were vascular as defined by 
the eligibility criteria of the study. Overall there was a lower incidence of events in the SOS 
arm. Improvements in statin prescribing and cholesterol control (and cholesterol levels) 
observed at follow up in the SOS practices may have influenced these, but this is a hypothesis 
requiring further testing in a sufficiently powered study. It is reassuring that the direction of 
the effect is in favour of the intervention.  
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5.5 Summary of results 
 
Patients in practices exposed to the SOS intervention had statistically significant 
improvements (p < 0.001) in the primary outcome, and the following secondary outcomes: 
Prescribing of simvastatin; Prescribing of simvastatin 40mg; Prescribing of any statin at any 
dose; Prescribing of simvastatin 40mg and cholesterol tested since baseline.  
 
The following secondary outcomes showed the SOS intervention to be more effective than 
UC, reaching the pre-specified significance level of p ≤ 0.05: Cholesterol levels tested since 
baseline; Mean cholesterol levels (all patients) and Cholesterol controlled. The difference (in 
favour of the SOS intervention) noted in the secondary outcome: Cholesterol levels of patients 
prescribed simvastatin 40mg, did not reach statistical significance (p = 0.221).  
 
While the intervention demonstrated improvements in these outcomes, the relative scale of the 
improvements differed considerably, depending on the outcome, and compared with baseline 
findings. For example, at baseline, the overall proportion of patients (with or without a statin) 
with controlled cholesterol was 38.6% (Appendix VII). This increased over time in the UC 
arm practices, to 63.6% of patients while the SOS intervention resulted in an increase to 
69.5% of patients. This improvement reached the a-priori level of statistical significance (OR 
1.11; 95% CI 1.00 – 1.23: p = 0.046. Table 5.6).  
 
However, when the impact of SOS intervention on statin prescribing is considered, the effect 
was greater. For example, at baseline, 41.5% of patients were prescribed a statin (Table 4.5, 
obtained by averaging the proportion in SOS and UC prescribed a statin) and this increased to 
86.9% in patients from SOS practices and 74.9% in UC practices (OR 1.82; 95% CI 1.60 – 
2.06; p < 0.001. Table 5.6).  
 
Further, when the change in prescribing of the target statin at the target dose is included in the 
outcome measure, the magnitude of the improvement in SOS is greater still. For example, the 
primary outcome of ‘prescribed simvastatin 40mg and cholesterol controlled’ reached 44.9% 
in SOS arm practices compared with 27.9% in the UC practices. The odds ratio in this case 
was 1.79 (95% CI 1.61 – 1.98; p < 0.001). At baseline, this measure was 9.9% (Table 4.6).  
 
Therefore the extent to which the intervention increased the proportion of patients receiving 
Simvastatin 40mg with their cholesterol controlled was greater than the extent to which it 
increased measures of cholesterol control. The impact of SOS on all outcomes was mediated 
by the key intervention introduced by the pharmacists: prescription of Simvastatin 40mg for 
eligible patients. It is likely that the intervention achieved a statistically significant difference 
as a result of more patients receiving Simvastatin 40mg and more patients taking this 
prescription after initiation during the study and more patients within this target group 
attending their practice for cholesterol checks (without which, cholesterol remains unknown).  
 
The intervention was effective for patients who were eligible and known to the practice at 
baseline, and for those who became eligible during the period of the intervention. However, of 
those patients linked from baseline to follow up, the intervention effect did not reach statistical 
significance for the subgroups with a CABG and those with more than 2 vascular diagnoses.  
 
Characteristics of non participants from SOS and UC arms of the study were balanced. 
However, non participants’ characteristics (demographics, qualifying diagnoses, cholesterol 
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and statin prescribing) differed from those of patients who were included at follow up. The 
reason for these differences is unclear, and requires further investigation.   
 
An unintended but potentially important effect of the SOS intervention was to reduce the 
range of values for each of the outcomes studied, such that practices in the SOS arm showed 
higher values for the lower limits, compared with UC practices. The SOS intervention arm 
practices did not achieve higher values for each outcome; a ceiling effect was noted in each 
case. Subgroups showing persistently positive outcomes included males, patients from more 
socioeconomically deprived practices, patients known to the practices at baseline, those 
without a statin at baseline and patients with fewer vascular diagnoses. 
 
There was no increase in vascular adverse events, evaluated through the appearance of new 
onset vascular diagnoses between 2.2 and 2.8 years after randomisation, in the subgroup of 
patients linked from baseline to follow up. 
 
The clinical significance of these and other, untested effects arising from the SOS intervention 
remains to be confirmed, but these data prove the hypothesis that pharmacist led SOS 
intervention impacts favourably on a number of pragmatic, prescribing and surrogate clinical 
outcomes, across a wide range of practices and patient subgroups, up to 2.2 years post 
randomisation. 
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Chapter 6 
 
Discussion 
 
6.1 Overview 
 
The continuing need for high-quality, unbiased physician education regarding drug therapies 
was recently reiterated by one of the researchers involved in the original academic detailing 
studies (Avorn 1983, 2011).  
 
Throughout this thesis, the view has been that unbiased education is important but insufficient 
to reach patients in greatest need of support, and insufficient in itself, to sustain a change in 
prescribing practice. Therefore, in addition to education, practical, “hands on” help was 
provided by pharmacists to practices, for patients.  
   
This chapter provides a discussion of the trial context, key findings, strengths, weaknesses, 
and potential reasons why the SOS intervention was successful, in comparison with other 
studies.   
 
 
6.2  Trial context and summary of recent literature on pharmacist prescribing 
support 
 
The SOS intervention involved close collaboration with GPs, nurses, practice staff and 
secondary care specialists. Some have described this type of multifaceted model as a 
‘Complex intervention’ (MRC 2011), others have labelled it a ‘Collaborative model of care’ 
(Foy 2010; Unutzer 2002; Katon 2010). Because of the difficulty in accessing primary care 
physicians in some countries, the rising cost of secondary care and variation in the uptake of 
clinical evidence, greater use of collaborative models of care involving pharmacists has been 
widely advocated. The extended role of the pharmacist has been encouraged by governments 
in several countries including the UK (Medicine Use Reviews), USA (Medication Therapy 
Management), Australia (Comprehensive Home medicines review) and Canada (pharmacists 
have prescribing rights in Alberta, British Colombia and Quebec). It is therefore likely that 
pharmacists will continue to support prescribing and disease management, but the lack of 
evidence demonstrating added value in terms of morbidity / mortality outcomes may be a 
limiting factor in the widespread rollout of pharmacist led prescribing support in general. 
 
In most cases, a direct patient facing model of support is advocated e.g. face to face 
medication review involving the pharmacist and the patient. This approach, if it is 
collaborative, is known to improve prescribing in line with guidelines of disease management 
and safety (Mackie 1999, Krska 2001, Zermansky 2001, Hanlon 1996, Furniss 2000, Sykes 
1996, McGuire 1996). However, meta-analyses suggest a dearth of empirical evidence for 
benefit in terms of morbidity/mortality endpoints (Holland 2007, Royal 2006, Chisholm-Burns 
2010).  
 
The SOS trial was not powered to detect such endpoints but did include cholesterol lowering 
and cholesterol control as a secondary outcome. The link between cholesterol lowering 
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(control) and improved outcomes is strong and consistent across many robust studies: it is 
possible but less convincing to extrapolate these results into expected patient benefit. 
 
The lack of evidence of clinical benefit from stand alone trials involving pharmacists’ 
collaborative models of care may have spurred the recent increase in the number of 
methodologically robust studies with longer follow up. Since the end of the literature review 
period (February 2004), several studies have involved pharmacists, aiming to improve 
prescribing. These studies have included the testing of collaborative interventions (in which 
specialist trained pharmacists are employed) in primary care. Fihn (2011) tested the 
effectiveness of a pharmacist and specialist nurse collaborating to improve guideline 
implementation for patients with stable angina. Improvement of statin prescribing formed part 
of this, but no additional effect was found on a range of ‘hard’ endpoints. To date, 
collaborative care interventions involving pharmacists have not been shown to improve 
clinical outcomes in IHD or vascular disease.  
 
Tests of the processes and outcomes of treatment for patients with depression, and diabetes 
have shown benefit (Unutzer 2002, Katon 2010). Meta-analysis of small trials, suggesting that 
the inclusion of a specialist pharmacist in collaborative, multidisciplinary team based care of 
patients with heart failure reduces hospitalisations (Koshman 2008). The use of specialist 
pharmacists in these and most other trials may reduce the generalisability of the findings and 
limit implementation potential. In contrast, a non specialist, pharmacist-led model of 
collaborative medication review in primary care, recently gave a neutral result (Lowrie 2011).  
 
Soorapan tested the effect of pharmacist medication review intervention on type 2 diabetics in 
2002 and found improvements in blood pressure but not HbA1c (Soorapan 2002). Mehuys 
updated this work by providing evidence, from a cluster randomised controlled trial, of the 
effectiveness of community pharmacists consulting with diabetic patients in Belgium (Mehuys 
2011). Pharmacists met with patients monthly, delivering an intervention that comprised 
advice rather than recommendations for medicine changes. Their intervention appeared to be 
intensive (evidenced by the number of educational elements covered during consultations, 
although the duration of each contact was not given) and repeated up to six times in six 
months. They were able to show a statistically significant reduction in fasting plasma glucose, 
and HbA1c. The former remained reduced after 18 months while HbA1c had returned to pre-
intervention levels by that time. Of note and of particular relevance to the findings from the 
SOS study, was the authors’ observation that the reductions in fasting plasma glucose and 
HbA1c were mainly attributable to those in the intervention group who had received changes 
to their hypoglycaemic agents during the period of intervention. The intervention did not 
include changes to medicines and the pharmacists did not initiate these changes; general 
practitioners introduced the changes. This suggests that the effectiveness of their intervention 
was mediated at least in part, through GPs’ changes to patients’ medicines. The authors also 
noted (as we have) the relatively greater effect in those patients who had more to gain (poor 
glycaemic control at baseline). They recommended longer term follow up of pharmacist-led 
intervention, and (after acknowledging the likely impact of GP- mediated changes) stressed 
the importance of formal collaboration with GPs and the need to build prescribing change into 
the pharmacists’ intervention.  
 
In 2010, Villeneuve published a study demonstrating a neutral effect on cholesterol control, 
when community pharmacists teamed with physicians in Canada (Villeneuve 2010). Their 
intervention comprised advice on dietary measures to reduce cholesterol, and included 
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repeated patient contact which is thought to play an important role in achieving change (Dolan 
Mullen 1985). In their collaborative agreement, doctors were responsible for prescribing of 
lipid lowering therapy which is known to have a more rapid and powerful effect on cholesterol 
lowering compared with advice on dietary intervention. At follow up, patients in the 
intervention group were less likely to receive high potency lipid lowering agents, which offset 
the impact of pharmacists’ counselling intervention and produced a neutral result.  
 
Taken together with Mehuys’ findings, it might be concluded that outcomes would have 
improved if the pharmacists had direct responsibility for initiation and up-titration of lipid 
lowering agents. Other studies have shown that pharmacists were able to adjust doses 
autonomously and produce statistically significant improvements in cholesterol targets, 
through direct patient interaction (Geber 2002, Cording 2002; Till 2003; Straka 2005; Rehring 
2006).  
 
More recently, Carter (2010) described the design of their ongoing multicentre cluster 
randomised controlled trial of pharmacist-physician collaborative blood pressure management 
with 5 year follow up. Carter reiterated the underlying aim shared by all prescribing support 
models and related research: “to implement models that work, overcome provider and health 
system barriers, and sustain the effect of interventions so that they can eventually be scaled up 
for broader use” (Carter 2010).  
 
These recent studies re-state the need to demonstrate effectiveness in the short and long term, 
from pharmacist-led prescribing support. The studies appear to have improved internal and 
external validity, compared with previous research. However, overall, the quality of 
medication therapy management studies (and therefore the usefulness of their findings) shows 
room for improvement. For example, a recent review of randomised controlled medication 
therapy management trials (Kucukarslan 2011) applied internal validity criteria as 
recommended by Chalmers (1981), to assess trial quality. The review found only eight studies 
(from a possible 1795 published before 2009) meeting Chalmers’ quality inclusion criteria. 
While the review focussed only on medication therapy management (most of which were led 
by pharmacists) as a model of prescribing support, the low number of valid trials highlights 
the need to conduct methodologically robust research if results are to be assumed as due to the 
interventions under investigation rather than misinterpreted due to confounding, bias or 
chance. In addition, none of the eight trials included follow up of longer than 12 months.  
 
Meta analysis and systematic reviews are common, but publication bias may lead to meta 
analyses including more positive than neutral or negative findings. For example, a recent 
systematic review and meta-analysis of North American pharmacists’ impact as team 
members on patient care, found favourable effects across many therapeutic and safety 
outcomes (Chisholm-Burns 2010). However, unlike Kucukarslan, the study by Chisholm-
Burns failed to describe how they assessed the quality of their included studies. They included 
several studies of questionable methodological rigour (many of which had been rejected 
previously in Kucukarslan’s analysis), leaving their conclusions open to criticism. Chisholm-
Burns included the results from 298 studies compared with Kucukarslan’s eight studies.  
 
Across a wide range of settings, the studies described above underscore the potential for 
pharmacists’ interventions to improve public health. To date, the following three features 
appear important, in combination, and were therefore incorporated into the SOS model:  
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1. Collaboration with existing care providers (general practitioners);  
2. Repeated intervention;  
3. Intensive intervention.  
 
However, that there is no definitive evidence of clinical benefit over the long term, indicates 
the medication review model (or the studies to date), have limitations. The medication review 
model, in which the pharmacist consults directly with the patient then recommends changes to 
the GP, may not be the best model to influence GP prescribing over the long term. GPs may 
revert back to pre-intervention habits after the intervention is withdrawn, and this may lead to 
benefits being lost. However this has not been tested. The principle seems to apply to patients: 
after showing a reduction in heart failure hospitalisations, Murray found a rapid return to pre-
intervention levels of hospitalisation in their study when pharmacist-led adherence support for 
patients with heart failure was withdrawn (Murray 2007). 
 
 
Translating lessons from previous work into the SOS intervention   
 
The model of prescribing support described and tested in this thesis attempts to achieve 
change and sustain it, by bringing pharmacists into an educational and organisational support 
role, within practices, collaborating fully with GPs, nurses and other practice staff. It 
incorporates theoretical behavioural change principles e.g. repetition and reinforcement of the 
main message, practical support for initial stages of change (Armstrong 1996, Bradley 1992, 
Oxman 1995, Dolan Mullen 1985). Core components of the SOS intervention include 
collaboration with existing providers of medication therapy management (GPs), repeated 
contacts and intensive support. All of which increase the chances of achieving a more 
sustained effect.  
 
 
6.3  Strengths of the study 
 
In 2002, the Cochrane collaboration reviewed trials of educational outreach, and made 
recommendations. These included describing interventions adequately, designing research 
more appropriately and analysing findings appropriately e.g. by considering the impact of 
clustering. Longer follow up was recommended, together with the selection of more useful 
outcomes (clinical or surrogate clinical e.g. HbA1c, Cholesterol) (O’Brien 2002). In planning 
and delivering the SOS intervention and study, we attempted to address these 
recommendations.  
 
 
6.3.1 Complex intervention development 
 
The SOS intervention was piloted and designed in accordance with the recommendations 
made by the Medical Research Council in 2000 and in 2011. Evidence points towards the 
increased likelihood of interventions working effectively, and studies being methodologically 
more robust, if MRC guidance is followed. Pilot testing was extensive, involving 5 different 
pharmacists working in 5 different practices, over a 1 year period. Pilot work enabled 
evaluation of the feasibility, acceptability, estimation of sample size and power. It also led to a 
consensus on the preferred components of the intervention, from pharmacist and general 
practitioner perspectives. A key strength of the study was the number of pharmacists who 
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delivered it: involvement of 11 different pharmacists leads to improved reproducibility of the 
intervention, and compared favourably with previous outreach research (Chapter 2). Another 
key feature was each pharmacist being able to adhere to the core parts of the intervention 
described in Chapter 3.   
 
While intensive, the intervention did not overburden practices (or pharmacists) and was 
acceptable to 14 from 15 practices who agreed to receive it. Informal feedback on the model 
from practices to pharmacists and pharmacists to the study team was continuous, because the 
pharmacists communicated freely with GPs, nurses and other practice staff throughout their 
time in the practice.  
 
 
6.3.2 Design 
 
The SOS study was designed and is reported in line with recommendations for cluster 
randomised trials (Campbell 2004, MacLennan 2003). The unit of randomisation, allocation 
and intervention was the practice, as recommended for educational outreach trials in primary 
care. Following the recommended guidance is likely to lead to easier interpretation of the 
results, on dissemination, because the key features of the trial will be systematically described, 
in an accepted order and in sufficient detail to enable critical appraisal.  
 
A stepped wedge (block randomisation) design (Brown 2006) offered an alternative 
methodological approach, but this was not practical because of the duration of the SOS 
intervention, and therefore, potentially even longer delays between study initiation and 
completion.  
 
For the first time in a study of outreach, the pharmacists had full access to all relevant medical 
information held in the practice. This contrasts with previous work which has focussed on 
community pharmacists or specialists, working remotely, accessing anonymised prescribing 
trends.  
 
The maximum duration of follow up previously described in this type of research was 12 
months (Pearson 2003). Our median follow up was 20 months, ranging from 17 to 26 months, 
which is longer than previous studies of this type or medication review type interventions, 
excepting the recent HOOPS (Lowrie 2011). Longer follow up enables more accurate 
determination of the impact on clinical outcomes if the results are favourable. Persistence of 
the intervention effect after the intervention finished was therefore evident up to 16 months in 
some practices (the intervention lasted 12 months). Practice level simvastatin 40mg 
prescribing data up to 6 years post intervention showed a ‘washover’ effect in SOS arm 
practices (Appendix XVI), which breaks new ground in relation to effect duration, although 
this is outwith the controlled circumstances of the SOS trial and therefore less reliable. 
 
Reduction of non formulary prescribing (in the case of Statins, the non-formulary choices at 
the time of the intervention were Rosuvastatin and Ezetimibe) is often the target of prescribing 
support models. The SOS model appears to have had a marked effect on reducing non-
formulary prescribing, compared with UC practices judging by the trend shown beyond the 
designated follow up period (Appendix XVII).  
 
  
153 
Our process for selection of practices for inclusion in the trial was random, the aim being to 
recruit a representative sample to maximise external validity. This contrasts with most 
previous outreach trials, which have selected healthcare professionals on the basis of their 
capacity to benefit from the intervention on offer. While their approach to recruitment 
increases the likelihood of a positive result, ours maximises opportunities for transferability 
(Thomson 2005, Oxman 1995). There were few differences between participating and non-
participating practices at baseline, indicating representativeness of practices, due to a 
successful, randomised process of practice enrolment (Lowrie, Morrison, McConnachie 2010). 
It involved following up those who had received an invitation, until an answer had been 
obtained. The desired effect was to reduce the chances of non participation by invited, busy or 
research-wary practices, ensuring generalisability of the practice sample. The study involved 
15 single handed practices and the intervention, through improving outcomes in single handed 
practices, is likely to have improved QoF points in the domains covered by cholesterol control. 
Both factors are unusual because of the finding that smaller Scottish practices appeared less 
likely to participate in research and achieve fewer clinical or non-clinical Quality and 
Outcomes Framework points in the period 2002 to 2006 (Mackay 2010).   
 
Key patient level variables at baseline and follow up were comparable to other statin trials and 
surveys, reinforcing external validity (Chapter 4). In particular, the large number of patients 
with data reported at baseline (4040) and follow up (7586) gives the results considerable 
weight. 
 
Our sample size (practices and patients) was greater than anticipated, which perhaps improved 
our chances of finding a positive result, but also helped to minimise any remaining variability.  
 
We controlled for confounding by pairing practices of similar baseline characteristics then 
stratifying, as recommended for cluster randomised trials involving few clusters (Donner 
2000). Baseline data was collected before randomisation to minimise bias. Outcomes were 
assessed at the same time (relative to randomisation) in both members of each pair of 
practices, and by blinded, independent researchers. No interpretation was involved in the 
collection of outcome data. Transcription errors were a possibility, although the risk was 
minimised by the two researchers working together across 29 practices at follow up, which 
enabled cross checking for accuracy and completeness.  
 
We randomly allocated practices to the SOS intervention or UC while maintaining blinding. 
Blinding is desirable because it minimises the chances of performance and detection bias. 
However, we could not ensure the ‘quadruple blinding’ approach described by Chalmers 
(1981), because practices were notified of their allocation in writing. Performance bias was 
therefore possible through UC practices trying harder to achieve the outcomes for which their 
SOS group counterparts received support. Further, participating doctors and other practice 
staff were not made aware of the ongoing results of the trial. Patients remained blinded to 
allocation throughout the study, because there was no requirement for written consent at 
patient level (Chapter 3).  
 
All analyses were checked by an independent statistician, blinded to allocation, from the 
Robertson Centre for Biostatistics. We are confident that outcomes were due to the 
intervention, rather than any dissimilarity at baseline.  
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To date, assessment of the impact of outreach visits has focussed on markers of healthcare 
professional behaviour change e.g. the quality and quantity of prescribing or referrals. The 
SOS trial is the first to show benefit on cholesterol control and cholesterol levels, in the 
context of a randomised controlled trial.  
 
Within the time period of the SOS trial, we were unable to evaluate any potential effect on 
hospitalisation, or mortality because the study was not powered to do so and this did not form 
part of the protocol. However, this may be followed up through a post hoc analysis, on 
completion of this thesis, alongside an economic evaluation.  
 
 
6.4  Weaknesses of the study 
 
Pre-intervention distribution of five variables of potential prognostic importance (cholesterol 
recorded, statin prescribing, statin prescribing at optimal dose, number of vascular co-
morbidities and proportion of patients with angina/ischaemic heart disease) was 
disproportionate between the SOS and UC arms of the study. These imbalances may have 
been due to the small number of clusters however, they were not expected to have biased our 
findings for three reasons: 
 
1. Their distribution acted against the intervention effect;  
2. Cholesterol related measures (levels and extent of control between arms) were 
balanced; 
3. Simvastatin (optimal dose) prescribing was balanced. 
 
If the baseline imbalances were thought to influence the results, use of a regression model 
adjusted for these variables might be an alternative approach to analysis e.g. use of a stepwise 
selection to create a multivariate model.  
 
Only practices from Greater Glasgow Health Board were considered in this study, and the 
intervention was delivered at practice level. The success of the intervention was therefore 
highly conditional, depending on the payment system and priorities at that time. 
Generalisability to other healthcare systems may therefore be questionable, particularly those 
with different primary care systems. 
 
In common with other interactive educational outreach interventions tested in a controlled 
trial, participants allocated to the control group could not be blinded to their treatment 
allocation. This created two possible effects. The first is the ‘Hawthorne effect’ (Chapter 2, 
Section 4.6) which may have increased the statin prescribing of the control group as a result of 
an awareness of prescribing practices being under external scrutiny. The second effect is 
additive and may also have acted against the intervention: involvement in the study led to 
baseline data collection in each practice, by a pharmacist identifying a cross section of eligible 
patients and collecting relevant datum. Practices in each group had full access to this 
information, which remained in practices throughout the study. This information provided 
control group practices with a starting point for targeting eligible patients for statins and 
therefore, is likely to have improved outcomes in the control group beyond levels achieved by 
practices not participating in the study. These factors, together with the strong contextual 
influence of the QoF and the dissemination in December 2003 of the GG&C Cholesterol 
guideline, are likely to have led to the observed improvements in the UC practices. The extent 
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of improvement in UC arm practices between baseline and follow up was considerable: 
Appendix VII shows 36.8% of patients had cholesterol controlled in 2003 at baseline, while 
Table 5.6 shows 69.5% of patients in SOS and 63.6% in UC practices had controlled 
cholesterol at follow up in 2005/6.  
 
This interpretation highlights a weakness of the overall research in not generating 
accompanying qualitative research to enhance our understanding of the reasons why the SOS 
intervention worked and to characterise the context for practices and patients in GG&C at that 
time. 
 
6.4.1 Delays in reporting 
 
There were significant delays in the completion and reporting of the SOS study. This perhaps 
represents a weakness of the study planning process. Reasons for the delay include having to 
rely on 11 pharmacists (at baseline) and two researchers (at follow up) for data collection. 
Therefore these phases lasted longer than expected. This led to significant delays between the 
start (2002) and finish date (2009; when follow up data collection was complete). Another 
reason for the delay in reporting was due to the time spent summarising and analysing the 
large data set generated by 7586 patients and multiple secondary outcomes and subgroups.  
 
In the interim, statin prescribing is likely to improve and this will tend to reduce the impact of 
the SOS intervention and reduce the need to implement our findings. For example, Kumar 
recently reported the prescribing of statins for patients with vascular disease in the USA had 
reached 84% (Kumar 2009). Their survey included 19,007 patients, making it the largest 
survey of statin prescribing to date. This level of achievement is very close to that shown in 
the SOS study at follow up (prescribing of any statin at any dose in the SOS group was 86.9% 
compared with 74.9% in the UC group. Kumar did not collect data on doses or cholesterol 
levels. Due to the time delay between study completion and reporting, the SOS intervention 
may have become less useful for most general practices, but more useful for general practices 
with more modest levels of statin prescribing and dosing. The delay in reporting will be turned 
to our advantage by extending the follow up period. 
 
Delays also increase the likelihood of similar research reaching publication, superseding our 
work. However, between 2003 and 2010, there does not appear to have been any published 
randomised controlled trials or other scientific investigations focussing on general practice 
based pharmacists improving statin prescribing and cholesterol control for patients with 
vascular disease, through educational outreach-type approaches. The RaPP trial was 
comparable in some ways. Starting in 2002, the authors aimed to achieve better prescribing of 
antihypertensives (mainly thiazides) and statins for a primary prevention cohort (Fretheim 
2003; 2006) through group based educational outreach delivered by pharmacists. Improved 
outcomes were limited to thiazide prescribing, with no effect on statins or cholesterol control.  
 
6.4.2 Attrition 
When data are collected over at least two time periods, most studies have some degree of 
dropout of patients or in this case, clusters and patients. Attrition may introduce bias if the 
patients or practices dropping out are systematically different from those remaining in the 
study. The SOS study was different in that more patients were included at follow up, than 
were included at baseline (Figures 5.1 and 5.2). This included larger numbers of incident 
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patients in both arms (SOS: 999 / 4234 (23%) and UC: 927 / 3352 (28%). However, we have 
not yet compared the characteristics of different subgroups.  
 
However, we had no reason to believe that these limitations biased the results. Baseline 
characteristics (Tables 4.2, 4.4, 4.5 and 4.6), suggested groups were well balanced at baseline.  
Outcomes (and subgroup analyses) strongly favoured the intervention and were consistently 
positive for the group identified at follow up (n = 7586; Table 5.2) and the subgroups: eligible 
at baseline (n = 5660; Table 5.4) and eligible after baseline (n = 1926; Table 5.4). Of the 5660 
patients who were eligible at baseline, 2619 (SOS: 1491 / 2373 (63%) and UC: 1128 / 1667 
(67%). Table 5.2 and Figure 5.1) were linked from baseline to follow up, and outcomes were 
also positive for this subgroup.  
 
The proportions of patients who could not be linked from baseline to follow up because of 
missing data e.g. CHI, was similar in both study arms: SOS: 880 / 2373 (37%) and UC: 541/ 
1667 (32%). However, some of the characteristics of these non-participants differed from the 
characteristics of those patients who were linked from baseline to follow up (Tables 5.2.1 to 
5.2.5). In particular, non participants appeared to be older and more likely to be female 
compared with those who were identified at baseline and followed through the study. Thus the 
possibility remains that the intervention effect is untested in this subgroup of patients. While 
subgroup analyses of the primary and secondary outcomes showed improvement in males and 
females, Section 5.3.1.3 describes some evidence, from subgroup analyses, of a preferential 
effect of the intervention in males compared with females. The intervention did not appear to 
be of reduced effectiveness in older age groups as defined by the threshold: < 60 years 
compared with ≥ 60 years. It is therefore possible that a more detailed analysis of the effect of 
age using smaller increments may show a different result.  
 
However, the size of the differences in age (3.2 years), gender (6.4%) and other variables e.g. 
qualifying diagnoses between participants and non participants (Table 5.2.4) while statistically 
significant, may not be of clinical importance. One difference does stand out: non participants 
were less likely to have diabetes than participants. This requires further exploration and may 
be attributable to there being fewer non participants from practices serving predominantly 
South Asian communities where the occurrence of diabetes was found to be greater at baseline 
(Section 4.3.2). 
  
We found no statistically significant difference in mortality in the 82% (1168/1421) of non 
participants who had sufficient data to enable determination of their status. Approximately one 
third of non participants died prematurely before the end of the study. As the proportions of 
non participants dying prematurely before the end of the study was balanced between SOS and 
UC groups, this is unlikely to have biased the results.  
 
Previous research into the effectiveness of various outreach models has focussed only on GP 
or family physician’s prescribing or test ordering activities, without describing the 
characteristics of patients or whether they were known to the GPs / physicians at baseline. 
Compared to previous research of this type, we had a more detailed description of patients and 
differentiated between prevalent (known at baseline, n = 5660) and incident (n = 1926). 
Evaluation of the impact of the SOS intervention on patients tracked from baseline to follow 
up (as is the norm in individually randomised trials) was therefore another novel aspect of our 
study.  
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6.4.3 Therapeutic topic  
 
The intervention focussed on a relatively restricted area of therapeutics, and the underlying 
reasons for disparities between clinical practice and systematically developed guidelines are 
known to vary from one clinical problem to another. Our pilot work, training of pharmacists 
and the SOS model were tailored to the specific and temporal needs of practices and statin 
prescribing. Further pilot work and a different training programme may therefore be required, 
to test the model on a different topic. However, we have provided prima facie evidence that 
the method might work, when applied to another therapeutic area.  
 
By only targeting changes in statin prescribing behaviour for patients with vascular disease, 
the intervention may be regarded as having relevance only for a relatively small (high risk) 
group of patients. This is not a problem per se, but may become difficult to sustain if an 
economic model shows the approach not to be cost effective.  
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6.4.4 Design considerations 
 
Importance of sample size calculations 
Sample size calculations are a means of estimating the required number of participants in each 
arm of a randomised controlled trial, in order that a clinically important difference is 
detectable, when the occurrence of the most important outcome in the intervention group is 
compared with the control group.  
 
If a study is too small, it will not be able to answer the question posed. Sample size 
calculations are important because they guard against over or under recruitment of 
participants, both of which may impact on ethical, cost and risk implications, depending on the 
type of trial. The SOS study was a pragmatic (practical, effectiveness or management) trial 
conducted using NHS resources, nested in routine care through the delivery of pharmacist led 
prescribing support to improve adherence with established GG&C statin prescribing guidance. 
The intervention was introduced in addition to usual care; practices and patients were not 
denied any service as a result of the study. Re-organisation of the delivery of a NHS funded 
pharmacist support service together with standardisation of an outreach/organisational support 
intervention minimised any ethical concerns and additional costs. Senior management within 
NHS GG&C were supportive of the trial proceeding using NHS resources within routine 
service delivery to inform decision making in relation to the effectiveness of pharmacist led 
prescribing support in primary care. 
 
The sample size depends on the type I and II error rate and the effect size of the intervention. 
The sample size goes down inversely as the square of the effect size. In the case of cluster 
randomised controlled trials, the sample size calculation takes account of a measure of the 
correlation between individuals within a cluster and the size of the cluster.  
 
In the case of the SOS study, the sample size calculation (based on pilot work conducted in 
2002) focussed on the effect size of the outcome: the proportion of patients with CHD who 
had cholesterol controlled. This outcome was chosen because of the finding (following an 
extensive literature review) that pharmacist led interventions had not previously shown any 
improvement in surrogate clinical outcomes, and surrogate clinical outcomes are more useful 
markers of effect to the NHS and patients, compared with changes in prescribing. To derive 
empirical evidence of improvement in cholesterol control through a practice level intervention 
would therefore break new ground and represent a valuable outcome for patients and NHS 
GG&C. Analysis of pilot work subsequently showed that the intervention generated a 
measurable improvement in cholesterol control. The study sample size and power calculation 
were based on this outcome. At that time, one of the secondary outcomes was the proportion 
of patients with controlled cholesterol, prescribed simvastatin 40mg.  
 
However, during this period, there was an increasing focus (instigated by the director of 
finance in NHS GG&C and communicated through to pharmacist prescribing support teams) 
on prescribing cost containment. Statin prescribing and costs were increasing and some of the 
increase was due to more expensive statins e.g. Atorvastatin 10mg costed £18.03 for 28 days 
compared with £1.32 for Simvastatin 40mg for 28 days (BNF 2009). The statin prescribing / 
cholesterol guideline for secondary prevention was introduced to improve the quality of 
prescribing (encouraging more eligible patients to receive a statin) and to minimise the costs 
associated with statin prescribing by encouraging the prescribing of Simvastatin 40mg. The 
guideline adopted the eligibility criteria of the Heart Protection Study, superseding the 
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previous eligibility criteria used in our pilot work: coronary heart disease. Following 
discussion with finance and management colleagues, it was therefore decided to revise the 
main target of the study to reflect the prevailing ethos of cost containment, while retaining the 
focus on cholesterol lowering. Therefore the primary outcome became the proportion of 
patients with vascular disease who were prescribed Simvastatin 40mg with controlled 
cholesterol.  
 
For pragmatic reasons, the study therefore had a sample size and power calculation based on a 
secondary outcome. This raised the possibility of the study being over or under powered to 
detect the primary outcome.  
 
The power of the study can be re-calculated using follow up data: 
 
- assuming 7586 patients in total (3793 per arm) in 29 practices (7586/29 = 261 
per practice). 
 
- design effect (D) = 1 + 0.05 (261 – 1) = 14 (Section 3.2.4) 
 
- effective sample size is 3793 / 14 = 271 patients per group 
 
Therefore the study had 94% power to detect the difference in the rate of the primary outcome 
of 88% in SOS versus 76% in UC, and 98% power to detect 44.9% in SOS compared with 
27.9% in UC.  
 
Both outcomes (primary and secondary) were binary. The power of each was sufficient to 
detect a difference of a similar magnitude: 88% versus 76% in the original calculation 
compared with 44.9% versus 27.9% in the calculation shown above. 
 
 
The persistence shown during the recruitment process may have contributed to one practice 
dropping out. This is because the practice may not have had sufficient opportunity to 
appreciate the intensity and duration of the SOS intervention. Our invitation process 
comprised systematic follow up through personal visits, letters, faxes and telephone calls until 
confirmation of consent or non participation had been received from each practice. In some 
cases, the practice received a letter, fax, phone call and visit to discuss the programme. This 
enthusiastic approach led to the recruitment of three practices which had not previously 
participated in any research. Of these three practices, one disbanded prior to the date of 
randomisation, one dropped out and one remained in the study.  
 
We did not formally evaluate GP, practice nurse, practice staff, patients’ or pharmacists’ 
views. We do know from practice staff in the SOS arm that there was no negative feedback 
from the patients who did receive some form of communication or changed prescription. GPs 
and nurses appeared appreciative of the pharmacists’ input; all 35 GPs and 21 nurses willingly 
participated in the study although 1 GP and a practice nurse (from the same practice) dropped 
out. Patient views of outreach services delivered to GPs have not, as far as we are aware, been 
reported. Literature on GPs’ views of academic outreach visits is limited to one short report 
that indicates a preference by GPs for other GPs to deliver these interventions (Young 2003). 
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At baseline, using available data, we found patients’ characteristics were comparable to those 
described in landmark, placebo controlled trials from the same period. However we did not 
collect additional data e.g. the number and type of non-vascular co-morbidities, weight, 
height, previous hospitalisations or smoking status. Physiological variables e.g. blood pressure 
and eGFR would enable better characterisation of the population, and thereby enable other 
researchers to compare and contrast our findings more widely.  
 
At baseline (and therefore randomisation) there were significant differences between the SOS 
and UC arm practices in the following covariates: proportion of patients with 
Angina/Ischaemic Heart Disease (significantly greater in SOS intervention practices), vascular 
co-morbidities (greater in SOS practices) and cholesterol recorded (lower in SOS practices). 
Together these data indicated SOS allocated practices had a greater burden of patients eligible 
for statins, but less information on which their prescribing decisions could be based (fewer 
patients with available cholesterol levels at baseline). Also, proportions in SOS intervention 
practices without a statin were higher and prescribing of optimal doses of statins was lower. 
Both these imbalances suggest practices in the SOS arm had a larger gap to bridge to improve 
on the levels noted in UC. In turn, this may have led to a need for proportionately more effort 
to achieve a given target statin prescribing and cholesterol control. Therefore, the baseline 
imbalances did not appear to bias the results in favour of the intervention. 
 
Critically, the groups were balanced in relation to the primary outcome: simvastatin prescribed 
and cholesterol controlled at baseline.  
 
Measurement of adverse events is an important consideration in the clinical trial setting but 
less so for complex interventions health services research. We chose to evaluate new 
diagnoses of vascular disease because this study was primarily about the impact of SOS 
intervention rather than the impact of statins per se. Vascular diagnoses (limited to those 
included in the eligibility criteria) were collected through electronic record linkage of those 
patients who had CHI recorded and were identifiable at baseline and follow up. Electronic 
searching and reporting is likely to have been more accurate, complete and efficient because 
of the lack of outcome interpretation required by researchers. However, in this case, the 
process involved remote searching of participating general practices’ databases using a central 
server, of unknown accuracy and completeness. Therefore, that SOS and UC arms were found 
to be comparable in relation to adverse events, cannot be taken as conclusive. The low number 
of events in each group led to wide confidence intervals, indicating considerable uncertainty 
around the results. The proportion and time to occurrence of new diabetes diagnoses, where 
the intervention showed superiority over UC, is likely to have driven the significant difference 
in the overall safety analysis of all events. There was no scientific rationale for there to be 
delayed onset of new diabetes in the SOS arm of the study. One recent report noted the 
opposite: a possible link between increased risk of diabetes and statin use, in women (Vos 
2011). Subgroup analyses for the presence or absence of diabetes in the primary or secondary 
outcomes confirmed there to be no significant difference in the impact from the SOS 
intervention. 
 
Post-hoc analyses to detect adverse effects arising from complex interventions may be useful 
to generate a hypothesis rather than confirm or refuting a prior hypothesis. In exploratory trials 
e.g. those involving new medicines, safety analyses are important because of the need to 
confirm safety in use in a heterogeneous group of patients. However some observers regard 
safety analyses in complex intervention trials as unnecessary (John Norrie, personal 
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communication) because of the difficulty attributing causation of potentially unrelated 
outcomes, following the application of a multifaceted intervention in the context of a complex 
system with many interacting factors.  
The effect size of our study was larger than expected from pilot work, which led to our 
decision to conduct a post hoc analysis because of the possibility that systematic application of 
the statin/cholesterol guideline in a heterogeneous population led to an effect not previously 
considered. The SOS study was not powered to detect any differences in safety outcomes and 
the analysis of vascular events at follow up did not form part of the original protocol. In 
addition, the method used to collect the number and type of events further limited the 
usefulness of these results: 
1. The number of patients identified through this analysis (215 / 1911 (11%) over 8 months is 
considerably greater than the expected approximate rate of 2% over 8 months (30% over 10 
years). Practice level verification of these events and their associated coding did not take 
place. Without these in process quality controls, the results cannot be regarded as conclusive.  
2. The method used to identify the occurrence of new vascular events had not been previously 
tested or validated therefore was of unknown specificity and sensitivity.  
3. The period (between 2 and 2.8 years) chosen for the evaluation of vascular events was 
chosen for pragmatic reasons, rather than any a-priori decision underpinned by an evidence 
base relating to when adverse events of this nature may occur.  
4. Collection of adverse events was limited to new presentations of diagnoses comprising the 
eligibility criteria for Simvastatin 40mg. No other relevant outcomes were sought. These 
might have included ascertaining the level of reported side effects from simvastatin. However, 
during the HPS (which included 20,536 UK adults), these were already known to be rare: less 
than 0.5% in the case of alanine aminotransferase elevated more than four times the normal 
range; less than 0.2% in the case of creatinine kinase elevated more than 10 times the normal 
range and less than 0.1% for rhabdomyoloysis. We had no reason to believe there was a need 
to evaluate the incidence of these or other side effects from a commonly used, licensed 
medicine. 
 
Patient level non-vascular mortality was not sought as part of the post-hoc analysis for two 
reasons: 
1. This was not requested in the original ethics committee application  
2. Resources were not available to enable unique identification of mortality using Information 
Services Division record linkage or other verification processes.  
3. Non-vascular mortality rates in a heterogeneous population receiving Simvastatin 40mg is 
already established. The HPS showed any non-vascular causes of death in the intervention 
group reached 5.3% (547 / 10269) with 5.6% (570 / 10267) in the placebo group; death rate 
ratio 0.95; 95% confidence interval: 0.85 – 1.07; p = 0.4) 
 
For these reasons, the results of the SOS post hoc analysis cannot be taken to imply causation. 
If the diabetes result in the safety analysis is taken as a signal of a protective effect from 
simvastatin 40mg, further investigation of this finding in the context of an adequately powered 
study is required.  
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6.5  Key findings 
 
At baseline in our sample, half of those eligible were treated with a statin and half of those 
treated were uncontrolled. The ‘rule of halves’ (Wilber 1972) was also evident at baseline for 
other measures of statin prescribing and cholesterol control. The prescribing of the 
recommended statin (simvastatin 40mg) for eligible patients was considerably less than 50% 
at baseline: 8.9% in SOS practices (211/2373) and 9.4% in UC practices (157/1667) (Tables 
4.5 and 4.6). 
 
We found that a new, high intensity, collaborative SOS model of pharmacist-led prescribing 
support delivered over 1 year, involving a combination of personalised educational outreach 
and organisational support delivered to unselected general practices, improved statin 
prescribing and cholesterol levels, of patients at highest risk of suffering a vascular event.  
 
Patients with confirmed evidence of vascular disease in practices receiving the SOS 
intervention were almost twice as likely to have simvastatin 40mg prescribed with controlled 
cholesterol. Most subgroups benefited, but the following benefited more than their opposites: 
males, those who were living in areas of greater socioeconomic deprivation and patients 
diagnosed with vascular disease before the start of the intervention.  
 
Patients from practices receiving the SOS intervention had increased prescribing of target dose 
simvastatin or any other Statin. Patients were more likely to have their cholesterol tested (in 
accordance with guidelines, when this was due), controlled (less than 5mmol/l) and have 
lower cholesterol levels. 
 
The intervention effect was strong enough to show a statistically significant improvement 
across most outcomes, despite improvements in the processes of care of patients with vascular 
disease, financially incentivised from 2004 by the GMS QoF. 
 
There were some statistically significant differences between patient non participants (who 
could not be followed up at the end of the study). Premature death is likely to have accounted 
for loss to follow up in one third of cases although mortality was comparable between SOS 
and UC as were all other baseline variables. 
 
6.6  Interpretation 
 
An average, 261 eligible patients with vascular disease were identified per practice, at follow 
up. Of patients from practices receiving the SOS intervention, 59% were prescribed 
simvastatin 40mg at follow up compared with 38% in the UC group. Therefore in SOS 
intervention practices, for every 100 eligible patients, 21 more were prescribed simvastatin, 
which approximates to the number needed to treat for 5 years, to prevent 1 event (heart attack, 
stroke or revascularisation (Appendix III). With 261 patients per practice and 14 practices 
receiving the SOS intervention, an estimated 35 events were prevented between 2005 and 
2010, in the SOS allocated practices, with the following assumptions: 
 
- Prescribing of simvastatin reached a plateau at the point of follow up data collection;   
- Risk predictions from the Heart Protection Study applied to our sample (26% event 
rate without and 21% with simvastatin 40mg); 
- Patients took at least 80% of their statin. 
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Pharmacists working collaboratively with practices supported an increase in simvastatin 40mg 
prescribing from 8.9% to 58.9% at follow up, while in UC practices, a considerable increase 
from 9.4% to 37.8% was noted, without pharmacists’ support. 
 
It is likely that as time passes, the margin for improvement from the SOS intervention will 
diminish, in line with the general improvement in uptake of incentivised prescribing through 
the ‘pay for performance’ system in the United Kingdom (Roland 2004, Campbell 2007). 
Crude estimates of the overall rise in prescribing of simvastatin (primary and secondary 
prevention) in the SOS intervention practices compared with UC beyond the period of the 
study is shown in Appendices XV and XVI, suggesting an increase over time, and also 
persistence of the effect of the intervention, at least six years later. The dramatic increase in 
simvastatin 40mg prescribing in the UC arm coincides with the introduction of the GMS QoF. 
 
The model could be applied to improve the use of other guideline based therapies, where 
uptake is suboptimal; perhaps an area not covered by the GMS QoF e.g. the prescribing of 
guideline recommended beta blockers for patients with symptomatic heart failure due to left 
ventricular systolic dysfunction. However, it is difficult to predict whether practices would be 
sufficiently motivated to receive the support of the pharmacist without the additional prospect 
of (contractual) financial incentives for achieving higher rates of prescribing or dosing. 
 
 
6.7  Key features of the intervention 
 
The SOS intervention was delivered by 11 different pharmacists, but core components of the 
intervention were delivered as standard by all. These components were described in relation to 
setting, timing, duration, content, structure.  
 
As with other complex interventions (O’Brien 2002; MRC 2000 and 2011), it is not clear 
which components were essential although access to patient level clinical and prescribing 
information was a pre-requisite. The following are likely to have been vital:  
 
1. Prolonged, intensive prescribing support. This enabled relationship building, with 
associated trust, which led to agreement on prescribing recommendations. It also 
enabled the pharmacist to have sufficient time to carefully identify eligible patients and 
categorise them in relation to their required action e.g. needing cholesterol checked, or 
a prescription for simvastatin 40mg. Both male and female pharmacists delivered the 
intervention effectively in their allocated practices and there was no obvious link 
between the number of years or type of experience or possession of a postgraduate 
qualification and a successful outcome.  
2. Identification of barriers to change (GP, nurse, practice, and to a certain extent, 
patient barriers). Pharmacists exchanged and shared different approaches to solving 
problems that were common between their colleagues in different practices. 
Organisational support is known to help overcome prescribing inertia (Nazareth 2002), 
and the additional capacity to deal with this, clearly helped overcome workload 
constraints.  
3. Access to all practice based demographic, diagnostic and prescribing information.  
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4. Provision of the means to overcome (practice specific) organisational barriers e.g. 
creation of “free” slots in nurse or GP daily lists, so that eligible patients can appear for 
cholesterol tests or to receive a statin prescription; 
5. Provision of individualised information. Tailored interventions are known to be 
powerful predictors of effectiveness (Hulscher 1998, Figueiras 2001). The SOS 
intervention was tailored to each practitioner and their practice circumstances. 
6. Systematic follow up and updating of practice based patient records to ensure 
maximum uptake and minimum dropout. 
7. The hard work and enthusiasm of the pharmacists delivering the intervention.  
 
To drill down any further would require a prospective (cluster) randomised controlled trial of 
different components of the SOS intervention, accompanied by the views of practice staff on 
their perceptions of the strengths and weaknesses of the intervention. 
 
 
6.8  Primary outcome 
 
We chose a primary outcome combining simvastatin 40mg prescribing and cholesterol control, 
because this captured uptake of main prescribing message communicated to practices while 
including a measure of whether patients began taking simvastatin. It was therefore considered 
to be the most appropriate means of evaluating the impact of the intervention, while giving an 
indication of the real world consequences of improved prescribing (cholesterol lowering and 
control).  
 
The effect size (OR 1.79; 95% CI 1.61 – 1.98) of the primary and many of the secondary 
outcomes was greater than previous educational outreach interventions or collaborative 
approaches to prescribing change (Bloom 2005). 
 
The primary outcome effect was greater in males, patients from areas of greater 
socioeconomic deprivation and patients with fewer vascular co-morbidities. These findings 
were unexpected, particularly the greater impact on patients from practices in areas of greater 
deprivation, a finding which applied across all secondary outcomes and subgroups and merits 
further exploration, perhaps through examination of individual level deprivation scores. The 
greater effect on practices with higher average mSIMD becomes more striking when taken in 
context of the deprivation scores for practices across Scotland (Section 4.1.2). Most 
participating practices were within the 9th or 10th (most deprived) deciles, suggesting the 
intervention can improve outcomes in practices from the most deprived areas of Scotland. The 
intervention may provide a means of addressing the inverse care law (Hart 1971), particularly 
if the principles are applicable to other conditions e.g. supporting general practices in more 
deprived areas to increase the uptake of cardiovascular health check screening (O’Donnell 
2009 internal report) This application has been tried with good results, since the findings of 
the SOS trial became clear (Lowrie 2010b internal report).  
An important role of implementation research is to reduce the differential uptake of clinical 
evidence, because significant variation is likely to lead to inequities. A reduction in the range 
of each outcome was observed in the SOS arm practices. In each case this was due to the SOS 
intervention re-setting a higher (improved) minimum value. Together, this provides strong 
evidence that the SOS intervention effectively reduces between-practice variability in the 
minimum achievement in each of the outcomes studied, by re-setting the minimum level to a 
higher value. This is useful for patients in practices where the starting point is lower. 
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A comparison of the upper limits of the ranges achieved at follow up revealed minimal 
difference between SOS and UC practices. It indicates that practices not receiving the SOS 
intervention are able to achieve the targets achieved by pharmacists’ support. Therefore if 
practices use their patient level demographic and prescribing information differently and have 
sufficient additional focussed time and effort then improvements of the scale introduced by the 
SOS intervention are possible. It is also likely that the proportionately greater effect of the 
SOS intervention in more deprived areas reflects the ability of the model to overcome the 
added difficulty usually experienced by these practices due to additional workload.  
 
The similarity of the upper limits reached for each practice (SOS and UC) suggests a ceiling 
effect. It is possible that general practices have difficulty achieving levels beyond the 
thresholds indicated e.g. 93.6% of eligible patients prescribed a statin, or 69% of patients with 
cholesterol controlled. The consistency of this finding across most outcome measures perhaps 
suggests that factors outwith the control of the practice were at play in limiting scope for 
100% achievement. Possibilities include the remaining eligible patients declining a statin (or 
an increase in dose), statin intolerance, some patients not being easy to engage. Reasons for 
poor engagement were encountered by pharmacists and practices in their course of 
systematically contacting eligible patients. They included patients who had moved house 
without informing the practice, housing block destroyed, relocated, not willing to cross 
boundaries between their home and the practice for territorial reasons or not able or willing to 
pay two different bus fares to attend an appointment in the practice during their work hours. 
Many of these findings were encountered again (confirming their validity) in 2010 during a 
separate programme of work focussing on improving practices’ engagement with people from 
areas of socioeconomic deprivation in Glasgow (Lowrie 2010b internal report).  
 
To achieve a greater extent of achievement in the primary outcome is perhaps unrealistic with 
the SOS model; further improvements may require more interventions directed towards 
patients e.g. for improvement of adherence. Outreach to patients’ homes would undoubtedly 
help overcome subsequent barriers and this approach may be tested next. Variability in 
response to statins and lifestyle measures (diet and exercise, both of which influence 
cholesterol levels) are also possible explanations for the gap between the ceiling levels we 
observed and 100% achievement.  
 
 
 
6.9 Subgroups and secondary outcomes 
 
6.9.1 Gender 
 
De Wilde (2003) found men were more likely than women to receive a statin, but the 
difference disappeared after adjustment for age and severity of ischaemic heart disease. Both 
sexes are known to benefit equally from statins (25% reduction in cardiovascular disease 
incidence), but women tend to be under represented in statin trials (Bartlett 2005). A meta-
analysis of five major statin trials (4S, LIPID, CARE, AFCAPS/TexCAPS and WOSCOPS) 
found the risk reduction in major coronary events was similar between men and women (La 
Rosa 1999). In the HPS, a comparable reduction in events was demonstrated in males and 
females. There does not appear to be a clear report in the literature of the relationship between 
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statin prescribing and gender in primary care, but the clinical evidence overwhelmingly asserts 
statins should be offered to both males and females based on risk stratification.  
 
Our findings are consistent with some reports of higher uptake of statin prescribing among 
men with ischaemic heart disease (13.3%) compared with women (8.2%) e.g. Majeed 2000, 
Reid 2002, but not others e.g. Bartlett 2005). A recent systematic review of primary care 
programmes to prevent cardiovascular disease found no evidence of gender inequalities in 
uptake (Pennant 2010).  
 
There was no preferential targeting of males by pharmacists in the SOS intervention. This may 
suggest greater uptake of recommendations to start or up-titrate doses in males, or a greater 
number of males were identified as requiring improvements, or a combination of both. 
Alternatively, women may have declined more offers of improvement to their statin 
prescribing. Further work is needed to explore the reasons why the impact on males was 
greater than in females.  
 
 
6.9.2 Age  
 
Age differences were investigated as a subgroup because of the evidence that increasing age 
(in the range 55 to 84 years) has been shown to reduce the odds of receiving a statin (De 
Wilde 2003). This (erroneous) perception surfaced during some one to one discussions 
between GPs and pharmacists, when GPs raised concerns about the scope for the elderly to 
benefit from statins. Available evidence suggests that the benefit from statins is not attenuated 
with increasing age. Therefore pharmacists delivering the SOS intervention were made aware 
of this and asked to encourage prescribing according to level of risk rather than age, in line 
with the recommendations of a meta-analysis of five randomised controlled trials involving 
30,817 participants (La Rosa 1999).  
 
Differences in response according to age (we used a pragmatic distinction of 60 years or less 
compared with over 60 years) were not apparent in either the UC practices or SOS practices at 
follow up: proportions of patients in the UC and SOS arms achieving the primary outcome in 
each age band were similar. This finding applied to the subgroup analyses of primary and 
secondary outcomes. As with the other subgroups, a statistically significant increase was noted 
in SOS arm practices, in the proportion of patients achieving the primary and secondary 
outcomes. These findings suggest that the SOS intervention achieved improvements in 
prescribing in line with guidance on risk rather than age.  
 
 
6.9.3 Existing versus newly diagnosed patients 
 
The SOS intervention achieved a greater impact in the primary outcome and in the secondary 
outcome of ‘cholesterol levels tested since baseline’, for patients known to the practice at 
randomisation.  
 
This result was expected: in SOS practices, pharmacists provided an updated, cleaned list of 
their eligible patients, using data collected at baseline. Implementation of the SOS 
intervention’s key messages for new cases relied on the practice continuing to identify, call 
and recall eligible patients for statin initiation. Setup of these systems were encouraged by the 
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pharmacists but may have been less robust, more opportunistic and therefore less successful 
than the systematic approach to identification of all eligible patients at baseline. ‘Existing’ 
patients had been invited through letters and / or phone calls, or offered a statin 
opportunistically while attending for an unrelated, scheduled appointment.  
 
However, the intervention was also effective for those patients who became eligible after 
baseline. One reason why the intervention effect persisted for the newly diagnosed cohort in 
the SOS arm practices compared with UC was possibly due to the pharmacists ensuring at 
least one named member of the practice assumed responsibility for following up statin 
prescribing and cholesterol checking for this group of patients. The result stresses the 
importance of providing practical support and helping practices to overcome what has been 
previously described as “organisational barriers”. The same explanation could be an 
explanation of why there appeared to be a continued effect on practices’ simvastatin 40mg 
prescribing (for all patients, primary and secondary prevention) beyond the period of the study 
(Appendix XVI). In some SOS arm practices, there was already a reasonably tight system for 
patient identification and call/recall. In these practices, the pharmacists’ intervention mainly 
focussed on educational rather than organisational support. 
 
Subgroup analyses of the primary and several secondary outcomes e.g. cholesterol levels 
controlled and tested, prescribing of any statin, reinforced the finding that patients known at 
baseline fared better than those identified at some point afterwards. The most convincing 
evidence came from the outcome ‘cholesterol tested’ which is not surprising: one of the first 
tasks of the pharmacist in SOS arm practices was to identify those requiring cholesterol tests 
and systematically invite them to attend an appointment for a cholesterol test. Patients in this 
subgroup at baseline had a longer time to receive changes to their prescription, make an 
appointment at their practice and attend for a cholesterol test. Practices in the UC arm 
appeared less likely to have applied such rigorous approaches to call and recall for this 
focussed group of patients, resulting in less baseline-eligible patients attending for a 
cholesterol test.  
 
 
6.9.4 Deprivation 
 
The practice level mSIMD was used to measure deprivation and within those practices 
recruited, an arbitrary division made between higher and lower mSIMD. Patient level mSIMD 
is a more sensitive measure, and could be considered in further analyses. 
 
There is conflicting evidence about whether deprivation status influences statin prescribing 
rates (Ward 2007, Reid 2002). In Glasgow, the extent and depth of deprivation is greater than 
most other areas in Western Europe and the incidence of Ischaemic Heart Disease and related 
disorders is greater than the rest of Scotland. Socioeconomic deprivation is known to increase 
the risk of developing ischaemic heart disease and worse outcomes are expected as a result. 
Under these circumstances, the SOS intervention may be of particular interest to practices and 
policymakers faced with addressing cardiovascular health inequalities.  
 
In planning the SOS trial and providing training to pharmacists, we anticipated some 
additional efforts would be required to engage with patients from practices serving areas of 
greater deprivation, based on awareness of the problem from the published literature (Gardner 
1999; Tod 2001) and our own observations. In these practices, or for patients in other practices 
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with a history of poor attendance, pharmacists expected to spend more time providing 
additional setup support to generate accurate lists of eligible patients and to expect additional 
difficulties e.g. missing phone numbers or frequently changed addresses. Our expectations 
were confirmed: with few exceptions, while working in these practices, pharmacists observed 
and informally reported less stringent call and recall arrangements than in practices serving 
patients from more affluent areas. In practices where systems were already in place, these 
tended to be less effective when confronted by patients who perhaps had countless more 
pressing priorities in their lives than to attend for an additional appointment in their practice. 
The Pharmacists were clear that their role was to ensure each eligible patient received an offer 
of an appointment or a statin.  
 
Increased time spent by pharmacists identifying eligible patients and supporting the practice in 
their attempts to contact and re-contact patients, are likely to be key reasons for the noted 
improvement in outcomes. Another important reason was that pharmacists were able to 
scrutinise patient records for missing phone numbers and updated addresses, which were often 
‘hidden’ in discharge notes from Accident and Emergency or NHS 24 consultations. Practice 
computer records were then updated accordingly. Using recent contact details, practice staff 
had a greater chance of contacting patients. Given the known difficulties experienced by 
smaller practices in more deprived areas in relation to attainment of organisational aspects of 
QoF (Wang 2006), the success of the SOS intervention provides a model of joint pharmacist-
practice working that is capable of delivering improved statin prescribing and cholesterol 
control.  
 
Because of the additional workload involved, it is unlikely that this support was received 
across all practices in the UC arm of the study. In practices serving more deprived areas, the 
pharmacists noticed a disproportionately greater number of patients receiving initiation or 
dose modification of statins opportunistically, during appointments for other purposes. The 
pharmacists therefore met with reception staff to explain the SOS intervention approach and 
this led to booking of double appointments for some eligible patients, when these patients had 
booked a single appointment for an acute problem. In some cases, when these patients arrived 
in the practice for collection of repeat prescriptions, reception staff referred them into the 
practice nurse who initiated simvastatin 40mg and agreed a repeat appointment for follow up 
cholesterol levels liver function tests, if indicated. It is possible that this concerted action led 
to the surprise finding of a higher proportion of patients from practices with higher mSIMD 
who had simvastatin 40mg, attending for cholesterol checks (Figure 5.7). It is possible that 
reduced practice nurse availability e.g. invited, non-participating practices, would have had 
more difficulty responding in this way.  
 
The burden of ill health in poorer areas and the resulting increased demands on general 
practices is known to be associated with poorer access to care, reduced consultation times and 
lower patient enablement for psychosocial problems (Mercer 2007). Acknowledging the need 
to change this status quo, the results presented here suggest that pharmacist-led support can 
improve access to optimal dose statins, increase the likelihood of cholesterol control and 
reduce cholesterol levels among those in greatest need. Endpoints were maintained up to 2.2 
years post intervention suggests a higher level of acceptability of changes to GPs and patients 
than has been shown previously in educational outreach interventions. It is possible that in 
supporting statin prescribing and cholesterol management to this degree, GPs in the most 
deprived practices had more time to focus on the psychological distress and other issues 
commonly presenting in consultations. More work is needed to confirm the latter.   
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6.9.5  Coronary Artery Bypass Graft  
 
For most secondary outcomes, the subgroup of patients with CABG or angioplasty showed no 
significant improvement following delivery of the SOS intervention. However, confidence 
intervals were wide, indicating more uncertainty, due to lower numbers of patients. 
Prescribing of statins for patients with CABG may have been optimal prior to application of 
the SOS intervention, leaving little room for improvement (Chap 5). De Wilde found a similar 
result in their survey of lipid lowering drugs in 142 general practices across England and 
Wales (De Wilde 2003). Patients who had a history of revascularisation were more likely to 
receive a statin than those with angina. Reasons for better prescribing of statins in this group 
were unclear from De Wilde’s work and from our work. However, if the underlying 
socioeconomic gradient for access to CABG and angioplasty (Hippsley-Cox 2000) was 
operating, these patients may have had better communication skills and awareness of the need 
for statin treatment, both of which would be expected to increase the prescribing of statins. 
Alternatively, the influence of secondary care initiation of statins, post operatively, may have a 
role, or GPs knowing the increased risk of this cohort, introducing and up-titrating statins 
more readily than in patients with angina.  
 
 
6.9.6  Cholesterol controlled at baseline 
 
These subgroups were analysed because they gave an indication of whether one of the more 
contentious messages in the educational outreach programme was accepted: the need to 
introduce simvastatin 40mg for patients who already had controlled cholesterol.  
 
The SOS intervention increased the proportion of patients in both groups prescribed 
simvastatin 40mg. There was no interaction between the groups indicating no significant 
preferential effect on one subgroup over another. Therefore compared to UC, pharmacists 
delivering the SOS intervention managed to convince GPs to modify either the choice of statin 
or dose, or both, in line with guideline advice, regardless of starting cholesterol level.   
 
 
6.9.7  Practice type 
 
At the design stage, we hypothesised that some Single Handed practices would have less 
success at initiating, and titrating statins or their methods of call/recall for cholesterol testing, 
would be less robust compared with Group practices. In keeping with this, Wang et al later 
confirmed that Scottish urban single handed practices had lower attainment of QoF 
organisational domain contract points (Wang 2006). Stratification removed the risk of this 
impacting on the results.  
 
We found a statistically significant difference in the SOS intervention effect for prescribing of 
simvastatin, in favour of patients from Group practices. This indicates group practices (and 
their patients) were more likely to respond to the SOS intervention. However this pattern was 
not repeated across other secondary outcomes and the opposite was true for the outcome 
‘cholesterol levels of patients prescribed simvastatin 40mg’ which was more improved in 
Single Handed practices than Group practices. Single Handed practices and their patients also 
  
170 
responded better than Group practices and their patients, in relation to attendance for 
cholesterol checks, which might have accounted for the higher proportions of patients in 
Single Handed practices with controlled cholesterol levels.  
 
In the EBOR trial, community pharmacists visited general practices to encourage the uptake of 
prescribing guidelines (Nazareth 2002). Larger practices responded less than smaller practices, 
which is broadly similar to our findings.  
 
It is possible that the observed shifts in Group practices were significantly less than those 
resulting from application of the SOS intervention in Single Handed practices because of a 
‘ceiling effect’: patients in Group practices were already close to the upper limit. Attempts at 
further improvement might have followed a law of diminishing returns. By comparison, Single 
Handed practices, in having a lower starting point, had more room for improvement. On a 
pragmatic level, the same time was spent by pharmacists in Single Handed and Group 
practices, which suggests that Single Handed practice staff and patients received 
proportionately greater intensity and duration of input from the pharmacists, resulting in better 
outcomes.  
 
Without a process evaluation running in parallel to the main trial, it was difficult to confirm 
the reasons for these observations. However, pharmacists delivering the SOS intervention in 
Single Handed practices consistently reported that the GPs were more appreciative of their 
help (the pharmacists did not report this level of positive feedback so often in Group 
practices). In some Single Handed practices, the support bordered on one to one outreach, one 
day per week for a year. In Single Handed practices, we found that GPs tended to have greater 
awareness of their patients and their histories together with that of their families. It is possible 
that patients from Single Handed practices, due to a stronger ‘personal’ relationship with their 
GP, were more likely to accept the GPs’ advice and recommendations. Part of the greater 
effect size in smaller practices might be attributable to this. Our finding of improved outcomes 
in Single Handed practices indicates the usefulness of SOS as a mechanism for supporting 
organisational and educational quality improvement.  
 
Greater Glasgow Health Board had the highest concentration of Scotland's ethnic minority 
population. (General Register Office for Scotland 2004). At the time of the study, diabetes 
prevalence in Glasgow was known to be higher in South Asians than in the indigenous white 
population (4.8% compared with 1.3%) (National Resource centre for Ethnic Minority 
Health/Public Health Institute for Scotland 2003). The problem was particularly severe for 
patients over 70 years where prevalence of type 2 diabetes was nearly 14 times higher than 
among those under 50 years (National Resource Centre for Ethnic Minority Health and The 
Scottish Diabetes Group 2004).  In line with the results of the main study, outcomes were 
improved in two practices allocated to the SOS arm, serving patients within predominantly 
South Asian communities.  
 
While South Asians represent a particularly high risk subgroup, there is evidence that the 
inverse care law applies: the use of services is less for Ethnic Minority groups (NHS Scotland. 
April 2002) with reduced access in cases where English is not the patient’s first language (Free 
1998). At the time of the SOS study, over half of Scotland’s Local Health Care Co-operatives 
did not document the cultural or religious requirements of their patients and one fifth do not 
provide patients with access to interpreters (Diabetes in Minority ethnic groups in Scotland 
(National Resource Centre for Ethnic Minority Health and the Scottish Diabetes Group 2004)  
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There is some evidence that key medicines known to improve diabetes related outcomes are 
prescribed less frequently amongst Ethnic Minority patients (Patel 2002). Statins may be 
under-prescribed in minority ethnic patients (Ashworth 2006).  
 
The intervention achieved a significant level of improvement in the prescribing of statins and 
cholesterol control, in a subgroup of minority ethnic patients from practices where the 
majority of patients and the GPs, were of South Asian origin. SOS has therefore managed to 
overcome the inverse care law as it relates to the narrow yet important area of statin 
prescribing for South Asians in primary care. This finding could be set in the wider context of 
health inequalities which can be shaped by inequalities in access, availability and quality of 
services or linguistic, cultural and gender barriers often embedded in clinical practice (Dans 
2007).   
 
 
6.9.8  Statin prescribing at baseline 
 
Patients without statins at baseline were more than twice as likely as those without, to have 
achieved the primary outcome after the SOS intervention. Alternatively, this could be 
interpreted as SOS having a larger benefit for those patients with no statin at baseline because 
of a lower starting point, with a comparable final outcome being achieved in UC and SOS. 
Either way, this finding was anticipated because GPs in both UC and SOS were thought to be 
less likely to change stable patients’ statins to simvastatin 40mg if the original prescription 
(choice of statin and dose) was well tolerated. However the impact of the SOS intervention in 
the group already prescribed a ‘statin at baseline’ was statistically significant, confirming the 
high level of acceptance of the main message to prescribe simvastatin 40mg in preference to 
other statins.  
 
Together these findings are important because in most outreach / educational support studies 
to date, practices or healthcare professionals have been targeted for recruitment on the basis of 
their increased capacity to benefit from the intervention. The SOS intervention is therefore 
likely to be effective when applied to an unselected population of practices and patients, 
conditional on baseline prescribing and cholesterol levels being comparable to ours.  
 
 
6.10  Cost minimisation 
 
One of the key messages from the SOS intervention was the need to prescribe the least 
expensive statin with the greatest amount of clinical evidence of effectiveness and safety, at 
optimal dose. This approach was in the spirit of public interest detailing, to counter increasing 
use of more expensive medicines with no greater efficacy or safety profile e.g. Rosuvastatin or 
Ezetimibe, often driven by pharmaceutical industry or advocates within the NHS. The 
challenge of prescribing statins in line with the evidence yet managing to remain within 
prescribing budget in primary care is well known (Evans 2000). In prescribing more statins in 
SOS arm practices compared with UC, our results indicate prescribing costs will have 
increased as a result of the intervention. However, in each case, the intervention addressed 
unmet need; in view of the benefits of statins in reducing the risk of clinical events, and a full 
economic analysis is required to evaluate cost effectiveness from an NHS perspective.  
 
 
  
172 
6.11  Impact of SOS intervention on cholesterol 
 
In primary care, there are several steps between prescribing a statin and achieving a lower 
cholesterol level. Statins need to be taken regularly for at least 2 – 3 months, to inhibit 
cholesterol synthesis to the point where a lower steady state plasma level is achieved. Each 
step is potentially subject to patient dropout or non adherence.  
 
The SOS intervention arm practices had a greater proportion of patients with their cholesterol 
tested, controlled, and lower mean cholesterol levels. For those in whom it was tested, mean 
cholesterol decreased by approximately 0.1mmol/l as a result of the SOS intervention. In 
comparison with landmark statin trials e.g. HPS, our reduction is of the order of 10 times less 
but our participants differed from those recruited in HPS not least because there was no 
requirement for pre-trial demonstration of acceptable medication adherence. The clinical 
significance of better statin adherence was illustrated in the WOSCOPS trial: patients who 
took 75% or more of their Pravastatin reduced their risk of death from any cause by one third 
more than those who took less than 75% (LaRosa 2005) and, like the findings from the HPS, 
this effect was independent of cholesterol lowering.  
 
The intervention did not include any attempt to improve adherence with statins, through direct 
patient interaction. It was therefore more difficult for the intervention to improve adherence, 
compared with improving Statin prescribing. However, cholesterol control was significantly 
improved in SOS arm practices. This is likely to result from the increased prescribing of 
statins in the SOS arm, the increased use of higher doses, more patients attending for 
cholesterol checks, or a combination of these factors. Further work is needed to confirm the 
precise cause, because the complex intervention affected all outcomes. Alternatively, other 
influences were involved e.g. a higher level of adherence by patients in the SOS arm practices 
perhaps in response to their practice contacting them and showing an interest in their 
prescribing and cholesterol.  
 
Systematic bias is likely to have been minimised by the randomised enrolment of practices and 
the randomised controlled trial design.   
 
Statin adherence is known to be poor in the community and improving adherence is known to 
be more difficult than improving statin prescribing. At one year, adherence to statins is 
estimated to be about 60% in patients with previous cardiovascular events (Colivicc 2007; 
Blackburn 2005; Jackevicius 2002). A recent study reported an unsuccessful pharmacist-led 
adherence support intervention for patients prescribed statins (Ma 2010). In their 
recommendations for further work, the authors suggested a stronger focus on influencing 
physicians to increase statin prescribing.  
 
Other studies involving pharmacists aiming to reduce cholesterol levels have focussed on 
community pharmacists’ activities. Most (including a meta-analysis by Machado in 2008) 
have shown some degree of improvement in cholesterol levels, albeit with pharmacists 
working directly with a small number of patients (Tsuyki 2004). The most recent report is 
from Canada, where a cluster randomised controlled trial tested the effectiveness of a 
collaborative care model involving community pharmacists and physicians (Villeneuve 2010). 
The primary outcome (change in LDL cholesterol level) was not reached after 12 months’ 
follow up, nor was the secondary outcome (the proportion of patients achieving their target 
lipid levels). Key differences (in addition to the setting) between their intervention and our 
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SOS intervention included the direct contact between pharmacists and patients (5 
consultations in the pharmacy over 12 months) rather than educational outreach by 
pharmacists to general practice staff. Community pharmacists modified statin dosages, after 
the GP had issued the initial prescription. The intervention did reduce LDL cholesterol (by 
1.1mmol/l), but this did not reach statistical significance.  
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Chapter 7 
 
Conclusion 
 
The hypothesis that ‘primary care, general practice based pharmacists delivering the Statin 
Outreach Support intervention to general practices can increase the proportion of patients 
prescribed simvastatin 40mg with their cholesterol controlled’ has been confirmed.  
 
The intervention worked for a combination of reasons, the most important of which were the 
time (duration) and effort (intensity) of the support provided by the pharmacists to practices. 
Individualisation of assistance at the GP, nurse and practice level, repetition of the main 
educational and practical messages, help given to practices to identify, call and recall suitable 
patients, the independence of the pharmacists from commercial or personal gain and good 
links with secondary care based experts all contributed to improving the uptake of the local 
cholesterol guideline. The key message for implementation included quality improvement and 
cost minimisation. This combination is intuitively acceptable to pharmacists delivering and 
practices receiving the support, and is likely to have contributed to the successful outcome.  
 
Of note from the many subgroups found to benefit from the intervention, patients registered 
with practices in areas of greater socioeconomic deprivation and their Practice staff appeared 
to respond better. An explanation for this lies in the increased awareness among pharmacists, 
of the difficulties experienced by patients in areas of deprivation, and the hard work and time 
by pharmacists trying to systematically improve engagement and associated prescribing. 
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Chapter 8 
 
Recommendations 
 
Conditional on current prescribing and cholesterol management in primary care, the SOS 
intervention should be offered to practices allocated to the Usual Care arm. 
 
The SOS model could be offered to other practices with baseline prescribing and cholesterol 
control comparable to baseline levels in the SOS trial. 
 
Practices caring for patients in areas of socioeconomic deprivation are likely to benefit to a 
greater extent. 
 
The Outreach Support model could be extended to focus on maximising the implementation of 
evidence in other therapeutic areas.  
 
Follow up of clinical endpoints should be considered. In January 2012, participants from the 
SOS study will have reached 7 years follow up. With this length of follow up there is a 
possibility that the treatment effect between patients in the SOS intervention practices and UC 
has generated a statistically significant difference in morbidity/mortality outcomes. This 
length of follow up and improvement in important outcomes has not previously been shown in 
any educational outreach intervention study, or any previous pharmacist led intervention 
study. If these endpoints are improved, an economic analysis should be conducted, using data 
collected during the trial. 
 
The findings should be submitted for publication in a mainstream medical journal.  
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Appendices 
 
Appendix I 
 
Mechanism of atherosclerosis and the effect of statins 
‘Plaques’ are fatty deposits in blood vessels, which contribute to narrowing and 
vasoconstriction with resulting shortage of blood supply to the area beyond. If the area beyond 
is cardiac tissue then a heart attack is more likely or if the blood supply to the brain is affected 
then a stroke or transient ischaemic attack is likely. The deposits are made up of a range of 
constituents, including Low Density Lipoprotein (LDL) cholesterol and High Density 
Lipoprotein (HDL) cholesterol. These are two sub fractions found circulating in the blood 
supply.  HDL is known to be protective while high relative levels of LDL increase the risk of 
vascular events. 
 
Figures 1 and 2 describe some of the main processes thought to contribute to formation of 
atherosclerotic plaques, which are often found to be associated with vascular disease. The 
formation of LDL and HDL are key parts of the process, because their metabolic pathway has 
steps which can be targeted and inhibited in a way that stops their production, limiting the 
resulting plaques. One step in this process involves an enzyme called HMGCo enzyme A 
reductase. 
 
 (Adapted from A.D.A.M)  
Figure 1.  The effect of a raised LDL level 
 
High circulating levels of LDL 
↓ 
Increased oxidation of LDL 
↓ 
 LDL-O passes into lesion in the intima of a blood vessel 
↓ 
Monocytes (inflammatory cells) are attracted to the lesion 
↓ 
Monocytes mature to macrophages and engulf the LDL-O 
↓ 
Forms foam cells which clump to form a fatty streak 
↓ 
Attracts smooth muscle cells 
↓ 
Plaque formation 
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Figure 2.  Formation of a fibrous plaque 
 
1 . 
2.   
3.  
4.
5.  
 
1. This is a normal coronary artery with no 
atherosclerosis and a widely patent lumen that can 
carry as much blood as the myocardium requires 
 
 
 
 
 
 
 
 
 
2. Fibrous Plaque, Leading to 
Atherosclerosis 
This picture depicts the first stages of plaque 
formation. 
Possible stages: 
1) Damage to arterial endothelium 
2) Monocytes migrate from bloodstream into 
the intima and over time fats, cholesterol, 
fibrin, platelets, cellular debris and 
calcium enter area and these are devoured 
by the Monocytes. This leads to the 
thickening of the area with a soft cheese-
like substance. (Picture 3) 
3)  LDL, which contains specific functional 
groups that allow it to be recognised by 
most cells in the body, readily passes 
through the endothelium. 
4)  LDL once “trapped” in the wall gets 
oxidised. This leads to “modified” 
lipoproteins which are readily taken up my 
smooth muscle cells leading to formation of 
“foam” cells contributing to the 
development of plaques. 
5) Plaque formation begins as fatty streaks on 
the inner arterial wall and over time the fat 
deposits grow, narrowing the lumen of the 
artery 
6) With time, the Atherosclerotic Plaque or 
Atheroma collects calcium deposit, may 
become brittle, and may rupture. Blood 
may then enter the ruptured atheroma, 
making it larger, so that it narrows the 
artery even more. 
7) Subsequent damage to the endothelial 
walls causes platelets to adhere and 
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6-10.  
contributes to blood clot formation. 
8) A ruptured atheroma may also spill its fatty 
contents and trigger the formation of a 
blood clot (thrombus). The clot may further 
narrow or even occlude the artery, or it 
may detach and float downstream where it 
causes an occlusion (embolism). 
9) Surrounding muscle also proliferates to 
form larger plaques. 
10) Hardening of the arterial walls is due to 
various depositions within the plaque 
including lipids, cholesterol crystals and 
calcium salts. These depositions make the 
arteries bone like rigid tubes and very 
brittle. 
 
An enlarged view of an atherosclerotic vessel 
 
 
How statins reduce cholesterol 
On absorption from tablet form in the gastrointestinal tract, statins competitively inhibit 
HMGCo enzyme A reductase. The reductase enzyme is the rate limiting step in cholesterol 
synthesis in the liver, therefore statins reduce cholesterol synthesis in the liver (also in 
macrophages) thus decreasing the total cholesterol in the blood. Through a separate process, 
statins increase the number of LDL receptors in the liver which has the effect of binding more 
LDL and contributing to a lowering in this circulating (harmful) sub fraction. Dose dependent 
reductions in LDL cholesterol of 17-61% are common while there is a smaller reduction in 
plasma triglyceride and a small increase in HDL cholesterol.  
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In the process, when plaques do form on the intima of blood vessel walls, the plaques are less 
likely to rupture and cause harm, because the ratio of lipid is lowered. Over time, if statins are 
taken daily, existing plaques regress through a process of remodelling, but this is not thought 
to be the main reason for the beneficial effect, because benefits of statins precede the onset of 
remodelling.  
 
Non lipid lowering effects of statins 
These may also contribute to the beneficial effect, through modification of one or more of the 
following areas:                                       
1. Blood vessel wall 
2. Blood flow 
3. Blood constituents 
 
Blood vessel wall 
Within the blood vessel wall, statins reduce cholesterol synthesis in macrophages and affect 
immune function, through an enzyme called Prostaglandin Generating Factor (PDGF) and an 
inflammatory marker called C - reactive protein (CRP). Macrophages synthesise cholesterol, 
carry oxidised LDL into the plaque, and stimulate smooth muscle cell growth, replication and 
plaque neovascularisation. They release cytokines and other inflammatory mediators which 
stimulate smooth muscle cells and plaque neovascularisation. Macrophages then release 
enzymes which weaken the cap of the plaque, causing increased risk of plaque rupture. In 
reducing cholesterol synthesis in macrophages, statins reduce macrophage activity. Statins 
also regulate and inhibit a number of natural cytotoxic agents in vitro and these observations 
are substantiated in clinical practice by the observation of reduced rejection at one year post 
cardiac transplant for patients receiving statins. 
 
PDGF contributes to the migration of macrophages, platelets, smooth muscle cells and 
fibroblasts to atherosclerotic lesions. Statins inhibit PDGF induced DNA synthesis. High 
circulating CRP levels are an independent risk factor for atherosclerosis, primarily because 
CRP activates monocytes, which mature to macrophages.  
 
Blood flow 
One of the consequences of high cholesterol levels is an abnormality in the nitric oxide (NO) – 
L-arginine pathway with an inadequate supply of NO causing increased atherogenesis and 
thrombosis. Statins increase NO generation which causes vasodilation and improved blood 
flow.  The use of statins improves endothelial function and vasomotion thus reducing 
myocardial ischaemia. 
 
Blood constituents 
Hypercholesterolaemia results in the following changes in the constituency of blood: 
 Increased hypercoagulability 
 Enhanced platelet reactivity at the site of acute vascular damage due to the alteration of the 
calcium content of the platelet cell membrane 
 Increased fibrinogen (a key factor in the blood clotting cascade pathway) levels 
The consequence of hypercholesterolaemia is therefore increased thrombus formation on 
plaque rupture. Statin effects upon blood constituents include decreased fibrinogen levels and 
reduced ADP-induced aggregation of platelets. 
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Appendix II 
 
Cardiovascular disease risk predictor 
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Appendix III 
 
Heart Protection Study – Subgroups for 1st vascular event (CHD / CVA / revascularisation) 
Category N Placebo Simvastatin ARR NNT   
Coronary Heart Disease 13386 27.5% 21.8% 5.7% 18      
 
Any PVD 6748 32.7% 26.4% 6.3% 16    
PVD alone 2701 30.5% 24.7% 5.8% 17 
 
CVA (any stroke) 3280 29.8% 24.7% 5.1% 20 
CVA (stroke alone) 1820 23.6% 18.7% 4.9% 20 
 
Diabetes Mellitus (any diabetes) 5963 25.1% 20.2% 4.9% 20 
Diabetes Mellitus (diabetes alone)  3982 18.6% 13.8% 4.8% 21 
 
Total Cholesterol <5 4072 23.1% 17.7% 5.4% 19 
Total Cholesterol ≥5 but <6 7883 24.5% 18.9% 5.6% 18 
Total Cholesterol ≥6 8581 26.8% 21.6% 5.2% 19 
 
ARR=absolute risk reduction; NNT=number needed to treat for 5 years to prevent one event
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Appendix IV 
 
Cholesterol guidelines (pre-HPS era) 
 
UK guidelines 
 
The joint recommendations of the British Cardiac and Hypertension Societies and the 
British Hyperlipidaemia and Diabetic Associations, published in 1998, advised estimating 
the absolute risk of CHD using Framingham based criteria, which include HDL cholesterol 
as a variable. Coronary risk charts are readily available, which allow identification of 
individuals at risk of a coronary event.  Priority for treatment was given to those with 
established CHD or with an estimated risk of  ≥ 15% over the following 10 years. All 
individuals in these categories with serum total cholesterol ≥ 5mmol/l or LDL cholesterol 
≥ 3mmol/l should receive lifestyle advice aiming to reduce the values to < 5mmol/l and < 
3mmol/l respectively. Lipid lowering treatment was recommended for those whose 
cholesterol remained above the threshold. Since then, more recent guidance appeared for 
England and Wales in the National Service Framework for CHD (Department of Health 
2000), and in Scotland, in the Scottish Intercollegiate Guideline Network. These 
recommended that patients with CHD or at high risk (defined as ≥ 30% over 10 years) 
should be managed by diet and statins with the aim of lowering serum total cholesterol 
below 5mmol/l or by 20-25%, whichever would result in the lowest level.  
 
 
European guidelines 
 
The Third Joint Task Force of European and Other Societies’ guidelines focus on the 
prevention of fatal CVD rather than CHD events (De Backer 2003). Assessment of CVD 
risk is based on the systematic coronary risk evaluation score system, high risk being 
defined as ≥ 5% chance of fatal CVD within 10 years. High risk subjects should have their 
total and LDL cholesterol lowered to less than 5mmol/l and 3mmol/l respectively, unless 
they have overt CVD, diabetes or serum total and LDL  cholesterol concentrations which 
are already below these values, in which case the targets are lowered to < 4.5mmol/l and < 
2.5mmol/l respectively.  
 
 
North American guidelines 
 
The third report of the National Cholesterol Education programme (NCEP) reiterated the 
use of the LDL cholesterol reading as the criterion for when to initiate treatment and as a 
therapeutic goal. The greater the risk of CHD, the lower the concentration of LDL 
cholesterol at which treatment is initiated, and the lower the target level (Expert panel on 
detection, evaluation and treatment of high cholesterol in adults 2001). Patients with CHD, 
diabetes or multiple risk factors conferring a 10 year risk of CHD of > 20% over 10 years 
are deemed to be at high risk. Most people will require lipid lowering drug therapy to 
achieve the LDL cholesterol goal of < 2.6mmol/l but therapeutic lifestyle changes may 
achieve the less severe targets of < 4.1mmol/l and < 3.4mmol/l recommended for those at 
low and moderate risk respectively.  
  
184 
Appendix V 
 
MEDLINE search terms 
 
1. Prescriptions, Drug/ or prescribing.mp. 
2. Education, Medical, Continuing/ or academic detailing.mp. 
3. facilitation.mp. or SOCIAL FACILITATION/ 
4. outreach visit$.mp. 
5. 1 and (2 or 3 or 4) 
6. limit 5 to humans 
7. Meta-Analysis/ 
8. meta analy$.tw. 
9. metaanaly$.tw. 
10. meta analysis.pt. 
11. (systematic adj (review$1 or overview$1)).tw. 
12. exp Review Literature/ 
13. or/7-12 
14. harmacy.ab. 
15. embase.ab. 
16. (psyclit or psychlit).ab. 
17. (psycinfo or psychinfo).ab. 
18. (cinahl or cinhal).ab. 
19. science citation index.ab. 
20. bids.ab. 
21. cancerlit.ab. 
22. or/14-21 
23. reference list$.ab. 
24. harmacyey$.ab. 
25. hand-search$.ab. 
26. relevant journals.ab. 
27. manual search$.ab. 
28. or/23-27 
29. selection criteria.ab. 
30. data extraction.ab. 
31. 29 or 30 
32. review.pt. 
33. 31 and 32 
34. comment.pt. 
35. letter.pt. 
36. editorial.pt. 
37. animal/ 
38. human/ 
39. 37 not (37 and 38) 
40. or/34-36,39 
41. 13 or 22 or 28 or 33 
42. 41 not 40 
43. Randomised Controlled Trials/ 
44. randomised controlled trial.pt. 
45. Random Allocation/ 
46. Double Blind Method/ 
47. Single Blind Method/ 
48. clinical trial.pt. 
49. exp Clinical Trials/ 
50. or/43-49 
51. (clinic adj trial$1).tw. 
52. ((singl$ or doubl$ or treb$ or tripl$) adj (blind$3 or mask$3)).tw. 
53. PLACEBOS/ 
54. placebo$.tw. 
55. randomly allocated.tw. 
56. (allocated adj2 random).tw. 
57. or/51-56 
58. 50 or 57 
59. case report.tw. 
60. letter.pt. 
61. historical article.pt. 
62. review of reported cases.pt. 
63. review, multicase.pt. 
 
64. or/59-63 
65. 58 not 64 
66. ECONOMICS/ 
67. “Costs and Cost Analysis”/ 
68. Cost Allocation/ 
69. Cost-Benefit Analysis/ 
70. Cost Control/ 
71. Cost Savings/ 
72. Cost of Illness/ 
73. Cost Sharing/ 
74. “Deductibles and Coinsurance”/ 
75. Medical Savings Accounts/ 
76. Health Care Costs/ 
77. Direct Service Costs/ 
78. Drug Costs/ 
79. Employer Health Costs/ 
80. Hospital Costs/ 
81. Health Expenditures/ 
82. Capital Expenditures/ 
83. Value of Life/ 
84. exp Economics, Hospital/ 
85. exp Economics, Medical/ 
86. Economics, Nursing/ 
87. Economics, Pharmaceutical/ 
88. exp “Fees and Charges”/ 
89. exp BUDGETS/ 
90. (low adj cost).mp. 
91. (high adj cost).mp. 
92. (health?care adj cost$).mp. 
93. (fiscal or funding or financial or finance).tw. 
94. (cost adj estimate$).mp. 
95. (cost adj variable).mp. 
96. (unit adj cost$).mp. 
97. (economic$ or pharmacoeconomic$ or price$ or pricing).tw. 
98. or/66-97 
99. 65 or 64 or 98 
100. 6 and 99 
101. harmacye$.mp. 
102. exp Education, Professional/ 
103. exp Drug Utilization/ 
104. exp Professional Practice/ 
105. 1 or 103 
106. 2 or 3 or 4 or 101 or 102 or 104 
107. 105 and 106 
108. 107 and 99 
109. limit 108 to humans 
110. exp family practice/ 
111. exp physicians, family/ 
112. exp primary health care/ 
113. exp community medicine/ 
114. (general adj pract$).ti,ab. 
115. exp community health services/ 
116. exp community pharmacy services/ 
117. exp primary nursing care/ 
118. (community adj3 (harmacy$ or nurse$ or nursing or care 
or practice)).ti. 
119. (primary adj3 (care or nurse$ or nursing or practice)).ti. 
120. ((general or gp) adj1 (practice or practitioner$1)).ti. 
121. ((practice or district or practitioner$1) adj1 (nurse$1 or 
nursing)).ti. 
122. (health adj visitor$1).ti. 
123. gps.ti. 
124. or/110-123 
125. 109 and 124 
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Appendix VI 
Ethical approval 
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 Appendix VII 
 
Cholesterol control at baseline 
 
 
 
Practice 
ID 
Number per 
practice 
Number of eligible patients 
with cholesterol not 
controlled (%) 
Number of eligible 
patients with cholesterol 
controlled (%) 
1 253 213 (84.2) 40 (15.8) 
2 155 108  (69.7) 47 (30.3) 
3 296 202 (68.2) 94 (31.8) 
4 100 69 (69.0) 31 (31.0) 
5 255 176 (69.0) 79 (31.0) 
6 117 76 (65.0) 41 (35.0) 
7 234 141 (60.3) 93  (39.7) 
8 133 74 (55.6) 59 (44.4) 
9 216 144 (66.7) 72 (33.3) 
10 261 171 (65.5) 90 (34.5) 
11 215 125(58.1) 90 (41.9) 
12 132 77 (58.3) 55 (41.7) 
13 80 48 (60.0) 32 (40.0) 
14 237 125 (52.7) 112 (47.3) 
15 90 48  (53.3) 42 (46.7) 
16 108 38 (35.2) 70 (64.8) 
  17§ 57 43 (75.4) 14 (24.6) 
18 63 49 (77.8) 14 (22.2) 
19 135 94  (69.6) 41 (30.4) 
20 33 21 (63.6) 12 (36.4) 
21 53 34 (64.2) 19  (35.8) 
22 57 38  (66.7) 19( 33.3) 
23 76 48 (63.2) 28 (36.8) 
24 89 52 (58.4) 37 (41.6) 
25 97 47 (48.4) 50 (51.6) 
26 39 18 (46.2) 21 (53.8) 
27 50 21 (42.0) 29 (58.0) 
28 114 54 (47.4) 60 (52.6) 
29 63 28 (44.4) 35 (55.6) 
30 133 63 (47.4) 70 (52.6) 
31 99 34  (34.3) 65 (65.7) 
 4040 2479 (61.4) 1561 (38.6) 
§ 
 Practice disbanded prior to randomization, unknown to the research team until after randomization  
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Appendix VIII 
Secondary prevention of coronary heart disease and 
stroke 
 
 
 
  
 
Patients with established atherosclerotic disease are at high risk and 
should be treated with a statin regardless of total blood cholesterol 
concentration 
i.e. Previous MI / pre- or post-CABG / pre- or post-Angioplasty / Angina / Angiographic coronary artery 
disease / Ischaemic stroke or TIA / Peripheral Arterial Disease / Patients with diabetes aged ≥ 40 years 
ATHEROSCLEROTIC ARTERIAL DISEASE IS OF MULTIFACTORIAL ORIGIN. NO SINGLE 
RISK FACTOR, INCLUDING CHOLESTEROL CONCENTRATION, SHOULD BE VIEWED IN 
ISOLATION. 
• Encourage smoking cessation (consider nicotine replacement therapy) 
• All other risk factors hypertension, diabetic control, should be addressed (see separate guidelines) 
• Aspirin 75mg (not enteric coated) should be taken by all those with occlusive arterial disease in the 
absence of contraindications (active peptic ulceration, a bleeding disorder or true hypersensitivity) 
• Consider treatment with ACE-inhibitors especially in patients with left ventricular dysfunction or heart 
failure 
• β
‡ Consider referral to lipid clinic in resistant cases, if liver transaminases > 2x normal, or if statin not tolerated.  
† Discuss with lipid clinic if in doubt
 
*Do within 24 hours of onset of acute MI 
Random non-fasting test for total 
cholesterol* and LFT’s 
Consider secondary causes & 
familial hyperlipidaemia if 
Cholesterol >8.0 mmol/L† 
 See BNF for cautions, contra-indications and clinically 
important interactions. 
Re-test at 1 month 
Random non-fasting total cholesterol + triglycerides + LFT’s  
GOALS OF TREATMENT BY THREE MONTHS  
Total cholesterol concentration <5.00 mmol/l 
(<4.2 mmol/L for post CABG patients)  
AND  
Reduce cholesterol concentration by ≥ 25% 
  
Cholesterol goals not achieved 
Discuss concordance. Switch to 
Atorvastatin 40 – 80mg depending on 
response. Consider addition of 
ezetemibe if necessary. The use of other 
lipid-lowering agents is not 
recommended without specialist advice. 
Triglycerides > 4.0mmol/L 
Check fasting sample‡  
 
 
Cholesterol Goals Achieved 
Annual review to ensure continued 
concordance. 
 
Treat all patients with statin regardless of 
baseline cholesterol concentration 
Recommended drug & daily dose 
Simvastatin 40mg daily 
Consider Atorvastatin 80mg in acute coronary syndrome with elevated troponin 
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Appendix IX 
 
Baseline Data Collection   
 
Practice ID: ……………………………   Today’s date:……………………… 
Patient I.D.: ……………………………  DOB: ………………  M / F 
1. Relevant Diagnoses 
Secondary prevention definite possible Primary Prevention yes no unclear 
 Previous MI/ Date:     
Pre/Post CABG/ Date:    
 
   
 
 Hypertension: Syst 
>160 or Diast >90 or 
on antihypertensive 
therapy 
 
 
 
 
 
 
Pre/Post Angioplasty/ 
Date: 
   
 
   
 
Angina / IHD/ Date:    
 
   
 
FH of CHD: Father 
<45yrs or Mother 
<55yrs 
 
 
 
 
 
 
PVD/ Intermittent 
claudication/ Date: 
   
 
   
 
Smoker    
Diabetes/ Date: 
 
   
 
   
 
Stroke/Date:    
 
   
 
TIA/ Date:    
 
   
 
Other (specify): 
 
2. About the statin prescription… 
 
Statin: Dose 
None       
Simvastatin  10mg  
Pravastatin  20mg  
Atorvastatin  40mg  
Fluvastatin  80mg  
Other: 
…………………. 
Other: 
…………… 
Current Cholesterol level : 
 
………………mmol/l     (LDL ….….. 
...........HDL…..….) 
 
Date…………………………………………… 
 or  
None   
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Appendix X 
Allocation schedule 
 
Practices‡    Allocation 
   SOS         Usual Care 
G1   (1,1) 
G2     (1,0) 
G3   (2,1) 
G4     (2,0) 
G5   (3,1) 
G6     (3,0) 
G7   (4,1) 
G8     (4,0) 
G9     (5,0) 
G10   (5,1) 
G11   (6,1) 
G12     (6,0) 
G13     (7,0) 
G14   (7,1) 
G15   (8,1) 
G16     (8,0) 
     
S1   (1,1) 
S2     (1,0) 
S3     (2,0) 
S4   (2,1) 
S5   (3,1) 
S6     (3,0) 
S7     (4,0) 
S8   (4,1) 
S9   (5,1) 
S10     (5,0) 
S11     (6,0) 
S12   (6,1) 
S13   (7,1) 
S14     (7,0) 
 
Practices are shown in the pairs resulting from stratification.  
‡G = Group, SH = single handed. The disbanded SH practice had been part of the only triple, allocated to the 
SOS arm.  
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Appendix XI 
 
Clinical Facilitation: a summary for practices 
 
This is a multifaceted intervention, rooted in the belief that more intensive efforts to alter 
prescribing practice are generally more successful. Clinical Facilitation§ involves 
prescribing support pharmacists meeting individually with GPs or nurses to identify any 
obstacles standing in the way of offering patients statins to lower cholesterol and then 
providing specific, practical solutions (facilitation) to overcome these obstacles. Some 
techniques used to reach agreement on what support is required to address gaps in the 
implementation of the evidence may include a practice based clinical audit, open, honest 
communication and an acknowledgement of what may be  required to change prescribing 
practice and patient attendance. Increasing the extent of implementation of local guidelines 
encouraging the prescribing of simvastatin 40mg for patients with vascular disease will 
feature in each meeting. 
 
Pre – meeting 1 
Prior to meeting 1, the pharmacist searches the practice computer to ascertain numbers of 
patients with confirmed vascular disease who are not treated with statins in line with the 
local guideline.  
 
Meeting 1 (up to 30 minutes) 
Outline of process. Identification of GP/nurse learning needs (knowledge based or 
organisational) and identification of each practitioner’s preferred learning method. The 
information gathered pre meeting 1 is summarised, displayed graphically and shared with 
the GP/nurse during the first meeting. If expert opinion is requested to address 
uncertainties in therapeutic management, this is sought and incorporated into the second 
meeting. Discussion of need and methods to address the gap between guideline and 
implementation.  
Key outcome: Agreement on individual information /practice organisational barriers that 
prevent the identified patients with vascular disease being identified and offered statins. 
Targets for changes in prescribing are discussed and agreed if possible.  
 
Meeting 2 (up to 1 hour) 
Interactive, individualised presentation by pharmacist facilitator. Delivery of therapeutic 
information about the practice’s prescribing of statins and summarised trial information in 
a concise, unbiased, understandable format. The pharmacist suggests and seeks agreement 
for solutions to questions/barriers raised at 1st meeting. Anonymised patient specific 
prescribing and clinical data are used to simulate therapeutic challenges. The pharmacist 
will offer the views of respected peers/specialists. 
Key outcome: Commitment by the GP/nurse to changing their approach to prescribing 
statins for patients identified pre meeting 1, with vascular disease, with or without a statin. 
Responsibilities for behavioural change and timelines for action agreed. If agreed action 
involves the pharmacist committing to ongoing support for creating a register of patients 
with vascular disease, the pharmacist agrees when this can be done. Pharmacist will then 
facilitate change by visiting the practice weekly until the agreed actions are carried out. 
The actions may involve the identification of suitable patients followed by mailing of 
letters to patients explaining benefits of statins and requesting the patient’s attendance at 
clinic for a review.  
 
Meeting 3 (up to 30 minutes) 
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Positive reinforcement of changes made since meeting 2. The pharmacist searches the 
practice computer system to identify a sample of patients with coronary heart disease to 
assess the impact of the facilitation process. Key messages are repeated. Additional 
barriers to change management are identified and addressed. Graphical presentation of how 
the practice’s prescribing statistics have changed is fed back.  
Key outcome: Practice agree ongoing, systematic approach to optimising statin use in line 
with guideline  
 
§   Statin Outreach Support, SOS  
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Appendix XII 
 
Example of power point presentation for SOS meeting 
 
Statin Outreach Support Project 
Dr XXX & Partners  
  March 2004: Meeting 2 
Information For Dr XXX 
 
 
MEETING 1-Summary 
 Gathered information about your statin use 
 Briefly discussed the HPS & proposed new Glasgow guidelines on cholesterol 
management 
 Agreed in principal to increased prescribing of simvastatin 40mg 
 Identified the information you would like to receive to bring you up to speed with 
the current evidence 
 You requested specific information about: 
 cholesterol management in the elderly 
 In those with excess alcohol intake. 
 if there was a level of cholesterol below which it becomes harmful 
 
 
What’s happened since Meeting 1? 
 Formal launch of the new Guidelines on Cholesterol Management 
 We have looked for answers to some of your queries from a variety of expert 
sources: 
 Consultants Miles Fisher & Stuart Cobb 
 GRI Drug Information 
 Biochemist at Western Infirmary 
 Extensive Literature Search 
 
 
Objectives to be met in meeting 2 
 Delivery of a concise summary of the Key Outcomes of the Heart Protection 
Study 
 Highlight the important changes to the Glasgow guidelines on cholesterol 
management and underline how this will affect your current working practice 
 Answer specific questions 
 Put forward a workable plan to implement the new guidelines in current and 
future patients with established vascular disease 
 
 
My Proposal/Overall Aim 
 To ensure all your current and future patients with vascular disease are offered 
40mg Simvastatin 
Why is this important ? 
 There’s a big problem out there! 
 Here in Shettleston:  
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38% greater incidence of Heart Disease than Scottish average* 
40% greater incidence of Stroke than Scottish average** 
*Worst incidence of all Glasgow Wards 
**Second worst for stroke 
 
 
Good reasons for tackling the problem now 
 Our patients will quickly benefit: 
 Strong evidence from the HPS - 25% reduction in risk of major vascular 
event 
 This means If we prescribe Simvastatin 40 for all currently untreated 
vascular patients in this Practice (n=178) we will prevent (at the very 
minimum) 
 9 major vascular events 
 3 deaths 
 
 
 Practice will benefit financially: 
 Baseline audit: 
 17% of your vascular disease patients currently have a chol <5mmol/l 
 GP contract requires: 
 90% with cholesterol level noted in previous 15 months 
 60% with a cholesterol <5mmol/l 
 
 
 
GP Contract points 
Information requested 
 HPS key outcomes 
 Learning Points 
 Who is classified as having established vascular disease 
 Who should be treated with a statin 
 
 
 Update on Glasgow Primary and Secondary prevention guidelines 
 Learning Point 
 Understand the difference in absolute risk between primary and 
secondary prevention candidates 
 Importance of using Joint Risk Charts 
 
 
How do Statins work? 
 HMGCoA reductase Inhibitors 
 Act by blocking the key enzyme in the production of cholesterol in the liver 
 The resultant fall in circulating cholesterol levels stimulates an increase in the 
expression of LDL-receptors that remove circulating LDL from the blood 
 End result is a fall in LDL cholesterol (range 25-60%) and hence total 
cholesterol 
 
  
194 
 
Mode of Action of Statins in lowering cholesterol 
Do statins have any other important actions? 
Non-cholesterol lowering  
effects of statins 
 Inhibit macrophages 
 stabilise atherosclerotic plaque 
 Inhibit natural cytotoxic agents 
 ↓ transplant rejection 
 Inhibit PDGF/Fibrinogen 
 reduced thrombus formation 
 Increased NO formation 
 ↑ vasodilation/blood flow 
 Reduced CRP 
 independent risk factor for atherosclerosis 
Which Statin, Which dose? 
 There are more potent statins than Simvastatin 
 Atorvastatin 
 There is limited safety data on Atorvastatin 
 Limited mortality data 
 Less cost effective 
 Rosuvastatin 
 No information on mortality or morbidity 
?Concerns over safety 
GGHB Drug of Choice 
 Simvastatin 40mg 
 Safe 
 Effective –lowers LDL by ~40% 
 Morbidity & Mortality data available 
 Now off Patent 
 Most Cost Effective choice 
 
 
Let’s look at the evidence for Simvastatin 40mg 
 Heart Protection Study (HPS) 
 Data sheet 
 Other studies 
 
 
HPS 
 Largest trial of cholesterol-lowering in the world – Used Simvastatin 40mg in 
0ver 20,000 patients for 5 years 
 Included a wide range of patient groups: 
 CHD (MI, angina, CABG, PTCA) 
 TIA, CVA 
 PVD 
 Diabetic patients over 40 (with and without CHD) 
 Wide age range 40-80 years 
 25% were women 
 *Inclusion criteria: total cholesterol ≥3.5mmol/l 
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Key Outcomes from HPS 
 Simvastatin 40mg reduced the risk of a major vascular event by 25% 
 Risk reduction seen in ALL categories of patients: 
 old/young; 
 male/female; 
 PVD 
 CHD 
 TIA/CVA 
 Diabetes (with and without CHD) 
 Those with “normal cholesterol” 
 
Important Point 1:  
Patients NOW recognised as having established Vascular Disease: 
 
 Post MI Angina Angioplasty Diabetics (>45 yrs old) Stroke/TIA PVD CABG 
 
Important Point 2: 
 **Treat patients on basis of risk NOT cholesterol level** 
 Start simvastatin 40mg in all vascular patients whether cholesterol is 
raised or not 
Main Message from HPS 
 Adding Simvastatin 40mg to existing treatment* SAFELY produces substantial 
additional benefits for a wide range of high risk patients, irrespective of their 
initial cholesterol level. 
 NNT=19 
 
 
Safety of Simvastatin 40mg 
 Serious adverse effects (development of abnormal Liver function or muscle 
damage) was very rare during the HPS study. 
 No significant difference in incidence between  active and placebo arms – in 
the number of participants who stopped treatment because of elevated LFTs 
or muscle symptoms (0.5% vs 0.3% and 0.5 vs 0.5% respectively ) 
 
Myopathy/Rhabdomyolysis 
(data sheet) 
 Risk of Myopathy is dose related and rare 
 Incidence: 
 0.02% at 20mg 
 0.07% at 40mg 
 0.3% at 80mg 
*If myopathy occurs (CK>10 times ULN) STOP STATIN 
*If muscle pain and CK >3 times ULN, stop, re-measure and once normalised can 
try dose reduction or different statin. Monitor more closely 
 Risk of myopathy increased with concurrent Amiodarone or Verapamil 
 Recommend maximum dose of 20mg simvastatin 
 Risk of myopathy increased with concurrent erythromycin, clarithromycin, 
itraconazole, ketoconazole 
 Suspend simvastatin until course is finished 
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Statins in those with deranged liver function 
 HPS excluded patients with chronic liver disease (cirrhosis or hepatitis) or ALT 
>1.5x ULN 
 Glasgow Guideline:  consider referral to lipid clinic if ALT >2 x ULN 
 Data sheet: C/I in ACTIVE liver disease or unexplained persistant elevation of 
serum transaminases (ALT, AST). 
 Data sheet: Caution in patients predisposed to rhabdomyolysis – this includes 
those who abuse alcohol –check CK prior to starting 
 
 
Statins in the Elderly (>65yrs) 
 Absolute coronary risk increases with age 
 Over 25,000 patients >65 years old have been included in well done clinical 
trials (pooled data) 
 Risk reduction in the elderly taking statins is at least as good than in middle-
aged adults 
 HPS has provided evidence of benefit up to 85 years of age (28% over 70yrs at 
entry). 
 On completion of HPS &Prosper the oldest patients were 85 yrs 
 BUT The frail, elderly should be considered on an individual basis 
 
 
Side effects in the elderly 
Opinion of Dr John Byrne (Cardiologist S/General): 
 “The elderly are more prone to side effects with most drugs BUT for statins, it is 
important to remember the benefits are substantial for secondary prevention” 
 No documented evidence incidence of side effects from statins is higher in the 
elderly 
 
 
Other side effects 
 Very well tolerated overall. Incidence of side effects seems to be around 1% 
 Minor Side effects are relatively uncommon and may be dose related. If they 
occur and cannot be tolerated try reducing the dose or try another statin 
 Rash- withdraw treatment, if resolves try another statin. If rash not related to 
statin, restart simvastatin 40mg 
 
 
Monitoring-What and how often? 
 HPS demonstrated excellent safety of simvastatin 40mg 
 HPS advocates starting simvastatin in high risk patients regardless of initial 
cholesterol level 
 The majority of patients will reach target cholesterol level on this dose 
 Do we need regular monitoring of cholesterol or LFTs? 
 
 
Monitoring- Why do we need it? 
 Glasgow Guidelines advocate baseline recording of Cholesterol and LFTs then 
repeat after 1-3 months 
 GP Contract wants baseline Cholest and LFTs (within previous 15 months) 
 Evidence that regular monitoring improves compliance 
 Checks desired outcome achieved 
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Primary vs. Secondary prevention 
 Need to think about absolute risk when prescribing statins: 
 NNT for 5 years to avoid a vascular event in a patient with IHD = 26 
(secondary prevention) 
 These patients are at HIGH risk ≥30% in 10years 
 NNT for 5 years to avoid a vascular event in a patient with hypertension and 
no other risk factors = 125 (primary prevention) 
 This patient is at much lower risk ≤5% in 10 years 
 
 
Prescribing Simvastatin 40mg for Primary Prevention 
 Primary prevention is for patients with NO EVIDENCE of established vascular 
disease but the presence of risk factors 
 Hypertension 
 Hypercholesterolaemia 
 smoking 
 Diabetes (if <40) 
 Use joint risk charts to work out 10 year risk. START SIMVASTATIN 40MG 
ONLY IF RISK IS >30% OVER 10 YEARS 
 
 
New Glasgow guidelines for cholesterol management 
 The Glasgow Guidelines have changed in response to the KEY OUTCOMES from the 
HPS 
 Both the Primary Prevention AND Secondary Prevention guidelines have changed 
Update on Glasgow Cholesterol management guidelines 
 Old secondary prevention guidelines: 
 Considered established CHD patients only (MI, angina, CABG, angioplasty) 
 Commence statin only if cholesterol>5* 
 Start statin at lowest dose and titrate up 
 Aim for cholesterol level <5* and at least 1mmol/l reduction 
Update on Glasgow Cholesterol management guidelines 
 Updated secondary prevention guidelines (January 2004): 
 Consider ALL patients with vascular disease (CHD, CVA/TIA, PVD, diabetics 
over 45years) to be at HIGH RISK 
 No need to titrate- Commence Simvastatin 40mg REGARDLESS of 
cholesterol level 
 Aim for chol level <5* and at least 1mmol/l reduction 
 
Implementing the evidence-base in this Practice 
Patients with vascular disease NOT on a statin (178) 
Process: 
 Jan to produce updated list for screening 
 GP to review list to exclude unsuitable patients 
 Jan to draft invite letter proposing statin initiation and inviting patient to 
surgery for bloods before starting 
 Approval of letter 
 send 20 letters/week (copy in notes and flag notes for opportunistic initiation) 
 Practice nurse/GP to see for baseline bloods and sales pitch 
 GP to confirm LFTs ok and Rx Simvastatin 40mg 
 identify non attenders and follow up (phone etc) 
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Implementing the evidence-base in this Practice 
 Patients with vascular disease on lower dose statin but not at target (117) 
 Jan to produce updated list for screening 
 Jan to draft letter proposing dose increase and/or invite for bloods if no level 
in last 15 month 
 1.send all letters where only script required and put approx retest 
appointment time (staggered) 
 2. send 20 letters/wk with letter +invite for bloods and tag notes for 
opportunistic dose increase 
 Practice nurse/GP to see for updated baseline bloods and sales pitch 
 GP –confirm LFTs ok, change to Simvastatin 40mg [*or other] 
 Jan to identify non attenders and follow up 
 
 
Current Statin Use 
 
Aims for the future? 
 
 
Proposal 
 To ensure all your current and future patients with vascular disease are offered 
40mg Simvastatin 
 
SUMMARY -Why Simvastatin 40mg 
 HPS (and 4S) confirms tolerability and SAFETY and positive morbidity/mortality 
benefits (not just cholesterol lowering) in >25,000 patients 
 Simvastatin is now off patent and in Drug-tariff: price has already fallen 
substantially in current drug tariff and will fall further 
 Simvastatin is the GGHB drug of choice for lowering cholesterol in both 
Primary and secondary prevention 
 Simvastatin 40mg is most cost-effective option for both primary and 
secondary prevention 
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Appendix XIII 
 
Pharmacists’ training regimen 
 
Training 
day  
Aim Objective Learning methods Assessment 
method 
1st 
September 
2003 
- One to one 
discussion with 
principal 
investigator.  
- Completion 
of questions on 
HPS, answers 
assessed by 
principal 
investigator. 
- Evidence that 
the pharmacist 
has considered 
potential 
barriers to 
uptake and 
ways to 
overcome these 
30th 
September 
2003 
To become a 
credible 
expert in 
statin use and 
evidence base  
To develop 
understanding 
of the HPS and 
Glasgow 
Guidelines, and 
likely reasons 
for lack of 
uptake at 
practice and 
patient level 
 
To complete a 
critical 
appraisal on the 
HPS, and to be 
able to describe 
the rationale, 
methods and 
results 
-Self directed study. 
- Protected time to read 
and learn relevant 
published research and 
understand rationale and 
application of Glasgow 
statin guidelines 
- Didactic lecture from 
cardiologist  
-Critical appraisal 
checklist for HPS  
- One to one discussion 
with principle 
investigator, covering 
completed checklist, 
with feedback 
- identification of 
additional learning 
needs  - Detailed, 
accurate 
understanding 
of HPS  
9th and 
16th 
October 
2003 
To develop 
fluency in 
describing the 
costs and 
benefits of 
rational statin 
treatment for 
vascular 
disease  
To learn and be 
able to describe 
the rationale, 
need, 
therapeutic 
indications, 
side effects, 
costs and 
benefits of 
statins for 
vascular 
disease  
- Interactive lecture by a 
GP/ 
Educationalist/Professor 
of General 
Practice/Primary Care 
on Adult learning and 
Problem Based learning  
- Group discussion 
- In pairs, completion of 
a problem based 
learning task  
Evaluation of 
performance by 
two 
experienced 
GPs and a 
Practice Nurse 
with special 
interest in 
cardiology  
28th 
October 
2003 
Educational 
Outreach and 
SOS trial 
methodology 
To develop 
understanding 
of the methods 
adopted for 
educational 
outreach.  
- role play  
- Didactic lectures 
Evaluation of 
performance by 
GP/lecturer in 
Department of 
General 
Practice and 
Primary Care  
1st 
November 
2003 
SOS delivery To become 
familiar with 
the delivery of 
meeting one of 
SOS 
- role play and rehearsal 
of meeting 1 interaction 
- peer review 
6th To gain an To be able to To collect and interpret Preparation of 
  
200 
November 
2003 
understanding 
of the relative 
status of 
statin 
prescribing in 
each allocated 
SOS practice 
describe key 
characteristics 
of each 
nominated 
practice’s statin 
prescribing 
population level 
historical statin 
prescribing data (cost 
and volume) for 
allocated SOS practice, 
compared with the rest 
of the Glasgow practice 
population 
brief summary 
of the status of 
the practice’s 
statin 
prescribing and 
cost 
 
 
Examples of learning needs identified after critical appraisal and 1:1 discussion 
 
Further learning need Examples of 
potential sources 
of information  
1a. What would you say about the incidence and consequences of 
raised LFTs in the study? 
b. What would you advise practices to do in relation to LFTs in their 
population of HPS patients? 
c. What do the proposed new guidelines suggest for LFTs? 
2. How would you summarise the findings relating to incidence of 
muscle pain/weakness in the study and what would you conclude? 
3. Describe the patient groups and numbers of patients excluded 
from the study following attendance at the initial screening clinic 
visit.  
4. We thought there may be a ‘Diabetes Subgroup Analysis’ 
produced by the London Medicines Information Service. Can you 
source this? 
5. Could you clearly explain the concept of the placebo group 
having patients who also received simvastatin? 
6. In practice, assuming all else is equal, how many days of statin 
could a patient omit and still benefit as much as the patients in HPS? 
7. At a cellular level, what other effects do statins have, other than 
lipid lowering? 
8. Explain the term ‘95% CI’ with reference to the study outcomes.  
9. What are the common adverse drug reactions associated with 
statins? Is there a dose-response relationship? 
10. What is the evidence for patients with a history of Coronary 
Artery Bypass Graft requiring cholesterol to be less than 4mmol/l? 
(Corollary: does this matter any more?) 
11. Please comment on the guidance given in the ‘old’ Glasgow 
guidelines for the secondary prevention of CHD in relation to  
- doses of statins 
- age threshold 
- dietary advice 
12. Can you confidently describe some basic features of each of the 
3 previous secondary prevention studies (4S, CARE, LIPID)? 
13. What were the cut off points for LDL and total cholesterol levels 
in HPS? 
14. Describe how and where patient recruitment occurred? 
15. Could you explain Figure 7 to someone with a limited 
knowledge of the trial and statistical methods? 
16. What is a 95% Confidence Interval? How does it relate to p-
 
 
 
 
 
 
 
 
 
NNTs: Bandolier 
for general, EBM 
Online for statin 
trials. 
 
 
 
Confidence 
Intervals, p values: 
Master of Primary 
Care Statistics 
module lecture 
notes. 
 
 
 
Yusuf S. Two 
decades of progress 
in preventing 
vascular disease. 
The Lancet 
2002;360:2-3. 
 
 
 
Law MR, Wald NJ, 
Rudnicka AR. 
Quantifying the 
effect of statins on 
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values? 
17. Please explain Relative and Absolute Risk reductions in relation 
to one of the trial outcomes.  
18. Explain the relevance of cholesterol level as an indicator of 
baseline vascular risk. 
19. Describe the incidence and clinical significance of dropout as a 
result of raised LFTs in the active and control groups. 
20. Describe the incidence and clinical significance of muscle 
enzyme problems. 
21. Explain ARR, RRR and NNT to a GP/Nurse who has limited 
understanding. 
22. Explain (with workings) how the following are different ways of 
describing the benefits/costs of a cardiac rehabilitation programme 
for heart attack victims: 
-reducing the rate of deaths by 20% 
-producing an absolute reduction in deaths by 3% 
-increasing patients’ survival rate from 84% to 87% 
-needing 31 people to enter the programme to avoid 1 death 
23. What is your interpretation of the compliance issues raised by 
the study?  
24. Briefly summarise the details of previous primary (WOSCOPS, 
AFcaps/TEXcaps) and secondary prevention trials (CARE, 4S, 
LIPID). 
25. What would you say to convince a GP/Nurse that the beneficial 
effects of statins are additive to that of other secondary preventive 
drug strategies? 
low density 
lipoprotein 
cholesterol, 
ischaemic heart 
disease and stroke: 
systematic review 
and meta-analysis. 
BMJ 2003; 
326:1423-1436. 
 
 
Problem Based Learning task (used in training day 3:  9th October 2003) 
 
A 79 year old female (smoker, sedentary lifestyle) died suddenly last week. The cause of 
death was Myocardial Infarction. She had a past medical history of MI (2 years ago) and 
angina (3 years). Last recorded total cholesterol was 4.6mmol/l (1 year ago). 
Drug history: Aspirin, Nitrate, Statin (all taken for the past 3 years). ACE inhibitor (for the 
past 2 years). 
 
Each of the five pairs of pharmacists was asked to find explanations for the following key 
features of the task:  
  
- The short and long term pathophysiological processes potentially leading to the MI; 
- Possible mechanisms contributing to the benefits of statin therapy; 
- How and to what extent recognised risk factors contribute to the risk of suffering a 
vascular event; 
- How to describe and quantify the combined benefits of statins, ACEs, Aspirin and 
Beta Blockers in decreasing the risk of a vascular event; 
- What information to communicate to patients at risk, and how to communicate this 
risk.   
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Appendix XIV 
 
Duration of follow up by practice pairs 
 
Group / 
Single 
Handed 
Active / 
control 
Pair Duration of follow up for 
prescribing and cholesterol 
endpoints (yrs) † 
Duration of follow up 
for vascular events 
detection  (yrs) ‡ 
G Active 1a 
G Control 1c 
 
1.4 
 
2.7 
G Active 2a 
G Control 2c 
 
1.7 
 
2.7 
G Active 3a 
G Control 3c 
 
1.5 
 
2.8 
G Active 4a 
G Control 4c 
 
1.8 
 
2.6 
G Active 5a 
G Control 5c 
 
1.4 
 
2.7 
G Active 6a 
G Control 6c 
 
2.1 
 
2.7 
G Active 7a 
G Control 7c 
 
1.8 
 
2.7 
G Active 8a 
G Control 8c 
 
1.4 
 
2.3 
S Control 1c 
S Active 1a§ 
 
1.6 
 
2 
S Active 2a 
S Control 2c 
 
1.4 
 
2.5 
S Active 3a 
S Control 3c 
 
1.7 
 
2 
S Active 4a 
S Control 4c 
 
1.4 
 
2 
S Active 5a 
S Control 5c 
 
2.2 
 
2.8 
S Active 6a 
S Control 6c 
 
1.5 
 
2.7 
S Active 7a 
S Control 7c 
 
2.2 
 
2.7 
 
Mean (range) 
 
1.7 (1.4 – 2.2) 
 
 
2.5 (2 – 2.8) 
 
† period between randomisation (4th November 2003) and earliest start date of  follow up data collection in each pair of 
practices    
§ Lost to follow up ‡  for patients traced from baseline to follow up 
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Appendix XV 
 
Practice and patient flow: enrolment and allocation 
Assessed for eligibility (49 practices, 173,046 population) 
 18 practices: refused to 
participate (15); no reply (3) 
Baseline data collection (31 practices; 116,558 population, 
10,307 patients screened, 4040 included) 
Randomised (31 practices) § 
Allocated to SOS intervention: 16 practices, 
37GPs, 20 Practice nurses, 2373 patients 
 
(one practice disbanded prior to 
Allocated to UC: 15 practices, 35 GPs, 18 
Practice nurses, 1667 patients  
 
 
E 
N 
R 
O
L 
L
M
E
N 
T 
A
L
L
O
C
A
T 
I 
O
N 
§ 1 practice (Single Handed)  disbanded  pre randomisation (unknown at time of randomisation) 
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C
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Sim
vastatin
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-
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s
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Jan
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-
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ay
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Simvastatin 40 as % of total statin items, Oct-Dec '04
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£203,808
£223,223
£230,381
£246,785
£255,369
£239,600
£231,883
£285,671
£239,509
£250,715
£163,339
£177,708 £178,603
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intervention
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Non formulary statin prescribing: SOS vs. UC 
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